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iZusammenfassung
Die letzten Jahre waren durch weitreichende biotechnologischeWeiterentwicklungen gekennze-
ichnet, welche die Untersuchung der Zusammenha¨nge von genetischen und molekularen Mark-
ern mit komplexen Krankheiten in bis dato nicht bekannter Tiefe ermo¨glichen. Daru¨berhin-
aus werden oft multiple Traits von Pha¨notypen erhoben und liegen zur Analyse vor. Um die
Information dieser reichen und komplexen Daten jedoch nutzen zu ko¨nnen um biologische
Erkenntnisse zu gewinnen, sind angemessene statistische Methoden notwendig. In der vor-
liegenden Dissertation liegt der Fokus auf Genassoziationsstudien mit multiplen Pha¨notypen,
insbesondere auf der Analyse von (i) seltenen genetischen Varianten und (ii) kausalen direk-
ten genetischen Effekten. Fu¨r solche Untersuchungen sind vorhandene statistische Methoden
nicht immer valide.
Mit diesem Hintergrund ist das erste Ziel dieser Arbeit, zwei neue statistische Methoden
fu¨r Assoziationsanalysen von genetischen Markern mit multiplen Pha¨notypen zu entwick-
eln, die Methoden effizient und robust zu implementieren, so dass sie fu¨r die Analyse von
Daten aus Hochdurchsatzverfahren benutzt werden ko¨nnen, und die Methoden im Vergleich
zu anderen statistischen Ansa¨tzen in realistischen Szenarien zu u¨berpru¨fen. Der erste Ansatz,
genannt C-JAMP (Copula-based Joint Analysis of Multiple Phenotypes), ermo¨glicht multiple
Traits gemeinsam, bedingt auf genetische Varianten und Kovariaten, zu modellieren um die
statistische Power von Assoziationstests der genetischen Varianten zu erho¨hen. Der zweite
Ansatz, genannt CIEE (Causal Inference using Estimating Equations), ermo¨glicht den indi-
rekten genetischen Effekt u¨ber intermedia¨re Pha¨notypen zu entfernen um direkte genetische
Effekte valide und robust zu scha¨tzen und testen. C-JAMP wird in dieser Arbeit fu¨r Genas-
soziationsstudien von seltenen genetischen Varianten mit quantitativen Traits evaluiert, und
CIEE fu¨r Genassoziationsstudien von ha¨ufigen genetischen Varianten mit quantitativen Traits
und Ereigniszeiten als prima¨ren Pha¨notypen.
Die Ergebnisse von umfangreichen Simulationsstudien zeigen, dass beide Methoden eine
unverzerrte und effiziente Parameterscha¨tzung ermo¨glichen und die statistische Power von As-
soziationstests im Vergleich zu existierenden Methoden erho¨hen ko¨nnen - welche ihrerseits in
vielen Szenarien keine valide Analyse erlauben. Diese Eigenschaften von C-JAMP und CIEE
werden in Anwendungen fu¨r das zweite Ziel dieser Arbeit genutzt, welches darin besteht,
neue genetische und transkriptomische Marker fu¨r kardiometabolische Traits zu identifizieren.
In der ersten Anwendung wird ein existierender empirischer Datensatz analysiert, welcher
genetische Marker, Genexpressionsmaße, und Blutdruckmaße entha¨lt, um neue Blutdruck-
marker zu identifizieren. In einer zweiten Anwendung werden Daten einer Studie analysiert,
die im Rahmen der Dissertation durchgefu¨hrt wurde, um den Zusammenhang von genetis-
chen Markern und Genexpressionsmaßen aus RNA-Sequenzierung mit Adipositasmaßen aus
Magnetresonanztomographiescans zu untersuchen.
In den Analysen konnten mehrere neue Kandidatenmarker und -gene fu¨r Blutdruck und
Adipositas identifiziert werden. Dies unterstreicht den Wert, neue statistische Methoden zu
entwickeln, evaluieren, und implementieren - um neue Erkenntnisse u¨ber Krankheitsmarker zu
gewinnen und Hypothesen u¨ber zugrundeliegende biologische Prozesse fu¨r Follow-up Studien
zu generieren. Fu¨r beide entwickelten Methoden sind R Pakete verfu¨gbar, die ihre Anwendung
in weiteren empirischen Studien ermo¨glichen.
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Summary
In recent years, the biotechnological advancements have allowed to investigate associations
of genetic and molecular markers with complex diseases in much greater depth. In addition,
multiple phenotypic measures are often available for the analysis. However, in order to make
use of the rich and complex data and to provide valid insights, appropriate statistical methods
are needed for the investigation of biologically meaningful models. In this thesis, the focus is
on genetic association studies with multiple phenotypes, and in particular on (i) the analysis
of rare genetic variants and (ii) the identification of direct genetic effects. For such studies,
available statistical methods are not always valid.
With this background, the first aim of this thesis is to develop two new statistical methods
for the association analysis of genetic markers with multiple phenotypes, to implement them
in a computationally efficient and robust manner so that they can be used for large-scale
analyses, and evaluate them in comparison to existing statistical approaches under realistic
scenarios. The first approach, called the copula-based joint analysis of multiple phenotypes
(C-JAMP) method, allows investigating multiple traits in a joint model conditional on ge-
netic variants and covariates to improve the statistical power for identifying associated genetic
variants, and is evaluated for genetic association analyses of rare genetic variants with quan-
titative traits. The second proposed approach, called the causal inference using estimating
equations (CIEE) method, allows removing indirect genetic effects through intermediate phe-
notypes in order to estimate and test direct genetic effects on the primary phenotype in a
valid and robust manner, and is evaluated for genetic association analyses of common genetic
variants with quantitative and time-to-event primary phenotypes.
The results of extensive simulation studies show that both approaches provide an unbiased
and efficient estimation of parameters and can improve the power of association tests in
comparison to existing approaches, which are invalid in many scenarios. These properties
of C-JAMP and CIEE are used in application studies for the second goal of this thesis, to
identify novel genetic and transcriptomic candidate markers associated with cardiometabolic
traits. C-JAMP and CIEE are applied to one existing empirical dataset which contains
genetic markers, gene expression measures and blood pressure traits, to identify novel blood
pressure loci. Furthermore, they are applied in an empirical study which was planned and
conducted as part of this dissertation, to assess genetic markers and gene expression from
RNA-sequencing and test their association with obesity phenotypes from magnetic resonance
imaging scans.
In the analyses, several novel candidate markers and genes are identified, which highlights
the merit of developing, evaluating, and implementing appropriate statistical approaches in
order to gain new insights about disease markers and to build hypotheses about biological
processes for follow-up studies. R packages are available for both methods and enable their
application in further empirical studies.
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1Chapter 1
Introduction
1.1 Motivation and aim
Current trends in society feature aspects of health and technology across many different dis-
ciplines, lifestyles, and areas. In everyday life, smartphone apps can be used to measure
physiological data including body temperature, heart rate, or physical activity, to count calo-
ries intake or also blood glucose levels. In the healthcare system, efforts are made to digitalize
and integrate patient registries, and to combine electronic health records. Finally in biomed-
ical research, the technological advancements allow to study molecular processes in greater
depth, collaborative efforts are made to enable the analysis of large multi-center cohorts, and
efficient bioinformatics pipelines and quality control recommendations are set up. All these
examples create and deal with data that can be used to gain a deeper understanding of the
contributing risk factors to health and disease. However, due to the resulting complex and
high-dimensional datasets, such studies require appropriate and powerful statistical methods
for the analysis of the multitude of predictor and outcome variables as well as an efficient com-
putational implementation, in combination with appropriate epidemiological study designs
and biomedical expertise.
Regarding the development and application of statistical methods, it is critical that any
proposed method is (i) properly evaluated in realistic scenarios and compared to existing
methods, (ii) implemented efficiently and in a robust manner so that it can be applied to
large-scale data and integrate the information from the multitude of measured molecular and
phenotypic variables, and that (iii) any new identified biological signals in the analyses are
interpretable and carry useful biological information on new markers or structures. While
these points might seem intuitive, they have not always been considered in previous studies.
The focus in this thesis is on genetic association analyses and in particular on rare variant
analysis and the identification of direct genetic effects. It will be shown that in these fields,
some recently proposed methods are invalid for the analysis of empirical data, do not have
the proposed statistical properties in a finite-sample setting, and are even inferior to simple
standard approaches in many scenarios.
The first aim of this thesis is then to develop two new statistical methods called C-JAMP
and CIEE, for the association analysis of genetic markers with multiple outcome variables
(i.e., phenotypes), to implement them in a computationally efficient and robust manner so
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that they can be used for large-scale analyses, and evaluate them in comparison to standard
statistical approaches and recently proposed approaches under realistic scenarios.
Aim 1
Develop, implement, and evaluate two novel powerful statistical approaches
for genetic association analyses with multiple phenotypes.
Both methods can be applied to a large variety of datasets, phenotypes, and biological
questions, and are presented and evaluated here for specific analyses: The copula-based anal-
ysis of multiple phenotypes (C-JAMP) method is evaluated for the association analysis of rare
genetic variants with multiple quantitative traits, and the causal inference using estimating
equations (CIEE) method is evaluated for the identification of direct effects of common ge-
netic variants on a primary quantitative or time-to-event phenotype. In an evaluation of
existing statistical methods for these analyses, it will be shown that most of them are invalid
in some scenarios and the following thesis is proposed:
Thesis
1. Modeling multiple phenotypes with C-JAMP in a joint model or with
CIEE in a directed acyclic graph yields valid and efficient genetic effect
estimates, and can increase the power of hypothesis tests compared to
separate univariate models.
2. The two proposed methods provide an improvement over existing
methods for
(a) association analyses of rare genetic variants and
(b) the identification of direct effects of common genetic variants.
In a second aim, the proposed methods are applied to empirical data in order to identify
new candidate genetic markers and genes for cardiometabolic traits. First, genetic associa-
tions with blood pressure (BP) are investigated in published data from the Genetic Analysis
Workshop (GAW) 19. Second, a study was planned and conducted in order to identify new
candidate markers and genes associated with obesity traits, by measuring single nucleotide
variants (SNVs) and gene expression levels in adipose tissue (AT) through RNA-sequencing
(RNA-Seq; Wang et al., 2009; Ozsolak & Milos, 2010), and applying C-JAMP and CIEE.
Aim 2
Identify novel genetic and transcriptomic effects on cardiometabolic traits
by conducting empirical studies and applying the proposed statistical meth-
ods.
1.2. THESIS OUTLINE 3
As a result, the interdisciplinary projects in this thesis incorporate statistical, computa-
tional, bioinformatic and molecular epidemiological aspects, proposing appropriate methods
and evaluating them in a meaningful way for aim 1, as well as planning and conducting a
molecular epidemiological study and using the developed methods in the analysis for aim 2.
1.2 Thesis outline
Regarding the structure of this thesis, the next section 1.3 gives an overview about the
scientific contributions in this thesis. Following the introductory chapter, chapter 2 gives
some relevant epidemiological, statistical, and computational background. More specifically,
section 2.1 outlines the public health relevance of investigating risk factors for cardiometabolic
traits and describes their assessment and results from genetic association studies. Section 2.2
gives an overview on existing statistical approaches and methods for the analysis of complex
genotype-phenotype data. First, methods to analyze multiple genetic markers jointly are
described, which have mainly been developed for the analysis of rare genetic variants. Second,
an overview about methods to analyze multiple phenotypes is given. Section 2.3 presents some
relevant computational aspects for the implementation of statistical approaches and analysis
of high-dimensional genotype-phenotype data.
Next, the development of two novel statistical approaches is presented in chapter 3, in-
cluding their theoretical derivation and their respective implementation in packages of the
statistical software R (R Core Team, 2017). The first proposed approach is called C-JAMP
and uses copula functions to build joint models of multiple traits of a phenotype conditional
on genetic markers and other covariates (section 3.1). The statistical details of C-JAMP
are described in section 3.1.1 with a focus on the analysis of quantitative traits, and section
3.1.2 gives details regarding the implementation of C-JAMP in R. In section 3.2, the second
novel approach called CIEE is presented. CIEE fits a directed acyclic graph using estimating
equations to estimate and test direct effects of genetic markers on a primary phenotype while
removing indirect genetic effects through intermediate phenotypes. The statistical details
are described in section 3.2.1 with a focus on the analysis of quantitative and time-to-event
primary traits. Implementation details of the developed R package are given in section 3.2.2.
After the development of the new statistical methods, C-JAMP, CIEE and existing ap-
proaches are evaluated and compared for association analyses of genetic markers by using
simulation studies in chapter 4. First, in section 4.1, existing methods are evaluated and
compared for the analysis of rare genetic variants with quantitative phenotypes, to evaluate
whether or when popular models aggregating multiple genetic markers in a region (multi-
marker tests, MMT: SKAT, Wu et al., 2011; SKAT-O, Lee et al., 2012; and a burden test,
Lee et al., 2014) have higher power compared to simple separate Wald-type t-tests of each
genetic marker (single-marker tests; SMT). The results show that in all considered scenar-
ios, the SMT allows valid estimation and inference and has a higher power compared to the
MMTs in many realistic situations. Consequently, the following evaluation of C-JAMP and
CIEE focuses on their use as SMTs. Section 4.2 describes a large simulation study investi-
gating the properties of C-JAMP and compares its performance to the simple SMT based
on a univariate model of a trait as well as the univariate MMTs (SKAT, SKAT-O, burden
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test), multivariate SMTs (MultiPhen, O’Reilly et al., 2012; aSPU, Kim et al., 2016) and
multivariate MMTs (MURAT, Sun et al., 2016b; aSPUset, aSPUset-Score, Kim et al., 2016),
for association studies or rare variants. Finally, section 4.3 evaluates the statistical properties
of CIEE, and compares its empirical type I error and power to alternative methods for esti-
mating and testing direct effects of common genetic variants, namely traditional regression
methods, the structural equation modeling method (Bollen, 1989), and G-estimation methods
(Robins, 1986, 1992; Robins & Greenland, 1994; Goetgeluk et al., 2008).
Following the evaluation of the proposed statistical approaches, C-JAMP and CIEE are
applied to two different empirical studies in chapter 5. In section 5.1, they are applied in the
GAW19 data (Blangero et al., 2016) to infer overall as well as direct genetic effects on BP. The
data contains whole genome-sequence data, gene expression in lymphocytes measured with
microarrays, BP phenotypes, as well as non-genetic covariates of 81 unrelated individuals from
the T2D-GENES Consortium. C-JAMP is used to model the joint distribution of systolic
BP (SBP) and gene expression conditional on each SNV within the gene, and conditional on
the nongenetic covariates (see Figure 1.1, left panel). CIEE is applied to infer direct genetic
effects on SBP while removing indirect genetic effects through gene expression and adjusting
for measured and unmeasured confounding effects as illustrated in the underlying directed
acyclic graph (DAG) in Figure 1.1 (right panel).
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Figure 1.1: Assumed models in the GAW19 analysis, of the potential effects between the SNVs, gene
expression levels, systolic BP and non-genetic covariates in the analyses using C-JAMP (left panel) and
CIEE (right panel) in section 5.1. In both analyses, systolic BP is considered as a trait censored by
anti-hypertensive medication use.
Section 5.2 describes the application of C-JAMP to estimate and test genetic and tran-
scriptomic effects on obesity traits (Figure 1.2, left panel) and of CIEE to estimate and test
direct genetic effects on obesity traits while removing indirect genetic effects through gene
expression (Figure 1.2, right panel). For the analysis, a study was planned and conducted
to assess whole-transcriptome gene expression levels in abdominal AT with RNA-Seq cross-
sectionally in a population-based sample of 200 probands from the European Prospective
Investigation into Cancer and Nutrition (EPIC) Potsdam substudy (Wientzek et al., 2014;
Neamat-Allah et al., 2015). SNVs in coding regions were called from the RNA-Seq data, and
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previously validated data from magnetic resonance imaging (MRI) scans gives a direct quan-
tification of body fat mass (measured through the amount of subcutaneous AT, SAT) and
body fat distribution (measured through the amount of SAT relative to the amount of total
AT, TAT) in different body compartments (Wald et al., 2012; Neamat-Allah et al., 2015).
Finally, chapter 6 summarizes the results from the methods’ evaluation, which can be
used as a guide for practical data analysis, discusses the two developed methods and their
improvement relative to established methods, and discusses the identified new candidate
SNVs and genes from the applications in chapter 5. The references for all sections are shown
in the following section.
In the appendix, first, a declaration is given that I have worked on this thesis indepen-
dently in section A.1. Some sections in this thesis including their tables and figures are based
on published manuscripts or manuscripts currently under review. A complete list of these
manuscripts and publications, an overview about my contributions in the publications, and
details regarding which publications are underlying which sections are given in sections A.2-
A.3. Further details and results of the analyses in chapters 3-5, supplementary tables and
figures, and an outline of the R code of the developed R packages can be found in the further
sections A.4-A.7 of the appendix.
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Figure 1.2: Assumed models in the obesity study, of the potential effects between the SNVs, gene
expression levels (GE), obesity traits SAT mass and SATTAT (SAT mass relative to TAT mass) and non-genetic
covariates in the analysis of the EPIC Potsdam substudy data using C-JAMP (left panel) and CIEE (right
panel) in section 5.2.
1.3 Contributions
In this thesis, two novel statistical approaches for genetic association studies are developed,
implemented in R, evaluated in extensive simulation studies, and applied to real data. A
detailed overview about my contribution to these developments and the related publications
is given in section A.2. To the best of my knowledge, C-JAMP is the first implementation of
copula models to model the dependence of multiple phenotypes for genetic association studies
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and whose efficient and robust implementation allows performing genome-wide analyses, and
CIEE is the first valid approach for the analysis of log-linear models of time-to-event primary
phenotypes. Both approaches are evaluated for specific analyses but are widely applicable to
different datasets, can adjust for covariates, and can be easily extended to multiple outcomes
and adapted to outcomes with different distributions.
The evaluation of existing statistical approaches and of the two proposed approaches
in simulation studies yields several new results which are important for practical analyses
(and are summarized in chapter 6). Simulation studies were chosen as the primary tool for
evaluation since the situations of interest (rare genetic variants, traits of high dependence)
investigate parameters on the boundary of the parameter space so that theoretical consider-
ations might not be true, especially in the finite-sample setting. The first new result from
the simulation studies is that simple single-marker tests are valid for the analysis of rare vari-
ants with quantitative traits and have actually equal or higher power compared to popular
multi-marker tests in many realistic scenarios (and lower power in some scenarios). Second,
it is shown that a number of existing approaches for rare-variant analyses as well as for the
identification of direct genetic effects are invalid, provide biased effect estimates and inflated
type I errors. On the other hand, it is shown that both proposed approaches allow unbi-
ased and efficient estimation of overall/direct genetic effects, and can increase the power of
genetic association tests of rare variants, and of direct genetic effects compared to existing
approaches. Extensive simulation studies show their robustness and efficiency over many dif-
ferent scenarios, and also indicate against which model misspecifications the approaches are
robust and against which model specifications they are sensitive which have to be checked
in practical applications. In order to conduct these extensive simulation studies, an efficient
parallelization of the computations on a computing cluster and integration of the results was
necessary to handle the computational burden of more than 300 computing years. For exam-
ple, for an evaluation of C-JAMP (and the other existing statistical approaches) regarding
their empirical type I error for a nominal level of α = 2.5 × 10−6, data was generated and
evaluated 10,000,000 times for each null model.
In addition to the evaluation of the existing and new approaches on artificial data, C-
JAMP and CIEE were applied to real data in several application studies. For this, one existing
dataset was analyzed to identify novel genetic markers for blood pressure, and one empirical
study was planned, the biological experiments supervised, the bioinformatic processing and
quality control performed, and the different datasets integrated in order to identify novel
candidate genetic and transcriptomic markers for obesity. The analyses confirmed the results
from the simulation studies that both C-JAMP and CIEE yield smaller p-values compared
to univariate approaches and can thereby identify more candidate markers that would be
missed by existing approaches. More specifically, the genetic association analyses identified 1
novel candidate SNV for BP, 1 novel candidate SNV for body fat mass and 6 novel candidate
SNVs for body fat distribution, and further promising SNVs with suggestive evidence. The
transcriptomic association analyses identified 441 genes associated with body fat mass and
225 genes associated with body fat distribution. These results suggest new pathways that
might be involved in blood pressure and obesity.
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2.1 Public health relevance and genetic epidemiological back-
ground
In this thesis, two novel statistical methods are developed that incorporate multiple pheno-
types in genetic association analyses. In the empirical data analysis in chapter 5 using the
two novel methods, the focus is on the analysis of cardiometabolic traits, and in particular
on the cardiovascular phenotype BP and the metabolic phenotype obesity. Throughout this
thesis, the term phenotype is used as a synonym of any measured nongenotypic characteristic,
encompassing multiple traits. Cardiometabolic traits in general subsume different cardiovas-
cular and metabolic traits such as abdominal adiposity, hypertension, dyslipidemia, hyper-
insulinemia, and glucose intolerance. These clustered disorders, also termed cardiometabolic
disease or cardiometabolic syndrome (Castro et al., 2003; Fisher, 2006), are themselves risk
factors for some of the most prevalent chronic diseases such as diabetes, heart disease, or
stroke. For example, current estimates suggest that the overall global prevalence of hyper-
tension was 26.4% in 2000, and project a prevalence of 29.2% in 2025 equaling 1.56 billion
adults (Kearney et al., 2005). Regarding diabetes, current estimates suggest that 415 million
adults are affected worldwide with an expected rise to 642 million adults by 2040, equaling
a prevalence of 9% and accounting for 12% of global health spendings (Aguiree et al., 2013).
The identification of molecular correlates of cardiometabolic traits can contribute to a more
detailed understanding of the disease etiology, to an identification of new biomarkers and a
deeper understanding of established biomarkers. Such biomarkers can be valuable and in-
formative markers for disease, and can be used in prevention guidelines as well as potential
targets for treatment (Tam et al., 2011; Fisman & Tenenbaum, 2014). While the main fo-
cus in this thesis will be on genetic association analyses, they are often only a first step in
the analysis of complex traits. Assessing gene expression levels can yield more detailed hy-
potheses about molecular processes and can serve as a starting point to further investigations
using high-throughput approaches in the fields of proteomics, metabolomics, epigenetics and
others.
As genetic markers, single nucleotide variants (SNVs) are considered throughout this
thesis, which are genetic polymorphisms (i.e., variations) of a single nucleotide at specific
positions in the genome, with any frequency of the minor and major alleles. The distinction
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between common and rare SNVs is usually made based on their minor allele frequency (MAF),
and a threshold of 0.01 or 0.03 is popularly used to declare a SNV as being rare. Using
microarrays, whole exome or whole genome DNA-sequencing methods (Goodwin et al., 2016;
Mardis, 2017) allows to assess the variation of millions of SNVs, and genome-wide association
studies (GWAS) have identified many common variants associated with a large number of
complex traits, and explained some of the estimated heritability (Welter et al., 2014). The
refinement of high-throughput technologies and the decrease in sequencing costs now allow
investigating the role of rare variants in greater depth as well. However, despite evidence that
many rare variants play a functional role in complex traits and in the regulation of biological
processes (Gorlov et al., 2011; Nelson et al., 2012; Purcell et al., 2014), only a relatively small
number of rare variants have been found to be associated with complex diseases so far (Hunt
et al., 2013; Lohmueller et al., 2013; UK10K Consortium, 2015) with one likely reason that
frequently used statistical tests have been underpowered.
For a more detailed description of the metabolic phenotype obesity, it can first be noted
that obesity is defined through the amount of accumulated AT in the body. The most popular
traditional anthropometric measures of obesity include the body mass index (BMI), waist
and hip circumference (WC, HC), and the waist-to-hip ratio (WHR). However, they only
provide surrogate measures of the body volume or body fat. Using a direct quantification
of fat mass with computed tomography or MRI provides a more reliable and less biased
quantification (Ross et al., 2003; Bosy-Westphal et al., 2008; Bredella et al., 2010; Taylor et
al., 2012; Karlsson et al., 2013; Lee & Kuk, 2013) and also allows to differentiate between the
different body fat compartments. In terms of volume, SAT and visceral AT (VAT) are the
largest body fat compartments that constitute TAT. Regarding genetic association studies
with cardiometabolic traits, there exist a number of recent large-scale meta-analyses with
obesity traits such as BMI (Locke et al., 2015) or body fat distribution (BMI adjusted for
waist-hip-ratio; Shungin et al., 2015), which have identified 97 and 49 associated genetic
loci, respectively. Overall, there are currently 895 reported associations with BMI in the
NHGRI-EBI GWAS Catalog (Hindorff et al., 2017; MacArthur et al., 2017), in addition to
associations with other obesity traits.
For some background regarding the cardiovascular phenotype BP, the most popularly
investigated traits include systolic and diastolic BP, mean arterial pressure, pulse pressure,
and the hypertension status. While the BP traits are not directly tissue-based, tissues such
as the kidney can be of specific interest in investigations into disease etiology (Tsai et al.,
2017). Regarding the assessment of BP, there exist measure considerations (e.g., combining
at least 3 subsequent measures to form a more robust mean BP measure) and statistical
considerations, for example the adjustment of BP for antihypertensive medication intake
requires special attention (Tobin et al., 2005; Konigorski et al., 2014). In the NHGRI-EBI
GWAS Catalog, there are currently 263 reported genetic loci with associations to the above
BP traits, which are driven to a large extent by recent large-scale GWAS and meta-analyses
(Ehret et al., 2016; Liu et al., 2016; Surendran et al., 2016; Warren et al., 2017).
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2.2 Existing statistical approaches for genetic association stud-
ies
In order to integrate and analyze complex genotype-phenotype data to answer specific biolog-
ical questions, appropriate statistical methods with an efficient implementation are needed.
One of the main methodological challenges is how to deal with the high dimensionality of
the data (”curse of dimensionality”). The simplest statistical approach for any analysis as-
sociating genetic markers with phenotypes is to separately test each genetic marker for its
association with each phenotype. However, the results have to be integrated later and the
analyses cannot incorporate any dependencies between markers or traits. Furthermore, the
multiple testing burden increases exponentially when multiple phenotypes are included. As a
variation, genetic markers can be combined by using some form of aggregation or dimension
reduction technique. After this dimension reduction step, the aggregated measures can be
investigated in association tests, but it is unclear if this yields an improvement in general.
Finally, statistical approaches can be used to analyze multiple traits simultaneously. This
allows investigating more complex models and incorporating dependencies between variables
and also increases the face validity of the results. More details are described in the following.
2.2.1 Models including multiple genetic markers
Aggregating genetic markers or traits under consideration can reduce the computational
complexity and multiple testing burden. At the same time, however, such approaches rely
on the assumption that the aggregated measures carry some biological meaning. Therefore,
important considerations have to be whether the assumptions are biologically appropriate,
and any comparison of MMTs versus SMTs has to consider that different hypotheses are
tested. This will be illustrated for the context of genetic association studies in the following:
For GWAS, the unit of MMTs can be a region of the genome such as a gene or a pathway
spanning multiple genes. Accordingly, MMTs are testing whether a given combination of the
genetic markers in a given region (”burden-type tests”) or any of the markers in a given region
(variance-component-type tests) is associated with the trait of interest, whereas SMTs are
testing whether a given marker is associated with the trait of interest. More formally, for a
given region including k markers, the tested hypotheses for SMTs are
H0j : βj = 0 vs. HAj : βj ̸= 0 for j = 1, . . . , k (2.2.1)
where βj is the effect of the j-th marker on the trait under consideration; and the tested
hypotheses for MMTs are
H0 : β = 0 vs. HA : β ̸= 0 (2.2.2)
where β is the effect of the region on the trait of interest, which could be a single parameter in
burden-type tests, or a vector of parameters for the k marker effects in variance-component-
type tests with
H0 : β = (β1, . . . , βk)
T = 0 vs. HA : βj ̸= 0 for at least one j. (2.2.3)
Hence, if SMTs and MMTs are compared by evaluating the power for identifying a given
causal marker (SMT) and a given causal region (MMT), respectively, any conclusion that
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one approach is more powerful than the other is questionable since different hypotheses are
tested. For a valid comparison, their power has to be compared for identifying the same
genetic locus, such as a gene.
Specific approaches how to aggregate multiple genetic markers have been a focus in the
analysis of rare variants. Their development has been motivated by arguments that SMTs
have inflated type I error and very low power when testing rare SNVs in the analysis of binary
traits (Li & Leal, 2008), and might not provide valid statistical inference when testing very
rare SNVs or single base-pair mutations. MMTs use different approaches to combine the rare
genetic variants’ information in a given region and test the association of the region with the
phenotype. They can be broadly classified as (i) burden tests, which obtain genetic scores
by collapsing rare variants in a region/gene (Morgenthaler & Thilly, 2007; Li & Leal, 2008;
Madsen & Browning, 2009; Morris & Zeggini, 2010), (ii) extensions of burden tests (Price et
al., 2010; Lin & Tang, 2011; Chen et al., 2012), (iii) variance-component tests, which collapse
single-variant score statistics in a region (SKAT in Wu et al., 2011; and other tests in Basu
& Pan, 2011, Neale et al., 2011), (iv) combinations of burden and variance-component tests
(SKAT-O in Lee et al., 2012; aSPU in Pan et al., 2014, 2015; and other tests in Derkach et
al., 2013; Sun et al., 2013), and (v) other approaches (Xu et al., 2012; Mieth et al., 2016).
Detailed comparisons of rare variant association tests for binary traits (Madsen & Browning,
2009; Basu & Pan, 2011; Kinnamon et al., 2012; Xing et al., 2012; Pan et al., 2014) showed
that SMTs (Score tests, Wald tests, and Fisher’s exact tests) have deflated empirical type
I errors and much lower power compared to MMTs across most considered scenarios. For
the analysis of quantitative traits such as BP or obesity, however, extensive comparisons
are lacking and few studies have compared SMTs with MMTs with inconclusive evidence
(for more details, see Konigorski et al., 2017). Hence, a valid comparison of SMTs with
MMTs for the analysis of quantitative traits, which is described in section 4.1, can have wide
implications.
2.2.2 Models including genetic markers and multiple traits
In general, many different statistical methods have been developed for multivariate analyses,
and can be grouped into supervised and unsupervised methods, parametric and nonparamet-
ric tests, and approaches from machine learning and from statistics. In this thesis, the focus
is on genetic association analyses and hence on statistical methods that have been proposed
therefore. Some of the proposed methods are based on SMTs and some on MMTs, and an
overview about traditional and recently proposed methods for genetic association studies is
given in the following in sections 2.2.2.1 (methods for joint models of multiple phenotypes)
and 2.2.2.2 (methods to infer direct genetic effects incorporating multiple phenotypes). Many
of these methods can be extended to the analysis of multi-level omics data (e.g., including
genomic, transcriptomic, epigenomic, proteomic, metabolomic, and/or phenomic data), how-
ever, the analysis of such data has also brought forward specialized methods which have been
summarized in, for example, Ritchie et al. (2015), Kristensen et al. (2014), and Gomez-
Cabrero et al. (2014). Such methods often contain a larger focus on efficient implementation
and exploratory analyses in contrast to a more detailed focus on specific statistical models
and their interpretation such as in this thesis. Also, most of them focus on integrating mul-
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tiple sets of predictors to predict one outcome rather than predicting multiple phenotypes,
and are not further discussed here.
2.2.2.1 Genetic association analysis using joint models of multiple phenotypes
For genetic association analyses incorporating multiple phenotypes, most commonly, methods
based on multivariate regression models, dimension reduction methods, or methods combining
results from univariate analyses are employed. First, regarding regression-based approaches,
multivariate analysis of variance (MANOVA), multivariate generalized linear mixed effects
models (GLMMs), frailty models, or generalized estimating equation (GEE) models can be
used to predict the effect of one or more genetic predictors on multiple phenotypes. In
another approach, O’Reilly et al. (2012) proposed to invert the typical regression approach
and to regress genetic markers on multiple phenotypes (”MultiPhen”) for an SMT by using
ordinal or multiple logistic regression approaches. Second, classical dimension reduction
methods include principal component analysis and factor analysis (Pearson, 1901; Hotelling,
1933; Jolliffe, 2002; Bartholomew et al., 2011), structural equation modeling (SEM; Bollen,
1989) and canonical correlation analysis (CCA; Hotelling, 1936), which all allow extracting
latent features from genotypes and from phenotypes and associating them. More specialized
approaches targeting the explained variance by genetic variants have been developed in the
form of principal component of heritability (PCH; Ott & Rabinovitz, 1999) and further
extensions. An overview of methods from these two categories can also be found in Schillert
& Konigorski (2016). Third, methods combining results from univariate analyses generally
derive the distribution of a weighted linear combination of univariate test statistics to test
the joint effect on multiple phenotypes. Proposed approaches include the O’Brien method
(O’Brien, 1984) and methods described in Xu et al. (2003b), Zhang (2005) or Pan (2009).
Instead of combining test statistics, TATES (van der Sluis et al., 2013) combines p-values
from testing the association with multiple traits and derives a p-value for testing the joint
association with all traits by correcting for the dependence between traits. In addition to
this non-exhaustive list, many further approaches and extensions have been proposed. An
overview about applications of machine learning approaches to learn associations between
genetic markers and (multiple) phenotypes is given in Szymczak et al. (2009), and examples
of Bayesian methods for association studies with multiple phenotypes can be found in Bottolo
et al. (2013), Xu et al. (2014) and Jiang et al. (2015), but they are not further described
here.
Overviews and reviews about the different approaches are given in Yang & Wang (2012)
and Shriner (2016), and comparisons through simulation studies can be found in Galesloot
et al. (2014), Zhang et al. (2014), Zhu et al. (2015) or Liang et al. (2016). The comparisons
indicate that there is not one uniformly optimal test and that under different scenarios, dif-
ferent tests have the highest power. One major difference between the different approaches
is whether they perform a multiple degree-of-freedom (df) test to evaluate the overall genetic
association with all traits, or whether they perform single-df tests testing the genetic associa-
tion with each trait separately. While multi-df tests generally have the highest power when a
genetic variant affects all tested traits, they provide less or no information on which traits are
relevant, and they loose power when only one or a few traits are affected. Further differences
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include whether the approaches are able to model different dependence structures and trait
distributions, and whether the dependences are rather treated as nuisance or as additional
information.
In general, all of the above methods can be applied to association analyses of rare variants
as well, however, the performance and validity of many approaches have not been described.
Specialized rare-variant tests incorporating multiple phenotypes have been proposed in MU-
RAT (Sun et al., 2016a, 2016b) and the multivariate aSPU and aSPUset tests (Zhang et
al., 2014; Kim et al., 2016). MURAT is a multivariate extension of SKAT (Wu et al., 2011)
yielding a gene-based MMT. aSPU and aSPUset are multivariate extensions of the univariate
aSPU test described in Pan et al. (2014, 2015), which is an adaptive test combining different
powered score tests. aSPU performs a multivariate SMT for each marker, aSPUset performs
a MMT of all markers in a gene with a variation to additionally include a GEE Score test
in the derived test statistic (”aSPUset-Score”). The different tests contained in the class of
powered score tests have great similarity or encompass the CCA and MANOVA tests, which
are in turn similar to MultiPhen, TATES, and other tests (Zhang et al., 2014). These tests
are considered in the evaluation of C-JAMP in section 4.2. Other tests have been recently
proposed in, for example, Broadaway et al. (2016), Liang et al. (2016), Wang et al. (2016)
and Kaakinen et al. (2017), but are not further considered in this thesis.
2.2.2.2 Models to infer direct and indirect genetic effects
In addition to the methods described above, which mainly focus on overall genetic effects
on multiple phenotypes, another class of approaches has been developed for the estimation
and testing of direct genetic effects. For some background regarding their importance, as
mentioned above, many genetic associations have been identified, for example, with obesity
traits and type 2 diabetes (Fuchsberger et al., 2016; Locke et al., 2015). Some of these genetic
markers are associated with multiple anthropometric traits (Ried et al., 2016), anthropometric
and metabolic traits (Pickrell et al., 2016), and birthweight and type 2 diabetes (Zeng et al.,
2017). However, it is unknown if these studies, and association studies in general, truly
show evidence of functional genetic effects (e.g., through genetically-determined circulating
biomarkers on type 2 diabetes, Lotta et al., 2016, or coronary artery disease, Helgadottir et
al., 2016), of pleiotropic genetic effects on multiple phenotypes, or if the observed associations
are due to indirect effects through some other intermediate phenotypes. Also, the genetic
effects might be mediated or confounded by regulatory factors such as epigenetic markers
(Feil & Fraga, 2012; Relton & Davey Smith, 2012a, 2012b; Corradin et al., 2016). As an
example, Vansteelandt and colleagues (2009) showed that the effect estimate of a previously
found association between a genetic marker and lung function was biased and could not be
confirmed when the indirect effect of the genetic marker through weight was removed. For
an example regarding BP, the association of genetic markers might be partially mediated by
intermediate phenotypes such as, for example, gene expression (Huan et al., 2015a, 2015b).
In addition to falsely identified markers, the direct genetic effects can also be masked in
traditional statistical methods when there are indirect effects or confounded indirect effects
in opposing direction of the direct effect. This background highlights the importance of using
appropriate statistical methods that help disentangling direct and indirect genetic effects -
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or more general molecular effects - through intermediate phenotypes, and if possible with
robustness against effects of measured and unmeasured confounding factors.
For an overview of different statistical approaches, consider the situation of one genetic
marker, one primary phenotype, one or more intermediate phenotypes and additional factors.
Two traditional methods are (i) to include the genetic marker, intermediate phenotypes and
factors as covariates in a multiple regression model of the primary phenotype, or (ii) to first
regress the primary phenotype on the intermediate phenotypes and factors, and then regress
the extracted residuals on the genetic marker (regression of residuals). The two approaches
are frequently used for the analysis of primary phenotypes that are continuous (using a linear
regression model; LM), and the multiple regression approach is frequently used for the analysis
of binary or categorical primary phenotypes (using generalized linear regression models),
or potentially censored time-to-event primary phenotypes (using, for example, proportional
hazards (PH) or accelerated failure time (AFT) regression models). However, both traditional
approaches can lead to biased point estimates and invalid testing of direct genetic effects on
the primary phenotype in some situations, by removing part of the true association or by
failing to remove the effect of the intermediate phenotype (i.e., of the indirect genetic effect)
or unmeasured confounders (Rosenbaum, 1984; Cole & Herna´n, 2002; Goetgeluk et al., 2008;
Vansteelandt et al., 2009).
More elaborate approaches have been proposed to overcome these limitations, including
the SEM method described in the previous section. Further approaches have been devel-
oped in studies on causal inference using structural nested models and G-estimation methods
(Robins, 1986, 1992; Robins & Greenland, 1994; Goetgeluk et al., 2008), or the inverse prob-
ability weighting method (Robins et al., 2000). A more detailed overview of these different
approaches can be found in Vansteelandt & Joffe (2014). Applications of the sequential
G-estimation method to DAGs for estimating and testing direct genetic effects have been
described for quantitative (Vansteelandt et al., 2009) and time-to-event primary phenotypes
(using PH and AFT regression models, Lipman et al., 2011, and Aalen additive hazard
models, Martinussen et al., 2011). These approaches include two steps: first, an adjusted
phenotype is obtained by removing the effect of the intermediate phenotype from the pri-
mary phenotype. Then, the association of the genetic marker with the adjusted phenotype is
tested by accounting for the additional variability obtained due to the estimation in the first
stage in addition to the second stage (see section 3.2.1.1 for a formal description). Large-
sample results of the estimator are provided for the analysis of Aalen additive hazard models
in Martinussen et al. (2011). However, the focus of the sequential G-estimation methods for
linear quantitative and log-linear time-to-event primary phenotype models was on testing the
absence of direct genetic effects, and the standard errors and confidence intervals of the direct
genetic effects were not investigated. Finally, the extension of the sequential G-estimation
method described for time-to-event primary phenotypes using the PH and AFT regression
models (Lipman et al., 2011) is invalid as will be shown in sections 4.3 and A.4.3.
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2.3 Computational aspects
For measuring genetic data for the analysis, different technologies are available to provide
in-depth information on a base-pair resolution, and sequencing technologies are currently
a popular choice. In the bioinformatics processing steps, it is important that efficient and
robust pipelines are used to extract, process and filter, quality-control and transform the
relevant information from the raw data to the final datasets for the main analysis. For this,
many different software tools and workflows are available for each processing step including
the preprocessing, mapping to the reference genome, post-alignment processing and variant
calling for whole-genome or whole-exome DNA-sequencing, and preprocessing, transcriptome
assembly construction (if necessary) and read alignment, post-alignment processing and ex-
pression quantification for RNA-Seq analysis, followed by respective quality control and data
analysis tools. Overviews and reviews are given in, for example, Bao et al. (2014), Pirooznia
et al. (2014) and Hwang et al. (2015) for variant calling and DNA-sequencing, and Yang
& Kim (2015), Conesa et al. (2016) and Everaert et al. (2017) for RNA-sequencing. Here,
in the data analysis in section 5.2, the Tophat-HTSeq pipeline is used for read mapping and
gene expression quantification, and samtools (Li et al., 2009; Li, 2011) is used for variant
calling.
In the analysis of the generated high-dimensional genotype-phenotype data, whether a
statistical method can be used depends on an efficient and robust implementation. Separate
analyses of each genetic marker with each phenotype have a very low computational complex-
ity and can be easily parallelized. In a joint modeling of a large number of genetic markers
and phenotypes, one high-dimensional model has to be fitted. Here, efficient reformulations
of the statistical model (e.g., for GLMMs, Lippert et al., 2011), approximations (Listgarten
et al., 2012; Mandt et al., 2017) or a parallelization of the computation can help to scale
the approach with the number of analyzed individuals (e.g., from cubic or square scaling to
linear scaling; Lippert et al., 2011) and make it applicable for the analysis. As further help
to reduce the computational and statistical testing burden, biological restrictions can be im-
posed on the analysis through prespecified assumptions regarding the relationships between
phenotypes and SNVs. For example, the search for expression quantitative trait loci (eQTL)
can be restricted to cis-acting loci (Konigorski et al., 2016).
For the two proposed methods in this thesis, parameter and standard error estimates
for C-JAMP are obtained using the quasi-Newton, variable metric BFGS (Broyden-Fletcher-
Goldfarb-Shanno; Gentle, 2009) method and from the inverse Fisher information matrix. For
CIEE, the efficient least squares (LS) estimation and derived closed-form solutions are used.
Since Wald tests are employed for hypothesis testing of the parameter estimates, there are
no further computational costs. Both approaches are employed as single-marker tests so that
they can be easily parallelized and in all analyses reported in this thesis, the separate analysis
of all SNVs was spread over up to 500 cores at the Max Delbru¨ck Center (MDC) computing
cluster. This allowed to obtain all results of the data applications and simulation studies.
Especially in the simulation studies, hundreds of millions of replicates had to be analyzed in
order to obtain empirical type I error and power estimates under all scenarios, which led to
a high computational burden with computations taking more than 300 computing years.
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Developed statistical methods
3.1 C-JAMP: Copula-based joint analysis of multiple pheno-
types
The general goal of C-JAMP (copula-based modeling of multiple traits of a phenotype) is to
jointly model two (or more) traits of a phenotype conditional on a genetic marker of interest
using copula functions, in order to estimate and test the association of the marker with either
trait. Here, the underlying argument is that through the joint modeling of multiple traits, the
power of the association test with a given trait can be increased by using the information from
the genetic association with the other traits and their dependence to increase the efficiency
of the estimation.
For an intuition about the potential power increase when analyzing two traits jointly
instead of one trait, consider the following simple scenario with two normally-distributed
traits Y1, Y2 and a genetic marker X. Based on a simple linear regression model,
Y1 = α0 + αXY x+ ε, ε ∼ N(0, σ2),
the null hypothesis H0 : αXY = 0 vs. HA : αXY ̸= 0 can be tested using the Wald-type test
statistic W = αˆXY
SˆE(αˆXY )
with SˆE(αˆXY ) =
√
1
n−2 ·
∑
εˆ2i∑
(xi−x¯)2 . In a joint model of Y1 and Y2
given x, an upper bound to the power can be thought of as doubling the sample size, hence
appending Y1 with the second trait Y2 and similarly appending the predictor values x with x.
Then, the standard error estimate of αˆXY would be SˆE(αˆXY ) =
√
1
2n−2 ·
∑
εˆ2i∑
(xi−x¯)2 . Hence,
in the joint model, the standard error could be maximally decreased by about
√
1/2 (i.e.,
≈ 30% smaller). In general, for a joint modeling of p traits, the upper bound on the standard
error decrease is therefore of the order
√
1/p.
3.1.1 Statistical details
In the following, copula functions and C-JAMP will be described in more detail. Copulas
are functions used to construct a joint distribution by combining the marginal distributions
with a dependence structure (Joe, 1997; Nelsen, 2006). In contrast to multivariate normal
models, which model the linear dependence of two random variables coming from a bivariate
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normal distribution with a certain Pearson’s correlation, more general dependencies can be
flexibly investigated using copula functions. This can be helpful when the conditional mean
of Y1 given Y2 is not linear in Y2. In addition, transformations of Y1 and Y2 can change the
value of Pearson’s correlation but copulas based on a nonparametric correlation measure are
invariant under strictly increasing transformations of the margins. Additional properties of
copula models are that they allow the investigation of the dependence structure between the
phenotypes separately from the marginal distributions. Also, the marginal distributions can
come from different families and not necessarily from the normal distribution. Copula models
can then be used to make inference about the marginal parameters and to identify genetic
markers associated with one or multiple phenotypes, which will be the main aim explored
here. They can also be used to make inference about the copula dependence parameters,
for example, for an alternative definition of pleiotropy and to identify genetic variants that
explain the dependence between two phenotypes (Konigorski et al., 2014). More formally:
Definition 3.1.1 (Copula). A p-dimensional copula is defined as a function C : [0, 1]p →
[0, 1] which is a joint cumulative distribution function with uniform marginal cumulative
distribution functions.
Hence, C is the distribution of a multivariate random vector, and can be considered
independent of the margins. For Y1, . . . , Yp and a covariate vector z, the joint distribution F
of Y1, . . . , Yp, conditional on z, can be constructed by combining the marginal distributions
of Y1, . . . , Yp, F1, . . . , Fp, conditional on z, using a copula function Cψ with dependence
parameter(s) ψ:
F (Y1, . . . , Yp|z) = Cψ(F1(Y1|z), . . . , Fp(Yp|z)). (3.1.1)
For continuous marginal distributions, the copula Cψ is unique and the multivariate distri-
bution can be constructed from the margins in a uniquely defined way (Sklar, 1959):
Theorem 3.1.2 (Sklar, 1959). Let F be a p-dimensional distribution function with univariate
margins F1, . . . , Fp. Then, there exists a copula Cψ such that for all z = (z1, . . . , zp)
T ∈ Rp,
F (z1, . . . , zp) = Cψ(F1(z1), . . . , Fp(zp)). Cψ is uniquely determined on the joint range of all
Fl, i.e. on F1(R)× · · · × Fp(R). Hence, it is unique if F1, . . . , Fp are continuous.
The following theorem implies the converse, which is used in the construction of multi-
variate distributions:
Theorem 3.1.3. Let F1, . . . , Fp be univariate distribution functions and Cψ a p-dimensional
copula function. Then, F : Rp → [0, 1] defined through F (z1, . . . , zp) = Cψ(F1(z1), . . . , Fp(zp))
is a p-dimensional distribution function with margins F1, . . . , Fp.
There exist several proofs of Theorem 3.1.2 using different approaches, for example in
Schweizer & Sklar (1974) and Carley & Taylor (2002) for 2-dimensional copulas. Proofs for
the general p-dimensional case, also covering the case when one or more margins are discrete,
can be found in Burchard & Hajaiej (2006) and Ru¨schendorf (2009). While a detailed proof
is not within the scope of this thesis, some intuition can be gained for the case of continuous
margins, where Cψ can be determined as Cψ = F
(
F
[−1]
1 (z1), . . . , F
[−1]
p (zp)
)
for all z ∈ (0, 1)p
with F
[−1]
l being the quasi-inverse of Fl, F
[−1]
l (t) := inf(z : Fl(z) ≥ t).
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Popular copula functions include the Clayton family (Clayton, 1978)
Cϕ(u1, . . . , up, ϕ) =
((
p∑
l=1
u−ϕl
)
− (p− 1)
)−1/ϕ
(3.1.2)
with ϕ > 0, and the Gumbel-Hougaard family (Gumbel, 1960)
Cθ(u1, . . . , up, θ) = exp
⎛⎝−[ p∑
l=1
(− log(ul))θ
]1/θ⎞⎠ (3.1.3)
with θ > 1. A third family which includes both (3.1.2) and (3.1.3) for θ = 1 and ϕ → 0 is
the 2-parameter copula family
Cψ(u1, . . . , up, ϕ, θ) =
⎛⎝[ p∑
l=1
(
u−ϕl − 1
)θ]1/θ
+ 1
⎞⎠−1/ϕ (3.1.4)
with 0 ≤ ul, ul′ ≤ 1, and the copula parameters ψ = (ϕ, θ)T , ϕ > 0, θ ≥ 1, which allows a
flexible modeling of both the lower- and upper-tail dependence. All three above families are
examples of Archimedean copulas (Genest & Rivest, 1993), which are defined as follows.
Definition 3.1.4 (Archimedean copula). Let ξψ be a decreasing convex function on the unit
interval with ξψ(1) = 0. A copula Cψ is called Archimedean, if it can be represented as
Cψ(u1, . . . , up, ψ) = ξ
−1
ψ (ξψ(u1) + · · ·+ ξψ(up)). (3.1.5)
For an investigation of the dependence between the traits, different dependence measures
can be derived from the copula parameters. In the description and evaluation of C-JAMP,
Kendall’s τ is used as measure of dependence, which is the probability of concordance minus
the probability of discordance. For the copula family in (3.1.4), it can be derived as (Joe,
1997)
τ = 1− 2
θ(ϕ+ 2)
. (3.1.6)
A visual illustration of the different dependence structures captured by the Clayton copula
is shown in Figure 3.1.
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Figure 3.1: Scatterplots of bivariate data (Y1 and Y2) from Clayton’s copula with dependence Kendall’s
τ = 0.2, 0.5, 0.8 and standard normal margins.
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Additional dependence parameters of interest can be the lower and upper tail dependence
(λL, λU , respectively), which explain the amount of dependence between extreme values, and
can give more insight in identifying pleiotropic variants. For the copula family in (3.1.4),
these dependence measures are (Joe, 1997)
λL = 2
− 1
θϕ , λU = 2− 2 1θ .
In the following, C-JAMP is presented for the analysis of two quantitative, normally-distributed
traits Y1 and Y2, which are modeled conditional on a covariate vector z = (z1, z2, x)
T including
one genetic marker X and covariates Z1 and Z2. As marginals, linear models are considered:
Y1 = α0 + α1z1 + α2z2 + αXY x+ ε, (3.1.7)
Y2 = β0 + β1z1 + β2z2 + βXY x+ ε
′, (3.1.8)
with the parameter vectors α = (α0, α1, α2, αXY )
T , β = (β0, β1, β2, βXY )
T and ε ∼ N(0, σ21),
ε′ ∼ N(0, σ22), under the assumption that the covariates are mutually independent. The
fact that the parameters measuring the dependence between Y1 and Y2 do not appear in the
marginal distributions is very useful for estimating the effect of a genetic marker X on Y1 or
Y2 while considering the dependence between Y1 and Y2.
Focusing on fully parametric models, maximum likelihood estimates (MLEs) ωˆ of the pa-
rameter vector ω = (ψ,α,β, σ1, σ2)
T can be obtained by maximizing the likelihood function
of the data in (3.1.9), which is derived in Lemma 3.1.5 for the 2-parameter copula and used
in the implementation of C-JAMP. Alternatively, two-stage pseudo-likelihood methods could
be used (Shih & Louis, 1995; Joe, 1997).
L (ω) =
n∏
i=1
[
∂2F (y1i, y2i|z1i, z2i, xi)
∂y1i∂y2i
]
=
n∏
i=1
[
∂2Cψ (F1 (y1i|z1i, z2i, xi) , F2 (y2i|z1i, z2i, xi))
∂y1i∂y2i
]
=
n∏
i=1
[
∂2Cψ (F1 (y1i|z1i, z2i, xi) , F2 (y2i|z1i, z2i, xi))
∂F1 (y1i|z1i, z2i, xi) ∂F2 (y2i|z1i, z2i, xi)
]
(3.1.9)
×
[
∂F1 (y1i|z1i, z2i, xi)
∂y1i
]
×
[
∂F2 (y2i|z1i, z2i, xi)
∂y2i
]
.
Lemma 3.1.5. Consider the 2-parameter copula function in (3.1.4) with marginal models in
(3.1.7), (3.1.8). Then, the likelihood can be derived as
L (ω) =
n∏
i=1
f1f2F1
−ϕ−1F2−ϕ−1
[
F1
−ϕ − 1]θ−1[F2−ϕ − 1]θ−1[((F1−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−2
·
[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−2 · ((1 + ϕθ) [(F1−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ + (θ − 1)ϕ)
with f1 =
1
σ1
φ
(
y1i−α0−α1z1i−α2z2i−αXY xi
σ1
)
, f2 =
1
σ2
φ
(
y2i−β0−β1z1i−β2z2i−βXY xi
σ2
)
, as well as
F1 = Φ
(
y1i−α0−α1z1i−α2z2i−αXY xi
σ1
)
and F2 = Φ
(
y2i−β0−β1z1i−β2z2i−βXY xi
σ2
)
, where φ is the
standard normal probability density function (PDF) and Φ is the standard normal cumulative
distribution function (CDF).
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Proof Lemma 3.1.5:
L (ω) =
n∏
i=1
∂2
{[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ + 1}− 1ϕ
∂F1∂F2
· f1 · f2
=
n∏
i=1
∂
⎧⎨⎩
[((
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−1[(F1−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−1[F1−ϕ − 1]θ−1 [F1−ϕ−1]
⎫⎬⎭
∂F2
· f1 · f2
=
n∏
i=1
f1f2
[
F1
−ϕ − 1]θ−1F1−ϕ−1
⎛⎜⎜⎜⎜⎜⎝
⎧⎪⎪⎪⎨⎪⎪⎪⎩
∂
⎧⎨⎩
[((
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−1
⎫⎬⎭
∂F2
[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−1
⎫⎪⎪⎪⎬⎪⎪⎪⎭
+
⎧⎪⎨⎪⎩
[((
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−1 ∂
[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−1
∂F2
⎫⎪⎬⎪⎭
⎞⎟⎟⎟⎟⎟⎠
=
n∏
i=1
f1f2
[
F1
−ϕ − 1]θ−1F1−ϕ−1
⎛⎜⎜⎝
⎧⎨⎩
{
(1 + ϕ)
[((
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−2[(F1−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−1
· [F2−ϕ − 1]θ−1 [F2−ϕ−1]} · [(F1−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−1
⎫⎬⎭+
⎧⎨⎩
[((
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−1
·
{
(θ − 1)ϕ ·
[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−2[F2−ϕ − 1]θ−1 [F2−ϕ−1]}
⎫⎬⎭
⎞⎟⎟⎠
=
n∏
i=1
f1f2F1
−ϕ−1F2−ϕ−1
[
F1
−ϕ − 1]θ−1[F2−ϕ − 1]θ−1[((F1−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−2
·
[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−2 ·
⎛⎜⎜⎝{(1 + ϕ) [(F1−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ}
+
{
(θ − 1)ϕ
[((
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]}
⎞⎟⎟⎠
=
n∏
i=1
f1f2F1
−ϕ−1F2−ϕ−1
[
F1
−ϕ − 1]θ−1[F2−ϕ − 1]θ−1[((F1−ϕ − 1)θ + (F2−ϕ − 1)θ) 1θ + 1]− 1ϕ−2
·
[(
F1
−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ−2 · ((1 + ϕθ) [(F1−ϕ − 1)θ + (F2−ϕ − 1)θ] 1θ + (θ − 1)ϕ) .
Under some regularity conditions and the assumption that the model is correct, the MLEs
ωˆ are consistent estimates of ω and
√
n (ωˆ − ω) d→ MVN(0, I−1(ω)) in distribution, where
I(ω) is the Fisher information matrix I(ω) = E
[
−∂2logL(ω)
∂ω∂ωT
]
. Therefore, variance estimates
for the MLEs ωˆ = (ψˆ, αˆ, βˆ, σˆ1, σˆ2) in (3.1.9) can be obtained from the inverse of the observed
information matrix using the Delta method, if necessary.
More specifically, in the implementation in R described in section 3.1.2, C-JAMP is de-
scribed for the Clayton and 2-parameter copula models with normal marginal models, and
parameter estimates are derived for log(ϕ), log(θ − 1), log(σ1), log(σ2) and α,β. Hence, the
variance estimates from the Fisher information matrix are for these transformed parameters
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and can be retransformed using the Delta method. For example, for the 2-parameter copula in
(3.1.4) and the normal marginal models in (3.1.7)-(3.1.8) including the predictors Z1, Z2, X,
the standard error estimates of the MLEs ωˆ = (ϕˆ, θˆ, αˆ0, αˆ1, αˆ2, αˆXY , βˆ0, βˆ1, βˆ2, βˆXY , σˆ1, σˆ2)
are:
SˆE(ϕˆ) =
√
[I−1(ω)]1,1 · ϕˆ2,
SˆE(θˆ) =
√
[I−1(ω)]2,2 · (θˆ − 1)2,
SˆE(αˆ0) =
√
[I−1(ω)]3,3, SˆE(αˆ1) =
√
[I−1(ω)]4,4,
SˆE(αˆ2) =
√
[I−1(ω)]5,5, SˆE(αˆXY ) =
√
[I−1(ω)]6,6,
SˆE(βˆ0) =
√
[I−1(ω)]7,7, SˆE(βˆ1) =
√
[I−1(ω)]8,8,
SˆE(βˆ2) =
√
[I−1(ω)]9,9, SˆE(βˆXY ) =
√
[I−1(ω)]10,10,
SˆE(σˆ1) =
√
[I−1(ω)]11,11 · σˆ21, SˆE(σˆ2) =
√
[I−1(ω)]12,12 · σˆ22,
where [I−1(ω)]i,j indicates the (i, j)-th element of the inverse Fisher information matrix.
To test whether the genetic marker X is associated with Y1 and Y2, large-sample methods
based on the likelihood function can be used. In this thesis, it is proposed to test the null
hypotheses H0 : αXY = 0 (vs. HA : αXY ̸= 0) and H0 : βXY = 0 (vs. HA : βXY ̸= 0),
respectively, by using the large-sample Wald-type test statistics αˆXY
SˆE(αˆXY )
and βˆXY
SˆE(βˆXY )
.
Finally, for testing goodness-of-fit of the copulas, the embedding the proposed copulas in
an expanded family of copulas can be used. For example, to test the fit of copula models
(3.1.2) and (3.1.3) (i.e., H0 : θ = 1 and H0 : ϕ→ 0), the likelihood ratio test (LRT) statistic
logLR = 2 ·
(
L(αˆ, βˆ, ψˆ)− L(αˆ(ψ0), βˆ(ψ0), ψˆ0)
)
(3.1.10)
can be used, where ψˆ = (ϕˆ, θˆ) and ψˆ0 = (ϕˆ(θ = 1), 1) when testing the Clayton copula, or
ψˆ0 = (0, θˆ(ϕ = 0)) when testing the G-H copula. Here, αˆ(ψ0) and βˆ(ψ0) are the maximum
likelihood estimates (MLEs) of α and β under the null model ψ = ψ0. Evaluating the
likelihood ratio statistic (3.1.10) means testing parameters on the boundary of the parameter
space where the usual chi-square approximation is inaccurate. However, it has been shown
that (3.1.10) is asymptotically distributed as 0.5 + 0.5χ2(1) under the null hypothesis ψ = ψ0
and under the assumption that other free parameter in ψ0 don’t lie on the boundary of the
parameter space (Self & Liang, 1987).
3.1.2 Computational details & implementation
C-JAMP is implemented in the R package CJAMP for the joint analysis of two phenotypes
Y1 and Y2 conditional of one or more predictors z with linear marginal models in (3.1.7),
(3.1.8), for the Clayton and 2-parameter copula. CJAMP is currently available upon request
as a bundled package. It can be installed through the zipped tar file with
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install.packages("pathtofile/CJAMP_0.1.0.tar.gz", repos = NULL)
and then loaded with
library(CJAMP)
CJAMP was generated using RStudio Version 1.0.143 based on R version 3.4.1 (R Core
Team, 2017) using the devtools package (Wickham & Chang, 2017). The documentation of
the functions and generation of help pages was done using the roxygen2 package (Wickham
et al., 2017). Finally, knitr (Xie, 2017) and rmarkdown (Allaire et al., 2017) were used for
the detailed long-form documentation (vignette), which is available through
browseVignettes("CJAMP")
More details for each function can be obtained through the regular help files, for example,
?cjamp
In the following, an outline of the implementation is given, as well as details regarding
the application to genome-wide analyses. Examples for the use of the R functions are shown
in the appendix in section A.7.1.
3.1.2.1 Data generation functions
Data Y1, Y2 can be sampled from the Clayton copula (with standard normal margins) using
the generate_clayton_copula() function. This uses the steps described in Box 3.1 to
generate Y1, Y2 from the Clayton copula Cϕ(Φ(Y1),Φ(Y2)) = Cϕ(U1, U2) with standard normal
marginal distributions, where Φ is the standard normal cumulative distribution function:
1. Generate uniform random variables U1, U˜2 ∼ Unif(0, 1).
2. Generate Y1 from the inverse standard normal distribution of U1, Y1 := Φ
−1(U1).
3. In order to obtain the second variable Y2, use the conditional distribution of U2
given U1, set U˜2 =
∂Cϕ(U1,U2)
∂U1
and solve for U2. This yields
U2 =
(
1− U−φ1 ·
(
1− U˜−φ/(1+φ)2
))−1/φ
.
4. Generate Y2 from the inverse standard normal distribution of U2, Y2 := Φ
−1(U2).
Box 3.1: Steps to generate data from the Clayton copula.
In order to generate sample data including SNVs and covariates, different functions are
provided. The functions generate_singleton_data(), generate_doubleton_data() and
generate_genodata() can be used to generate genetic data in the form of single nucleotide
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variants. generate_singleton_data() generates singletons (i.e., SNVs with one observed
minor allele); generate_doubleton_data() generates doubletons (i.e., SNVs with two ob-
served minor alleles), and generate_genodata() generates n observations of k SNVs with
random minor allele frequencies. The minor allele frequencies of the generated SNVs can be
calculated using the function compute_MAF().
Next, the functions generate_phenodata_1_simple(), generate_phenodata_1(), as
well as generate_phenodata_2_bvn() and generate_phenodata_2_copula() can be used
to generate phenotype data based on input SNVs, covariates, and a specification of the co-
variate effect sizes. Here, generate_phenodata_1_simple() and generate_phenodata_1()
generate one normally-distributed or binary phenotype Y conditional on input SNVs and
covariates X1, X2. generate_phenodata_2_bvn() and generate_phenodata_2_copula()
generate two phenotypes Y1, Y2 with dependence Kendall’s τ conditional on the SNVs and
covariates X1, X2 from the bivariate normal distribution or the Clayton copula function
with standard normal marginal distributions. generate_phenodata_2_copula() is using
the function generate_clayton_copula() described above.
For genetic association analyses, the amount of phenotypic variance that can be explained
by the SNVs might be of interest. This can be computed based on four different approaches
using the function compute_expl_var() (see the help pages of the function for more details).
3.1.2.2 C-JAMP functions
C-JAMP is implemented for the joint analysis of two phenotypes Y1, Y2 conditional on one
or more predictors z. Functions are available to fit the joint model
F (Y1, Y2|z) = Cψ(F1(Y1|z), F2(Y2|z))
for the Clayton and 2-parameter copula Cψ, with marginal models
Y1 = α
Tz + ε1, ε1 ∼ N(0, σ21)
Y2 = β
Tz + ε2, ε2 ∼ N(0, σ22).
Na¨ıve coefficient estimates of the parameter vector ω = (ψ,α,β, σ1, σ2)
T can be obtained
using the get_estimates_naive() function, which fits separate linear regression models of
Y1 and Y2. For these or any other parameter estimates, the log-likelihood (or rather the minus
log-likelihood) of the copula model can be computed with the function minusloglik() for the
Clayton and 2-parameter copula. minusloglik() (and the cjamp(), cjamp_loop() functions
below) use an additive model, which means that if categorical predictors are to be analyzed
with more than 2 levels, then dummy variables have to be created beforehand. Accordingly,
if single nucleotide variants (SNVs) are included as predictors, the computation is based on
an additive genetic model if SNVs are provided as 0-1-2 genotypes and on a dominant model
if SNVs are provided as 0-1 genotypes.
The lrt_copula() can be used to test the model fit of different nested copula models
with the same marginal models using likelihood ratio tests. To test the fit of the 1-parameter
Clayton copula model fit versus the 2-parameter copula (i.e., H0 : φ → 0), the likelihood
ratio test statistic in (3.1.10) is used with ψˆ0 = (ϕˆ(θ = 1), 1). P-values are obtained by using
that logLR is asymptotically distributed as 0.5 + 0.5χ21 under the null hypothesis ψ = ψ0
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and under the assumption that other free parameters in ψ0 don’t lie on the boundary of the
parameter space (Self & Liang, 1987). Likelihood ratio tests of marginal parameters within
the same copula model can be performed using the lrt_param() function.
Finally, the function cjamp() can be used to obtain MLEs of ω, standard error estimates,
and perform hypothesis tests of the parameters, for the Clayton or 2-parameter copula. For
maximizing the nonlinear log-likelihood function (i.e., minimizing minusloglik()), cjamp()
uses the optimx() function of the optimx package. The parameters SE_est and pval_est
allow to control whether standard error estimates are obtained from the observed inverse
information matrix extracted from the optimization, and whether large-sample Wald-type
hypothesis tests are performed to test the absence of the marginal genetic effects on both
traits (i.e., H0 : αXY = 0 and H0 : βXY = 0), as well as of the other marginal effects on each
phenotype. Multiple predictors can be supplied, and if the goal is to test a large number
of predictors sequentially with the same marginal models (such as in genetic association
studies), the function cjamp_loop() provides an easy wrapper of the cjamp() function and
only extracts the coefficient and standard error estimates as well as the p-values for the
predictors of interest, and not for all other covariates. Both cjamp() and cjamp_loop()
return cjamp objects as output, so that the written summary.cjamp() function can be used
through the generic summary() to provide a reader-friendly output of the results.
For more technical details, preliminary investigations showed that the fastest and most
robust convergence was achieved using the BFGS optimization method among the different
available optimization algorithms, which is hence recommended. Different starting values on
a grid are automatically tried in cjamp(), and the maximum number of tries can be con-
trolled through the parameter n_iter_max. Some technical steps involve the multiplication
of the second trait with −1 if the dependence between Y1 and Y2 is negative (since both the
Clayton and 2-parameter copula can only fit positive dependencies), noted with a warning
in the output for the interpretation. Furthermore, the parameter scale_var can be used to
automatically scale all predictors. This is recommended, since the BFGS optimization can
be sensitive to a different scaling of the predictors, which can result in a non-convergence of
the optimization. In order to deal with convergence problems, several checks are built into
cjamp(), such as checking the finiteness of the likelihood function as well as whether the
optim convergence code indicates convergence and the Karush-Kuhn-Tucker (KKT) condi-
tions are both satisfied. If any condition is not satisfied, the optimization is restarted with
the next starting value until convergence or until the maximum number of n_iter_max is
reached. In the latter case, standard errors and p-values are not computed.
3.1.2.3 C-JAMP application details
The multiple robustness checks and optimization attempts using different starting values
increase the running time of cjamp(), but are necessary if the function is to be applied for
a genome-wide association analysis - since in this case, manual checks are not possible. For
GWAS, C-JAMP can be applied by either sequentially computing cjamp() on all SNVs of
interest, or by supplying a matrix of multiple SNVs to the cjamp_loop() function. The
running time of cjamp() increases with the number of covariates and the sample size, which
is visualized in Figure 3.2. As can be expected, computing C-JAMP based on the 2-parameter
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copula takes longer than based on the Clayton copula, since one more (dependence) parameter
has to be estimated. As a concrete example, for a sample size of n = 1000, two traits Y1
and Y2, 1 SNV and 5 covariates, C-JAMP takes on average about 1.5 minutes running time
to finish and obtain estimates as well as p-values. This is obviously much slower compared
to univariate regression models, but still sufficient to allow for genome-wide analyses. A
GWAS including 1,000,000 SNVs with a sample size of n = 1000, two traits Y1 and Y2, and
5 covariates can be computed in about 2 days on a cluster using 500 computing cores.
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Figure 3.2: Computation time of C-JAMP. Shown are the mean computation times in seconds (’user
times’ obtained through the R system.time() function) of the cjamp() R function based on 10 runs, for
a SNV with random MAF, using the Clayton or 2-parameter copula with marginal models as in equations
(3.1.7)-(3.1.8) with different numbers of covariates, and data generated under model (4.2.1) with the effect
size cY1 = cY2 = 0.3 of the causal SNV.
Amore detailed illustration of the memory and running time used by the cjamp() function
is shown in Figure 3.3, and highlights again that the computationally expensive part lies in
the optimization.
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Figure 3.3: Detailed computation time and memory use of C-JAMP. Shown are the memory use (in
MB) and computation time (in ms) of each of the steps of the cjamp() R function, computed using
the profvis() function of the profvis R package (Chang & Luraschi, 2017), using the Clayton or 2-
parameter copula with marginal models as in equations (3.1.7)-(3.1.8), and data generated under model
4.2.1 with n = 1000 and the effect size cY1 = cY2 = 0.3 of the causal SNV.
3.2 CIEE: Causal inference using estimating equations
After the investigation of joint models using copula functions in the previous section, the focus
in this section is on the estimation and testing of direct causal effects. For example, a given
SNV might affect the gene expression level of gene s (eQTL) which further affects obesity
traits, but the genetic effect on gene expression is dependent on other factors. Also, post-
transcriptional regulation of the gene expression levels might play a role in their involvement
in obesity. In such situations, while the indirect mediated effects are biologically interesting, a
priori knowledge about the regulation and mediation would be necessary to model them. If the
intermediate and confounding factors are not measured, the genetic effect can be obscured.
If, however, the ”direct” genetic effect (containing all effects on obesity not through gene
expression) is separated from the indirect effects through gene expression, it can be revealed
using the approach described in the following, and might be able to provide hypotheses about
the regulatory mechanisms. In such situations, C-JAMP as well as regression models are often
not able to separate direct and indirect effects, and can result in biased effects of the marginal
parameters.
For a valid estimation and testing of the direct genetic - and generally molecular - effects,
it is important to consider all potential effects between the genetic marker, phenotypes, and
confounding factors. To this aim, under a directed acyclic graph setting, a new method is pro-
posed to estimate and test the direct genetic effect on the primary phenotype. The standard
error of the direct genetic effect estimate is estimated by using the so-called robust Huber-
White sandwich variance estimator. Using unbiased estimation equations allows drawing on
the known asymptotic properties of estimators and test statistics. The proposed approach
called CIEE (causal inference method based on estimating equations) can be applied to dif-
ferent models with different error distributions, and it is presented here for the analysis of
primary phenotypes that are normally-distributed (quantitative) or log-normally distributed
time-to-event traits.
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3.2.1 Statistical details
For disentangling direct and indirect genetic effects through intermediate phenotypes, causal
diagrams (Pearl, 1995) are helpful for visualizing the research setting. Here, the DAG in
Figure 3.4 is considered, which includes the direct effect of a genetic marker X on the primary
phenotype Y and an indirect genetic effect through a secondary phenotype K. The model
further includes measured and unmeasured factors L and U , respectively, which potentially
confound the effect of K on Y . The goal of this study is to estimate and test the direct genetic
effect αXY , while removing the indirect effect of X on Y through K, and with robustness
against effects of L and U . Without restriction of generality, it is assumed that there are no
factors affecting X and that any factors are included as covariates in the analysis or have
been dealt with using other approaches. For genetic effects, such factors are limited to family
structure or population stratification, which can be included by methods described in Price
et al. (2006) or Eu-ahsunthornwattana et al. (2014). For the investigation of other predictors
X than genetic markers, previous knowledge has to be available to justify the assumed model.
In the assumed DAG in Figure 3.4, it is assumed that αLY = 0 so that L is a factor influencing
K. However, CIEE provides also valid inference if L is a measured confounder of K → Y (i.e.,
αLY ̸= 0 and αXL = 0), as will be shown in section 4.3. If both αXL ̸= 0 and αLY ̸= 0, then
the effect of L as intermediate phenotype can be removed from Y in the analysis analogously
to K.
CIEE follows the general idea of the two-stage sequential G-estimation method (Vanstee-
landt et al., 2009), which first removes the effect of intermediate phenotypes from the primary
phenotype, and then tests the genetic association with the adjusted primary phenotype. As
a major difference, CIEE is one-stage and coefficient estimates of all parameters are obtained
simultaneously by solving estimating equations.
For some background, consider observations of the primary phenotype yi, i = 1, . . . , n,
and of covariates z1i, . . . , zdi, i = 1, . . . , n.
Definition 3.2.1 (Estimating function, estimating equation). An estimating function U(ω)
for a (k× 1) parameter vector ω is a (k× 1) vector U(ω) =∑Ui(ω) of real-valued functions
of yi, z1i, . . . , zdi,ω. An estimating equation is an equation U(ω) = 0 based on an estimating
function. It is called unbiased if E[Ui(ω)] = 0.
Estimating equations can be used to obtain an estimate ωˆ of ω. For unbiased (and
some asymptotically unbiased) estimating equations, asymptotic properties of ωˆ have been
established that will be used for the estimation and inference in CIEE.
This also allows obtaining robust sandwich standard error estimates considering the ad-
ditional variability of the estimates from the phenotype adjustment.
3.2.1.1 Analysis of a quantitative primary trait with CIEE
At first, I focus on the analysis of a quantitative, normally-distributed primary phenotype
Y with n independent observations. For this situation, the sequential G-estimation method
(Vansteelandt et al., 2009) is as follows. In the first stage, the effect of K on Y , α1, is
estimated and αˆ1 is obtained using the LS estimation method under the model
Yi = α0 + α1ki + α2xi + α3li + εi, εi ∼ N
(
0, σ21
)
. (3.2.1)
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Figure 3.4: Assumed DAG in the methods description of CIEE. Y is the primary outcome measure of
interest; K is a secondary phenotype; X is the genetic marker of interest and αXY is the direct effect of
interest. It is assumed that αLY = 0 so that L is a measured predictive factor of K, however CIEE is also
valid if L is a measured confounder of K → Y (i.e., αXL = 0). U represents unmeasured factors and
confounders potentially influencing L and Y .
Then, to block all indirect paths of X on the primary phenotype Y , the adjusted pheno-
type Y˜ is obtained by removing the effect of K on Y with
y˜i = yi − y¯ − αˆ1(ki − k¯), (3.2.2)
where y¯ = 1n
n∑
i=1
yi and k¯ =
1
n
n∑
i=1
ki. In the second stage, the significance of the direct effect
of X on Y , αXY , is tested under the model
Y˜i = α4 + αXY xi + ε
′
i, ε
′
i ∼ N
(
0, σ22
)
(3.2.3)
using the proposed test statistic in Vansteelandt and colleagues (2009). Building on this
idea, I propose to formulate unbiased estimating equations U(ω) = 0 are formulated for
a consistent estimation of the unknown parameter vector ω =
(
α0, α1, α2, α3, σ
2
1, α4,
αXY , σ
2
2
)T
, where
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U (ω) =
(
∂l1 (ω)
∂α0
,
∂l1 (ω)
∂α1
,
∂l1 (ω)
∂α2
,
∂l1 (ω)
∂α3
,
∂l1 (ω)
∂σ21
,
∂l2 (ω)
∂α4
,
∂l2 (ω)
∂αXY
,
∂l2 (ω)
∂σ22
)T
(3.2.4)
l1 (ω) =
n∑
i=1
[
− log (σ1) + log
(
φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))]
(3.2.5)
l2 (ω) =
n∑
i=1
[
− log (σ2) + log
(
φ
(
yi − y¯ − α1
(
ki − k¯
)− α4 − αXY xi
σ2
))]
, (3.2.6)
and φ(.) is the PDF of the standard normal distribution. To give an intuition on how these
estimating equations are obtained, l1 (ω) is the log-likelihood function under the model in
(3.2.1) and l2 (ω) is the log-likelihood function under the model in (3.2.3) given that α1 is
known. Therefore, by solving the first five estimating equations based on l1 (ω) in equation
(3.2.5), the model in (3.2.1) is fitted to obtain estimates of α0, α1, α2, α3, σ
2
1, that is obtaining
the MLEs under the model in (3.2.1). Analogously, solving the last three estimating equations
based on l2 (ω) in equation (3.2.6) yields estimates of α4, αXY , σ
2
2. Hence, the estimate of ω
is obtained, denoted by ωˆ, by solving U(ω) = 0. In more detail, the estimating equations
can be derived as:
U1(ω) =
∂l1 (ω)
∂α0
=
∂
∑n
i=1
[
− log (σ1) + log
(
φ
(
yi−α0−α1ki−α2xi−α3li
σ1
))]
∂α0
=
∂
[
−n2 log (2π)− n log (σ1)− 12σ21
∑n
i=1 (yi − α0 − α1ki − α2xi − α3li)2
]
∂α0
=
n
σ21
(
y¯ − α0 − α1k¯ − α2x¯− α3 l¯
)
= 0,
and similarly
U2(ω) =
∂l1 (ω)
∂α1
=
n
σ21
(
ky − α0k¯ − α1k2 − α2kx− α3kl
)
= 0,
U3(ω) =
∂l1 (ω)
∂α2
=
n
σ21
(
xy − α0x¯− α1xk − α2x2 − α3xl
)
= 0,
U4(ω) =
∂l1 (ω)
∂α3
=
n
σ21
(
ly − α0 l¯ − α1lk − α2lx− α3l2
)
= 0,
where v¯ denotes the arithmetic mean of a variable v. This can be simplified to
⎛⎜⎜⎜⎝
U1 (ω)
U2 (ω)
U3 (ω)
U4 (ω)
⎞⎟⎟⎟⎠ = 1σ21Z(y −ZTα)T = 0 with Z = (1,K,X,L)T , α = (α0, α1, α2, α3)T ,
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and
U5 (ω) = − n
2σ21
− 1
2σ41
(
y −ZTα)T (y −ZTα) = 0,(
U6 (ω)
U7 (ω)
)
=
1
σ21
Z˜
(
y˜ − Z˜T α˜
)T
with Z˜ = (1, X)T , α˜ = (α4, αXY )
T ,
U8 (ω) = − n
2σ22
− 1
2σ42
(
y˜ − Z˜T α˜
)T (
y˜ − Z˜T α˜
)
= 0.
As a difference to the two-stage sequential G-estimation method, all parameters in ω are
estimated simultaneously and the additional variability obtained in the phenotype adjustment
in (3.2.2) is considered by using the robust Huber-White sandwich estimator of the standard
error of ωˆ. The point estimate of the genetic effect αˆXY from CIEE coincides in this model
with the estimate from the two-stage sequential G-estimation method. Based on the Theorem
3.2.2 shown below, the robust Huber-White sandwich estimate of the standard error of αˆXY
can be obtained as SˆE(αˆXY ) =
√
1
nCn(ωˆ)7,7. Using the estimate of αXY and its standard
error estimate, a Wald-type test statistic can be computed for testing H0 : αXY = 0 versus
HA : αXY ̸= 0. Here, the large-sample Wald-type test statistic W = αˆXY
SˆE(αˆXY )
is used which
has asymptotically standard normal N(0, 1) distribution.
Theorem 3.2.2 (White, 1982). Let Uj be the j-th element of the vector in equation (3.2.4)
and q = 8. Under mild regularity conditions,
√
n(ωˆ−ω) is asymptotically normally distributed
with mean 0 and covariance matrix C(ω), which can be consistently estimated with Cn(ωˆ),
where
Cn (ω) = An(ω)
−1 Bn (ω)
[
An(ω)
−1
]T
(3.2.7)
An (ω) = − 1
n
(
∂U (ω)
∂ω
)
(3.2.8)
Bn (ω) =
1
n
n∑
i=1
[
Uj (yi, ki, xi, li;ω) · Uk(yi, ki, xi, li;ω)T
]
j,k=1...q
(3.2.9)
3.2.1.2 Analysis of a time-to-event primary trait with CIEE
For the analysis of survival times T , the right-censoring scheme with observed survival times
ti = min(Ti, Ci) and censoring indicator δi = I[Ti ≤ Ci] is considered for a random sample
of individuals i = 1, . . . , n, where Ti is the survival time, Ci is the censoring time and I[.] is
the indicator function. It is assumed that censoring is noninformative. I consider the AFT,
or log-linear, model of the form
Yi = log (Ti) = α0 + α1ki + α2xi + α3li + σ1εi, σ1 > 0 (3.2.10)
for the phenotype adjustment. The error term in equation (3.2.10) can come from any
distribution, and here the focus is on the log-linear model with εi ∼ N(0, 1) for illustration.
The estimating equations can be constructed similarly as described in the previous section,
but in order to remove the effect of K from Y , the true underlying log-survival times Yest
need to be estimated for censored survival times. Yest equals the observed log-survival time Y
for uncensored survival times. To estimate Yest for a censored survival time, the conditional
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expectation of Y given that it is greater than the observed log-transformed right-censoring
time and given the covariates is obtained (Konigorski et al., 2014), see Lemma 3.2.3. Then,
the adjusted phenotype is computed using
y˜i = yest,i − yest − α1(ki − k¯) (3.2.11)
with yest,i obtained from equation (3.2.13) and yest =
1
n
n∑
i=1
yest,i. Finally, the direct genetic
effect on the adjusted phenotype is modeled using
Y˜i = α4 + αXY xi + ε
′
i, ε
′
i ∼ N
(
0, σ22
)
. (3.2.12)
Lemma 3.2.3. Consider the log-linear model in (3.2.10), let f(.) denote the probability den-
sity function of Y given K, X, L and F (.) the cumulative distribution function of Y given K,
X, L under this model. Let further ω =
(
α0, α1, α2, α3, σ1, α4, αXY , σ
2
2
)T
, φ(.) denote
the standard normal PDF, and Φ(.) the standard normal CDF. Then, the true underlying
log-survival times Yest are
yest,i = δi · yi + (1− δi) ·
⎛⎝α0 + α1ki + α2xi + α3li + σ1 · φ
(
yi−α0−α1ki−α2xi−α3li
σ1
)
1− Φ
(
yi−α0−α1ki−α2xi−α3li
σ1
)
⎞⎠
Proof Lemma 3.2.3:
yest,i = δi · yi + (1− δi) · E [Yi|Yi > yi, ki, xi, li] (3.2.13)
= δi · yi + (1− δi) ·
(
E [Yi|ki, xi, li] + σ1
2 · f (yi|ki, xi, li;ω)
1− F (yi|ki, xi, li;ω)
)
= δi · yi + (1− δi) ·
⎛⎝α0 + α1ki + α2xi + α3li + σ1 · φ
(
yi−α0−α1ki−α2xi−α3li
σ1
)
1− Φ
(
yi−α0−α1ki−α2xi−α3li
σ1
)
⎞⎠ .
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Here, with z = (k, x, l)T , ν = 12
(
y−E[Y |z]
σ1
)2
, dν = y−E[Y |z]σ1 dy,
E [Y |Y > y0, z] =
∞∫
y0
yf (y|z;ω) dy
/
1− F (y0|z;ω)
= σ1
∞∫
y0
y
σ1
1√
2πσ1
exp
(
−1
2
(
y − E [Y |z]
σ1
)2)
dy
/
1− F (y0|z;ω)
=
[
σ1
∞∫
y0
y−E[Y |z]
σ1
1√
2πσ1
exp
(
− 12
(
y−E[Y |z]
σ1
)2)
dy + E [Y |z]
∞
∫
y0
f (y|z;ω) dy
]
1− F (y0|z;ω)
=
⎡⎢⎢⎢⎣σ1
∞∫
1
2
(
y0−E[Y |z]
σ1
)2
1√
2π
exp (−ν) dν + E [Y |z] (1− F (y0|z;ω))
⎤⎥⎥⎥⎦
/
1− F (y0|z;ω)
=
[
σ1√
2π
(− exp (−ν)) |∞
1
2
(
y0−E[Y |z]
σ1
)2 + E [Y |z] (1− F (y0|z;ω))
]/
1− F (y0|z;ω)
=
[
σ1√
2π
exp
(
−1
2
(
y0 − E [Y |z]
σ1
)2)
+ E [Y |z] (1− F (y0|z;ω))
]/
1− F (y0|z;ω)
= E [Y |z] + σ
2
1 · f (y|z;ω)
1− F (y|z;ω) .
The estimating equations for estimating ω =
(
α0, α1, α2, α3, σ1, α4, αXY , σ
2
2
)T
are
U (ω) =
(
∂l1 (ω)
∂α0
,
∂l1 (ω)
∂α1
,
∂l1 (ω)
∂α2
,
∂l1 (ω)
∂α3
,
∂l1 (ω)
∂σ1
,
∂l2 (ω)
∂α4
,
∂l2 (ω)
∂αXY
,
∂l2 (ω)
∂σ22
)T
= 0 (3.2.14)
with
l1 (ω) =
n∑
i=1
[
− δi log (σ1) + δi log
(
φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))
+ (1− δi) log
(
1− Φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))]
(3.2.15)
and
l2 (ω) =
n∑
i=1
[
− log (σ2) + log
(
φ
(
yest,i − yest − α1
(
ki − k¯
)− α4 − αXY xi
σ2
))]
, (3.2.16)
where φ(.) and Φ(.) are the standard normal PDF and CDF. U(ω) = 0 are unbiased esti-
mating equations with
√
n (ωˆ − ω) D→N (0,C (ω)) where C(ω) is estimated as described in
the previous section. Here, l1(ω) is the log-likelihood function under the model in equation
(3.2.10) and l2(ω) is the log-likelihood function under the model in equation (3.2.12) given
that α0, α1, α2, α3, σ1 are known. By solving the first five estimating equations based on l1(ω)
in equation (3.2.15), estimates of α0, α1, α2, α3, σ1 are obtained and solving the last three es-
timating equations based on l2(ω) in (3.2.16) yields estimates of α4, αXY , σ
2
2. In more detail,
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the functions l1(ω) and l2(ω) are derived as follows:
l1 (ω) =
n∑
i=1
δi · log (f (yi|ki, xi, li;ω)) + (1− δi) · log (1− F (yi|ki, xi, li;ω))
=
n∑
i=1
[
δi log
(
1
σ1
φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))
+ (1− δi) log
(
1− Φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))]
=
n∑
i=1
[
− δi log (σ1) + δi log
(
φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))
+ (1− δi) log
(
1− Φ
(
yi − α0 − α1ki − α2xi − α3li
σ1
))]
,
l2 (ω) =
n∑
i=1
log
(
1
σ2
φ
(
yest,i − yest − α1
(
ki − k¯
)− α4 − αXY xi
σ2
))
=
n∑
i=1
[
− log (σ2) + log
(
φ
(
yest,i − yest − α1
(
ki − k¯
)− α4 − αXY xi
σ2
))]
=
n∑
i=1
⎡⎢⎢⎣− log (σ2) + log
⎛⎜⎜⎝φ
⎛⎜⎜⎝δiyi + (1− δi)
(
α0 + α1ki + α2xi + α3li +
σ1φ
(
yi−α0−α1ki−α2xi−α3li
σ1
)
1−Φ
(
yi−α0−α1ki−α2xi−α3li
σ1
))
σ2
− yest − α1
(
ki − k¯
)− α4 − αXY xi
σ2
⎞⎟⎟⎠
⎞⎟⎟⎠
⎤⎥⎥⎦.
3.2.1.3 Estimation of standard errors using nonparametric bootstrap
As an alternative to the sandwich variance estimator based on estimating equations, non-
parametric bootstrap (Efron, 1981) can be used to obtain the standard error estimate of the
estimated direct genetic effect αˆXY . In step 1, a sample of n individuals is randomly selected
from the data with replacement. In step 2, the point estimate αˆXY,t is obtained by solving
the estimating equations in (3.2.4) or (3.2.14). These two steps are performed B times and
the bootstrap standard error estimate of αˆXY can be obtained as the standard deviation of
the αˆXY,t, t = 1, . . . , B.
3.2.2 Computational details & implementation
CIEE is implemented in the R package CIEE for both the analysis of continuous and time-
to-event traits subject to censoring as primary outcomes for the model in Figure 3.4. In
addition, functions are available to fit the same DAG with traditional regression approaches
and the structural equations modeling method. For an extension to include more covariates
or intermediate phenotypes, the estimating equations and R functions have to be adapted.
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CIEE is currently available upon request as a bundled package. It can be installed through
the zipped tar file with
install.packages("pathtofile/CIEE_0.1.0.tar.gz", repos = NULL)
and then loaded with
library(CIEE)
CIEE was generated using RStudio Version 1.0.143 based on R version 3.4.1 (R Core Team,
2017) using the devtools package. The documentation of the functions and generation of
help pages was done using the roxygen2 package. Finally, knitr and rmarkdown were used
for the detailed long-form documentation (vignette), which is available through
browseVignettes("CIEE")
More details for each function can be obtained through the regular help files, for example,
?ciee
In the following, an outline of the implementation is given, as well as details regarding
the application to genome-wide analyses. Examples for the use of the R functions are shown
in the appendix in section A.7.2.
3.2.2.1 Data generation functions
Simulated data can be generated from the model in Figure 3.4 using the generate_data()
function, which generates data for the quantitative outcome Y (or for time-to-event outcomes
T , Y = log(T ) and censoring indicator C), intermediate phenotype K, a genetic marker X
(SNV coded 0, 1, 2), and observed as well as unobserved confounders L, U .
3.2.2.2 Traditional regression and SEM functions
Two traditional approaches for fitting the model in Figure 3.4 are the multiple regression
(MR) and regression of residuals (RR) methods:
MR: Obtain the LS estimate of αXY by fitting
Yi = α0 + αXY xi + α1ki + α2li + εi, εi ∼ N(0, σ21). (3.2.17)
RR: First, obtain residuals εˆ1i = yi − (αˆ0 + αˆ1ki + αˆ2li) by fitting
Yi = α0 + α1ki + α2li + ε1i, ε1i ∼ N(0, σ21) (3.2.18)
using the LS estimation. Second, obtain the LS estimate of αXY by fitting
εˆ1i = α3 + αXY xi + ε2i, ε2i ∼ N(0, σ22). (3.2.19)
The two approaches are implemented in the functions mult_reg() and res_reg(). For
the analysis of a quantitative primary trait, point estimates and standard error estimates of
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the parameters as well as p-values from the default t-test of H0 : αXY = 0 versus HA : αXY ̸=
0 based on the lm() function are obtained. Under the AFT setting, only the MR approach
is implemented to fit the censored log-linear regression model in equation (3.2.10) using the
survreg() function in the survival R package in order to obtain parameter estimates and
to perform a Wald test for testing the null hypothesis H0 : αXY = 0.
As another approach, the SEM method (Bollen, 1989) can be used to obtain estimates of
αXY and its standard error. The function sem_appl() can be used to apply the SEM method
to the DAG in Figure 3.4 based on the following model equations:
Li = α0 + α1xi + ε1i, ε1i ∼ N
(
0, σ21
)
, (3.2.20)
Ki = α2 + α3xi + α4li + ε2i, ε2i ∼ N
(
0, σ22
)
, (3.2.21)
Yi = α5 + α6ki + αXY xi + ε3i, ε3i ∼ N
(
0, σ23
)
. (3.2.22)
sem_appl() uses the sem() function in the lavaan R package (Rosseel, 2012) with default
settings, to obtain parameter and standard error estimates and to obtain p-values for testing
H0 : αXY = 0 versus HA : αXY ̸= 0 using the default Wald-type test.
3.2.2.3 CIEE functions
Regarding the implementation of CIEE in this package, the est_funct_expr() function
contains the main part of the l1 and l2 functions in (3.2.5)-(3.2.6) and (3.2.15)-(3.2.16) as
an expression. The get_estimates() function obtains estimates of ω in (3.2.1)-(3.2.3) (for
normally-distributed Y ) or (3.2.10)-(3.2.12) (for time-to-event Y ) by using the lm() and
survreg() functions for computational purposes. These estimates are identical to estimates
obtained by solving the estimating equations.
In order to compute the robust Huber-White sandwich estimator of the parameters, in a
first step, the deriv_obj() function computes the expression of all first and second derivatives
of l1 and l2 with respect to α0, α1, α2, α3, σ
2
1, α4, αXY , σ
2
2 by using the deriv() function
and the expressions from the est_funct_expr() function as input. Then, the scores()
and hessian() functions are written to obtain the numerical values of all first and second
derivatives for the observed data and parameter estimates.
With these derivations, the robust Huber-White sandwich estimator of the standard er-
ror can be obtained using the sandwich_se() function. Alternatively, bootstrap standard
error estimates can be obtained using the bootstrap_se() function. Also, for comparison,
the function naive_se() computes naive standard error estimates of αˆ0, αˆ1, αˆ2, αˆ3, αˆ4, αˆXY
without accounting for the additional variability due to the two stages in (3.2.1)-(3.2.3) or
(3.2.10)-(3.2.12).
Finally, the ciee() function allows an easy integrated use of all above functions. ciee()
fits the model in equations (3.2.1)-(3.2.3) or (3.2.10)-(3.2.12) (e.g., the model in Figure
3.4), yields parameter estimates and standard error estimates, and performs hypothesis tests
of all parameters, for CIEE, the traditional regression approaches, and the SEM method.
ciee_loop() provides an extension of ciee() and allows the input of multiple exposure
variables (e.g., multiple SNPs) to be tested sequentially. In the output of ciee_loop(), only
the coefficient estimates, standard error estimates, and p-values with respect to the direct ef-
fect αXY are provided. Both ciee() and ciee_loop() return ciee objects as output, so that
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the written summary.ciee() function can be used through the generic summary() function
to provide a reader-friendly output of the results.
3.2.2.4 CIEE application details
For a genome-wide association analysis of direct genetic effects, CIEE can be used by either
applying the ciee() sequentially on all SNVs of interest, or by supplying a matrix of multiple
SNVs to the ciee_loop() function. The computation times of both functions show little
differences in general. For a higher number of supplied SNVs, the ciee_loop() function is
slightly more efficient, but at the same time, it requires more memory when the SNVs matrix
becomes very large. An overview about the computation time for the estimation and testing
of one SNV is shown in Figure 3.5 for the different approaches, for different sample sizes
for the analysis of a quantitative and time-to-event primary trait. It can be seen that while
CIEE is slower compared to all other approaches, is is still very fast and takes less than 1s
for a sample size of n = 100, 000. The running time for analyzing a time-to-event trait is not
affected by the amount of censoring and takes slightly longer.
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Figure 3.5: Computation time of CIEE. Shown are the mean computation times in seconds (’user times’
obtained through the R system.time() function) based on 10 runs of the different approaches using the
ciee() R function, for data generated in the power investigation in scenario 5 in Table 4.7, for the LM
and AFT setting, for a SNV of MAF= 0.2, aXY = 0.1 (and with 30% censoring).
A more detailed overview of the computation time and memory use of the different parts
of the ciee() function are shown in Figures 3.6-3.7. They show that the computation time is
quite evenly distributed over the multiple functions, and most of the running time is spent on
deriving the first and second derivatives and obtaining the sandwich standard error estimate.
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Figure 3.6: Detailed computation time and memory use of the ciee() R function under the LM setting.
Shown are the memory use (in MB) and computation time (in ms) of each part of the ciee() R function,
computed using the profvis() function of the profvis R package, for data generated in the power
investigation in scenario 5 in Table 4.7 under the LM setting with n = 100, 000, a SNV of MAF= 0.2 and
aXY = 0.1.
Figure 3.7: Detailed computation time and memory use of the ciee() R function under the AFT setting.
Shown are the memory use (in MB) and computation time (in ms) of each part of the ciee() R function,
computed using the profvis() function of the profvis R package, for data generated in the power
investigation in scenario 5 in Table 4.7 under the AFT setting with n = 100, 000, a SNV of MAF= 0.2,
aXY = 0.1 and with 30% censoring.
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Chapter 4
Evaluation: Simulation studies
4.1 Existing single-marker tests versus multi-marker tests
In a first empirical investigation through simulation studies, an SMT (Wald-type t-test) and
popular MMTs (a burden test, SKAT, and SKAT-O) were compared in genetic association
studies of rare variants with a quantitative trait. A normally-distributed quantitative trait
Y was generated given causal SNVs (under the alternative hypothesis scenarios) and two
covariates, with different scenarios varying the percentage of causal variants, their effect
sizes, and direction of effects. At first, the statistical properties of the SMT were assessed, and
whether it provides valid estimation and inference. Then, all tests were compared regarding
their empirical type I error and power to identify a causal gene.
4.1.1 Material and methods
4.1.1.1 Genetic data generation and simulation study set-up
For the main study, the genetic dataset provided in the SKAT package in R (Lee et al., 2016)
was used, which contains 10,000 haplotypes over a 200kb region (including 3,845 SNVs)
generated from a calibration coalescent model mimicking the linkage disequilibrium (LD)
structure of European ancestry. This was chosen to make our study comparable to the
evaluation of SKAT-O in (Lee et al., 2012). Accordingly, the kernels and other SKAT options
were chosen to reach an optimal performance for the power of SKAT and SKAT-O.
Similar to (Lee et al., 2012), 10,000 3kb regions from the 200kb region were randomly sam-
pled, to obtain genes with average length. Then, 2,000 haplotypes of these 10,000 genes were
randomly paired to generate m = 10, 000 replicates with genotypes of n = 1, 000 individuals
for the simulation study. With this, there were on average 33 non-monomorphic SNVs Xj
in each replicate (min = 19; max = 52 SNVs), and in total 325,393 SNVs in all m = 10, 000
replicates combined. Most of the SNVs were rare with MAF≤ 0.03. In detail, of the 325,393
SNVs, 132,797 SNVs had MAF = 0.0005 (minor allele count MAC = 1); 41,341 SNVs had
MAF = 0.001 (MAC = 2); 50,836 SNVs had 0.001 < MAF ≤ 0.005 (2 < MAC ≤ 10); 39,835
SNVs had 0.005 < MAF ≤ 0.03; and 60,584 SNVs had MAF > 0.03.
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4.1.1.2 Phenotype generation
To evaluate the type I error and the power of the test statistics, Y was generated conditional
on a binary covariate Z1 and a normally distributed covariate Z2 (and conditional on the
causal SNVs Xj under the alternative hypotheses). The same model and parameter values
were used as described in Lee et al. (2012) with additive genetic effects:
Y = 0.5z1 + 0.5z2 +
∑
βjxj + ε (4.1.1)
with Z1 ∼ Bin (p = 0.5) , Z2 ∼ N (0, 1) , ε ∼ N (0, 1) , βj = c · |log10 (MAFj)|, where different
values of c were considered in the simulation study. For the evaluation of type I error rates,
m = 10, 000, 000 replicates were analyzed, and for the power comparisons, m = 10, 000
replicates were used. The sample size of n = 1, 000 individuals was chosen for all simulations.
Table 4.1 gives an overview of the parameters in each scenario.
Investigation Scenario
% of causal
variants
Effect size
weights
Direction of effect:
Positive / Negative
Median (MAD) of
explained variance in %
Type I error 0 0% c=0 – –
Power
1 5% c=0.6 100% / 0% 0.9% (0.6)
2 5% c=0.3 100% / 0% 0.2% (0.2)
3 5% c=0.2 100% / 0% 0.1% (0.1)
4 10% c=0.6 100% / 0% 1.9% (1.4)
5 10% c=0.3 100% / 0% 0.5% (0.3)
6 10% c=0.2 100% / 0% 0.2% (0.2)
7 20% c=0.6 100% / 0% 3.8% (2.1)
8 20% c=0.3 100% / 0% 1.0% (0.6)
9 20% c=0.2 100% / 0% 0.4% (0.2)
10 50% c=0.6 100% / 0% 9.1% (3.0)
11 50% c=0.3 100% / 0% 2.4% (0.9)
12 50% c=0.2 100% / 0% 1.1% (0.4)
13-24 as in scenarios 1-12 80% / 20% as in scenarios 1-12
25-36 as in scenarios 1-12 50% / 50% as in scenarios 1-12
Table 4.1: Overview of the scenarios considered for the simulation study of the SMT and MMTs to
evaluate their type I error and power. The scenarios vary the percentage of causal variants, their effect
size, and the percentage of causal variants with effects in positive/ negative direction. Scenarios 13-24
and 25-36 have the same percentage of causal SNVs and the same effect sizes as scenarios 1-12, but 80%
/ 20% and 50% / 50% of effects in positive / negative direction. The percentage of causal rare variants
is with respect to the total number of rare variants with MAFj ≤ 0.03 in the gene. The effect size of a
variant with a given MAF on the trait Y is βj = c · |log10(MAFj)|. The percentage of explained variance
for a given gene is calculated as the sum of 2 ·MAFj · (1−MAFj) · β2j /V ar (Y ) over all variants Xj in
the gene. Reported are the median and the median absolute deviation (MAD) of this heritability estimate
over the 10,000 replicates.
For the type I error evaluation, empirical gene-level estimates were obtained for all ap-
proaches under the null hypothesis given in scenario 0 in Table 4.1. For the power evaluation,
36 different scenarios were considered, extending the investigation in Lee et al. (2012). They
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differ in percentages of causal rare variants, effect sizes, and direction of the effects of causal
rare variants. Causal variants were randomly chosen among all rare variants with MAF≤ 0.03.
Between 5% and 50% of the rare variants in a gene were set to be causal, and at least 1 rare
variant per gene was chosen as causal under the alternative hypothesis. The median of the
explained phenotypic variation by all causal SNVs in a gene was less than or equal to 1% in
most scenarios, and ranged between 0.1% in scenario 3 (5% causal SNVs in a gene with small
effect sizes) and 9.1% in scenario 10 (50% causal SNVs in a gene with larger effect sizes),
calculated as the sum of 2 ·MAFj · (1−MAFj) · β2j /V ar (Y ) over all variants Xj in the gene
(Laird & Lange 2011).
4.1.1.3 Investigated rare variant tests
In the comparison of the SMT and MMTs, all approaches were evaluated in their power to
identify a causal gene. In a simulation study including m replicates of a gene with multiple
SNVs, gene-level power estimates can be generally obtained with
Pˆower = Pˆ (Reject H0 | HA is true)
=
number of significant tests among the m replicates generated from HA
m
.
This was done for MMTs, and for SMTs it becomes
Pˆower =
number of replicates including at least one significant SNV
m
and an appropriate multiple testing correction for the tests within the gene is used. This
power calculation amounts to the minP approach (e.g., Madsen & Browning 2009; Basu &
Pan 2011; Pan et al., 2014; Xing et al., 2012). To evaluate the performance of SMTs, a linear
regression model of Y ,
Y = β0 + β1z1 + β2z2 + βXY xj + ε, ε ∼ N(0, σ2), (4.1.2)
was separately fitted for each SNV Xj in a gene using the lm() function in R, which provides
the MLE βˆXY of the coefficient βXY and its standard error estimate SˆE(βˆXY ) using the
unbiased estimate of σ2. Then, the Wald-type t-test statistic βˆXY
SˆE(βˆXY )
∼ tn−4 was obtained
for testing the null hypothesis in (2.2.1). In order to account for testing multiple SNVs in
a gene in the SMT to obtain gene-level tests, the Bonferroni and Benjamini-Hochberg (BH)
correction (Benjamini & Hochberg, 1995) was applied in the type I error evaluation, and
the BH-correction in the power estimation. With respect to multi-marker approaches, three
different tests were conducted incorporating all SNVs in a replicate (i.e., gene): a burden
test, SKAT, and SKAT-O. The burden test was conducted by obtaining a gene score as the
summation of the minor alleles of all SNVs in the gene (i.e.,
∑
xj) for each individual, and
testing the null hypothesis given in (2.2.2) under the linear regression model
Y = β0 + β1z1 + β2z2 + βXY
∑
xj + ε (4.1.3)
using the Wald-type t-test statistic obtained from the lm() function in R.
The sequence-kernel association test (SKAT; Wu et al., 2011) is a variance-component
test of the null hypothesis in (2.2.2) based on the test statistic
QSKAT = (y − yˆ)TK(y − yˆ), (4.1.4)
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where K = XWWXT is a weighted linear kernel matrix measuring the genetic similar-
ity between individuals, X = (X1, . . . , Xk) is the (n × k) matrix of the k SNVs, W =
diag(w1, . . . , wk) is a (k × k) weight matrix with weights wj based on the Beta distribution,
wj ∼ Beta (MAF(Xj), 1, 25) (see Supplementary Figure A.1 for an illustration), and yˆ are
the predicted phenotypes based on the linear mixed model
Y = β0 + β1z1 + β2z2 + β
T
XYX + ε (4.1.5)
with βXY = (βXY,1, . . . , βXY,k)
T following a multivariate distribution with exchangeable
correlation structure. The optimal sequence-kernel association test (SKAT-O; Lee et al.,
2012) is an extension of SKAT, deriving the variance-component test statistic
Qρ = (1− ρ)QSKAT + ρ QBURDEN
as the optimal combination of burden and variance-component tests to maximize the power
for testing the null hypothesis in (2.2.2). Here, ρ is determined through a data-adaptive grid
search. Both SKAT and SKAT-O were computed using the default linear-weighted kernel
(relating the genotypes to the phenotype) in the test statistic as it returned the highest power
estimates among all possible options provided in the SKAT() function in the SKAT package in
R. The weights in the weighted kernels of SKAT and SKAT-O are a function of the MAF
of SNVs. For the p-value estimation, the default ’davies’ setting was used for SKAT and
’optimal.adj’ for SKAT-O. All common and rare SNVs in the gene were included in the
analysis of the SMT and each MMT for a fair comparison. Additional results from analyzing
rare variants only are provided in the appendix as a sensitivity analysis. All computations
and visualizations were performed in R 2.15.0 and higher.
4.1.2 Results
4.1.2.1 Validity of estimates and test statistics of single-marker analysis
First, the coefficient estimates of SNVs and their standard error estimates in the linear
regression model (4.1.2) were assessed under the null hypothesis (scenario 0 in Table 4.1) by
focusing on singletons only, doubletons only, and all rare SNVs. The results showed that
the effect estimates are unbiased and that the standard error estimates are equal to the
standard deviations of the effect estimates, even when singletons and doubletons are under
consideration (Table 4.2).
Variant type mean
(
βˆXY
)
SD
(
βˆXY
)
mean
(
SˆE
βˆXY
)
Singleton 1.4× 10−4 1.00 1.00
Doubleton 1.0× 10−4 0.71 0.71
SNV with MAC=10 1.0× 10−4 0.32 0.32
Table 4.2: Bias and variance of the (restricted) MLEs from the SMT (linear regression) under the null
hypothesis. Datasets were generated from the null model described in scenario 0 in Table 4.1 with size
n = 1, 000 for m = 10, 000, 000 replicates. The table shows the mean and standard deviation of the
SNV effect estimates and the mean of the corresponding standard error estimates, for the 132,797,000
singletons in all replicates, the 41,341,000 doubletons in all replicates, and the 2,985,000 SNVs with 10
observed minor alleles (MAC = 10).
4.1. SMTS VERSUS MMTS 41
Investigation of the single-marker t-test statistic for testing the hypotheses in (2.2.1)
showed that the distribution assumption holds for SNVs of all MAF (Figure 4.1, Supplemen-
tary Figure A.2).
Figure 4.1: Distribution of SMT test statistics, for all SNVs, singletons only, and doubletons only. Datasets
were generated from the null model described in scenario 0 in Table 4.1 of size n = 1, 000 for m =
10, 000, 000 replicates. Q-Q plots are shown comparing the empirical quantiles of the t-test statistics of
singletons (left panel), doubletons (middle panel), and all SNVs (right panel) to the theoretical quantiles
of the tdf=1000−4 distribution. For computational purposes, each plot is based on a random sample of
1,000,000 t-test statistics, out of the 132,797,000 t-test statistics of all singletons in all replicates, out of
the 41,341,000 t-test statistics of all doubletons in all replicates, and out of the 325,393,000 t-test statistics
of all SNVs in all replicates. In grey ribbons, approximate 95% point-wise confidence intervals are shown.
4.1.2.2 Evaluation of type I error rates of the SMT and MMTs
Next, the empirical type I errors of the SMT and MMTs for testing the hypothesis in (2.2.2)
were investigated for different nominal levels, to assess whether they are well-controlled (Table
4.3). The results indicate that empirical type I errors of all approaches are close to the nominal
levels, allowing a valid comparison of the power estimates. For the power evaluations in the
following, the BH correction was used for the SMT in order to account for the multiple testing
of all SNVs within a gene and obtain gene-level power estimates, since some dependencies
were observed between SNVs and since the empirical type I errors were closer to the nominal
level compared to using the Bonferroni correction for most of the nominal levels.
Nominal α
MMTs SMT
SKAT SKAT-O Burden Bonferroni correction BH correction
5× 10−2 4.94× 10−2 5.22× 10−2 5.01× 10−2 4.39× 10−2 4.93× 10−2
1× 10−2 0.97× 10−2 1.10× 10−2 1.00× 10−2 0.90× 10−2 0.99× 10−2
1× 10−3 0.94× 10−3 1.12× 10−3 1.00× 10−3 0.88× 10−3 0.97× 10−3
1× 10−4 0.92× 10−4 1.17× 10−4 1.03× 10−4 0.91× 10−4 0.98× 10−4
1× 10−5 0.92× 10−5 1.10× 10−5 1.12× 10−5 1.16× 10−5 1.25× 10−5
2.5× 10−6 2.40× 10−6 2.40× 10−6 3.50× 10−6 2.40× 10−6 2.90× 10−6
Table 4.3: Empirical type I error of the SMT and MMTs for different nominal α levels. Data was generated
from the null model with size n = 1, 000 for m = 10, 000, 000 replicates.
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As a sensitivity check, misspecified distributions for the error term in model (4.1.2) were
considered. Data was generated from the null model in (4.1.1) with error terms from the t-
distribution with 4 and 8 degrees of freedom and from the standard log-normal distribution.
Then, the SMT, SKAT, SKAT-O and burden tests were conducted to test the absence of
genetic effects assuming normally-distributed errors as described in section 4.1.1. The results
are shown in Supplementary Table A.1) and indicate that only the burden test has valid type
I errors. The SKAT, SKAT-O and SMT are all sensitive to a misspecification of the error
distribution, and the SMT shows a much higher inflation of empirical type I errors. The
inflation can be slightly decreased by excluding SNVs with only 1 or 2 observed minor alleles
but is still substantial and much higher than of SKAT and SKAT-O.
4.1.2.3 Power for identifying a causal gene with the SMT and MMTs
Figure 4.2 and Supplementary Tables A.2-A.3 show the power estimates for all test statistics
under the scenarios 1-36 described in Table 4.1, when the type I error was 0.05 or 2.5× 10−6.
The burden test had the lowest power among all tests in all scenarios when all rare and
(non-causal) common variants were included in the analysis. Regarding a comparison among
the other MMTs, SKAT-O had generally similar power with SKAT and the only noticeable
differences were in scenarios 11, 12 (50% causal rare SNVs, all effects in the same direction)
when the power of SKAT-O was 7-11.5% higher for α = 0.05 and 3.5-10% higher for α =
2.5× 10−6. These results are in line with the literature (Lee et al., 2012).
Regarding the comparison of the SMT with MMTs, a first observation was that the
power differences between the SMT and MMTs were very small for a genome-wide scan
(α = 2.5 × 10−6), and more pronounced for candidate-gene testing (α = 0.05) when using
a sample size of n = 1, 000. The same tendencies held for both nominal significance levels,
and the further most important determinants of which test has higher power were the effect
size and the percentage of causal variants. As main results, the SMT had consistently the
highest power when the effect sizes were higher (c=0.6), for all percentages of causal SNVs
and both nominal significance levels (except when there were 50% causal SNVs in a gene and
α = 2.5×10−6. When the effect sizes were moderate (c=0.3) and small (c=0.2), the power of
SMTs and MMTs were very similar when there were 5% or 10% causal SNVs, SKAT/SKAT-
O had slightly higher power when there were 20%, and larger power when there were 50%
causal SNVs. For a given effect size, increasing the percentage of causal variants in a gene led
to a power increase for each test. The direction of SNV effects within a gene did not seem to
greatly influence the question which test has the highest power, illustrating the robustness of
SKAT/SKAT-O. For further details and sensitivity checks of the results, additional analyses,
and a comparison for generated case-control traits, see sections A.4.1.1-A.4.1.3.
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Figure 4.2: Empirical power estimates of the SMT and MMTs. Data was generated under an alternative-
hypothesis model described in scenarios 1-36 in Table 4.1 of size n = 1, 000 for m = 10, 000 replicates.
The nominal α was set to 0.05 (upper panel) and 2.5 × 10−6 (lower panel). In the lower panel with
α = 2.5 × 10−6, the coordinate system is shown on a log10-scale to better visualize the small power
differences between the approaches. Multiple testing corrections for the SMT of all SNVs in a gene were
done using the BH-correction.
44 CHAPTER 4. EVALUATION OF STATISTICAL METHODS
4.2 C-JAMP
In this section, the validity of the parameter and standard error estimates, the test statistic,
and the empirical type I error and power of hypothesis tests of genetic effects under the
C-JAMP model are evaluated - for the analysis of rare variants using simulation studies.
Weak (τ = 0.2), moderate (τ = 0.5) and strong (τ = 0.8) dependences between traits were
considered. Since the results in the previous section showed that SMTs can have larger or
equal power compared to MMTs as long as there are not a large number of causal SNVs in a
region all with small effect sizes, C-JAMP will be applied as a SMT. C-JAMP is compared to
the same SMT and MMTs as described in section 4.1, to the multivariate SMTs MultiPhen
(O’Reilly et al., 2012) and aSPU (Kim et al., 2016), as well as to the multivariate MMTs
MURAT (Sun et al., 2016b), aSPUset and aSPUset-Score (Kim et al., 2016).
4.2.1 Material and methods
The same underlying genetic data as described in section 4.1.1.1 was used for the simulation
study, with m = 10, 000 replicates of k = 1, 000 genotypes of n = 1, 000 individuals. Regard-
ing the phenotypic data, two traits Y1 and Y2 were generated from a bivariate distribution
with weak (τ = 0.2), moderate (τ = 0.5), and strong (τ = 0.8) dependence between the
traits using the Clayton copula model in (3.1.2), conditional on a binary covariate Z1 and a
normally distributed covariate Z2 (and conditional on the causal SNVs under the alternative
hypotheses) analogous to the description in section 4.1.1.2 with the same marginal models:
Y1 = 0.5z1 + 0.5z2 +
∑
βjxj + ε; Y2 = 0.5z1 + 0.5z2 +
∑
β′jxj + ε
′ (4.2.1)
with Z1 ∼ Bin (0.5) , Z2 ∼ N (0, 1) , ε, ε′ ∼ N (0, 1) , βj = cY1 · |log10 (MAFj)| , β′j = cY2 ·
|log10 (MAFj)|. Different values were considered for cY1 and cY2 . In addition to the scenarios
0-12 in the comparison of SMTs and MMTs in Table 4.1 with identical effect sizes cY1 , cY2 ,
five additional scenarios were considered with different effect sizes on the second trait (see
Table 4.4).
To evaluate C-JAMP, joint models of the generated phenotypes Y1 and Y2 given the SNV
x and covariates z1, z2 were fitted in the Clayton copula model in (3.1.2) with the normal
marginal models in (3.1.7)-(3.1.8) using the CJAMP R package. In the application of C-JAMP,
gene-level estimates of the empirical type I error and power are investigated, testing the
hypothesis in (2.2.2) that the gene shows a signal for being associated with the trait. Type I
errors were estimated under the null hypothesis in scenario 0 using m = 100, 000 replicates.
For the evaluation of the empirical power under scenarios 1-17, m = 10, 000 replicates were
analyzed. Causal variants were randomly chosen among all rare variants with MAF≤ 0.03
and all SNVs in the gene were analyzed. For scenarios 0-12, all results regarding type I error
and power estimates are similar for the two traits Y1 and Y2, and are reported for testing
the association with Y1. Scenarios 13-17 were analyzed to investigate the power of C-JAMP
on the first trait Y1 when there is no or only a smaller genetic effect on the second trait Y2,
and the power is reported with respect to Y1. In addition, the type I error rates for Y2 are
investigated in scenarios 13-15.
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Investigation Scenario
% of causal
variants
Effect size
weights
Direction of effect:
Positive / Negative
Type I error 0 0% cY1 = cY2 = 0 –
Power 1-12 as in Table 4.1 cY1 = cY2 as in Table 4.1 100% / 0%
Additional
scenarios of
type I error
and power
13 10% cY1 = 0.6; cY2 = 0 100% / 0%
14 20% cY1 = 0.3; cY2 = 0 100% / 0%
15 50% cY1 = 0.2; cY2 = 0 100% / 0%
16 10% cY1 = 0.6; cY2 = 0.1 100% / 0%
17 10% cY1 = 0.6; cY2 = 0.2 100% / 0%
Table 4.4: Overview of the scenarios considered in the simulation study of C-JAMP, for the type I error
and power comparison of C-JAMP with SMTs and MMTs. The scenarios vary the percentage of causal
variants, their effect size, and the percentage of causal variants with effects in positive/ negative direction.
The percentage of causal rare variants is with respect to the total number of rare variants with MAF≤ 0.03
in the gene. The effect size of a variant Xj with a given MAF on the trait Yl is βj = cYl · |log10 (MAFj)|.
The results of the univariate SMT, burden test, SKAT, and SKAT-O for scenarios 0-
12 have already been described in section 4.1 and are reprinted below for the comparison
with C-JAMP. The multivariate single- and multi-marker tests MURAT, MultiPhen, aSPU,
aSPUset, and aSPUset-Score are all evaluated under the null hypothesis in scenario 0 to
investigate their empirical type I errors based on m = 10, 000 replicates. Only the aSPUset
and aSPUset-Score tests provided empirical type I errors close to the nominal level and were
therefore investigated in the power comparison for scenarios 1-12 on m = 10, 000 replicates.
Since the aSPU and aSPUset tests compute p-values based on simulations or permutations,
they are very computationally intensive and could only be evaluated for a nominal α level
of 0.05. For example, the fitting and testing of one model analyzing 24 SNVs in data of size
n = 1000 with 10,000,000 permutations, which would be necessary to obtain p-values up to
10−8, took 27 hours on a computing cluster using 100GB memory.
For more details regarding the multivariate tests, the multivariate rare-variant associa-
tion test (MURAT; Sun et al., 2016b) is a multivariate generalization of the multi-marker
test SKAT, and derives a data-adaptive variance-component test based on a Score-type test
statistic, testing the overall effect of all SNVs on all traits. It is based on a multivariate ver-
sion of the linear mixed model in (4.1.5) with multivariate Y including p traits, assuming that
the effects (βXY,j,l)j=1,...,k;l=1,...,p of SNVs Xj on traits Yl follow a multivariate normal distri-
bution, with a common correlation ρ between the effects of the same SNV on the different
traits, cor(βXY,l,j , βXY,l′,j) = ρ for all 1 ≤ l, l′ ≤ p, and uncorrelated genetic effects of different
SNVs, cor(βXY,l,j , βXY,l,j′) = cor(βXY,l,j , βXY,l′,j′) = 0 for all j ̸= j′, 1 ≤ l, l′ ≤ p. MURAT
was computed using the MURAT() function in the R package of the same name (available
through install_github("GreenwoodLab/MURAT")), with default settings and the weight
matrix in the test statistic based on the Beta distribution (see Supplementary Figure A.1 for
an illustration), with weights wj ∼ Beta(MAFj , 1, 25) as suggested in Sun et al. (2016b).
MultiPhen (O’Reilly, 2012) inverts the standard approach of regressing phenotypes on
genotypes, and proposes to use proportional odds logistic regression to predict each geno-
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type Xj by the multiple phenotypes Y1, . . . , Yp. MultiPhen was computed using the mPhen()
function in the MultiPhen R package with default settings, which returns SMTs of the regres-
sion coefficients, testing the association of each SNV with each trait separately. In addition,
a LRT is performed to test the association of each SNV Xj with all traits, i.e. testing
H0 : βXY,j,1 = · · · = βXY,j,p = 0 where βXY,j,l is the effect of the phenotype Yl on Xj (’joint
model’ in the R package). Hence, MultiPhen performs SMTs, and the minP approach was
used to obtain gene-level tests of the null hypothesis in (2.2.2), with a Bonferroni correction
to adjust for the multiple tests of SNVs in a gene.
Finally, the multivariate aSPU, aSPUset, and aSPUset-Score tests are multivariate data-
adaptive tests which obtain the optimal combination of different powered score test statistics.
For this, they fit a multivariate marginal (generalized) linear model of the p traits Y1, . . . , Yp
conditional on one SNV (aSPU) or multiple SNVs (aSPUset, aSPUset-Score) using GEEs.
The test statistics are then derived as follows. Let Uβ denote the subcomponents of the score
vector with respect to the parameters of the genetic effects of interest. Then, the multivariate
single-marker aSPU test of a SNV Xj with all p traits takes the minimum p-value over all
p-values pκ, κ ∈ K, which are obtained based on the powered test statistics
SPU (κ) =
p∑
l=1
(Uβ,j,l)
κ .
Hence, the aSPU test chooses adaptively the optimum from the different powered test statis-
tics SPU (κ). Here, SPU(1) yields a burden-type test, SPU(2) yields a variance-component-
type test, and SPU(∞) is closely related to the TATES approach (van der Sluis et al., 2013).
Kim et al. (2016) suggest to use K = {1, 2, . . . , 8,∞}, and the p-values are computed through
simulations or permutations. For an extension as a multivariate MMT, aSPUset takes the
minimum p-value pκ1,κ2 over all κ1 ∈ K1, κ2 ∈ K2, which amounts to the most powerful
powered score test over all SNVs and traits. More specifically,
SPU (κ1, κ2) =
p∑
l=1
⎡⎢⎣
⎛⎝ k∑
j=1
(Uβ,j,l)
κ1
⎞⎠1/κ1
⎤⎥⎦
κ2
.
Finally, the aSPUset-Score test additionally incorporates the GEE score test statistic, and
derives the p-value as the minimum of the aSPUset and GEE-Score tests. As described in
Kim et al. (2016), the GEE-Score test is equivalent to the MANOVA. In the simulation
study, the three tests were computed using the GEEaSPU() and GEEaSPUset() functions in
the GEEaSPU R package (Kim & Pan, 2016) with powers K1 = K2 = {1, 2, . . . , 8,∞}, an
unstructured correlation structure of Y1, Y2, and otherwise default settings. aSPUset and
aSPUset-Score directly provide multivariate gene-level tests of the null hypothesis in (2.2.2),
i.e. testing the absence of effects of all SNVs on all traits, and aSPU was evaluated with
the minP approach using a Bonferroni correction for testing all SNVs within a gene to yield
gene-level p-values.
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4.2.2 Results
4.2.2.1 Evaluation of C-JAMP parameter estimates and test statistic
First, I investigated the parameter estimates and standard error estimates of the genetic
effect provided by C-JAMP. Slightly biased point estimates were observed for the effect of
SNVs with very few minor alleles (especially for MAC = 1, 2) in addition to deflated/inflated
standard error estimates for Kendall’s τ ≥ 0.5, which can be expected in such situations when
parameter values on the boundary of the parameter space are of interest (Supplementary
Table A.12). Accordingly, the asymptotic distribution assumption for the Wald-type test
may not hold for testing such SNVs with very few alleles (Supplementary Figure A.3 and
Supplementary Tables A.13-A.14), and maximum likelihood (ML) estimation as well as the
large-sample Wald-type test statistic require modification in such finite-sample settings. As
a consequence, adjusted Wald test statistics were obtained for Kendall’s τ ≥ 0.5 based on
an empirical study, which is described in more detail in section A.4.2.1. Supplementary
Figure A.5 shows histograms of the adjusted Wald test statistics, which indicate that they
are well-calibrated. Consequently, the adjusted Wald-test statistics were used for all analyses
of τ = 0.5, 0.8 in the simulation study that are reported in the following.
4.2.2.2 Empirical type I error rates of C-JAMP and other multivariate ap-
proaches
Next, the empirical type I error of C-JAMP based on the Wald test statistics (unadjusted
Wald test statistics for τ = 0.2, and adjusted Wald test statistics for τ = 0.5, 0.8) were
investigated for different nominal levels, to assess whether they are appropriately calibrated.
The results are shown in Table 4.5 and indicate that the empirical type I errors are generally
close to the nominal levels. The Bonferroni correction provides empirical levels closer to the
nominal levels compared to the BH correction and is therefore used in the power evaluation
in the next section.
Additional investigations of C-JAMP confirmed that the empirical type I errors are also
well-calibrated when evaluated on a SNV-level instead of the gene-level (Supplementary Table
A.16). All the reported type I error estimates are for testing the association with the first
trait, Y1, and the results are similar to those when investigating the association with the
second trait, Y2, when none of the two traits are associated with any rare SNV in the gene
(scenario 0 described in Table 4.4). In the scenario that SNVs are only affecting one of the
two traits in the joint model, the empirical type I errors are valid when there is a weak or
moderate dependence between the traits. If the traits have a strong dependence, however,
then the type I errors are slightly inflated (Supplementary Table A.18). Finally, the empirical
type I errors were investigated when the copula function is misspecified and does not correctly
model the observed dependence structure between the traits, by generating traits from the
bivariate normal distribution. In the analysis, the 2-parameter copula was used and did not
show inflated type I errors (Supplementary Table A.17). However, the correctness of the
chosen copula function should still always be checked in a first step. See section A.4.2.2 for
further details.
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Nominal α Dependence
C-JAMP
Bonferroni correction
C-JAMP
BH correction
5× 10−2
τ = 0.2 5.0× 10−2 5.6× 10−2
τ = 0.5 4.6× 10−2 5.1× 10−2
τ = 0.8 4.9× 10−2 5.4× 10−2
10−2
τ = 0.2 1.1× 10−2 1.2× 10−2
τ = 0.5 1.0× 10−2 1.1× 10−2
τ = 0.8 1.1× 10−2 1.2× 10−2
10−3
τ = 0.2 1.2× 10−3 1.3× 10−3
τ = 0.5 1.2× 10−3 1.3× 10−3
τ = 0.8 1.4× 10−3 1.5× 10−3
10−4
τ = 0.2 1.8× 10−4 2.0× 10−4
τ = 0.5 1.6× 10−4 1.7× 10−4
τ = 0.8 1.4× 10−4 1.5× 10−4
10−5
τ = 0.2 3.1× 10−5 3.1× 10−5
τ = 0.5 2.0× 10−5 2.0× 10−5
τ = 0.8 1.0× 10−5 1.0× 10−5
Table 4.5: Empirical type I error estimates of C-JAMP for different nominal α levels. Data was generated
from the null model described in scenario 0 in Table 4.4 for n = 1, 000 individuals with m = 100, 000
replicates, and under different dependencies between the two traits Y1, Y2 (Kendall’s τ = 0.2, 0.5, 0.8).
Adjustments for multiple testing of all SNVs in a gene were done using the Bonferroni or the BH correction.
Type I error estimates are for testing the association with the first trait, Y1, based on the adjusted Wald
test statistics described in section A.4.2.1.
Next, the empirical type I errors of the other multivariate tests were evaluated (see Table
4.6). The results showed that MURAT, the joint test of all traits in MultiPhen, and the
aSPU test all lead to inflated or highly inflated type I errors. The inflated type I errors of
MURAT could be slightly decreased to around 0.1-0.15 when the analysis was restricted to
rare variants with moderate MAF (e.g., with MAC > 5), but was still invalid. The test of the
genetic association with one trait in MultiPhen, on the other hand, provided highly deflated
type I errors and is also not valid. The aSPUset-Score test showed a slight inflation and
the aSPUset test was the only test with valid empirical type I errors. As a result, only the
aSPUset and aSPUset-Score tests were included in the power study.
4.2.2.3 Empirical power of C-JAMP compared to other approaches
For the power evaluation in the following, the adjusted Wald test statistics were used for C-
JAMP with the Bonferroni correction to account for multiple testing of SNVs within a gene.
The BH-correction was used for the SMT. Figure 4.3 shows the power estimates of C-JAMP
and the univariate SMT and MMTs, and Figure 4.4 shows the power of C-JAMP and the
multivariate MMTs, under the scenarios 1-12 described in Table 4.4, when the nominal type
I errors are 0.05 or 2.5× 10−6 (see Supplementary Tables A.19-A.20 for more details).
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Dependence MURAT MultiPhen Y1 MultiPhen Joint aSPU aSPUset aSPUset-Score
τ = 0.2 0.290 0.019 0.298 0.100 0.051 0.054
τ = 0.5 0.210 0.002 0.278 0.101 0.052 0.058
τ = 0.8 0.127 0.004 0.225 0.090 0.053 0.056
Table 4.6: Empirical type I error estimates of the considered multivariate tests for a nominal α level of
0.05. Data was generated from the null model described in scenario 0 in Table 4.4 for n = 1, 000 individuals
with m = 10, 000 replicates, and under different dependencies between the two traits Y1, Y2 (Kendall’s
τ = 0.2, 0.5, 0.8). Adjustments for multiple testing of all SNVs in a gene with MultiPhen and aSPU were
done using the Bonferroni correction. Type I error estimates are for testing the association with the first
trait Y1 in ’MultiPhen Y1’, and for testing the joint association with both Y1 and Y2 in all other tests.
The results in Figure 4.3 show that first, the power of C-JAMP increases with increasing
dependence between the traits. Second, in comparison to the SMT based on a univariate
model of the traits, C-JAMP leads to consistently higher power, and the power gain is larger
when there is a higher dependence between the two traits. Comparing C-JAMP with the
univariate MMTs when two strongly dependent traits are incorporated into the analysis, C-
JAMP is always more powerful than all univariate MMTs except when 50% of all rare SNVs
are causal and they have moderate or small effect sizes all in the same direction. Since the
power of C-JAMP (and the SMT) is not affected when some SNVs have a positive and some a
negative effect direction (scenarios 13-36 in Table 4.1), C-JAMP has higher power compared
to all other approaches in these scenarios.
Regarding the power of the multivariate aSPUset and aSPUset-Score tests shown in Figure
4.4, they are inversely affected by the dependence between traits: if the dependence between
traits increases, their power decreases. The power of aSPUset-Score is always higher compared
to aSPUset. Furthermore, the power of C-JAMP is consistently much higher compared to
both tests except when the dependence between traits is τ = 0.2, there are 20% causal SNVs
in a gene and effect sizes are high or there are 50% causal SNVs in a gene. Then, the power
of aSPUset-Score is similar to C-JAMP or slightly higher (scenarios 11, 12). In comparison
to SKAT-O, aSPUset-Score has higher power for τ = 0.2 and large effect sizes, and smaller
power in all other situations. In sensitivity checks, the SPU tests and aSPU were computed
with other correlation structures for modeling the dependence between traits (unstructured,
independence, exchangeable), with other power sets, and for analyzing only rare SNVs in a
gene, and the results were very similar.
Furthermore, if the genetic effects are only affecting the first trait and are absent on the
second trait (scenarios 13-17), then the power of C-JAMP is not affected and does not de-
crease (see Supplementary Table A.21). The power of aSPUset and aSPUset-Score, however,
decreases markedly when the genetic effect is absent or smaller on the second trait. As a sum-
mary, the results of the simulation study showed that SMTs based on joint copula models
outperform all other considered tests in almost all considered scenarios.
50 CHAPTER 4. EVALUATION OF STATISTICAL METHODS
l l l
l
l l
l
l
l
l
l
l
l l l l l l
l
l l
l
l
l
N
om
inal α
 =
 0.05
N
om
inal α
 =
 2.5
×
10
−6
1 2 
 5% SNVs causal
3 4 5 
 10% SNVs causal
6 7 8 
 20% SNVs causal
9 10 11 
 50% SNVs causal
12
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
Scenario
P
ow
er
Method lSKATSKAT−O
Burden
SMT
C−JAMP, τ = 0.2
C−JAMP, τ = 0.5
C−JAMP, τ = 0.8
Figure 4.3: Empirical power estimates of C-JAMP versus the univariate SMT and MMTs. Data was
generated under an alternative-hypothesis model described in scenarios 1-12 in Table 4.4 for n = 1, 000
individuals with m = 10, 000 replicates. The nominal α was set to 0.05 and 2.5× 10−6. Adjustments for
multiple testing of all rare SNVs in a gene with SMTs were done using the Bonferroni-correction. Power
estimates are for testing the association with the first trait, Y1.
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Figure 4.4: Empirical power estimates of C-JAMP versus multivariate MMTs. Data was generated
under an alternative-hypothesis model described in scenarios 1-12 in Table 4.4 for n = 1, 000 individuals
with m = 10, 000 replicates, and under different dependencies between the two traits Y1, Y2 (Kendall’s
τ = 0.2, 0.5, 0.8). The nominal α was set to 0.05. Adjustments for multiple testing of all rare SNVs
in a gene with C-JAMP were done using the Bonferroni-correction. Power estimates are for testing the
association with the first trait, Y1 for C-JAMP and for testing the association with both traits with aSPUset
and aSPUset-Score.
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4.3 CIEE
4.3.1 Material and methods
In the simulation studies to evaluate CIEE and existing methods, first, the properties of
the coefficient estimates αˆXY were investigated, and whether the effect of the intermediate
phenotype K is successfully removed from the primary phenotype Y . Next, the empirical
type I error and power estimates were assessed. For a quantitative primary phenotype, CIEE
was compared with the two na¨ıve regression approaches (MR and RR), the sequential G-
estimation method (Vansteelandt et al., 2009) and the SEM method (Bollen, 1989; Rosseel,
2012). Under the AFT model, CIEE was compared to the na¨ıve MR approach and the
extension of the sequential G-estimation method proposed by Lipman et al. (2011). A
general overview about the data generation is given in Box 4.1, and details of the scenarios
and parameter values can be found in Tables 4.7-4.8 and are visualized in Figure 4.5.
For the LM setting, data was generated from
Ui ∼ N
(
µU , σ
2
U
)
Xi ∼ Bin (n = 2, p = MAFX)
Li = αULui + αXLxi + εL,i; εL,i ∼ N
(
µL, σ
2
L
)
Ki = αXKxi + αLK li + εK,i; εK,i ∼ N
(
µK , σ
2
K
)
Yi = αUY ui + αKY ki + αXY xi + αLY li + εY,i; εY,i ∼ N
(
µY , σ
2
Y
)
For the data generation under the AFT setting, the following additional steps were
followed. First, the time-to-event phenotype Ti = exp(Yi) was generated for each
individual i = 1, . . . , n. Then, the right-censoring time Ci was generated from the
uniform distribution with parameters a, b so that on average, k% of the individuals
were censored as pre-specified:
Ci ∼ Unif(a, b)
The observed time-to-event data ti is then the minimum of Ci and Ti, ti = min(Ci, Ti),
and the censoring indicator δ is δi =
⎧⎨⎩1 if ti = Ti0 if ti = Ci .
The parameters a, b were chosen as described in Table 4.8.
Box 4.1: Overview of data generation in the CIEE simulation study.
The genetic marker X was generated with an additive genetic coding for minor allele
frequencies MAFX = 0.05, 0.1, 0.2, 0.4. The phenotypes and factors were then generated
from different subgraphs of the DAG in Figure 3.4 with different effect sizes, for a sample of
n = 1, 000 individuals and using m = 10, 000 replication datasets. Under the AFT model,
time-to-event traits with 10%, 30%, and 50% censoring were considered. The effect sizes
were set to simulate realistic situations with small genetic effects and small/moderate effects
of the intermediate phenotype and the measured as well as unmeasured factors on the pri-
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mary phenotype (scenarios 1-5). Under the LM null model, two additional scenarios were
investigated where scenario 6 contains confounding of the indirect effect through measured
factors, and scenario 7 equals scenario 4 but with larger effect sizes. In scenario 6, while
the data generation contains a non-zero effect of L on Y , the CIEE, SEM, and sequential
G-estimation methods assume αLY = 0 in the analysis, providing a test of robustness against
model misspecification.
Setting Investigation Scenario Censoring MAFX αUL αXL αXK αLK αLY αUY αKY αXY
LM
Type I error
1 – 0.05; 0.1; 0.2; 0.4 0 0 0.2 0 0 0 0.3 0
2 – 0.05; 0.1; 0.2; 0.4 0 0.2 0.2 0.3 0 0 0.3 0
3 – 0.05; 0.1; 0.2; 0.4 0.3 0.2 0.2 0.3 0 0 0.3 0
4 – 0.05; 0.1; 0.2; 0.4 0.3 0.2 0.2 0.3 0 0.3 0.3 0
5 – 0.05; 0.1; 0.2; 0.4 0.3 0.2 0.2 0.3 0 0.3 0 0
6 – 0.05; 0.1; 0.2; 0.4 0 0 0.2 0.3 0.3 0 0.3 0
7 – 0.05; 0.1; 0.2; 0.4 0.5 1 1 0.5 0 0.5 1 0
Power
1 – 0.2 0 0 0.2 0 0 0 0.3 0.1; 0.2
2 – 0.2 0 0.2 0.2 0.3 0 0 0.3 0.1; 0.2
3 – 0.2 0.3 0.2 0.2 0.3 0 0 0.3 0.1; 0.2
4 – 0.2 0.3 0.2 0.2 0.3 0 0.3 0.3 0.1; 0.2
5 – 0.2 0.3 0.2 0.2 0.3 0 0.3 0 0.1; 0.2
AFT
Type I error
1 10%; 30%; 50% 0.2 0 0 0.2 0 0 0 0.3 0
2 10%; 30%; 50% 0.2 0 0.2 0.2 0.3 0 0 0.3 0
3 10%; 30%; 50% 0.2 0.3 0.2 0.2 0.3 0 0 0.3 0
4 10%; 30%; 50% 0.2 0.3 0.2 0.2 0.3 0 0.3 0.3 0
5 10%; 30%; 50% 0.2 0.3 0.2 0.2 0.3 0 0.3 0 0
Power
1 30% 0.2 0 0 0.2 0 0 0 0.3 0.1; 0.2
2 30% 0.2 0 0.2 0.2 0.3 0 0 0.3 0.1; 0.2
3 30% 0.2 0.3 0.2 0.2 0.3 0 0 0.3 0.1; 0.2
4 30% 0.2 0.3 0.2 0.2 0.3 0 0.3 0.3 0.1; 0.2
5 30% 0.2 0.3 0.2 0.2 0.3 0 0.3 0 0.1; 0.2
Table 4.7: Overview of the scenarios considered in the simulation study of CIEE. In all scenarios, data was
generated for n = 1, 000 individuals andm = 10, 000 replicates, with αUX = 0, µU = µL = µK = µY = 0,
σ2U = σ
2
L = σ
2
K = σ
2
Y = 1.
Investigation Scenario Censoring αXY a b
Type I error
1 10%; 30%; 50% 0 0.3; 0.2; 0 14.75; 4.55; 2.48
2 10%; 30%; 50% 0 0.3; 0.2; 0 14.90; 4.58; 2.49
3 10%; 30%; 50% 0 0.3; 0.2; 0 15.00; 4.58; 2.49
4 10%; 30%; 50% 0 0.3; 0.2; 0 15.80; 4.70; 2.50
5 10%; 30%; 50% 0 0.3; 0.2; 0 14.25; 4.40; 2.42
Power
1 30% 0.1; 0.2 0.2 4.75; 5.00
2 30% 0.1; 0.2 0.2 4.81; 5.05
3 30% 0.1; 0.2 0.2 4.80; 5.05
4 30% 0.1; 0.2 0.2 4.94; 5.17
5 30% 0.1; 0.2 0.2 4.60; 4.85
Table 4.8: Overview of the parameters a, b in the Uniform distribution Unif(a, b) used to generate
censoring times in the simulation study of CIEE.
For CIEE, sandwich standard error estimates were obtained and Wald-type test were
performed. Also, standard errors were obtained using nonparametric bootstrap (with B =
1, 000 resamples). For the two traditional approaches, MR and RR, estimates of αXY were
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obtained from fitting the models in equations (3.2.17)-(3.2.19), and hypothesis tests of H0 :
αXY = 0 versus HA : αXY ̸= 0 were performed by using the mult_reg() and res_reg()
functions in the CIEE R package as described in section 3.2.2.2. In order to obtain estimates
of αXY and its standard error estimate under the SEM method and test H0 : αXY = 0
versus HA : αXY ̸= 0, the sem() function in the lavaan R package (Rosseel, 2012) was used
through the sem_appl() function in the CIEE R package with default settings as described in
section 3.2.2.2. To apply the sequential G-estimation methods, the functions CGcont() and
CGsurvreg() in the R package CGene (Lipman & Lange, 2011), obtained from https://cran
.r-project.org/src/contrib/Archive/CGene/, were used with default values and adapted
to the considered log-linear model for the analysis.
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Figure 4.5: Overview of the scenarios considered in the simulation study of CIEE. The models are sub-
models of the DAG in Figure 3.4 with some of the effects set to 0. Scenario 7 in the LM setting equals
scenario 4 in this figure with larger effect sizes. Scenario 6 in the LM setting contains a non-zero effect
of L on Y in the data generation, providing a test of robustness against model misspecification. Nonzero
direct effects of X on Y are considered under each scenario to investigate the power of the approaches.
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4.3.2 Results
4.3.2.1 Estimation of coefficients and standard errors
First, the coefficient estimates αˆXY of the direct genetic effect and their standard error
estimates were investigated for all methods, for the analysis of quantitative and time-to-
event primary phenotypes, under the null and alternative hypotheses (see Supplementary
Tables A.22-A.25). The results showed that the CIEE point estimates of the direct genetic
effect are unbiased across all scenarios. Also, the standard error estimates based on the
estimating equations’ Huber-White sandwich estimate, nonparametric bootstrap, and the
empirical standard deviation of point estimates (Supplementary Table A.26) were identical
up to 2 decimals. Further checks showed that the effect of K on Y was successfully removed
using the CIEE method so that Y˜ is uncorrelated with K (data not shown).
Regarding the na¨ıve approaches, the coefficient estimates under the MR and RR models
showed some bias whenever there was some unmeasured confounding (scenarios 4, 5 and
7 in Supplementary Table A.22 under the null hypothesis in the LM setting). The direct
effect can be underestimated as in the scenarios considered here, or overestimated if, for
example, the unmeasured confounding effect of U on Y is negative. When the effect of
the intermediate on the primary phenotype is only confounded through measured factors in
scenario 6, then both methods provide unbiased genetic effect estimates. The SEM genetic
effect estimates only showed some bias when there was a higher amount of unmeasured
confounding (scenario 7 under the null hypothesis in the LM setting), or when the DAG model
was misspecified (scenario 6 under the null hypothesis in the LM setting, when the estimation
falsely assumed αLY = 0 while the data was generated with αLY = 0.3). However, when the
model was changed to correctly model an effect of L on Y in scenario 6, then unbiased
genetic effect estimates were obtained (data not shown). The standard error estimates of
αˆXY obtained through MR, RR and SEM were close to the CIEE standard error estimates
when the amount of unmeasured confounding was small or medium. Under scenario 7, the
RR modeling approach underestimated the standard errors.
Among the investigated sequential G-estimation approaches, the method for analyzing
quantitative traits (Vansteelandt et al., 2009) provided the same unbiased genetic effect es-
timates as CIEE, however, the approach for time-to-event traits (Lipman et al., 2011) does
not remove the effect of the intermediate phenotype (see section A.4.3 in the appendix for
further details) and provided strongly biased direct effect estimates whenever there was some
effect of K on Y (Supplementary Tables A.24-A.25). In addition, the sequential G-estimation
methods do not provide a standard error estimate of the estimated direct genetic effect.
4.3.2.2 Empirical type I error and power
As a direct consequence of the bias of genetic effect estimates discussed above, all investigated
approaches except for the proposed CIEE method and the sequential G-estimation method
for continuous traits led to inflated empirical type I errors in some scenarios (see Tables 4.9-
4.10). Inference based on CIEE is valid for different MAFs of X, different effect sizes, with
a small or moderate amount of censoring under the AFT model setting, and also if unmea-
sured confounding through L is present. Statistical inference remains also valid for heavy
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censoring under the AFT model setting (e.g., 80% censoring) when there is no unmeasured
confounding (data not shown). In addition, CIEE is robust against distributional misspec-
ifications. For example, when Y given X, K, L, U is not normally distributed but follows
a t4, t8, or log-normal distribution, estimates of αXY remain unbiased and type I errors are
valid (Supplementary Table A.26).
Scenario MAF CIEE BS G-EST MR RR SEM
1
0.05 5.45% 5.40% 5.03% 5.35% 5.29% 5.04%
0.1 5.26% 5.18% 5.05% 5.34% 5.23% 5.05%
0.2 4.83% 4.88% 4.76% 4.94% 4.87% 5.34%
0.4 5.16% 5.17% 5.12% 5.06% 4.80% 5.24%
2
0.05 5.17% 5.12% 4.77% 4.71% 4.67% 5.57%
0.1 5.16% 5.13% 5.02% 5.12% 4.99% 4.75%
0.2 5.01% 4.91% 4.87% 5.16% 4.90% 5.46%
0.4 5.14% 5.14% 5.06% 4.91% 4.54% 4.86%
3
0.05 5.37% 5.27% 4.89% 4.89% 4.82% 5.18%
0.1 5.17% 5.11% 4.99% 5.00% 4.87% 4.85%
0.2 4.89% 4.90% 4.81% 5.25% 4.95% 5.19%
0.4 5.06% 4.96% 4.97% 4.77% 4.38% 5.21%
4
0.05 5.44% 5.30% 4.98% 5.15% 5.10% 5.32%
0.1 5.25% 5.21% 4.99% 5.27% 5.13% 4.87%
0.2 4.81% 4.79% 4.73% 6.03% 5.68% 4.98%
0.4 5.09% 5.14% 5.03% 5.90% 5.48% 5.43%
5
0.05 5.26% 5.11% 4.83% 4.94% 4.82% 5.42%
0.1 5.08% 5.02% 4.91% 5.42% 5.23% 5.24%
0.2 4.91% 4.93% 4.88% 6.01% 5.69% 5.42%
0.4 5.12% 5.14% 5.07% 6.11% 5.75% 5.40%
6
0.05 5.14% 5.21% 4.57% 5.35% 5.29% 5.62%
0.1 5.29% 5.27% 5.10% 5.13% 5.08% 5.83%
0.2 5.03% 4.99% 4.83% 5.25% 5.01% 6.01%
0.4 5.09% 5.04% 4.96% 4.94% 4.68% 6.33%
7
0.05 5.06% 4.97% 4.61% 36.14% 30.45% 21.33%
0.1 5.05% 5.16% 4.94% 56.37% 45.31% 33.26%
0.2 4.97% 4.93% 4.94% 73.78% 54.86% 45.47%
0.4 5.18% 5.23% 5.17% 82.96% 59.54% 55.24%
Table 4.9: Empirical type I error estimates of CIEE and the other considered approaches under the null
hypothesis in the LM setting. Data was generated for n = 1, 000 individuals and m = 10, 000 replicates.
CIEE is the proposed method using estimating equations; BS is CIEE using nonparametric bootstrap
standard errors; G-EST is the sequential G-estimation approach (Vansteelandt et al., 2009); MR is multiple
regression; RR is residual regression; and SEM is structural equation modeling.
The traditional methods provide valid testing whenever there is no unmeasured confound-
ing with RR being consistently more conservative (Table 4.9). SEM is slightly more robust
to small unmeasured confounding but had inflated type I error for larger unmeasured con-
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founding (scenario 7) or when the DAG model was misspecified (scenario 6). The sequential
G-estimation method (Vansteelandt et al., 2009) leads to valid type I errors for all consid-
ered scenarios when quantitative traits are analyzed. For the analysis of time-to-event traits,
however, the proposed G-estimation approach (Lipman et al., 2011) provides largely inflated
type I errors across almost all scenarios (Table 4.10).
Scenario Censoring CIEE BS G-EST MR
1
10% 5.29% 5.29% 22.81% 4.82%
30% 5.24% 5.13% 24.98% 5.00%
50% 5.29% 5.33% 20.24% 5.28%
2
10% 5.15% 5.45% 34.48% 5.28%
30% 5.13% 5.29% 37.83% 5.15%
50% 5.14% 5.20% 30.33% 4.74%
3
10% 5.10% 5.12% 34.54% 5.34%
30% 4.94% 4.92% 37.25% 5.30%
50% 4.88% 4.77% 30.66% 4.84%
4
10% 5.23% 5.19% 31.59% 6.07%
30% 5.15% 5.15% 35.40% 6.17%
50% 5.24% 5.14% 29.43% 5.68%
5
10% 5.15% 5.27% 4.94% 6.17%
30% 4.98% 5.08% 4.80% 5.79%
50% 4.93% 4.84% 4.33% 5.73%
Table 4.10: Empirical type I error estimates of CIEE and the other considered approaches under the null
hypothesis in the AFT setting. Data was generated for n = 1, 000 individuals and m = 10, 000 replicates.
The MAF of the marker X was set to 0.2. CIEE is the proposed method using estimating equations; BS
is CIEE using nonparametric bootstrap standard errors; G-EST is the sequential G-estimation approach
(Lipman et al., 2011); and MR is multiple log-linear censored regression.
For the power study, the same scenarios of the type I error study were considered under
the LM and AFT models, with direct genetic effect sizes αXY = 0.1, 0.2. The results were
highly consistent across all scenarios both for the analysis of quantitative traits (Table 4.11)
and time-to-event traits (Table 4.12). They showed that all approaches have very similar
power in each scenario where they have valid type I error. It is noteworthy that CIEE does
not lose power compared to the traditional approaches in scenarios 1-3 where they have valid
type I error. Furthermore, in the presence of unmeasured confounding in scenarios 4-5, the
power of CIEE decreases only minimally while the traditional methods have inflated type I
error (as well as lower power) and should not be applied.
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Scenario αXY CIEE BS G-EST MR RR SEM
1
0.1 42.33% 42.26% 41.98% 43.13% 42.63% 42.31%
0.2 94.62% 94.59% 94.54% 94.81% 94.68% 94.13%
2
0.1 42.52% 42.40% 42.22% 41.55% 40.53% 43.51%
0.2 94.22% 94.09% 94.09% 94.18% 93.81% 94.15%
3
0.1 42.35% 42.30% 41.98% 42.85% 41.90% 42.32%
0.2 94.20% 94.17% 94.06% 94.03% 93.68% 94.17%
4
0.1 39.90% 39.74% 39.53% 30.12% 29.30% 35.85%
0.2 91.88% 91.88% 91.78% 87.92% 87.38% 90.26%
5
0.1 39.04% 38.99% 38.76% 28.79% 28.11% 35.56%
0.2 92.48% 92.44% 92.38% 87.10% 86.66% 90.46%
Table 4.11: Empirical power estimates of CIEE and the other considered approaches under the alternative
hypotheses in the LM setting. In all scenarios, data was generated for n = 1, 000 individuals and m =
10, 000 replicates. The MAF of the marker X was set to 0.2. CIEE is the proposed method using estimating
equations; BS is CIEE using nonparametric bootstrap standard errors; G-EST is the sequential G-estimation
approach (Vansteelandt et al., 2009); MR is multiple regression; RR is residual regression. Highlighted in
red are those scenarios where the methods had inflated type I error so that their empirical power cannot
be interpreted.
Scenario αXY CIEE BS MR
1
0.1 38.30% 38.15% 38.15%
0.2 91.14% 91.10% 91.30%
2
0.1 38.24% 38.02% 37.50%
0.2 90.85% 90.86% 91.04%
3
0.1 38.15% 37.94% 37.54%
0.2 90.79% 90.74% 90.57%
4
0.1 35.37% 35.10% 25.85%
0.2 88.23% 88.14% 82.04%
5
0.1 35.46% 35.25% 25.90%
0.2 88.73% 88.52% 83.49%
Table 4.12: Empirical power estimates of CIEE and the other considered approaches under the alternative
hypotheses in the AFT setting. Data was generated for n = 1, 000 individuals and m = 10, 000 replicates
for a genetic marker with MAFX = 0.2, with 30% censoring. CIEE is the proposed method using estimating
equations; BS is CIEE using nonparametric bootstrap standard errors; and MR is the multiple log-linear
censored regression approach. Highlighted in red are those scenarios where MR had inflated type I error so
that its empirical power cannot be interpreted.
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Chapter 5
Applications of C-JAMP and CIEE
5.1 Genetic effects on blood pressure
In this section, the application of C-JAMP and CIEE to the Genetic Analysis 19 (GAW19)
data is described, with the goals (i) to identify genetic variants associated with BP by testing
in a joint model of BP and gene expression using C-JAMP, and (ii) to identify direct genetic
effects on BP by removing indirect effects through gene expression using CIEE. Both ap-
proaches were compared to traditional regression approaches, and C-JAMP was compared to
popular MMTs as well. In an additional study, the comparison of a simple SMT and MMTs
in the analysis of the GAW19 data is described in the appendix in section A.4.1.4.
5.1.1 Material and methods
5.1.1.1 Sample characteristics and data description
The analyses described in this section are based on the family dataset of the GAW19, which
contains information on 157 unrelated individuals from the San Antonio family studies pedi-
grees, including SBP and diastolic BP measurements, information regarding current use of
antihypertensive medication, and nongenetic covariates (sex, age, and current tobacco smok-
ing status) at one or more examination time points. Further information about the sample or
other covariates were not available for analysis, see Blangero et al. (2016) for a detailed data
description. Gene expression (GE) measurements in lymphocytes at the first time point are
available for 20,634 transcripts, which were already quality-checked, filtered for detectable
expression, and quantile-normalized. For n = 113 unrelated individuals, complete data is
available for BP, GE, and the nongenetic covariates, and among them, n = 81 individuals
have whole-genome sequence data. The genetic association analyses were conducted in this
subset of n = 81 unrelated individuals, which included 34 men and 47 women, with a mean age
of 53.1 years (SD=14.9 years) and a mean systolic blood pressure of 127.9 mmHg (SD=20.5
mmHg). 26% of the individuals were smoking, and 20% took anti-hypertensive medication.
The sequence data is available for odd-numbered chromosomes and was first processed before
the analysis, with standard quality control checks and the exclusion of SNVs with more than
20% missing base calls. BP measurements and nongenetic covariates are analyzed at the first
time point and of the two BP phenotypes, only SBP is considered.
In the analysis, I focused on SNVs on chromosome 19, as it contains the transcript with
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the highest association with SBP (IL12RB1, Kendall’s τ=0.24, p=2.5 × 10−4) among all
11,542 available mapped transcripts, and it can be hypothesized that its analysis could lead
to the largest power increase under the joint copula model compared to univariate models.
The gene expression of all measured 848 transcripts on chromosome 19 was investigated in
the analysis. In the C-JAMP analysis, all k = 68, 727 non-monomorphic, biallelic SNVs with
MAF equal to or greater than 0.015 (i.e., with at least 3 copies of the minor allele) lying
in cis within 5kb of the 848 genes were analyzed separately in copula models of SBP and
the corresponding GE. The smallest gene contained 4 SNVs and the largest gene contained
920 SNVs. Of the k = 68, 727 variants, 18,916 were rare variants with MAF between 0.015
and 0.05 (inclusive), and the remaining 49,811 variants had a MAF greater than 0.05. In
the CIEE analysis, the analysis was further restricted to SNVs with MAF greater than 0.05
which yielded k = 45, 200 SNVs after additional quality checks for the analysis. To obtain
physical positions of genes and SNVs, the annotations in the provided variant call format
(VCF) files, the provided mapping of gene names, and the Ensembl database with reference
genome GRCh37.p13 through BioMart were used.
5.1.1.2 Statistical details of C-JAMP analysis
In a preparatory step of phenotype definition for the C-JAMP analysis, the SBP and gene
expression measures were adjusted for the effect of the nongenetic covariates, including antihy-
pertensive medication. Adjusting SBP for the effect of BP-lowering medication is important
when the objective is to explain the variation in SBP (Tobin et al., 2005; Konigorski et al.,
2014). Following the method described in Konigorski et al. (2014), a censored regression
model was fitted conditional on the nongenetic covariates age, sex, and smoking status, with
medication use as a censoring indicator δ. For treated individuals, the ”true” underlying SBP
was estimated from the conditional expectation of SBP, given that the observed SBP is lower
than the true SBP, and also conditional on the nongenetic covariates. For further analysis,
adjusted SBP phenotypes SBPadj are the residuals obtained as follows: an untreated individ-
ual’s adjusted SBP is the difference between observed and fitted SBP; a treated individual’s
adjusted SBP is the difference between estimated true and fitted SBP. Adjusted gene expres-
sion phenotypes GEs,adj , s = 1, . . . , 848, for the following analysis steps are residuals obtained
from fitting a linear regression for each GEs on the nongenetic covariates age, sex, smoking
status, and antihypertensive medication.
In the genetic association analysis, a copula model was fitted for the joint distribution of
SBPadj and GEs,adj , s = 1, . . . , 848, conditional on each single variant xj in and around the
gene,
F (SBPadj , GEs,adj |xj) = Cψ(F1(SBPadj |xj), F2(GEs,adj |xj)), (5.1.1)
where Cψ is a copula function from the 2-parameter copula family in equation (3.1.4) with
dependence parameter ψ, and F1 and F2 are the marginal distributions of SBPadj andGEs,adj ,
respectively, with models
SBPadj = α0 + αXY xj + ε, (5.1.2)
GEs,adj = β0 + βXY xj + ε
′. (5.1.3)
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To identify SNVs associated with SBPadj and GEs,adj , the null hypotheses H0 : αXY = 0 (vs.
HA : αXY ̸= 0) and H0 : βXY = 0 (vs. HA : βXY ̸= 0) were tested, respectively, for all SNVs
Xj and genes Gs, by using the large-sample Wald test statistics. On average, 96 SNVs were
tested with each gene expression (some SNVs were tested with more than 1 gene expression
because of gene overlap/proximity).
For a comparison with univariate approaches, standard linear regression models of SBPadj
in equation (5.1.2) and GEs,adj in equation (5.1.3) were fitted independently. Aside these
SMTs, MMTs (a burden test, SKAT, and SKAT-O) were also considered. To have the best
possible performance of the SKAT and SKAT-O as a reference, all possible kernels, p-value
computation methods, and inclusions of variants (in gene only, in and around gene, rare
variants, or rare and common variants) of the SKAT() function in R were used, and the
minimum p-value of all these tests was extracted for a given gene. To assess the significance
of the results corrected for multiple testing, adjusted p-values were calculated using the R
function p.adjust() with the BH-adjustment, which controls the false discovery rate.
5.1.1.3 Statistical details of CIEE analysis
For the CIEE analysis, SBP was chosen as the primary phenotype Y and gene expression
as the secondary phenotype K that could mediate the genetic effect of SNVs Xj on Y . The
primary goal was to identify SNVs with a direct effect on SBP that is not (or only partially)
mediated through gene expression. I assume the underlying DAG in Figure 1.1 (right panel)
and that the covariates age, sex, and smoking are not related to the SNVs under investigation,
but can be confounders (denoted by L1, L2, L3) of the relationship between K and Y . As
described in the previous section, adjusting BP for the effect of BP-lowering medication
is crucial. Hence, this data analysis illustrates an application of CIEE when the primary
phenotype is subject to censoring.
Some of the analyzed 45,200 SNVs were considered for their association with more than
one gene expression, since they were in close proximity to more than one gene. For each of
the 53,151 tested associations, CIEE was applied under the AFT model in equations (3.2.10)-
(3.2.12) with measured confounders L1, L2, L3. Additionally, traditional censored regression
models were computed with or without taking gene expression as secondary phenotype into
account:
MR1 : Yi = α0 + α1l1i + α2l2i + α3l3i + α4ki + αXY xij + εi (5.1.4)
MR2 : Yi = α0 + α1l1i + α2l2i + α3l3i + αXY xij + εi (5.1.5)
5.1.2 Results
5.1.2.1 C-JAMP: Genetic effects on blood pressure and gene expression
For model selection, the Akaike Information Criterion (AIC) was computed. It was observed
that the copula model had a smaller AIC than a bivariate normal model conditional on
any SNV; therefore, it has a better model fit. In addition, the copula model had a smaller
AIC than the working independence model when there was a moderate association between
SBPadj and GEs,adj (i.e., when the estimated Kendall’s τ is greater than 0.11).
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Based on an α level of 0.05 and adjusted p-values, 5 SNVs in the gene CEACAM5 are
identified to be significantly associated with SBP under the copula model (Table 5.1). Addi-
tionally, 1,075 SNVs in 122 different genes are identified to be significantly associated with
their corresponding gene expression as local (cis) expression quantitative trait loci (eQTLs;
Table 5.2). For these significant SNVs, Kendall’s τ between the corresponding gene expression
and SBP is estimated as 0.21 or less. In comparison, none of the 68,727 SNVs are identi-
fied as significant based on the univariate regression model of SBP (Table 5.1), and based
on the univariate regression model of GE, 800 SNVs in 80 genes are significantly associated
with gene expression (Table 5.2). The power gain under the copula model compared to the
univariate model is shown in Figure 5.1, which shows plots of the p-values of all tested SNVs
under the copula model versus the univariate models of SBP and GE. In particular, smaller
p-values are much smaller under the copula model compared to the univariate models. The
power gain can also be obtained when the dependence between SBP and gene expression is
very low, and it is a result of (a) smaller SE estimates of the SNV effect under the copula
model, while point estimates are similar and the mean difference between point estimates is 0,
and (b) the different (asymptotic) null distribution of the association test statistics (normal
vs. t distribution). The top SNVs under the 2 models are in the same order with respect to
p-values, and are rare variants for SBP (Table 5.1), and common variants for gene expression
(Table 5.2).
SNV MAF Location
C-JAMP Univariate
αˆXY (SE) p-value Adj. p-value αˆXY (SE) p-value Adj. p-value
rs10402825 0.04 CEACAM5 (protein coding) 30.77 (6.52) 2.40× 10−6 4.42× 10−2 32.21 (6.63) 6.18× 10−6 1.12× 10−1
rs7258524 0.04 CEACAM5 (upstream) 30.75 (6.56) 2.77× 10−6 4.42× 10−2 32.28 (6.67) 6.86× 10−6 1.71× 10−1
Table 5.1: SNVs associated with SBP (i.e., with the smallest p-values in testing H0 : αXY = 0) using
C-JAMP in the GAW19 analysis, and according results using linear regression. Adj. p-value is the adjusted
p-value with BH-correction. The estimated Kendall’s τ between SBPadj and GECEACAM5,adj is -0.13.
Note: The markers are in very high linkage disequilibrium (LD) (r = 0.99). SNVs rs34155934, rs35091611,
and rs10415940 in the same gene are in perfect LD with rs7258524 and have identical association.
SNV MAF Location
C-JAMP Univariate
βˆXY (SE) p-value Adj. p-value βˆXY (SE) p-value Adj. p-value
rs2314667 0.32 UBA52 (upstream) 0.88 (5.42× 10−02) 6.47× 10−60 1.71× 10−55 0.88 (5.49× 10−02) 3.21× 10−26 8.71× 10−22
rs2314664 0.33 UBA52 (downstream) 0.85 (5.52× 10−02) 5.01× 10−54 7.97× 10−50 0.85 (5.59× 10−02) 7.24× 10−25 1.18× 10−20
rs2314666 0.34 UBA52 (downstream) 0.85 (5.66× 10−02) 2.88× 10−51 3.81× 10−47 0.85 (5.73× 10−02) 3.41× 10−24 4.62× 10−20
Table 5.2: Top 3 SNVs associated with gene expression (i.e., with the three smallest p-values in testing
H0 : βXY = 0) using C-JAMP in the GAW19 analysis, and according results using linear regression.
Adj. p-value is the adjusted p-value with BH-correction. The estimated Kendall’s τ between SBPadj and
GEUBA52,adj is -0.01. Note: The markers in the table are in very high linkage disequilibrium (LD) (with
0.96 ≤ r ≤ 0.99). SNVs rs6554 and rs10425018 in the same gene are in perfect LD with rs2314667 and
have identical association; also rs7258480 is in perfect LD with rs2314664.
After extracting the smallest p-values among all SKAT and SKAT-O options in the SKAT()
function in R and applying a multiple testing correction for p-values, 1 gene is identified to
be associated with SBP (which contains the 5 significant variants identified under the copula
model) and 36 genes are associated with GE. All of these genes are also identified in the
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analysis with C-JAMP. Table 5.3 shows the raw and adjusted p-values of the top genes
identified by SKAT and SKAT-O, and the minimum adjusted p-values of all variants in
or around the corresponding gene under the copula model for comparison. Much smaller
p-values are obtained using the single-variant analysis under the copula model.
SBP
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
ll
l l
l
ll
l
ll
l
lll
l
l
l
ll lll
l
l
l
l
l
ll
l
l
l
ll
l l
l
l
ll
l
l l
l
l
l
ll
l
l
l
l l l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
ll
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
ll
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
lll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
ll l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
0
2
4
0 2 4
GE
l lll
l
lll
l
lll
l l
ll
l
l
l
l
l
l
llll
l
ll
l
ll
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
lll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
0
20
40
60
0 10 20
−0.2
−0.1
0.0
0.1
0.2
Kendall's τ
Univariate LM
C
op
ul
a
Figure 5.1: Scatterplots of p-values from C-JAMP versus linear regression from the GAW19 analysis. The
p-values are from the testing of all common and rare SNVs for H0 : αXY = 0 (for SBP, left panel) and
H0 : βXY = 0 (for GE, right panel), and are shown on a − log10 scale. For each SNV, the strength of
the association (Kendall’s τ) between the gene expression (of the gene containing the SNV) and SBP is
shown by the color of the dots.
The type I error of the test statistics of the 3 modeling approaches was checked using
the observed data (see Figure 5.2). The p-values obtained using C-JAMP and using the
univariate regression models do not appear to show inflated type I errors, and the points
corresponding to high p-values lie on the diagonal line. There is some evidence for an inflated
type I error for the gene-based SKAT and SKAT-O tests, when the minimum p-value of all
options in the SKAT() function is used.
Gene
SKAT/SKAT-O C-JAMP
p-value Adjusted p-value p-value Adjusted p-value
UBA52 1.36× 10−12 1.15× 10−09 6.47× 10−60 1.71× 10−55
IGFLR1 3.79× 10−10 1.61× 10−07 3.74× 10−19 1.24× 10−15
ACP5 3.12× 10−09 8.83× 10−07 4.95× 10−12 5.33× 10−09
CNN2 4.96× 10−07 9.06× 10−05 2.01× 10−14 3.56× 10−11
ANKRD27 5.34× 10−07 9.06× 10−05 6.08× 10−13 7.94× 10−10
Table 5.3: Top 5 genes associated with gene expression (i.e., with the five smallest minimum p-values
in testing H0 : βXY = 0 for all SNVs in/around the gene) using C-JAMP in the GAW19 analysis, with
according p-values using SKAT, SKAT.
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Figure 5.2: Uniform Q-Q plots of the p-values from C-JAMP, univariate regression and SKAT/SKAT-
O from the GAW19 analysis. The p-values are on a − log10 scale from the testing of all common and
rare SNVs for H0 : αXY = 0 under the copula model (left panel), univariate model (middle panel), and
SKAT/SKAT-O (right panel). SNVs/genes which are significant after correcting for multiple testing are
highlighted in blue color.
5.1.2.2 CIEE: Direct genetic effects on blood pressure
Results from CIEE, MR1 and MR2 are shown for the 5 SNVs with the smallest p-values
obtained from testing the absence of the direct effect on SBP using CIEE (Table 5.4). None
of these SNVs were found to be associated with sex, age, or smoking (data not shown). The
SNV rs56202530 with the smallest p-value is upstream of the IL27RA gene, and its direct
effect on SBP is estimated to be -0.148 (SE=0.030, p-value = 7.2 × 10−7) using CIEE, and
-0.080 (SE=0.031, p-value = 9.5×10−3) using MR1. This was the only SNV with an adjusted
p-value less than 0.05 using CIEE. The results obtained through MR1 and MR2 were very
similar to each other. The 5 SNVs with the smallest p-values using MR1 are shown in Table
5.5. None of these SNVs returned an adjusted p-value less than 0.05.
In a comparison of the results using traditional multiple regression and CIEE, for the
SNVs in Table 5.4, the estimated direct effects were in the same direction but larger using
CIEE while estimated standard errors were similar - leading to different conclusions on the
statistical significance of the effect estimates. Assuming the correctness of the underlying
DAG in Figure 1.1 (right panel) and using the results from the simulation study, the most
plausible explanation of the effect estimate differences is that there is unmeasured confounding
of the indirect effect X → K → Y through L in opposite effect direction (e.g., X → Y
negative, U → L negative, L→ K,K → Y,U → Y positive effects). This suggests that using
traditional approaches without accounting for indirect effects of secondary phenotypes and
confounders might miss true causal SNVs (the SNVs 1, 2, 3 and 5 in Table 5.4).
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SNV MAF
αˆXY SˆE(αˆXY ) P-value Adjusted p-value
CIEE MR1 MR2 CIEE MR1 MR2 CIEE MR1 MR2 CIEE MR1 MR2
rs56202530 0.14 IL27RA -0.148 -0.080 -0.087 0.030 0.031 0.034 7.2× 10−7 9.5× 10−3 1.1× 10−2 0.038 1 1
rs3746061 0.05 BTBD2 -0.106 -0.057 -0.055 0.023 0.044 0.044 5.3× 10−6 2.0× 10−1 2.2× 10−1 0.281 1 1
rs60458566 0.13 AP2A1 -0.123 -0.082 -0.079 0.028 0.030 0.030 8.7× 10−6 5.9× 10−3 8.2× 10−3 0.461 1 1
rs62117661 0.09 KLK12 0.256 0.182 0.178 0.058 0.041 0.041 1.0× 10−5 8.7× 10−6 1.4× 10−5 0.552 0.461 1
rs883394 0.25 ACTN4 -0.102 -0.080 -0.062 0.023 0.022 0.023 1.1× 10−5 3.3× 10−4 6.9× 10−3 0.624 1 1
Table 5.4: Top 5 SNVs associated with SBP (i.e., with the five smallest p-values in testing H0 : αXY = 0)
using CIEE in the GAW19 genetic association analysis of 113,890 SNVs on chromosome 19, with the shown
gene (expression) as intermediate phenotype. The SNV is described by its rs identification number. For
these SNVs, point estimates, standard error estimates, raw p-values and Bonferroni-corrected (adjusted)
p-values obtained through CIEE and the multiple regression approaches MR1 and MR2 are shown.
SNV MAF
αˆXY SˆE(αˆXY ) P-value Adjusted p-value
CIEE MR1 MR2 CIEE MR1 MR2 CIEE MR1 MR2 CIEE MR1 MR2
rs62117661 0.09 KLK12 0.256 0.182 0.178 0.058 0.041 0.041 1.0× 10−5 8.7× 10−6 1.4× 10−5 0.552 0.461 1
rs1972785 0.31 ZSCAN5A -0.086 -0.093 -0.092 0.027 0.022 0.022 1.3× 10−3 1.8× 10−5 2.6× 10−5 1 0.936 1
rs62117661 0.09 KLK11 0.252 0.175 0.178 0.059 0.041 0.041 2.2× 10−5 1.8× 10−5 1.4× 10−5 1 0.940 1
rs10415616 0.35 ZSCAN5A -0.071 -0.089 -0.091 0.026 0.021 0.021 5.6× 10−3 1.8× 10−5 1.3× 10−5 1 0.943 1
rs7248173 0.31 ZSCAN5A -0.086 -0.093 -0.092 0.027 0.022 0.022 1.3× 10−3 2.2× 10−5 3.3× 10−5 1 1 1
Table 5.5: Top 5 SNVs associated with SBP (i.e., with the five smallest p-values in testing H0 : αXY = 0)
using the multiple regression model MR1 in the GAW19 genetic association analysis of 113,890 SNVs on
chromosome 19, with the shown gene (expression) as intermediate phenotype. The SNV is described by
its rs identification number. For these SNVs, point estimates, standard error estimates, raw p-values and
Bonferroni-corrected (adjusted) p-values obtained through CIEE and the multiple regression approaches
MR1 and MR2 are shown.
5.2 Genetic and transcriptomic effects on obesity traits
This section describes a study which was conducted to identify novel genetic and transcrip-
tomic loci associated with obesity traits, by measuring SNVs in coding regions, gene expres-
sion in SAT, obesity traits through MRI, and by applying C-JAMP and CIEE. In addition, it
will be shown in the analysis that using C-JAMP allows identifying more associated genetic
markers and genes compared to univariate analyses, and applying CIEE to infer direct genetic
effects identifies SNVs that would be missed by using traditional regression approaches.
5.2.1 Material and methods
5.2.1.1 Sample characteristics and study overview
The study was conducted within the large European Prospective Investigation into Cancer
and Nutrition (EPIC) Potsdam study (Riboli & Kaaks, 1997; Boeing et al., 1999). EPIC
Potsdam is an ongoing cohort study among 27,548 persons aged 35-65 at recruitment between
1994 and 1998 from the general population of the city of Potsdam and surrounding area
in Germany, conducted by the German Institute of Human Nutrition (DIfE) in Potsdam-
Rehbru¨cke, Germany. From 2010 to 2013, a randomly selected sample of 1472 participants,
stratified according to gender and age groups (35-45, 45-55, 55-65 years at baseline), were
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reinvited to the study center (Wientzek et al., 2014). 815 participants (≈ 3% of the original
cohort) attended this re-examination, forming the so-called EPIC Potsdam substudy, and
completed a detailed assessment of body composition, physical activity, diet, biofluid sampling
(Gottschald et al., 2016). MRI data was available on 594 participants (Neamat-Allah et al.,
2014), see section A.4.4.1 for more details, quality control checks, and descriptive statistics.
The MRI scans were performed in the Department of Diagnostic and Interventional Radiology,
Clinic Ernst-von-Bergmann, Potsdam, Germany, and the bioinformatic processing of images
was done at the Division of Medical and Biological Informatics, German Cancer Research
Center (DKFZ), Heidelberg, Germany. SAT biopsies were taken from 278 participants of in
total 673 eligible participants at the DIfE study center in Potsdam, with sufficient material
extracted from 200 participants (see section A.4.4.2). These 200 participants constitute the
sample for this study, with 160 of them having MRI measurements. The study was approved
by the Ethics Committee of the medical association of the state of Brandenburg (Germany)
and all participants provided written informed consent.
From the SAT biopsies, the total RNA was extracted and its quality verified at the Molec-
ular Epidemiology Research Group at the Max-Delbru¨ck-Center for Molecular Medicine in
the Helmholtz Association (MDC), Berlin, Germany (see section A.4.4.3). The RNA was
subsequently purified and prepared for sequencing, using polyA-selection to enrich mRNA,
fragmentation, and random hexamer priming for cDNA synthesis. These steps were per-
formed at the Genetics and Genomics of Cardiovascular Diseases Research Group at the
MDC Berlin. Next, the cDNA was appended with adapters for multiplexing and applied
on the flow cells for sequencing on the Illumina Hi-Seq 2000 at the Genomics Platform at
the MDC Berlin (see section A.4.4.4). 198 probes were sequenced with 6 samples per lane,
yielding on average 64,095,856 raw reads (SD=7,518,970), with minimum 43,373,110 and
maximum 85,591,020 raw reads per probe. 2 samples were sequenced in higher depth on one
lane each, for an evaluation of the sequencing depth. In addition, 6 probes were re-sequenced
due to minor technical problems during their run, and the repeated runs can be used for
reliability analyses. After the sequencing, in a first bioinformatics step, the raw reads were
demultiplexed and quality-controlled (see sections A.4.4.5, A.4.4.6). Next, the reads were
aligned to hg38 (GRCh38) using TopHat2 (Kim et al., 2013) and Bowtie 2 (Langmead &
Salzberg, 2012) and again quality-controlled (sections A.4.4.7, A.4.4.8). The aforementioned
bioinformatic steps were done in collaboration with the Genetics and Genomics of Cardio-
vascular Diseases Research Group at the MDC Berlin. All quality controls as well as the
bioinformatic steps described in the following were conducted by me. After the alignment,
≈50 million single reads (i.e., about 25 million paired reads) were available at high quality
per probe, and about 330 million single reads of the two deeply sequenced probes.
In order to obtain gene expression measures, the aligned reads (after filtering low-quality
reads as well as reads with multiple alignments, and only using properly aligned pairs) were
counted using htseq-count (Anders et al. 2015) and TMM-normalized TPM counts were
obtained (see sections A.4.4.9, A.4.4.10). The transcripts per million (TPM) within-sample
normalization (Li & Dewey, 2011) corrects for biases due to gene length and library size and
the between-sample trimmed mean of M-values (TMM) normalization (Robinson & Oshlack,
2010) computes the trimmed mean of M-values between each pair of samples to account
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for potential sequencing biases. Finally, the normalized read counts were quality-controlled,
low-expressed genes (expressed in less than 25% or the probands) were filtered, and the
Yeo-Johnson transformation (Yeo & Johnson, 2000) was used to remove skewness and yield
normally-distributed gene expression measures (section A.4.4.11). This yielded 30,917 genes
for the main analysis. For all analyses described in the following, the Yeo-Johnson transformed
TMM-normalized TPM counts were used as measure of gene expression.
Finally, in order to investigate genetic variants, SNVs (in coding regions) were called from
the RNA-Seq .bam files using the samtools mpileup tool (Li et al., 2009; Li, 2011). In total,
2,029,767 biallelic SNVs could be called as well as 79,618 multi-allelic (>2) SNVs and IN-
DELS. After quality-checks and filtering of non-monomorphic non-autosomal SNVs, 509,009
biallelic SNVs were retained for the main analysis (section A.4.4.12). Across all SNVs and
samples, the average coverage per position per sample was 6.6. Of the 509,009 SNVs, there
are 122,042 singletons with a MAF of 0.0025 and 34,452 doubletons with MAF=0.005. Fur-
thermore, 46,530 SNVs had MAF between 0.005 and 0.01, 151,114 SNVs had MAF between
0.01 and 0.05, and 153,348 SNVs had MAF greater than 0.05. In the analysis described in
the following, complete data analysis was performed yielding 482,507 SNVs.
In order to reduce the phenotype dimensionality, results of a preliminary study can be
used to choose those measures of body fat mass and body fat distribution as obesity traits,
which might best capture the metabolic activity of AT. In the preliminary study (see sections
A.4.4.13, A.4.4.14), gene expression in SAT and plasma concentrations were assessed of 6
adipokines with an established role in obesity and chronic disease, using quantitative poly-
merase chain reaction (PCR) and enzyme-linked immunosorbent assays (ELISA). As primary
aim, adipokine plasma concentrations were predicted by AT measures and gene expression,
and as secondary aim, the association of the AT measures with gene expression and plasma
levels was investigated (see section A.4.5). The relevant results for this thesis showed that
among the different compartments, SAT and TAT mass had the highest correlation with most
adipokines. Hence, SAT mass is chosen as first obesity trait for the analysis here. Regarding
body fat distribution, the ratio of SAT mass over TAT mass ( SATTAT) is used as second obesity
trait in the analysis. SAT mass was log-transformed for all further analyses so that it is
normally distributed. The association of log(SAT) with SATTAT was τ = 0.36.
5.2.1.2 Statistical details of C-JAMP analyses
In the first part of the analysis, the goal was to identify novel genetic and transcriptomic
obesity loci, by improving the power of association studies through a joint analysis of multiple
obesity traits with C-JAMP. The tested models are shown in Figure 1.2 (left panel), and
described in more detail in the following:
For the genetic association analysis, the following 2-parameter copula models were fitted:
F (Y1, Y2|z) = Cψ(F1(Y1|z), F2(Y2|z)) (5.2.1)
with marginal models
Y1 = α0 + α1z1 + α2z2 + α3z3 + α4z4 + α5z5 + αXY xj + ε, (5.2.2)
Y2 = β0 + β1z1 + β2z2 + β3z3 + β4z4 + β5z5 + βXY xj + ε
′, (5.2.3)
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where Y1 = log(SAT ), Y2 =
SAT
TAT , z = (z1, z2, z3, z4, z5, xj)
T including the SNVs Xj and
covariates Z1=sex, Z2=age, Z3=smoking, Z4=physical activity, Z5=education, and F1 and
F2 are the marginal distributions of Y1 and Y2. These models were fitted sequentially with
C-JAMP for all SNVs Xj , j = 1, . . . , 482, 507, and the large-sample Wald test statistics were
computed to test the null hypothesesH0,j : αXY = 0 (vs. HA,j : αXY ̸= 0) andH0,j : βXY = 0
(vs. HA,j : βXY ̸= 0). Since the dependence between Y1, Y2 is τ = 0.36, the Wald-type test
statistics were not adjusted based on the results in section 4.2.
For the transcriptomic association study, the 2-parameter copula models in equations
(5.2.1)-(5.2.3) were fitted analogously with gene expression (i.e., the Yeo-Johnson transformed
TMM-normalized TPM counts) as predictors Gs:
F (Y1, Y2|z) = Cψ(F1(Y1|z), F2(Y2|z)) (5.2.4)
with marginal models
Y1 = α0 + α1z1 + α2z2 + α3z3 + α4z4 + α5z5 + αGY gs + ε, (5.2.5)
Y2 = β0 + β1z1 + β2z2 + β3z3 + β4z4 + β5z5 + βGY gs + ε
′, (5.2.6)
and Y1 = log(SAT ), Y2 =
SAT
TAT , z = (z1, z2, z3, z4, z5, gs)
T including the Yeo-Johnson trans-
formed TMM-normalized TPM counts Gs and covariates Z1=sex, Z2=age, Z3=smoking,
Z4=physical activity, Z5=education. The model in equations (5.2.4)-(5.2.6) was fitted sep-
arately for all genes Gs, s = 1, . . . , 30, 917, using C-JAMP. MLEs and Wald test statistics
were obtained to test H0,s : αGY = 0 (vs. HA,s : αGY ̸= 0) and H0,s : βGY = 0 (vs.
HA,s : βGY ̸= 0).
For comparison with univariate approaches, linear regression models of equations (5.2.2)-
(5.2.3) and (5.2.5)-(5.2.6) were computed using the lm() function in R with default settings.
Here, the gene expression analysis allows evaluating whether C-JAMP can also increase the
power when testing quantitative predictors.
For an interpretation of the results, the SNVs with smallest p-values from the genetic
association analysis are annotated and discussed regarding their potential function and rel-
evance for obesity. Regarding the transcriptomic study, a follow-up analysis was conducted
to further investigate the associated obesity genes. First, a gene ontology (GO; Gene On-
tology Consortium, 2001) enrichment analysis (Alexa et al., 2006; Grossmann et al., 2007)
was performed in order to identify which gene ontology terms are enriched in the obesity-
associated genes compared to all 30,917 analyzed genes. For this, the topGO R package (Alexa
& Rahnenfu¨hrer, 2016) was used with the biological processes (”BP”) subontology, pruning
GO terms with less than 10 annotated genes before the enrichment analysis, and computing
gene-GO term mappings based on the ensembl gene identifiers. As enrichment tests, classic
Fisher’s exact test and the classic as well as adapted ”elim”Kolmogorov-Smirnoff (KS) gene-
set enrichment analysis tests were computed (Alexa et al., 2006; Ackermann & Strimmer,
2009).
5.2.1.3 Statistical details of CIEE analysis
As will be described in the following results section, the C-JAMP analysis identified 607
autosomal genes whose SAT gene expression levels are associated with either body fat mass
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(log(SAT)), body fat distribution ( SATTAT), or both. Regarding genetic predictors, while C-
JAMP identified some candidate SNVs with suggestive significance, none of the SNVs were
associated with log(SAT) or SATTAT with genome-wide significance. However, it might be the
case that some of the investigated SNVs do have an effect on obesity, but their ”indirect”effect
on obesity through gene expression is in opposite direction of the ”direct” effect on obesity
(which includes all non-measured pathways of the SNV effect on obesity other than through
gene expression). Such SNVs might not be detectable in joint models through C-JAMP or
any other model evaluating overall genetic effects. Therefore, CIEE was used to follow-up
the C-JAMP analysis to search for the presence of such markers.
More specifically, CIEE was used to test direct genetic effects of all 15,895 SNVs within
the 607 autosomal genes identified by C-JAMP, while blocking the indirect genetic effect
on obesity through gene expression and adjusting for the 5 covariates age, sex, smoking,
physical activity, education (see Figure 1.2, right panel). CIEE was computed under the
LM setting in equations (3.2.1)-(3.2.3) with SNVs Xj , primary phenotype Y being log(SAT)
or SATTAT , intermediate phenotype K being the gene expression (the Yeo-Johnson transformed
TMM-normalized TPM counts) of gene Gs containing SNV Xj , and the covariates L1, . . . , L5
being age, sex, smoking, physical activity and education. For comparison, the two traditional
regression approaches MR and RR were computed using the lm() R function with default
settings, with model (5.2.7) for MR and the according model of RR as described in equations
(3.2.18)-(3.2.19).
Y = α0 + α1l1 + α2l2 + α3l3 + α4l4 + α5l5 + α6gs + αXY xj + ε. (5.2.7)
CIEE, MR, and RR models were computed for the primary traits Y = log(SAT) or SATTAT , for
the genes Gs, s = 1, . . . , 607, and the contained SNVs Xj , j = 1, . . . , 15, 895.
5.2.2 Results
5.2.2.1 Descriptive statistics
Descriptive statistics of the study participants regarding their personal characteristics, disease
prevalence and AT measures are shown in Table 5.6. The sample contained slightly more
women than men (57% women, 43% men), with an average age of 65.1 years (SD=9.0 years),
a mean BMI of 27.9 (SD=4.2), and a low prevalence of cardiovascular and cardiometabolic
diseases. SAT was on average 20.1 kg (SD=5.2kg) for women, and 14.8 kg (SD=4.3kg) for
men.
As a validity check of the obtained gene expression measures that are analyzed in the
following, correlations between RNA-Seq and pPCR gene expression estimates were computed
for the 6 candidate genes that were investigated in the preliminary study described in section
A.4.5. The (Pearson) correlations were r = 0.36 for FABP4, r = 0.56 for leptin receptor,
r = 0.58 for adiponectin, and r = 0.85−0.87 for leptin, interleukin-6, and resistin, in line with
previous reports in the literature (Marioni et al., 2008; Wang et al., 2009, Lee et al., 2011).
As further checks, it was observed that the estimated correlations between gene expression
and obesity traits were similar when using RNA-Seq or PCR. For example, the correlation
between leptin gene expression and SAT mass was r = 0.59 using RNA-Seq and r = 0.56
using PCR. See section A.4.4.10 for further validity checks and details.
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Measures Women Men
Sample size 113 87
Age, years 62.9 (9.0) 67.9 (8.2)
Smoking, %
never 55.7 27.6
former 31.0 58.6
current 13.3 13.7
CPAI, %
inactive 9.7 8.0
moderately inactive 27.4 31.0
moderately active 32.3 28.7
active 30.1 32.2
Occupational training, %
no vocational training/ vocational training 41.6 36.8
technical college 27.4 11.5
university 30.1 51.7
Myocardial infarction, % 1 1
Stroke, % 0 0
Heart failure, % 0 0
Diabetes, % 1.8 11.5
Height, cm 162.2 (5.6) 174.2 (6.2)
Weight, kg 73.2 (12.6) 84.5 (11.7)
BMI, kg/m2 27.8 (4.5) 27.9 (3.8)
WC, cm 91.9 (11.7) 102.0 (10.0)
HC, cm 106.0 (10.1) 102.2 (6.5)
WHR 0.9 (0.1) 1.0 (0.1)
MRI AT measures
VAT, kg* 2.9 (1.2) 5.2 (1.7)
CAT, kg* 0.3 (0.1) 0.4 (0.2)
SAT, kg* 20.1 (5.2) 14.8 (4.3)
TAT, kg* 23.7 (5.4) 21.0 (5.9)
Table 5.6: Gender-stratified characteristics of the obesity study population. Values are relative frequencies,
mean and SD, or *median and median absolute deviation. MRI measures do not include arms and head.
CPAI, Cambridge physical activity index; HC, hip circumference.
5.2.2.2 C-JAMP: Genetic effects on obesity
First, results from the genetic association analysis with log(SAT) and SATTAT are reported. In
total, 482,507 SNVs were tested for their association with either trait. Using a significance
threshold of α = 1.0 × 10−7 (i.e., Bonferroni-correction for multiple testing), both C-JAMP
and univariate regression were not able to identify any SNV associated with either trait. Also,
if the analysis was restricted to the 304,457 SNVs with MAF> 0.01, none of the SNVs passed
the respective Bonferroni-adjusted level. Finally, if the genotype-obesity associations were
evaluated on the gene-level (as in section 4.2) instead of on the SNV level using C-JAMP,
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also no genes were identified (using the Bonferroni correction to adjust for testing multiple
SNVs within the gene and for testing multiple genes).
For a comparison of C-JAMP with univariate regression, Tables 5.7-5.8 show the 10
SNVs with smallest p-values under the C-JAMP model together with information about
their genomic position, and with p-values under C-JAMP and univariate regression - with
respect to testing genetic associations with log(SAT) (Table 5.7) and SATTAT (Table 5.8). As
a first observation, the p-values under C-JAMP tests are consistently smaller compared to
p-values under univariate models, for almost all SNVs in Tables 5.7 and 5.8, and also in
general for most other small p-values (see Figure 5.3 for a direct comparison of all p-values).
In addition, it can be noted that almost all of the top SNVs using C-JAMP were also among
the top SNVs using linear regression.
rsID CHROM POS Gene MAF C-JAMP LM
rs2514681 8 100213331 SPAG1 0.11 9.7× 10−7 1.4× 10−5
rs116280906 22 36257940 APOL1 0.03 6.6× 10−6 1.7× 10−5
– 1 29193089 MECR 0.03 1.1× 10−5 1.3× 10−5
– 20 29480155 ABBA01031664.1 0.03 1.5× 10−5 7.3× 10−5
rs8111684 19 48444069 GRIN2D, GRWD1 0.07 1.7× 10−5 7.0× 10−5
rs1284539 1 146994776 NBPF12 0.18 1.8× 10−5 9.0× 10−6
rs150506419 9 32987844 APTX 0.02 1.9× 10−5 3.3× 10−5
rs75033136 14 91871327 FBLN5 0.14 1.9× 10−5 1.0× 10−4
rs75525243 19 19527409 NDUFA13, YJEFN3 0.21 2.0× 10−5 2.9× 10−5
rs72829161 5 148875842 ADRB2, SH3TC2 0.06 2.2× 10−5 2.1× 10−5
Table 5.7: Top SNVs associated with log(SAT) using C-JAMP in the obesity study. Shown are the top
10 SNVs with smallest p-values (for testing H0 : αXY = 0) using C-JAMP, with information about their
genomic position and MAF, and the unadjusted raw p-values from single-marker tests using C-JAMP and
LM. rsID is the reference ID of the SNV.
Regarding a biological interpretation of the C-JAMP results, it was observed that the top
SNVs for body fat mass are very different from the top SNVs for body fat distribution, and all
top hits with respect to SAT don’t show any indication (even p-values<0.05) for an association
with SATTAT , and vice versa. Even though none of the SNVs passed a genome-wide significance
threshold, some of the SNVs in Table 5.7 and 5.8 could be interesting targets for follow-up
analyses. The most direct link might be drawn for rs116280906 in the APOL1 gene, which
encodes the high density apolipoprotein L1 and is involved in cholesterol and lipoprotein
metabolic pathways. rs116280906 was positively associated with SAT mass (αˆXY = 1.48,
SˆEαˆXY = 0.33, p-value=6.6× 10−6) and further investigations indicated that the SAT gene
expression of APOL1 was positively correlated with SAT mass (Pearson correlation r = 0.22,
p-value=0.005) while the SNV showed only a very weak positive association with APOL1
gene expression (βˆ = 0.55, SˆE
βˆ
= 0.30, p-value=0.06 from a linear regression of the gene
expression conditional on the SNV and covariates). This provides interesting hints that
rs116280906 and the APOL1 gene can be interesting candidates for follow-up studies. Other
interesting markers could be rs6838636 in MAN2B2 which is involved in saccharide metabolic
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pathways, and rs1048365 which is in vicinity of the VGF gene involved in insulin pathways
and generation of precursor metabolites.
rsID CHROM POS Gene MAF C-JAMP LM
rs147163321 19 40944788 CYP2B7P 0.01 4.3× 10−7 7.6× 10−6
rs6838636 4 6619461 MAN2B2 0.01 1.5× 10−6 6.6× 10−6
rs1048365 7 101161149 AP1S1, VGF 0.11 2.2× 10−6 5.0× 10−6
rs2303710 5 6602555 NSUN2 0.21 2.4× 10−6 1.8× 10−5
rs3747213 22 44186256 PARVG 0.26 2.6× 10−6 4.7× 10−5
rs60320548 4 187436265 RP11-91J3.3 0.40 2.7× 10−6 2.1× 10−5
– 9 110172513 AKAP2 0.05 3.1× 10−6 4.5× 10−5
rs9912684 17 82915191 TBCD 0.08 3.4× 10−6 2.4× 10−5
rs2368558 14 103764181 PPP1R13B 0.07 3.5× 10−6 2.9× 10−5
rs7374776 3 196555215 WDR53 0.06 3.5× 10−6 4.1× 10−5
Table 5.8: Top SNVs associated with SATTAT using C-JAMP in the obesity study. Shown are the top 10 SNVs
with smallest p-values (for testing H0 : βXY = 0) using C-JAMP, with information about their genomic
position and MAF, and the unadjusted raw p-values from single-marker tests using C-JAMP and LM. rsID
is the reference ID of the SNV.
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Figure 5.3: Scatterplots of p-values from C-JAMP versus linear regression from the genetic association
analysis with obesity traits. P-values are on a − log10 scale from C-JAMP models of SAT and SATTAT
conditional on SNVs and covariates with grey dashed lines at the Bonferroni-adjusted significance threshold,
for the 304,457 out of the 482,507 SNVs with MAF>0.01.
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5.2.2.3 C-JAMP: Transcriptomic effects on obesity
Next, results from the transcriptomic association analysis with log(SAT) and SATTAT are re-
ported. In total, 30,917 genes were each tested for their association with either trait. In a
first step, the results of analyses based on C-JAMP and univariate regression are compared.
Using a transcriptome-wide significance threshold of α = 3.2 × 10−5 (Bonferroni-adjusted
α = 0.05), C-JAMP identified more associated genes (441 with respect to SAT and 225 with
respect to SATTAT) as compared to univariate regression (410 with respect to SAT and 121 genes
with respect to SATTAT). Similarly to the genetic association analyses, C-JAMP and linear re-
gression yield the same top hits in a very similar order, but C-JAMP provides consistently
much smaller p-values. This can be seen in Tables 5.9-5.10 as well as in Figure 5.4, and
confirms the previous results that C-JAMP yields higher power to identify molecular loci
compared to univariate analyses.
CHROM Gene C-JAMP LM GO annotation
3 GLB1 4.7× 10−16 3.9× 10−14 Metabolic & catabolic processes, inflammation
X IRAK1 1.4× 10−15 1.2× 10−13 Signaling pathways, transcription regulation
1 CDC20 2.9× 10−15 3.0× 10−13 Cellular processes
22 SLC7A4 1.1× 10−14 2.5× 10−12 Cell transport
4 PALLD 1.6× 10−14 1.8× 10−12 Cellular processes & transport
22 P2RX6 2.0× 10−14 9.5× 10−13 Signaling pathways, cellular processes
17 ABCC3 7.0× 10−14 4.9× 10−13 Cell transport
12 SPX 7.2× 10−14 1.7× 10−12 Regulation of cardiometabolic processes appetite, blood pressure
17 RASL10B 1.4× 10−13 8.6× 10−13 Signal transduction, regulation of cardiometabolic processes blood pressure, hormones
4 UCHL1 1.7× 10−13 6.5× 10−12 Cell transport, neurological processes
Table 5.9: Top genes whose gene expression is associated with log(SAT) using C-JAMP in the obesity
study. Shown are the top 10 genes with smallest p-values (for testing H0 : βGY = 0) using C-JAMP, with
information about their genomic position, and the p-values using C-JAMP and LM. ’GO Annotation’ is a
summary of the GO terms associated with the gene.
CHROM Gene C-JAMP LM GO annotation
3 ALDH1L1-AS2 4.8× 10−13 6.9× 10−10 –
1 CDKN2C 8.2× 10−13 1.4× 10−10 Cell transport
15 TNFAIP8L3 1.3× 10−12 1.8× 10−10 Signaling pathways, metabolic processes
3 ALDH1L1 2.8× 10−12 8.2× 10−10 Metabolic and catabolic processes
7 GJC3 2.4× 10−11 1.6× 10−09 Neurological & sensory processes
11 PHLDA2 2.4× 10−11 2.3× 10−10 Cell transport, metabolic processes
7 SERPINE1 5.2× 10−11 1.6× 10−08 Cell transport, inflammation
16 LDHD 6.7× 10−11 1.1× 10−09 Metabolic processes
8 TRIM55 8.0× 10−11 2.2× 10−09 Signal transduction
7 AZGP1 8.4× 10−11 5.5× 10−09 Transport of cells & molecules
Table 5.10: Top genes whose gene expression is associated with SATTAT using C-JAMP in the obesity study.
Shown are the top 10 genes with smallest p-values (for testing H0 : βGY = 0) using C-JAMP, with
information about their genomic position, and the p-values using C-JAMP and LM. ’GO Annotation’ is a
summary of the GO terms associated with the gene.
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For a biological interpretation of the results, Tables 5.9-5.10 also show a summary of
the GO terms associated with each gene. While they provide a first idea about the role of
each gene, some of the genes have not been studied extensively, so that these descriptions
should be interpreted with caution. For a more robust picture, the results of C-JAMP were
followed-up with a GO-term enrichment analysis for SAT and SATTAT , respectively, based on the
441 genes associated with SAT and 225 genes associated with SATTAT . The analysis was based
on GO terms related to biological processes, and three different tests for enrichment (Fisher’s
exact test, classic and elim KS) were computed. As the main result of this analysis, the top
ranked GO terms indicate that the genes associated with SAT mass are mostly related to
processes and reactions of the immune system, inflammation, and cell transport. On the other
hand, the genes associated with the relative amount of SAT (i.e., SATTAT) are mostly related to
metabolic and catabolic processes, and immune system processes and inflammation as well.
This matches the results for the top ranked genes but provides a more robust picture.
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Figure 5.4: Scatterplots of p-values from C-JAMP versus linear regression from the transcriptomic asso-
ciation analysis with obesity traits. P-values are on a − log10 scale from C-JAMP models of SAT and SATTAT
conditional on gene expression and covariates with grey dashed lines at the Bonferroni-adjusted significance
threshold α = 3.2× 10−5.
In a more detailed discussion of the results, it can be seen that while some of these
biological processes are identified by all three tests, there are marked differences between the
top-ranked genes of each test. For an illustration, Table 5.11 shows an extract of the results
in form of the top 20 GO terms that are enriched in the 441 SAT-genes and 225 SATTAT -genes,
respectively, based on the classic KS-test. For the full results, see Supplementary Tables
A.28-A.33.
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SAT SATTAT
# GO ID GO term name # GO ID GO term name
1 0002376 immune system process 1 0044710 single-organism metabolic process
2 0006955 immune response 2 0044281 small molecule metabolic process
3 0002682 regulation of immune system process 3 0044699 single-organism process
4 0001775 cell activation 4 0044763 single-organism cellular process
5 0045321 leukocyte activation 5 0002376 immune system process
6 0002252 immune effector process 6 0001775 cell activation
7 0002684 positive regulation of immune system process 7 0006955 immune response
8 0016192 vesicle-mediated transport 8 0045321 leukocyte activation
9 0050776 regulation of immune response 9 0055114 oxidation-reduction process
10 0051234 establishment of localization 10 0006082 organic acid metabolic process
11 0046649 lymphocyte activation 11 0002684 positive regulation of immune system process
12 0051179 localization 12 0043436 oxoacid metabolic process
13 0050778 positive regulation of immune response 13 0002682 regulation of immune system process
14 0006810 transport 14 0032787 monocarboxylic acid metabolic process
15 0002263 cell activation involved in immune response 15 1902578 single-organism localization
16 0042110 T cell activation 16 0006954 inflammatory response
17 0002366 leukocyte activation involved in immune response 17 0019752 carboxylic acid metabolic process
18 0019882 antigen processing and presentation 18 0044765 single-organism transport
19 0048002 antigen processing & presentation of peptide antigen 19 0006091 generation of precursor metabolites and energy
20 0050896 response to stimulus 20 0006629 lipid metabolic process
Table 5.11: Results of the GO term enrichment analysis in the obesity study, of the 441 genes associated
with SAT (left panel) and 225 genes associated with SATTAT (right panel). Shown are the top 20 GO terms
with smallest p-values based on the classic KS test.
5.2.2.4 CIEE: Direct genetic effects on obesity
In a follow-up to the C-JAMP analyses in the previous sections, CIEE was used to test direct
genetic effects of the 15,895 SNVs in the identified 607 genes on both obesity traits, while
removing the indirect effect through gene expression. First checks showed that CIEE did not
provide valid inference for singletons and doubletons, and hence the analysis was restricted
to the 10,238 SNVs with at least 4 observed minor alleles (i.e., MAF≥ 0.01). Using the
genome-wide threshold of α = 1.0 × 10−7, CIEE identified 17 SNVs associated with SAT
and 52 SNVs associated with SATTAT . Of these SNVs, 7 SNVs (1 for SAT and 6 for
SAT
TAT) had
MAF≥ 0.025 (i.e., at least 10 observed minor alleles). An overview about these 7 SNVs with
genomic information and results from CIEE as well as the MR in equation 5.2.7 is shown in
Table 5.12. Regarding the traditional regression approaches MR and RR, both were not able
to identify any associated SNVs using the genome-wide threshold of α = 1.0 × 10−7 or the
more liberal α = 3.1× 10−6 (corrected for testing 15,895 SNVs).
The results in Table 5.12 show that while CIEE and MR provide similar standard error
estimates, the point estimates αˆXY of CIEE are much larger. Based on the results of the
simulation study in section 4.3 and assuming the correctness of the assumed DAG, it is
suggested that there is indeed either an indirect genetic effect in opposing direction of the
direct effect through gene expression, or that there is unmeasured confounding of the indirect
effect, which leads to biased estimates of the direct effect with MR. Regarding a biological
interpretation of the results, of particular interest might be the identified SNVs in GPT2
and ERAP1. GPT2 encodes the enzyme alanine aminotransferase 2 and is involved in the
amino acid metabolism. In our study, the SNV in GPT2 showed a negative association with
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SAT mass. While an unbiased estimation of the indirecte effect of the SNV on SAT mass
through gene expression would require more elaborate methods, the following results can give
some indication on the underlying biology and effects: The SAT gene expression of GPT2
was negatively correlated with SAT mass (Pearson correlation r = −0.22, p-value=0.001)
and while the SNP was not associated with GPT2 gene expression (βˆ = −0.44, SˆE
βˆ
= 0.35,
p-value=0.21), the overall indirect effect might be positive and hence in opposite direction as
the direct effect as estimated by CIEE (αˆXY = −0.96) - which caused MR to provide biased
estimates. Another candidate of interest for follow-up investigations could be ERAP1, which
encodes the endoplasmic reticulum aminopeptidase 1 and is involved in fat cell differentiation,
peptide catabolic processes and blood pressure regulation.
Trait
SNV αˆXY SˆE(αˆXY ) P-value
rsID CHROM POS MAF Gene CIEE MR CIEE MR CIEE MR
SAT – 16 46924178 0.03 GPT2 -0.96 -0.63 0.18 0.29 8.1× 10−8 0.03
SAT
TAT
rs12646586 4 15251025 0.04 RP11-665G4.1 -0.98 -0.24 0.18 0.13 7.3× 10−8 0.07
rs1460072 4 165873677 0.05 TLL1 0.88 0.07 0.15 0.15 1.4× 10−9 0.65
rs72753967 5 41150324 0.04 C6 -0.93 -0.17 0.15 0.15 2.3× 10−10 0.24
rs295670 5 58851926 0.04 RAB3C 0.85 0.28 0.13 0.14 2.8× 10−11 0.04
rs249957 5 96785338 0.03 ERAP1 0.99 0.21 0.15 0.20 1.8× 10−11 0.29
rs488492 11 79214799 0.11 TENM4 0.68 0.08 0.13 0.09 5.7× 10−8 0.37
Table 5.12: Results of the SNVs associated with SAT and SATTAT using CIEE. Shown is information about
their genomic position, coefficient and standard error estimates of the direct genetic effect and according
p-values, from CIEE and from MR. rsID is the reference ID of the SNV.
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Chapter 6
Discussion
6.1 Summary and data analysis recommendations
In this thesis, the two new statistical approaches C-JAMP and CIEE have been introduced,
described regarding their statistical details and implementation, and evaluated for genetic
association analyses incorporating multiple traits, hence meeting the goals set out in Aim 1.
While C-JAMP allows investigating multiple traits in a joint model conditional on genetic
variants and covariates which can improve the statistical power to identify associated genetic
variants, CIEE allows removing indirect genetic effects through intermediate phenotypes in
order to estimate and test direct genetic effects on a primary phenotype in a valid and robust
manner. Both approaches provide an unbiased and efficient estimation of parameters and
can be applied to different outcome variables analyzing multiple phenotypes and adjusting
for multiple covariates, and have a clear interpretation of the estimated parameters. Aim 2 -
to identify novel genetic and transcriptomic effects on cardiometabolic traits - has been met
through the two empirical applications of C-JAMP and CIEE.
In extensive simulation studies as well as in empirical applications, C-JAMP and CIEE
have been applied and evaluated for the analysis of common and rare genetic variants with
quantitative phenotypes as well as time-to-event phenotypes. First, single-marker and multi-
marker tests were compared for association analyses of rare variants, then C-JAMP was
compared with the univariate SMT and MMTs as well as multivariate MMTs, and finally
CIEE was compared to traditional and newly proposed approaches for the analysis of direct
effects of common genetic variants. The results indicate that C-JAMP and CIEE (1) yield
valid and efficient genetic effect estimates and can increase the power of hypothesis tests com-
pared to separate univariate models, and (2) provide an improvement over existing methods
for association analyses of rare genetic variants and for the identification of direct effects of
common genetic variants, hence supporting the proposed thesis in section 1.1. The results
can be summarized and combined with established results from the literature as shown in
boxes 6.1-6.2 in order to form guidelines for practical analyses. A more detailed discussion of
the two proposed methods, of the results from the simulation studies comparing the different
methods, and of the empirical findings from the application studies are given in the following.
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Association studies with rare genetic variants
1. Association analyses of quantitative traits generally yield higher
power compared to association analyses of dichotomized traits (sec-
tion A.4.1.3).
2. Association analyses based on joint models of multiple phenotypes can
improve the power compared to separate analyses (sections 4.2, A.4.2).
3. For the analysis of dichotomous phenotypes, many univariate SMTs
have inflated type I error and univariate MMTs have higher power
compared to univariate SMTs (see references in section 2.2.1 and sec-
tion A.4.1.3).
4. For the analysis of quantitative phenotypes:
(a) Univariate SMTs lead to more powerful association tests for iden-
tifying causal genes than univariate MMTs when the effect sizes
of causal variants in the gene are large, and less powerful tests
when causal variants have small effect sizes. For moderate effect
sizes, if at most 5% or 10% rare SNVs in a gene are causal, then
the univariate SMT has higher power when the sample size is
larger, and slightly less power for a smaller sample size (sections
4.1, A.4.1).
(b) Many of the proposed multivariate MMTs investigated here have
invalid type I errors and should not be used for rare variant anal-
yses (section 4.2).
(c) C-JAMP provides valid estimation and inference in the analysis
of rare variants - given that the dependence between traits is
correctly modeled and an appropriate test statistic adjustment
is made for the analysis of very rare variants with traits of high
dependence (section 4.2). C-JAMP has the highest power of all
investigated approaches if less than 50% of SNVs are causal and
the traits have high dependence.
Box 6.1: Summary for association studies with rare genetic variants.
6.2 Single-marker tests versus multi-marker tests
In the comparison of SMTs and MMTs in this thesis, the focus was on the association
analysis of rare variants with quantitative traits. First, it was shown that standard restricted
maximum likelihood estimation in a single-marker approach provides unbiased estimates and
single-marker Wald-type t-tests allow valid statistical inference even for very rare SNVs. Next,
the power of the SMT and MMTs was compared for identifying a gene that includes causal
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rare variants, and it was shown that SMTs or MMTs can be more powerful depending on
the scenario. More specifically, SMTs lead to more powerful association tests for identifying
causal genes than MMTs when the effect sizes of causal variants in the gene are large, and less
powerful tests when causal variants have small effect sizes. For moderate effect sizes, whether
SMTs or MMTs have higher power depends on the sample size and percentage of causal
SNVs. When at most 5-10% SNVs in a gene are causal, which might be the most realistic
scenario, the SMT has higher power when the sample size is larger, and slightly less power for
a smaller sample size. These results seem to hold consistently for different gene sizes, different
nominal α levels, different proportions of SNVs with positive/negative effect on the trait, and
different corrections for multiple testing of SNVs in a gene (Bonferroni and BH correction)
with SMTs. In the empirical data analysis of the GAW19 data in section A.4.1.4, the SMT
provided smaller p-values compared to the MMTs in the testing of previously identified blood
pressure genes.
Estimation and testing of direct genetic effects
1. All approaches rely on the assumption that the assumed directed
acyclic graph model is correct. Furthermore (see sections 4.3, A.4.3),
2. CIEE provides valid estimation of the direct genetic effect and its
standard error, as well as valid testing of the direct genetic effect in
all considered scenarios, also when there is unmeasured confounding
of the indirect genetic effect through observed factors - for both the
analysis of quantitative and time-to-event primary traits.
3. Its direct genetic effect estimates coincide with the estimates from the
G-estimation method for quantitative primary traits (Vansteelandt
et al., 2009), which also provides valid testing but does not provide
standard error estimates of the effect.
4. The G-estimation method for time-to-event primary traits (Lipman et
al., 2011) provides biased effect estimates and inflated type I errors in
hypothesis testing.
5. Traditional regression and structural equation modeling methods pro-
vide valid parameter estimates and hypothesis tests of direct genetic
effects, if there is no unmeasured confounding of the indirect effect.
6. The power of all approaches in hypothesis tests of the direct genetic
effect is similar in all scenarios where they provide valid testing.
Box 6.2: Summary for the estimation and testing of direct genetic effects.
For any gene-level investigation, a very important question is which SNVs should be
grouped together in a test. Including more true causal SNVs by extending the region under
consideration or by analyzing both common and rare SNVs can increase the power. At the
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same time, including more non-causal SNVs adds noise and decreases the power. Accordingly,
in the simulation study, the power of all approaches increased when the analysis was restricted
to rare SNVs, since only rare SNVs were chosen as causal SNVs in the data generation. The
same was observed in the real data analysis - but only consistently for the SMT - where the
reason might have been as well that there were not any common causal SNVs. The data
application also showed that while the SMT, SKAT, and SKAT-O are quite robust against
which sets of SNVs are investigated, the burden test is highly sensitive and can lead to vastly
different results.
It should be noted that in the simulation study, the data was generated from the same
model as in Lee et al. (2012) where the effect size of a SNV depends on the MAF of SNVs
through a specified function (see Table 4.1). Since the weighted kernel functions in SKAT
and SKAT-O are dependent on the MAF of SNVs as well, this gives SKAT and SKAT-O an
advantage and allowed evaluating and comparing the SMT in situations where the MMTs
have high power. Therefore, in real applications, the power of SMTs might compare even
more favorably to these MMTs.
The proposition to use SMTs for the analysis of rare variants is based on the fact that
maximum likelihood estimation returns valid estimates under the linear regression model,
even for the analysis of singletons and doubletons. Importantly, the strategy to include
singletons and doubletons in the analysis can substantially improve the power of SMTs. Of
course, this does not alleviate the need to check for genotyping errors and other biases, which
are especially relevant to singletons and doubletons. Also, while all investigated approaches
rely on normality assumptions, the Wald-type t-test (SMT) was much more vulnerable to a
distribution misspecification than the MMTs. When the residuals in the genetic association
test are not normally distributed for one or multiple SNVs (or when effects follow another
genetic model), adapting the test statistic is warranted.
Further simulation studies (data not shown) confirmed that for binary outcomes, standard
statistical tests such as Fisher’s exact test, logistic regression likelihood ratio tests, Wald tests,
and Score tests, should not be directly used for testing singletons and doubletons since they do
not allow valid inference. Therefore, for each test, all assumptions including the (asymptotic)
distribution assumptions and empirical type I errors have to be assessed before the analysis,
and significant test results have to be cautiously investigated, especially if they are based on
singletons or doubletons.
Secondary results of the simulation study provide suggestions regarding the study design
of rare variant association studies. It was observed that the power to identify causal low-
frequency SNVs is almost always much smaller compared to the power to identify gene regions
encompassing causal rare SNVs (cf. Ladouceur et al., 2012), except when very few SNVs in
a gene are causal, have higher MAF (i.e., MAF between 0.005 and 0.03) and higher effect
sizes. This should be kept in mind but not be considered as a power comparison between
MMTs and SMTs. Hence, the power of rare variant tests depends highly on which hypothesis
is tested, the number of causal SNVs, their effect size, and whether the ultimate goal is to
identify a causal gene or a causal SNV. The comparison between SNV-level and gene-level
association tests might also depend on the ratio of the number of genes to the number of
SNVs, which could be further investigated in future studies. Regarding MMTs, the results
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come with a loss in information because the exact position of causal variants is not revealed,
and to my knowledge, the currently available methodology does not allow to obtain power
estimates for identifying a causal SNV. If the focus of the analysis is on identifying causal rare
SNVs instead of genes, SMTs can be used in a genome-wide scan for variants, or alternatively
SMTs/MMTs can be used in the first stage to identify target genes and followed up by SMTs
of variants within these genes. Comparisons between such 1-stage and 2-stage approaches
were not the aim of this study, and could be an interesting avenue for future research by
incorporating correct adjustments for multiple testing, the 2-stage testing and biases such
as the winner’s curse (Sun et al., 2011). For choosing the most powerful statistical test for
specific situations in genetic association studies of rare variants, the locus of interest (gene or
variant) should be specified first, followed then by a comparison of different statistical tests.
These results add more details and shed a light on the comparison of single-marker and
multi-marker tests for quantitative traits, and provide clear suggestions under which assump-
tions MMTs should be used, and when a simple SMT is favorable. In contrast to popular
practice in epidemiological and medical studies, the additional results also highlight that
quantitative traits should be analyzed whenever possible instead of binary traits to maximize
the power of association tests.
6.3 C-JAMP
In the simulation studies and empirical applications, C-JAMP provided highest power com-
pared to all other - multivariate and univariate - approaches in all scenarios with two ex-
ceptions. As first exception, SKAT-O had slightly higher power compared to C-JAMP when
50% of all rare SNVs were causal and they had moderate or small effect sizes all in the same
direction. Second, the power of C-JAMP was similar to or slightly lower compared to the
aSPUset-Score test, when the dependence between traits was τ = 0.2, there were 20% causal
SNVs in a gene and effect sizes were high or there were 50% causal SNVs in a gene. Interest-
ingly, most investigated alternative approaches based on multivariate models yielded inflated
type I errors. Only two tests, aSPUset and aSPUset-Score had acceptable type I errors (even
though aSPUset-Score also showed a slight inflation), but had much smaller power compared
to C-JAMP in almost all considered scenarios. For a comparison of C-JAMP with standard
multivariate regression approaches, it can be noted that the aSPUset-Score test includes the
GEE-Score test (which is equivalent to the MANOVA), so that these approaches have been
implicitely incorporated in the comparison. Earlier work (Konigorski et al., 2014) also showed
that C-JAMP provided a much better model fit compared to a bivariate linear model.
A downside of aSPUset and aSPUset-Score, and of MMTs in general, is that they rely
on a multitude of assumptions (e.g., many SNVs in a gene are causal) and parameters (e.g.,
the choice of power sets), and even an integration of many different subtests does not yield
tests with ”optimal” power, as shown by the results of the simulation studies. On the other
hand, SMTs rely on much fewer assumptions. In addition, the aSPUset and aSPUset-Score
tests are computationally very intensive and not suitable for genome-wide analyses, where
evidence in form of p-values smaller than 10−5 of 10−8 is needed. That is, since permutation
or simulation approaches are employed to derive p-values of aSPUset and aSPUset-Score
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empirically, 10k permutations are needed to be able to obtain p-values that are potentially
as small as 1
10k+1
.
C-JAMP seems to be well-suited for many applications since it can fit different dependence
structures between two (or more) traits, does not lead to a power decrease when SNVs are
only associated with one trait - in contrary to omnibus multi-degree-of-freedom tests - and
is computationally fast enough to be employed on a genome-wide scale. Furthermore, C-
JAMP provides flexibility to use different genetic models for the effect of each SNV and to
use any marginal distribution of a given trait conditional on the SNV and other factors. As
further practical arguments for integrating multiple traits in the analysis, in many situations,
multiple traits of a phenotype with moderate or strong dependence (for example, Kendall’s
τ between 0.5 and 0.8) can easily be obtained, since they are often measured concurrently.
For example, systolic and diastolic blood pressure or different measures of body fat mass
and body fat distribution are assessed in most investigations into blood pressure or obesity,
and they often have high dependence. Consequently, the application studies in chapter 5
illustrated that C-JAMP identified more candidate SNVs and genes with potential function
in blood pressure and obesity genetics.
Regarding the application of C-JAMP to genome-wide analyses, it is fast enough to an-
alyze millions of SNVs within days by using a computing cluster, but is still much slower
compared to standard regression approaches, especially if large sample sizes and a large num-
ber of predictors are analyzed. The computational expensive part of C-JAMP consists of the
likelihood maximization (and looping over different starting values in case of non-convergence)
which is currently done using the BFGS algorithm in the optimx R package. This algorithm
was chosen since it provided the most robust optimization compared to all other methods
implements in the optimx package (and therefore available in optim and nlm) in addition
to speed. The focus was primarily set on robustness correctness of parameter estimates,
convergence, fulfilment of the KKT conditions, estimation of the Hessian matrix for the pa-
rameter estimates in order to obtain standard error estimates. Further problems can arise in
the optimization with BFGS when the different predictors have different scaling, which was
hence built into the cjamp() R function. Future work can investigate approaches to decrease
the running time. One avenue can be to investigate other optimization algorithms that are
available in R and also more efficient implementations of the optimization algorithms (Nash,
2014). Alternatively, restricting the parameter space could help, even if preliminary results
from an ongoing investigations indicate a loss of robustness. Finally, the computationally ex-
pensive part could be accelerated using graphics processing units (GPUs), for example using
CUDA libraries (for examples, see Buckner et al., 2010; Suchard et al., 2010).
As second caveat for the practical application of C-JAMP, an appropriate copula function
has to be chosen according to the dependence structure between the traits. The 2-parameter
copula function used in this study covers a wide range of possible dependencies suitable for
most applications, and can be complemented with the choice of a Gaussian copula. Third,
in the analysis of very rare SNVs with highly dependent traits, an adjustment of the Wald
test statistic was necessary to correct for inflated/deflated test statistics. While the approach
is generalizable and can be used in practical investigations as well, future work can focus
on the derivation of the theoretical distribution of the test statistic or also focus on an
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unbiased estimation of parameters and standard errors on the boundary of the parameter
space. Alternatively, SNVs with very low frequency can be deleted before the analysis to
avoid any problems, but this might lead to a small power decrease in gene-based tests, as
described in section A.4.1.1. Fourth, in the situation when there is a strong dependence
between the traits, but the SNV of interest is associated with only one of the traits, then
there is an indication for inflated type I errors for testing the association with the non-
associated trait. Even though this scenario might be unlikely in practice when two traits
with common biological underpinnings are investigated, comparing the results of C-JAMP
with univariate models can serve as a check. In future work, the implementation of C-JAMP
can also incorporate more than 2 phenotypes to allow building more complex models. It could
be expected that this allows to further increase the power, but at the same time a saturation
effect of the power increase caused by the increasing number of estimated marginal parameters
could come into play.
6.4 CIEE
In CIEE, I propose to use the estimating equation method to estimate direct genetic effects
on a primary phenotype, adjusting for indirect effects through intermediate phenotypes that
can also be influenced by measured or unmeasured confounding factors. Multiple influencing
factors and multiple intermediate phenotypes can be included in the model. CIEE yields
consistent estimates for the direct effect and provides accurate standard error estimates, even
when there is unmeasured confounding of the indirect effect through measured factors. For
the analysis of time-to-event data subject to censoring, CIEE includes a new approach for
the removal of the intermediate effect. Due to the use of the established theory of estimating
equations, the approach can be extended to different error distributions. At the same time,
the use of robust sandwich standard error estimates also provides valid inference if the error
distribution is misspecified, as shown in the simulation study. Of note, when analyzing quan-
titative traits, CIEE yields estimates equivalent to the LS estimates under the corresponding
models, which do not rely on any distribution assumption. Therefore, the resulting direct
effect estimate is accurate even if the distribution assumption is not satisfied.
Applying CIEE to genetic association studies can both identify genetic variants that
would be missed by traditional analyses, and can prevent false positive results - depending on
whether the indirect genetic effect with unmeasured confounders is in the same or opposite
direction of the direct effect. This was illustrated in the real-data applications in chapter 5,
where novel candidate markers were identified for systolic blood pressure, body fat mass, and
body fat distribution which were missed by traditional regression approaches. The results
of the simulation study also provided a detailed analysis when other methods provide valid
estimation and testing, and when they should not be used. Standard multiple regression
approaches were valid in all scenarios as long as there was no unmeasured confounding of
the indirect genetic effect. For example, they also provided valid inference when there was
measured confounding of the indirect genetic effect - which is in contrast to some claims in
the literature (Goetgeluk et al., 2008). The genetic effect estimates obtained from SEM were
also affected by unmeasured confounding of the indirect genetic effect, which exemplifies that
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SEM is highly dependent on the correctness of the assumed paths and edges and may lead to
biased estimates otherwise. Finally, the sequential G-estimation method (Vansteelandt et al.,
2009) provides equally valid testing compared to CIEE for the analysis of quantitative traits,
but the G-estimation approach proposed by Lipman et al. (2011) for the analysis of primary
time-to-event phenotype is not able to remove the effect of intermediate phenotypes leading
to biased direct effect estimates and invalid testing. In addition, the sequential G-estimation
methods do not provide a standard error estimate of the estimated direct effect.
For an application of CIEE and any other model to the analysis of DAG models, it should
be noted that despite the robustness properties of CIEE, there are still some assumptions that
are required for valid testing and estimation. One assumption is that there is no unmeasured
confounding of the direct genetic effect (i.e., factors both affecting the genetic marker and
primary phenotype). For genetic association studies, this assumption seems plausible and if
any such factors (e.g., population stratification) were present, they could be controlled for in
an initial step or by considering them as covariates. Furthermore, an a priori choice of relevant
intermediate variables and influencing factors (i.e., distinction between K, L) is important.
Next, while CIEE and the G-estimation methods are robust against unmeasured confounding
of the indirect effect through measured factors, they lead to biased point estimates and inflated
type I errors similar to traditional approaches if there is direct unmeasured confounding of
the indirect effect (e.g., if U affects K directly and not only through L) so that the DAG is
misspecified. Finally, additional results in the application of CIEE in section 5.2 showed that
the large-sample Wald-type tests can lead to inflated type I errors when very rare SNVs are
analyzed. This could be further investigated in future work. Also, future extensions of the
implementation can incorporate multiple intermediate phenotypes and multiple influencing
factors.
I believe that the application of CIEE to association studies in genetic epidemiology and
other biomedical fields can provide new insights about direct effects of variables. In addition,
future extensions of CIEE including multiple primary phenotypes in the analysis can provide
further possibilities to build more complex and realistic models.
6.5 Empirical findings from cardiometabolic association stud-
ies
In the real-data applications, all analyses confirmed that C-JAMP and CIEE can identify
candidate markers that would not be identified by traditional approaches. In addition, the
identified candidate markers can provide novel insights and help to generate new hypotheses,
in particular about markers and genes involved in obesity biology.
In the analyses of blood pressure in the GAW19 data, while none of the identified SNVs
reached genome-wide significance (i.e., had a p-value smaller than 10−8), both C-JAMP and
CIEE yielded some SNVs with suggestive significance that had an adjusted p-valued smaller
than 0.05 when using a Bonferroni-correction for multiple testing. C-JAMP identified 5 SNVs
in or upstream of the CEACAM5 gene, and CIEE hinted the potential role of a new genetic
locus upstream of the IL27RA gene, which is involved in anti-inflammatory processes and
immune response (Hunter & Kastelein, 2012). These SNVs would have been missed if a
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traditional regression analysis was performed.
In the second empirical study of obesity traits, a preliminary analysis investigated to what
extent plasma adipokine concentrations can be predicted based on MRI-derived measures
of AT mass of different body compartments, including SAT and VAT, and by SAT gene
expression (section A.4.5). Relevant for the main investigation, the results showed that
absolute body fat mass measures as well as relative body fat measures (which assess body
fat distribution) showed similar correlations with plasma levels, so that SAT and SATTAT were
used in the main analyses described in section 5.2. In the genetic association analyses of
total genetic effects on obesity with C-JAMP, none of the tested SNVs reached genome-wide
significance for either trait, but there were several SNVs with p-values smaller than 10−5.
Most interesting for follow-up studies and replication analyses with a larger sample size might
be rs116280906 in the APOL1 gene, which encodes the high density apolipoprotein L1 bound
to HDL and is involved in cholesterol and lipoprotein metabolic pathways. To date, the
APOL1 gene has mostly been investigated for its association with kidney disease (Genovese
et al., 2010; Dummer et al., 2015) but has also been linked to obesity and other chronic
diseases (Hu et al., 2012; Madhavan & O’Toole, 2014). Since in our study, an association
between APOL1 gene expression and SAT mass was not observed, the marker rs116280906,
the APOL1 gene and the respective apolipoprotein L1 seem interesting candidates for further
investigations regarding their role in obesity. Other interesting markers could be rs6838636
in MAN2B2 which is involved in saccharide metabolic pathways, and rs1048365 which is
in vicinity of the VGF gene involved in insulin pathways and the generation of precursor
metabolites.
In the genetic association analyses of direct genetic effects on obesity controlling for in-
direct effects through gene expression with CIEE, 1 new locus was identified for SAT and 6
new loci were identified for SATTAT (when restricting the analysis to SNVs with MAF ≥ 0.025;
and 17, 52 SNVs were identified when restricting to SNVs with MAF ≥ 0.01, respectively),
all with p-values smaller than 10−7 and 4 of them with p-values smaller than 10−8. Of
particular interest might be the identified SNVs in GPT2 and ERAP1. GPT2 encodes the
enzyme alanine aminotransferase 2 and is involved in the amino acid metabolism (synthesis
of pyruvate from L-alanine) and recent animal studies suggest an association GPT2 with
obesity (McCurdy et al., 2016). While hypotheses about its role in obesity are difficult to
make without a proper estimation of the indirect effect, the results described in section 5.2
suggest that the SNV in GPT2 has an overall negative (protective) effect on SAT mass, with
a positive (detrimental) indirect effect through GPT2 gene expression and a larger ”direct”
protective effect (through any other biological processes which are here summarized in the
”direct” effect). For biological hypotheses, the ”indirect” genetic effect through gene expres-
sion or any other specific intermediate phenotypes can often constitute the more interesting
pathways explaining the effect of genetic variants. Therefore, the development of new statis-
tical methods complementing CIEE for an unbiased estimation of the indirect effect can help
in the interpretation in future studies. A second candidate marker of interest for follow-up
investigations identified in the CIEE analysis could be rs249957 in the ERAP1 gene, which
encodes the endoplasmic reticulum aminopeptidase 1, is involved in fat cell differentiation,
peptide catabolic processes and blood pressure regulation.
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In the transcriptome-wide association analysis of SAT gene expression with SAT mass and
SAT
TAT , the results of the GO-term enrichment analysis based on the 607 identified genes whose
expression levels were associated with obesity suggest that different pathways are associated
with fat mass and fat distribution. While SAT mass was mostly related to processes and
reactions of the immune system, inflammation and cell transport, SATTAT was mostly related
to metabolic and catabolic processes, and immune system processes and inflammation as
well. For an interpretation of the results, the interplay between the different cells present
in the adipose tissue (adipocytes, innate cells such as macrophages, and adaptive immune
cells) can be considered (Huh et al., 2014). When searching for genes associated with fat
mass, it can be expected that many immunological processes and pathways are identified.
An investigation of body fat distribution in the form of the ratio SATTAT , however, might adjust
for these immunological cells and point to pathways specific for the SAT. This might have
been why metabolic and catabolic pathways were more present with a higher frequency in
genes associated with SATTAT - and also why fewer genes are associated with
SAT
TAT since parts of
the variance are removed.
Integrating the results of the genetic and transcriptomic association analyses, all results
indicate the role of pathways including metabolic and catabolic processes in obesity and sug-
gest specific candidates for relevant molecular processes. The fact that none of the SNVs with
a direct genetic effect on SAT and SATTAT identified by CIEE showed a statistically significant
total genetic effect with obesity suggests that they act as eQTLs on the gene expression levels
which in turn show an association in the opposite direction with obesity. For a more com-
plete picture, a transcriptome-wide search for eQTL in cis and trans could provide helpful
information.
These empirical results strongly support that including multiple molecular levels - here
genetic and transcriptomic (and plasma concentrations in the preliminary study) - in the
analysis together with multiple phenotypes can lead to the identification of candidate markers
and hypotheses about interesting pathways, even if only rather small sample sizes are available
for the analysis, if appropriate and powerful statistical methods are used. Including different
traits (such as fat mass and fat distribution) can also conceptionally be thought to represent
the different facets and possible pathways of the obesity phenotype. As a possible extension
of the analyses, it would be interesting to include molecular measures on additional levels
(e.g., epigenetic factors), or incorporate single-cell sequencing analyses (Vitak et al. 2017) of
the different cells present in the adipose tissue.
As limitations, the small sample size of the analyses likely prohibited to identify further
candidate variants. Also, replication analyses of all identified markers have not yet been
carried out. Even though extensive quality control checks have been performed on all levels
of the data generation, and all experiments were tested and performed according to protocol,
different biases can have influenced the results. First of all, in the SAT biopsies, the amount
of aspired tissue as well as the according RNA quality might depend on the obesity of the
proband. In the RNA extraction, only total RNA was interrogated so that shorter RNA
fragments and other regulatory elements were not assessed. This can be mostly seen as a
limitation since their association with obesity traits could not be investigated, but it might
also introduce some bias in the gene expression quantification if these short RNA molecules
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are predominantly transcribed in some regions. On the other hand, the multiple quality
control checks on all stages of the experiments and multiple normalization steps should limit
these effects and the high association between gene expression levels based on RNA-Seq
and PCR confirms the good validity of the RNA-Seq gene expression quantification. In the
RNA sequencing, a comparison of the gene expression quantification based on a much higher
sequencing depth indicated that the chosen depth (6 samples per lane) might be sufficient
for the study purposes here. A comparison of the gene expression for 6 re-sequenced probes
also indicated that the results are reliable. Furthermore, since the GO annotation of many
different genes was integrated and all confirmed the same overall picture, this allows a higher
certainty of the robustness of the results, and in the benefit of following-up the results in
further analyses.
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A.4 Supplementary results and study descriptions
A.4.1 Simulation study: single-marker versus multi-marker tests
A.4.1.1 Power for identifying a causal gene with the SMT and MMTs
For an illustration and explanation of the performance of the SMT described in section 4.1.2.3,
I provide more details for the main results of scenario 4 in the following. Here, the SMT had
a power of 26.3% to identify a causal gene in a genome-wide study under the nominal α level
of 2.5×10−6. That means that within 2,629 replicates (26.3% of the 10,000 replicates), there
was at least one rare SNV in a replicate (gene) with adjusted p-value smaller than 2.5×10−6,
which led to the identification of the gene as causal. In fact, 3,084 SNVs had adjusted p-value
smaller than 2.5×10−6 in the 2,629 replicates: 20 (of 15,108) causal singletons were correctly
identified, 14 (of 4,675) causal doubletons were correctly identified, 341 (of 5,874) causal SNVs
with MAF between 0.001 and 0.005, 428 (of 1,550) causal SNVs with MAF between 0.005 and
0.01, and 2,281 (of 2,989) causal SNVs with MAF between 0.01 and 0.03. If singletons and
doubletons had been excluded from the analysis of linear regression, the power would have
been slightly elevated to 28.0% in this scenario. On the other hand, for the candidate-gene
approach using a significance threshold of 0.05, the gene-level power of the SMT was 73.6%
and substantially more very rare variants were identified and drove the high gene-level power.
In more detail, 2,576 (of 15,108) causal singletons were correctly identified, 1,551 (of 4,675)
causal doubletons were correctly identified, 3,757 (of 5,874) causal SNVs with MAF between
0.001 and 0.005, 1,482 (of 1,550) causal SNVs with MAF between 0.005 and 0.01, and 2,980
(of 2,989) causal SNVs with MAF between 0.01 and 0.03. For this analysis, the power would
have been substantially decreased to 62.4% by excluding singletons and doubletons.
We conducted several sensitivity checks to add further details to the comparison. First,
phenotype data was generated for scenarios 1-12 under the alternative hypothesis using the
same parameter values as in Table 4.1, but for larger sample sizes and based on larger genes.
More specifically, I considered the same genetic dataset and the same percentage of causal
SNVs but with on average 58 SNVs or 572 SNVs per gene with a sample size of n = 5, 000.
Also, another genetic dataset (’SKAT.example’ data in the SKAT R package) including 67
SNVs per gene was used to generate data under scenarios 1, 4, 7, 8, 12 with a sample size of
n = 2, 000. The power estimates are shown in Supplementary Tables A.4-A.6, respectively,
and increased naturally for all methods. When a gene of average size 33 SNVs with a sample
size of n = 1, 000 was analyzed in comparison to a gene with average size 58 SNVs with a
sample size of n = 5, 000, the increased sample size helped SMTs with a higher power increase
compared to MMTs. For example, while the power of the SMT versus SKAT-O was 19.2%
versus 19.9% (for α = 0.05) and 0.5% versus 0.7% (for α = 2.5 × 10−6) in scenario 2 with
n = 1, 000 (Supplementary Tables A.2-A.3), it was 19.5% versus 15.3% (α = 2.5× 10−6) for
the larger sample and gene size. Hence, for larger sample sizes, SMTs are more powerful than
all MMTs also for moderate effect sizes. These conclusions did not change when the same
larger sample size (n = 5, 000) was analyzed with much larger genes including on average 572
SNVs (Supplementary Table A.5). The results of analyzing a sample size of n = 2, 000 and a
gene size of 67 yielded similar conclusions compared to the main analysis including n = 1, 000
individuals.
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As a second sensitivity check, I conducted the analysis under the alternative scenarios
by only analyzing rare SNVs (with MAF≤ 0.03) in a gene and disregarding the (non-causal)
common SNVs. The power of all approaches increased, but the conclusion which approach has
the highest power in each scenario did not change, for both nominal levels (see Supplementary
Tables A.2-A.3). As a notable difference, the power of the burden test was closer to the
power of SKAT and SKAT-O, which is in line with the results reported in Lee et al. (2012).
Furthermore, the power increase of SKAT and SKAT-O was marginally higher than of the
SMT. Third, if the more conservative Bonferroni correction is used to account for testing
multiple SNVs in a gene with SMTs, the power decreases slightly, but does not change any
of the conclusions regarding which method has the highest power in which scenario (see
Supplementary Table A.7).
In addition, the same simulation set-up was used to generate a case-control trait from
a logistic regression model to compare the SMTs and MMTs for an analysis of a binary
trait. Further details are given in the appendix in section A.4.1.1, and results of the power
comparison in Supplementary Table A.8. The results indicate that the power of all tests was
much lower compared to the analysis of quantitative traits. The decrease was much stronger
for the SMT, which had a very low power across all scenarios in line with previous studies
(Basu & Pan, 2011; Pan et al., 2014; Xing et al., 2012).
A.4.1.2 Power for identifying a causal variant versus a causal gene
After comparing the single-marker and multi-marker approaches in their ability to identify
a causal gene, another important question for practical applications is: What is the power
of the tests for identifying a causal variant for a quantitative trait, and how does it compare
to the power for identifying a gene containing causal SNVs (i.e., causal gene)? Importantly,
this question should not be confused with a power comparison of SMTs (which can be used
to identify both causal genes and causal variants) and MMTs (which can be used to identify
causal genes). Obtaining SNV-level power estimates for SMTs is straightforward, and Sup-
plementary Table A.9 shows power estimates of SMTs for identifying a causal single variant
with a given MAF in comparison to the power for identifying a causal gene (as shown in
Figure 4.2). For the interpretation of these results, it should be noted that the power esti-
mates are based on testing different hypotheses and corrected for multiple testing of 20,000
genes in the gene-level analysis and 500,000 SNVs in the variant-level analysis. For variants
with low MAF (e.g., MAF< 0.005), the power for identifying a single variant is very low
relative to gene-level tests across all scenarios, which corresponds to the reported low power
of SMTs in the literature. For SNVs with MAF≥ 0.005, the power of variant-level tests is
higher than the power of gene-level tests when there are 5% causal SNVs in a gene, and it is
again lower compared to gene-level tests when there are higher percentages of causal SNVs.
More specifically, when a variant was tested with 10 observed minor alleles (which equals
MAF= 0.005 in this study), then the power for identifying the causal SNV increased and was
around 20% for larger effect sizes (scenarios 13, 16, 19, 22 in Supplementary Table A.9) and
less than 6% for medium and small effect sizes in the other scenarios.
If SMTs or MMTs are first used to identify genes that are associated with the trait, then
SMTs have to be used in a second stage to identify causal SNVs, and the power estimates
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should be adjusted to account for the follow-up testing. Developing and evaluating the power
of such a 2-stage method was not the focus of this study, and as an upper limit to this
power, conditional power estimates are shown in Supplementary Table A.10, obtained by
applying the SMT in the second stage to test all SNVs in a gene which has been identified
as causal in the first stage. The conditional power was on average 13% for singletons and
85% for SNVs with 10 observed minor alleles for larger effect sizes (scenarios 13, 16, 19, 22
in Supplementary Table A.10), on average 2% and 23% for medium effect sizes (scenarios 14,
17, 20, 23 in Supplementary Table A.10) and on average 1% and 8% (scenarios 15, 18, 21, 24
in Supplementary Table A.10) for smaller effect sizes.
A.4.1.3 Analysis of binary traits
A.4.1.3.1 Data generation For a comparison of the power in studies of quantitative
traits and binary traits, case-control phenotypes were generated for the scenarios 1, 4, 7, 8,
12 in Table 4.1 using a logistic regression model, with the same genetic data (SNVs Xj),
same covariates Z1, Z2, the same effect sizes βj , and the same percentages of causal variants
and direction of effects as for quantitative traits. The disease status Y was generated from a
logistic regression model with
Y |z1, z2, x1, . . . , xk ∼ Bernoulli(p(z1, z2, x1, . . . , xk)),
where p(z1, z2, x1, . . . , xk) =
exp(0.5z1+0.5z2+
∑
βjxj)
(1+exp(0.5z1+0.5z2+
∑
βjxj)
for the k SNVs Xj in a gene, Z1 ∼
Bin(0.5) which was centered for the data generation, Z2 ∼ N(0, 1) and βj = c·| log10(MAFj)|.
A.4.1.3.2 Methods To evaluate the performance of SMTs, the following logistic regres-
sion model of Y was fitted separately for each SNV Xj in a gene,
Pr(Y = 1|z1, z2, xj) = exp(β0 + β1z1 + β2z2 + βXY,jxj)
1 + exp(β0 + β1z1 + β2z2 + βXY,jxj)
(A.4.1)
using the glm() function in R (with default settings), the MLE βˆXY and its standard error
estimate SˆE(βˆXY ) were obtained and the Wald test was computed for testing H0 : βXY = 0
for all SNVs Xj . Adjustments for multiple testing of all SNVs in a gene with the SMT
were done using the BH correction and the minimum p-value in a gene was extracted for the
gene-level evaluation.
For the burden test, the glm() function in R was similarly used with default settings
to obtain MLEs and to compute Wald tests for testing H0 : α = 0, by fitting the logistic
regression model
Pr(Y = 1|z1, z2, x1, . . . , xk) = exp(β0 + β1z1 + β2z2 + βXY
∑
xj)
1 + exp(β0 + β1z1 + β2z2 + βXY
∑
xj)
.
For SKAT and SKAT-O, the SKATBinary() function in the R SKAT package was used
with default settings.
A.4.1.3.3 Results Regarding the single-marker approach, while ML estimation in the
logistic regression model (A.4.1) did not provide valid point estimates and SE estimates for
testing singletons and doubletons, the type I errors of the SMT gene-level tests were not
inflated and rather very conservative (data not shown). The results of the power comparison
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are shown in Supplementary Table A.8 and indicate that the power of the SMT and MMTs
was much lower compared to the analysis of quantitative traits. The decrease was much
stronger for the SMT, which had a very low power across all scenarios.
A.4.1.4 Analysis of GAW19 data
For a comparison of the SMT and MMTs in a real data application, I performed a gene-level
association analysis of systolic blood pressure (SBP) in the Genetic Analysis Workshop 19
data described in section 5.1.1.1. I tested the association of 9 previously identified blood pres-
sure (SBP, diastolic BP, or pulse pressure) genes on chromosome 19 (INSR, RRAS, ZNF101,
ELAVL3, RGL3, AMH, DOT1L, PLEKHJ1, SF3A2) (Kato et al., 2015; Ehret et al., 2016;
Liu et al., 2016; Surendran et al., 2016) with SBP, using the complete data available for
103 unrelated individuals. Adjusted phenotypes SBPadj were obtained for the analysis as
described in section 5.1.1.2.
A query to the Ensembl database with reference genome GRCh37.p13 through BioMart
was used to define gene regions as 5kb around the gene start and end positions for the gene-
level testing. After basic standard quality checks and exclusion of SNVs with more than 5%
missing base calls, this yielded 2,779 common (MAF> 0.03) and rare (MAF≤ 0.03) SNVs in
the 9 defined gene regions for the gene-level association tests with SBPadj SBPadj . The SMT,
SKAT, SKAT-O, and burden test were computed as described in section 4.1: For SKAT and
SKAT-O, the SKAT() function in the SKAT R package was used with default settings. For the
SMT, a Wald-type t-test was computed under the linear regression model for each SNV, the
p-values in a gene were adjusted with the BH-correction, and the minimum adjusted p-value
was extracted for each gene for the gene-level association test. First, all 2,779 common and
rare SNVs were included leading to gene sizes between 59 and 1,395 SNVs with an average
gene size of 309 SNVs. Second, the analysis was restricted to the 1,746 rare SNVs, which led
to an average gene size of 194 SNVs.
In the genetic association analysis of the adjusted SBP phenotype, gene-level hypothesis
tests were performed using the SMT, SKAT, SKAT-O, and the burden test. The normal
distribution assumption for the error terms in the linear regression of the adjusted SBP
phenotype was satisfied. The p-values obtained under each test to assess the significance of
the 9 candidate genes are shown in Supplementary Table A.11, for the analyses based on
two different inclusion criteria of SNVs: all common and rare SNVs in each gene, and only
rare SNVs. The comparison showed that the SMT yielded the smallest p-value for most
candidate genes, and was the only approach with a p-value less than 0.05. Furthermore,
the power estimates of the SMT, SKAT, and SKAT-O are relatively consistent using either
inclusion criterion for SNVs. The burden test, on the other hand, is more strongly influenced
by the inclusion criterion. When the analysis was extended to test all 2,858 gene regions on
chromosome 19 including 273,636 common and rare SNVs and 218,198 rare SNVs, the same
above conclusions were reached but none of the approaches yielded a significant gene-level
test for a nominal level of 0.05 corrected for multiple testing.
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A.4.2 Simulation study: C-JAMP
A.4.2.1 Finite sample distribution of the C-JAMP estimates and Wald-type test
statistic
In this section, the empirical adjustment for the Wald-type test statistic obtained through
C-JAMP are described. After obtaining ML parameter estimates through C-JAMP, different
test statistics can be used for testing a SNV effect. First investigations showed that using the
Wald-type test statistic led to smaller empirical type I errors compared to LRTs (data not
shown), so that the Wald-type test statistic was used for all further tests. However, the results
indicated that the coefficient estimates and standard error estimates were slightly biased and
accordingly the type I error estimates of the Wald test were inflated/deflated when testing
the effect of SNVs with very low MAF when there was a moderate or strong dependence
between the traits (Kendall’s τ ≥ 0.5), see Supplementary Tables A.13-A.14. Histograms of
the Wald test statistics are shown in Supplementary Figure A.3 for Kendall’s τ = 0.2, 0.5, 0.8
and MAC = 1, 2, 4, 10. The underlying reason for this inflation was that the asymptotic
distribution assumption for the Wald test did not hold when testing the association of SNVs
with very few minor alleles (especially for MAC = 1, 2) under a finite-sample setting for
Kendall’s τ ≥ 0.5.
In order to obtain an approximation to the finite sample distribution of the test statis-
tic, the Wald test statistics were adjusted using the empirical approach described in the
following. Adjusted coefficient and standard error estimates could be obtained accordingly.
First, m = 1, 000 independent simulated sets of phenotypes were obtained under the null
hypothesis as described in section 4.2.1, but conditioning on only one SNV without other
covariates, for 251 different SNVs with MAC between 1 and 958 (which equal MAFs of
0.0005, 0.001, 0.0015, . . . , 0.4790 respectively). Next, C-JAMP point estimates βˆXY and their
standard error estimates SˆE(βˆXY ) were obtained and the Wald test statistic was computed
by W = βˆXY
SˆE(βˆXY )
. Standard normal Q-Q plots of these Wald test statistics suggested that
the actual finite-sample distribution is a non-standard normal distribution which can be ob-
tained as a linear transformation of the standard normal quantiles. Hence, in order to obtain
adjusted Wald test statistics that follow a standard normal distribution, first a linear regres-
sion of 1,000 (sorted) standard normal quantiles Z on the (sorted) 1,000 empirical Wald test
statistics W was computed for each Kendall’s τ = 0.2, 0.5, 0.8 and MAC = 1, . . . , 958:
Z = ατ,MAC + βτ,MAC ·W + ε. (A.4.2)
These estimates can then be used to obtain the adjusted Wald test statistics Wadj based on
Wadj = αˆτ,MAC + βˆτ,MAC ·W. (A.4.3)
The estimates, αˆτ,MAC and βˆτ,MAC from (A.4.2) are shown in Supplementary Figure A.4, and
illustrate again that there aren’t any problems for Kendall’s τ = 0.2 but that there is some
bias for SNVs with small MAF and Kendall’s τ ≥ 0.5. Next, these estimates were used to
compute adjusted Wald test statistics for τ = 0.5, 0.8 of the main simulation study results
in Supplementary Figure A.3. Histograms of the adjusted Wald test statistics are shown in
Supplementary Figure A.5 and indicate that all biases have been removed. Consequently, the
adjusted Wald-test statistics were used for all further analyses in the simulation study. In
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order to obtain an efficient generalization of this Wald test statistic adjustment which can be
used in the analysis of any other dataset, the following approach can be used: Based on the
estimated intercept and slope estimates of equation (A.4.2) in Supplementary Figure A.4, the
functional form of the relationship between MAC and Kendall’s τ with intercepts and slopes
can be estimated. The following functions could be used to explain the relationship between
MAC and intercept/slope:
Interceptτ=0.5,0.8 = −
1
(A+B ·MAC)C , (A.4.4)
Slopeτ=0.5 = 1 +
1
(A+B ·MAC)C , (A.4.5)
Slopeτ=0.8 = 1−
1
(A+B ·MAC)C . (A.4.6)
Fitting these functions to the data can be done using the least-squares estimation method
and the optimx() function in the optimx R package. The parameter estimates of A, B
and C are shown in Supplementary Table A.15, the estimated functions in Supplementary
Figure A.6, and histograms of the adjusted Wald test statistics using this functional approach
in Supplementary Figure A.7. They indicate a good fit to the points, yielded a similarly
acceptable adjustment of the Wald test statistics, and could be used in any application.
A.4.2.2 Empirical type I error of C-JAMP
In a first additional investigation of type I errors, C-JAMP was investigated for testing the
association of a gene with one trait Y2, when the two traits Y1 and Y2 are correlated, but
the genetic effects are only on the other trait Y1. The results (based on adjusted Wald
test statistics) showed that for a weak or moderate dependence between the traits, type I
errors are valid (and rather deflated) for association tests with the non-associated second trait
(Supplementary Table A.18). However, for the situation that there is a strong dependence
between the traits but the gene is only associated with one trait, there was a slightly increased
empirical type I error for testing the association with the second trait. Further investigations
indicate that the reasons are slightly biased point estimates and slightly higher standard error
estimates in this situation compared to the null model when both traits are unrelated with
the gene (data not shown). Hence, in this situation, the Wald test statistic adjustment is
not sufficient to estimate the correct finite sample reference distribution. This situation can
be checked in application to real data, by conducting additional tests based on univariate
models of traits as a sensitivity check.
The second additional investigation regarding type I errors concerns the situation when
the dependence structure is misspecified in C-JAMP. The results of the main simulation study
described here are based on using the Clayton copula for both generating the phenotypes as
well as for the analysis. For practical applications, the 2-parameter copula (which contains
the Clayton copula as a special case) encompasses a large variety of both symmetric and
non-symmetric dependence structures so that it can be a good fit for many different practical
datasets. Alternatively, other copula functions could be used, for example the Gaussian
copula for fitting multivariate normal dependence structures. For an investigation of the
empirical type I errors when the dependence structure is misspecified, the performance of
C-JAMP based on the 2-parameter copula is evaluated when the data is generated from a
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bivariate normal dependence structure. The same genetic data as in the main simulation
study was used, as well as the same marginal models for the traits Y1 and Y2, but they were
generated from a bivariate normal distribution, conditional on the covariates z1, z2:(
Y1|z1, z2
Y2|z1, z2
)
∼ N(µ,Σ),µ =
(
µ1
µ2
)
,Σ =
(
1 ρ
ρ 1
)
.
where µ1, µ2 are E(Y1|z1, z2), E(Y2|z1, z2) in the marginal models, respectively. Here, ρ was
specified to generate a weak, moderate, or strong dependence between the traits (i.e., so that
Kendall’s τ = 0.2, 0.5, 0.8) based on the relation ρ = sin( τ ·π2 ). The empirical type I error
levels of C-JAMP are shown in Supplementary Table A.17. They show that the nominal levels
are all close to the nominal levels for all considered situations based on testing the genetic
effect with the unadjusted Wald test statistics. Hence, they would be slightly inflated for
moderate dependence between the traits if the adjusted Wald test statistics were used (and
slightly deflated for τ = 0.8). It should be generally always checked in a first step, whether
the dependence structure is appropriately captured by the used copula family.
A.4.3 Simulation study: CIEE - Discussion of the G-estimation approach
for time-to-event traits
Lipman et al. (2011) proposed a method to detect direct genetic effects on a target time-
to-event phenotype in the presence of genetic associations with an intermediate phenotype
that affects the target time-to-event phenotype. The method is based on the methodology
introduced in Vansteelandt et al. (2009) where the target phenotype was a completely ob-
served continuous variable, which was modeled by a linear regression model. To estimate
and test the direct effect of a genetic marker on the target phenotype, Vansteelandt et al.
(2009) presented a two-stage method which includes an adjustment stage to remove the effect
of an intermediate phenotype on the target phenotype. This method uses the principle of
the sequential G-estimation (Goetgeluk et al., 2008) for making inference on direct effects in
linear models. In the first stage, the effect of the intermediate phenotype on the target phe-
notype is estimated and an adjusted target phenotype is obtained by removing the effect of
the intermediate phenotype. In the second stage, inference on the direct effect of the genetic
marker on the target phenotype is obtained by regressing the adjusted target phenotype on
the genetic marker.
The two-stage method works effectively under a linear regression model with a completely
observed outcome. The goal of Lipman et al. (2011) was to extend the two-stage method to
the setting in which the target phenotype is a time-to-event variable and subject to censoring.
They considered PH regression and AFT models of a time-to-event phenotype, and proposed
a new adjustment method to remove the effect of the intermediate phenotype on the target
time-to-event phenotype. They obtained the adjusted survival times by subtracting the mean
of observed survival times and the so-called ”partial” Deviance residuals from the observed
survival times (equation (4) in Lipman et al., 2011). In the following, we show that this
adjustment method does not remove the effect of the intermediate phenotype on the target
time-to-event phenotype.
We assessed whether the effect of the intermediate phenotype is removed from the defined
adjusted target time-to-event phenotype given in equation (4) of Lipman et al. (2011). To
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this end, we conducted a Monte Carlo simulation study. The design of our simulation study
is similar to that of Lipman et al. (2011), but to be able to explain our points easily, we
considered the simpler causal diagram in Supplementary Figure A.8. We generated 1,000
replicates, each of sample size 1,000. The genotype X was sampled from the Bernoulli distri-
bution with mean 0.25, representing a dominant genetic effects model, and the intermediate
phenotype K from the normal distribution with mean 0.5+1.0x and variance 1. Furthermore,
we generated the target phenotype (i.e., survival times T ) from the PH regression model with
hazard function h(t|k, x) = h0(t) exp(β1x+ β2k), where h0(t) is the Weibull baseline hazard
function with a unit scale parameter and shape parameter λ= 1.0 or 1.5. We considered a
simple scenario, where survival times are all observed and there is no censoring. This simple
setup allowed us a better examination of whether the adjustment method of Lipman & Lange
(2011) works.
After applying the adjustment procedure in Lipman et al. (2011) to each replication
sample, we investigated whether the intermediate phenotype K has any effect on the adjusted
target phenotype T˜ . To be able to assess the effect of K on T˜ , one option is to fit a plausible
parametric conditional model for T˜ given K and X (i.e., T˜ |K,X). Based on the assumption
that the effect of K on T˜ is removed, Lipman et al. (2011) suggested to use a standard linear
regression model of T˜ |X in their equation (5) to estimate the direct effect ofX on T . However,
there is no discussion why this model was used. The appropriateness of a linear regression
model of T˜ |K,X is in question. Nevertheless, we first considered the linear regression model
of T˜ |K,X as it was suggested. Under this model assumption, if the adjustment method
successfully removes the effect of the intermediate phenotype K on T , the coefficient of K
will be zero in the linear regression model of T˜ |K,X. Supplementary Table A.27 displays
the empirical means and standard deviations of least square estimates of the coefficient of K
over 1,000 replicates, which shows that the effect of K on the adjusted target phenotype T˜
has not been removed.
However, when we checked the linear regression assumptions, we observed that the lin-
earity and homoscedasticity assumptions were violated. We also noticed that it is difficult
to confirm a plausible distribution and a plausible model for T˜ |K,X. Therefore, we assessed
the association between the adjusted phenotype T˜ and the intermediate phenotype K using
a nonparametric association measure instead of assuming a parametric form to model the
causal relationship. We used a rank-based association measure, Kendall’s τ , to assess the
association between T˜ and K. Supplementary Table A.27 also shows the proportion of p-
values that are below the nominal value of 0.05 for testing the null hypothesis that K is not
associated with T˜ (i.e., H0 : τ = 0) for each stratum of X. We observed that there is still a
strong association between the adjusted target phenotype T˜ and the intermediate phenotype
K and the association becomes stronger as the effect of K on T , β2, increases.
Contrary to what is proposed in Lipman et al. (2011), we showed here that the effect of
the intermediate phenotype is not removed from the adjusted target time-to-event phenotype.
Hence, the direct genetic effect on the target time-to-event phenotype cannot be estimated
using the proposed approach under the causal directed acyclic graph. In addition, there is no
discussion on whether T˜ is adjusted for censoring and how a standard linear regression model
without considering censoring (as in equation (5) in Lipman et al., 2011) could be used to
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estimate the direct effect of a genetic marker X on the time-to-event variable T . Even when
there is no censoring, modeling the adjusted target time-to-event phenotype T˜ by using a
standard linear regression model of T˜ |X as in equation (5) in Lipman et al. (2011) is not a
valid approach, as is using the test statistic for testing the absence of a direct genetic effect
on the target time-to-event phenotype.
A.4.4 Detailed materials and methods description of the obesity study
A.4.4.1 Assessment of fat mass and fat distribution
As classic anthropometric measures, waist circumference (WC), height, and weight were taken
by trained personnel. BMI was calculated as weight (in kg) divided by squared height (in
m), and waist-hip-ratio (WHR) as the ratio of WC and hip circumference. Whole-body MRI
scans excluding head and arms were performed in Potsdam on Siemens 1.5T Avanto scanners
using a 2-point Dixon technique with a 3D gradient echo sequence, and body fat measures
were obtained using a fully-automated segmentation approach including image-processing
methods and statistical shape models (Wald et al., 2012). The technical details of the ap-
proach as well as the protocol, sample ascertainment, repeatability and reproducibility of the
measurements, and association with standard anthropometric measures have been described
in detail elsewhere (Wald et al., 2012, Neamat-Allah et al., 2014). Available measures include
the amount of VAT (in the abdominal cavity, i.e., around and between the organs in the ab-
domen), SAT (fat tissue under the skin), and CAT (fat tissue around the heart/ heart vessels)
compartments, with SAT also being measured in the abdomen and thigh. In addition, total
mass of skeletal muscle, bone marrow and total body volume (TBV) were assessed, and total
AT (TAT) was calculated as the sum of AT in all body compartments. Furthermore, the
ratios TATTBV ,
VAT
TBV ,
SAT
TBV ,
VAT
TAT ,
SAT
TAT ,
SAT
VAT , were obtained as relative measures of AT mass and
of AT distribution. Previous studies showed that AT quantification was highly reproducible
with a coefficient of variation of about 0.3% for SAT and TAT, and 3.5% of VAT (Wald et
al., 2012).
The variables including the quantification of absolute and relative fat mass were already
cleaned and quality-controlled in previous studies, and there was no indication for any further
problems or errors. SAT had a slighty skewed distribution and was log-transformed. See
Figures A.9-A.10 for a visualization of the distribution of SAT and SATTAT (stratified by gender).
A.4.4.2 Subcutaneous fat tissue biopsies
Of the 673 eligible participants for AT biopsies, 186 refused participation and 209 were
excluded (mostly due to reported use of anticoagulant or antiplatelet medication within the
last seven days). Further exclusion criteria were any form of prevalent coagulopathy, an
allergy against lidocain or plaster or a disposition for keloids were excluded from the fat
biopsy. The goal was to extract 0.4g or more of abdominal SAT with a needle aspiration
method. The biopsy was conducted by a specially trained physician, assisted by a nurse.
Subcutaneous anesthesia was achieved by infiltrating a skin area of approximately 5x5cm
with 10mL of 1% lidocaine. Afterwards, a 14G Strauss needle was inserted into the SAT and
using a syringe, approx. 4mL of sterile physiological saline solution was injected into the SAT.
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Afterwards, the plunger was fully retracted to create negative pressure in the syringe and to
aspirate tissue. With the plunger in this position, the needle was moved in all directions
under the skin two to four times. The syringe was then removed with the plunger pulled
back and the aspirate was transferred to a 50mL tube containing 12.5mL of 10% sodium
citrate solution. This procedure was repeated ten times. The tube with the fat, blood, saline
and sodium citrate solution conglomerate was then transferred to the laboratory and further
processed within 30 minutes. Larger blood components were removed manually using a 10mL
syringe. Then, sterile physiological saline solution was added and the tube centrifuged at 100g
for 2 minutes. The fluid below the AT was then removed with a syringe. This procedure was
repeated until no more blood components were visible. The AT was then transferred to a
cryotube and centrifuged again for 2 minutes at 100g. After removing the fluid below the AT,
saline solution was added again and the tube centrifuged for ten minutes at 100g. Residual
fluids were extracted using a syringe and the remaining AT was weighted and then frozen at
-80°C. 273 of the performed 278 biopsies yielded material, with on average 0.88g aspired AT
(mean=0.05g, max=3.51g).
A.4.4.3 RNA extraction from SAT Biopsies
From the SAT biopsies, the total RNA, genomic DNA, and total protein from the fat tissue
samples were purified and separated using the Qiagen All Prep DNA/RNA Mini Kit. The
purified genomic DNA has an average length of 15-30 kb. Regarding the RNA, only RNA
molecules longer that 200 nucleotides were purified and with the employed standard protocol,
all short RNA molecules with length less than 200 nucleotides were removed. These removed
small molecules include most of the ncRNA and short mRNA. The quantity and integrity of
the purified DNA and RNA was verified using the NanoDrop 1000 Spectrophotometer V3.7
(PeqLab) and the 2100 Bioanalyzer (Agilent), which uses an on-chip electrophoresis. For
the assessment of gene expression of candidate adipokines with PCR, 2µg RNA were reverse
transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems).
A.4.4.4 Library preparation & multiplexing
Next, the extracted RNA was prepared for sequencing using the TruSeq RNA and DNA
Sample Preparation Kit v2 (Illumina). First, it was polyA-selected to purify and enrich
for mRNA, fragmented into small pieces and primed (with random hexamers) for cDNA
synthesis. The cDNA products were then enriched with PCR and ligated to adapters in
order to index different samples (”multiplexing”). In the ligation, single indexes were used.
Finally, the cDNA libraries were created, validated, normalized (so that they had equal
volume) and pooled. The resulting pooled single-indexed paired-end libraries of different
samples were then applied to the flow cells (containing 8 lanes) on cBot (Illumina), so that
multiple samples could be sequenced together.
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A.4.4.5 Sequencing and demultiplexing
Next, the multiplexed probes were sequenced on the Illumina HiSeq 2000 platform in 201
sequencing cycles. For some intuition, the generated clusters are sequenced simultaneously,
and the nucleotide in the sequence is obtained by capturing its fluorescence signal with a
built-in camera. 198 probes were sequenced with the depth 6 samples per lane, and 2 probes
were sequenced each on one lane as a sensitivity check and to assess how many more genes
can be (reliably) detected with a greater sequencing depth. Of the 198 probes, there were
technical problems on one lane on one flow cell so that about 20% of the data from the
first base call of these 6 probes was missing. This run was repeated and the partly missing
sequences can be used for reliability checks. The raw data contains the sequences of quality-
scored base calls and was saved in .bcl files. Next, the CASAVA (Illumina) software was used
for converting the .bcl files to .fastq files. In the same step, the multiplexed samples were
demultiplexed and the raw reads of each sample are extracted and saved.
A.4.4.6 Quality control of the demultiplexed raw sequencing reads
At first, the quality metrics from the demultiplexed fastq files were inspected using the
bcl2fastq software (Illumina). Supplementary Figure A.11 gives an overview about the
number of raw reads of all probes, where the reads of the 6 re-sequenced probes are aggre-
gated. The mean number of raw reads (of all probes except the 2 deeply sequenced probes)
was 64,095,856 (SD=7,518,970), with minimum 43,373,110 and maximum 85,591,020 raw
reads.
For an assessment of the sequencing quality, Illumina uses the Q-score as quality scoring
method, which is a prediction of the probability of an incorrect base call. More specifically,
given a base call X, the quality score Q(X) is computed as Q(X) = −10 log10(P (¬X)) where
P (¬X) is the estimated probability of the base call being wrong. Hence, a quality score of
10 indicates an error probability of 0.1, a quality score of 20 indicates an error probability
of 0.01, a quality score of 30 indicates an error probability of 0.001 etc. All probes had
a high percentage (on average 88.0%, SD=1.9%) of bases with high quality (Q > 30), see
Supplementary Figure A.12. Only the first 6 sequenced probes had a slightly lower percentage
around 80%, and all other probes had a percentage between 85% and 93%. The mean quality
score of bases in a probe was 32.5 (SD=0.5) and showed a very similar pattern (Supplementary
Figure A.13).
Next, more details of the quality checks are reported by investigating the sequence qual-
ity, GC content, sequence base content, the presence of adapters and duplicated reads using
the FASTQC tool (Andrews, 2010). The sequence quality was high for all probes, across all
base pair positions of all reads, see Supplementary Figures A.14-A.15 with one representative
probe as example. The GC distribution across all reads was close to the expected theoret-
ical distribution for all probes, with only minor deviations from some probes which didn’t
indicate systematic biases or deviations, see Supplementary Figure A.16 for a representative
illustration of one probe. The sequence base content was not random for the first 10 bases
across all reads (see Supplementary Figure A.17), but this was observed for all probes as
a usual artefact due to the (non-)random hexamer priming, and is not considered a reason
for concern. Next, there was no indication for any problems with adapters (Supplementary
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Figure A.18). Due to the PCR-steps involved in the cluster generation in RNA-Seq, duplicate
sequences were naturally observed (Supplementary Figure A.19), around 50% for all probes.
There were not any specific sequences that were reported to be systematically duplicated,
hence there don’t seem to be any systemic problems.
As a summary, the quality control checks of the raw reads showed a consistently high read
quality without indication for systematic sequence biases, presence of adapter sequences, or
duplication levels beyond what can be expected from RNA-Seq. Hence, the fastq files were
parsed to the alignment stage with TopHat2 without trimming or deleted of reads.
A.4.4.7 Read alignment
The reads were aligned to the human reference genome GRCh38 (Homo sapiens.GRCh38.78)
using TopHat2 (version 2.0.12) with Bowtie2 (version 2.0.6.0) and samtools (version 0.1.18.0),
which maps the RNA reads in the presence of insertions, deletions and gene fusions. Since
Bowtie2 has limitations with respect to alignments containing large gaps, TopHat2 addresses
these issues so that, for example, noncoding RNAs can be mapped as well as transcripts
spanning introns. TopHat2 uses the .bcl files and generates .bam files with the aligned reads.
In the alignment, all reads were used without trimming or discarding reads with low-quality
calls.
A.4.4.8 Quality control of the aligned reads
In the following, descriptive statistics of the alignment quality metrics are investigated. Sup-
plementary Figures A.20-A.21 show the number of mapped reads in absolute and relative
frequencies, and Supplementary Figures A.22-A.23 the number of aligned pairs in absolute
and relative frequencies. In these plots, the reads of the 6 re-sequenced probes are aggregated.
On average, 90.3% (SD=1.2%) of all reads could be aligned. Furthermore, on average, 85.7%
(SD=1.9%) or all raw reads could be aligned in pairs and on average 91.8% (SD=1.3%) of
the mapped reads had a high mapping quality (Supplementary Figures A.24-A.25). These
plots and metrics illustrate that in addition to the high sequencing quality, the alignments
had high quality.
For additional investigations, alignments using TopHat (Trapnell et al., 2009) or TopHat2,
Bowtie (Langmead et al., 2009) or Bowtie2, and alignments to GRCh37 were generated and
inspected. In comparisons, it was observed that (i) alignments using TopHat2 with Bowtie2
provided more aligned reads and more aligned reads with high mapping quality compared to
TopHat with Bowtie2, which in turn provided more (high-quality) aligned reads compared to
TopHat2 with Bowtie, (ii) alignments to GRCh38 yielded more aligned reads (but also more
multiple alignments) compared to alignments with GRCh37.
A.4.4.9 Read counts as raw measures of gene expression levels
The aligned reads were first sorted using samtools and then htseq-count was used to obtain
counts as a raw measure of the gene expression levels. Counts were obtained for genes with
respect to ensembl gene identifiers. Default settings were used to discard aligned reads with
mapping quality smaller than 10. Since all mapped reads had either mapping quality higher
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than 30 or lower than 10, only high-quality-mapped reads were used to obtain counts. Reads
overlapping multiple genes were not counted for any gene (based on the default mode ”union”).
For an illustration of the amount of filtered probes (reads which were not properly paired,
of low mapping quality, or where the reads or mates had multiple alignments), Supplementary
Figure A.26 shows the absolute number of mapped and counted reads (median 23,850,000
counted reads per probe), and Supplementary Figure A.27 shows the percentage of mapped
and counted reads relative to the raw reads, which was on average 56.7% (SD=3.0%).
A.4.4.10 Quality control and normalization of read counts
The ensembl database (Aken et al., 2016; Hubbard et al., 2002) lists in total 64,253 genes for
the reference genome GRCh38.78 (obtained from http://dec2014.archive.ensembl.org/
index.html). Based on the obtained raw gene expression levels, 48,126 genes were expressed
in at least one probe. Interestingly, only 107 of the 48,126 genes (≈ 0.2%) were uniquely ob-
served in the 2 deeply sequenced probes which yielded 6 times as many reads. On average, the
expression of 27,690 genes was observed per sample (SD=1,274, min=25,430, max=33,280),
19,460 genes had at least 5 counts per sample (SD=1,042, min=17,600, max=25,910), 17,500
genes had at least 10 counts per sample (SD=940, min=15,890, max=23,580), and 13,630
genes had at least 50 counts per sample (SD=696, min=12,420, max=18,470). An illustration
of the distribution of these numbers is shown in Supplementary Figure A.28. From another
perspective, Supplementary Figure A.29 shows histograms of the average number of observed
counts per gene, contrasting the changes when probes were sequenced at the depth of 1 sam-
ple per lane, 3 samples per lane (aggregating the 6 re-sequenced probes), and 6 samples per
lane. As can be expected, the number of genes without observed counts decreases, and the
average count per gene as well the maximum number of counts per gene increases, but the
shape of the average observed counts per gene and the overall pattern don’t change with
sequencing depth.
For further details regarding the comparison of different sequencing depths, Supplemen-
tary Figure A.30 shows the relative frequency of gene classes that are detected with the
different sequencing depths, for one probe sequenced at 1 sample per lane and one probe
sequenced at 6 samples per lane. In the left panel, the percentage of detected features (e.g.,
protein coding genes) in each probe is shown. As could be expected, this percentage is always
higher for the deeper sequenced probe, but again, the differences are not substantial especially
for protein coding genes. The right panel shows the relative abundance of genes within each
sample and, for example, that between 50% and 60% of detected genes are protein coding.
Supplementary Figure A.31 shows the same figures contrasting the two deeper sequenced
probes, and doesn’t indicate any differences.
In the analysis of gene expression measures from RNA-Seq, the observed counts are often
dependent on the gene length (the longer the gene, the higher the counts), which can affect
downstream analyses (Hansen et al., 2012). Hence, instead of the raw counts, normalized
gene expression measures should be used. Popular measures include CPM (counts per million:
counts scaled by the number of genes per million), RPKM (reads per kilobase of exon model
per million mapped reads: counts per total counts in million and per gene length in kilobases;
Mortazavi et al., 2008), and TPM (transcripts per million: counts per gene length adjusted
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for total counts per gene lengths in million; Li & Dewey, 2011). All are within-sample
normalizations, and RPKM as well as TPM correct for gene length and library size (i.e., total
number of reads). Advantages of TPM are that it allows for between-sample comparisons
(Wagner et al., 2012) and it was chosen as normalization measure here.
TPM-normalized counts were computed for the 48,019 genes which had non-zero counts
in at least 1 sample as follows: Let d denote the number of genes under investigation, Counts
their observed counts, and Lengths, s = 1, . . . , d their gene length. Then, for a given gene s:
TPMs = RPKs · 10
6∑d
s=1RPKs
,
where RPKs = Counts · 103Lengths are the read counts divided by the gene lengths per kilobase.
The gene lengths were obtained from the ensembl database through biomaRt (Durinck et al.,
2009) at dec2014.archive.ensembl.org (accessing GRCh38.78).
In addition to the within-sample normalization, the TMM (Robinson & Oshlack, 2010)
method was used for a between sample normalization to account for potential sequencing
biases. TMM computes the trimmed mean of M-values between each pair of samples and
thereby normalizes for RNA composition using scaling factors for the total number of reads
(i.e., library sizes), which minimizes the log-fold changes between samples. The effective
library size is computed and used instead of the observed library size.
It has been shown that the GC-content of a gene mentioned in section A.4.4.6 can bias
downstream analyses (Hansen et al., 2012; Risso et al., 2011). Hence, it was investigated for
the TMM-normalized TPM values (see Supplementary Figure A.32). The shown scatterplots
of the mean gene expression (i.e., TMM-normalized TPM value over all samples) versus the
GC content of all genes don’t indicate an association, and a linear regression confirmed that
there wasn’t any (linear) association. As a result, the gene expression measures were not
further normalized for GC content in order not to remove true biological variance and the
TMM-normalized TPM values were used as primary measure of gene expression. All genes
with observed counts for at least one individual were passed on to the following stages of the
data processing.
For an illustration, the distribution of the TMM-normalized TPM values is plotted in
Supplementary Figure A.33 for the candidate genes investigated in the study described in
section A.4.5. This shows that the distribution is normally distributed for some genes, but
very skewed for others. Supplementary Figures A.34-A.35 illustrate the differences between
TMM-normalized and non-normalized TPM values, which shows that they are very similar
and confirms that there are few biases between experiments (i.e., between samples).
As further validity checks, the correlation between gene expression measures obtained
from RNA-Seq and PCR for 6 candidate genes has been described in section 5.2.2.1. See
Supplementary Figure A.36 for an illustration of these associations. In addition to these
results, the correlations between the TMM-normalized TPM values and PCR gene expression
were higher or equal compared to using other measures of RNA-Seq gene expression (e.g.,
TMM-normalized or raw RPKM or CPM values, or raw counts), supporting the use of TMM-
normalized TPM values as gene expression measure for the main analysis.
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A.4.4.11 Transformations of normalized read counts
Next, the distribution of the gene expression measures was investigated. First, the skewness
distribution of all genes with non-zero counts in at least 1 of the 198 regularly sequenced
probands is shown in Supplementary Figure A.37. It shows that there are few genes whose
gene expression had a left-skewed distribution (minimum skewness = −1.1). The gene expres-
sion of many genes was slightly skewed, but about half of all genes had a strongly right-skewed
distribution. Transformations (such as a log-transformation) lead to problems for very lowly
expressed genes, where almost everyone has an observed count of 0. Hence, the following
analyses and transformations were restricted to those 30,917 genes, where at least 25% of the
people (i.e., at least 50 probes) had non-zero observed counts. The skewness distribution of
these genes is shown in Supplementary Figure A.38, and confirms that most lowly expressed
genes had a very skewed distribution. Of the 30,917 genes, 15,569 had skewness greater than
1, and 5498 had skewness greater than 2.
Next, a log-transformation was applied to those genes whose gene expression had a dis-
tribution with skewness greater than 1. For these genes, before the log-transformation, the
value 0.000001 was added to the (TMM-normalized TPM) gene expression to ensure that
only positive values were log-transformed (the minimum non-zero gene expression value in
all genes was 0.00014). The skewness after this transformation is shown in Supplementary
Figure A.39, and shows that while there were no right-skewed genes anymore, the result is
not satisfactory since now there were consequently many left-skewed genes.
As a result, another approach was pursued, and the skewed genes (i.e., with skewness
greater than 1) were transformed using the Yeo-Johnson transformation (which is the Box-Cox
transformation of U + 1 for nonnegative values, and of |U |+1 with parameter 2−λ for U neg-
ative) using the yjPower() function in the car R package (Fox & Weisberg, 2011), where the
parameter λ for the transformation is determined in a first step using the powerTransform()
function. This approach seemed to be successful in removing the skewness for all genes, as
shown by the histogram of the skewness of all genes in Supplementary Figure A.40, and his-
tograms of the gene expression of the first 50 genes in Supplementary Figures A.41-A.42. Still,
7,953 genes didn’t seem to be normally distributed according to the Kolmogorov-Smirnoff test
with a p-value smaller than 0.001, for example, due to bimodal or other forms of distribu-
tions. However, for those genes, there wasn’t a clear indication which transformation could
yield normally distributed measures. Hence, the Yeo-Johnson transformed gene expression
measures were used as final measure for the analysis. To incorporate that the normality of
some genes is questionable, robust analyses incorporating multiple genes (e.g. the GO term
enrichment analysis) were performed, and top associated genes with highest significance in
the main analyses were inspected manually.
A.4.4.12 SNV calling
In order to investigate genetic variants, SNVs (in coding regions) were called from the RNA-
Seq .bam files using samtools and only correctly paired reads. In more detail, samtools
mpileup and bcftools view were used to call the SNVs and generate the base call format
(.bcf) and variant call format (.vcf) files. All samples were used as input simultaneously
call the genotypes of all observed SNvs for all samples, by using priors and the information
A.3 SUPPLEMENTARY RESULTS - OBESITY STUDY 121
from the other samples for samples where the SNV was not observed. This also yields a
higher calling quality. For a better computational efficiency, the genome was divided into 550
regions (including the X and Y chromosomes, MT DNA, and scaffolds of unknown position),
and SNVs were called separately for the regions. In the calling, no filters regarding depth or
calling quality were used, and these quality control steps were done in the following. In total,
2,029,767 biallelic SNVs could be called as well as 79,618 multi-allelic (>2 allelic) SNVs and
INDELS. The 2,029,767 biallelic SNVs included 1,978,091 autosomal SNVs, 45,874 SNVs on
the X and Y chromosomes, 760 mitochondrial SNVs, and 5,042 referenced SNVs on scaffolds.
All analyses in the following focus on the autosomal SNVs. The separate vcf files were
aggregated by chromosome, and the next filtering steps (by depth and quality) were done on
the chromosome level (also for higher computational efficiency). More specifically, SNVs were
filtered if the read depth was smaller than 100 (based on high-quality reads across all 200
samples), if their depth was larger than 3 times the average depth (possible PCR amplification
bias) and if their quality score was smaller than 15. After these basic filtering steps, 538,506
(autosomal) SNVs were retained. Deletion of monomorphic SNVs yielded 531,397 SNVs,
and after deleting SNVs which had a p-value smaller than 10−7 in the exact test of the
Hardy-Weinberg equilibrium (computed using the genetics R package; Warnes et al., 2013),
509,009 SNVs were available for the main analysis. Across all SNVs and samples, the average
coverage per position per sample was 6.6. Next, genotypes (0, 1, 2) were computed, MAFs
were calculated, and the genotypes of those SNVs with MAF>0.5 were reverted and the
MAF recomputed. For an illustration of the MAF distribution of all 509,009 SNVs, see
Supplementary Figure A.43.
A.4.4.13 Assessment of gene expression of candidate adipokines with PCR
After extracting the RNA and converting it to cDNA, quantitative real time PCR was used to
evaluate the gene expression in SAT of 9 target genes: adiponectin (AdipoQ), leptin (LEP),
soluble leptin receptor (sOB-R), resistin (RETN), fatty acid binding protein 4 (FABP4),
tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), as well as 11β-hydroxysteroid de-
hydrogenase type 1 and type 2 (11β-HSD1, 11β-HSD2). qPCR was performed using the
Applied Biosystems 7500 Fast Real-time PCR system with TaqMan technology (ABI, Darm-
stadt, Germany). The two-step PCR conditions were 20s at 95°C, 40 cycles with 3s at 95°C,
and 30s at 60°C (5µL reaction volume, 4ng template). In each amplification cycle, a cycle
threshold (Ct) value was obtained. For each probe and for each gene, gene expression was
measured in triplicates and the three Ct values were averaged for each individual to gain a
more robust measure. In addition, the expression of the reference rRNA housekeeper gene
18S was measured for each probe on the same plate for four genes (adiponectin, resistin, IL6,
TNF-α), also in triplicate, and the three Ct values were averaged as well. These four 18S av-
erage Ct values were very similar across plates, and further averaged for each probe to obtain
the reference 18S expression (in form of a grand average Ct value) for each probe. Relative
normalized gene expression levels ∆Ct in comparison to the reference gene were obtained for
each gene and each probe, from the difference between the averaged candidate gene Ct value
and the 18S grand averaged Ct value. As measure for gene expression in the analysis, 2−∆Ct
values were used, assuming that the number of amplified target molecules at the threshold cy-
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cle is identical for the candidate genes and the housekeeper (Livak & Schmittgen, 2001). Gene
expression of one sample was significantly different from all other probes for all genes and the
housekeeper, so that the probe was discarded from further description and analysis, yielding
a sample size of 199 for the analysis of gene expression. For resistin, SAT gene expression
levels were very low leading to unobservable Ct values across triplicates for 2 samples, which
had to be excluded from the analysis of resistin gene expression. The inter-assay coefficient
of variation (across the four 18S Ct measures of each probe on the 4 different plates) was
on median 1.2%. For all genes, the median intra-assay coefficient of variation (across the
triplicate Ct measures of all sample probes on all 84 plates) was smaller than 1.5%.
A.4.4.14 Assessment of plasma concentrations of candidate adipokines
In the study, the plasma levels of the adipokines adiponectin, leptin, soluble leptin receptor
(sOB-R), resistin, interleukin 6 (IL6) and fatty acid binding protein 4 (FABP4) were ex-
amined. Blood samples were collected during the reinvitation of participants from 2010-12,
processed, divided into 1ml nunc tubes and stored in -80° C freezers. EDTA plasma probes
were thawed, split into predetermined volumina necessary for the different ELISA kits and
then further stored at -80°C. Plasma levels of total, high molecular weight (HMW), and HMW
+ medium molecular weight (MMW) adiponectin were measured using ELISAs from Alpco
(Salem, USA), and concentrations of MMW and low molecular weight (LMW) adiponectin
computed by subtraction. Leptin, sOB-R, resistin and FABP4 were measured using ELISAs
from BioVendor (Brno, Czech Republic), and IL6 was measured using an ELISA from R&D
Systems (Minneapolis, USA). All samples were measured in duplicates according to standard
protocol on the TECAN Infinite 200 PRO reader (Ma¨nnedorf, Switzerland). Concentration
estimates adjusted for reference absorption and background noise were obtained using the ob-
served absorption measures and a 4-parameter logistic (4PL) model (Ritz & Streibig, 2005),
fitted with the optimx package in the statistical software R version 3.3.1.
Among the 3,136 measures of all biomarkers of all participants, 9 single absorption mea-
sures were missing and 16 measures yielded low absorption measures so that their concentra-
tion couldn’t be estimated using the 4PL model. This included 6 measures for leptin, 1 for
sOB-R, 5 for FABP4, 3 for total adiponectin, 4 for HMW adiponectin and 6 for HMW+MMW
adiponectin. For these low absorptions, concentrations were set to half of the respective
minimally possible detected concentration so that after averaging duplicate measures, con-
centrations were missing for 1 sample for leptin, LMW and MMW adiponectin. The median
intra-assay coefficient of variation (across the duplicate measures of all sample probes on all
48 plates) was <5% for all biomarkers, except for sOB-R, where it was 11%. The inter-assay
coefficient of variation (of the averaged estimated concentrations of the two measures of a
pooled probe across all 48 plates) was 6% for leptin, 14% for sOB-R, 11% for resistin, 6% for
IL6, 8% for FABP4, 4% for total adiponectin, 8% for HMW+MMW adiponectin, and 11%
for HMW adiponectin.
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A.4.5 Study to predict adipokine plasma levels based on body fat com-
partments and adipose tissue gene expression
A.4.5.1 Overview
Over the past years, a number of circulating adipokines have been identified and proposed as
mediators for the association of obesity with chronic disease risk. However, it is unclear to
what extent the amount of subcutaneous (SAT) and visceral (VAT) adipose tissue (AT) and
gene expression levels in AT predict adipokine concentrations on a population level. In a cross-
sectional analysis of 200 participants from the population-based EPIC Potsdam cohort study,
measures of AT mass were obtained using anthropometry and magnetic resonance imaging.
In addition, gene expression in SAT, collected by biopsy, and plasma concentration of the
cytokines adiponectin, leptin, soluble leptin receptor, resistin, interleukin 6 and FABP4 were
measured. The primary aim of this study was to investigate to what extent different imaging-
based AT measures and gene expression predict the circulating levels of these adipokines. In
addition, it was evaluated which AT measures are best representing the metabolic activity of
adipose tissue. This measure was then further used in section 5.2.
For leptin and FABP4, 77% and 37% variance of circulating levels were explained by
SAT as well as VAT mass and gene expression. Leptin showed stronger correlations with
SAT compared to VAT mass, while there was little difference between AT compartments
regarding their correlation with FABP4. For both adipokines, plasma concentrations were
more strongly correlated with AT mass compared to gene expression. For the remaining
adipokines, less than 16% of the variance was explained by SAT, VAT, and gene expression.
The data suggest that except for leptin and FABP4, SAT, VAT and gene expression in AT
predict adipokine concentrations only to a small extent. These data point to other predictors.
Further, while our findings do not contradict a potential role in disease development, these
adipokines are unlikely to account for a large proportion of the association between adiposity
and disease risk observed in epidemiological studies.
A.4.5.2 Introduction
Obesity is an established risk factor for a number of chronic diseases. Investigations into the
underlying molecular processes have identified circulating adipose tissue-derived biomarkers,
so-called adipokines (Fantuzzi & Mazzone, 2007; Pischon, 2009), that are - among various
pathways - involved in glucose and lipid metabolism, inflammation, insulin signaling, and
energy homeostasis (Ouchi et al., 2011; Fasshauer & Blu¨her, 2015). A number of these
adipokines have also been associated with risk of cardiovascular disease, diabetes, hyperten-
sion, and cancer, and have been proposed as mediators for the association of obesity with
chronic disease risk (Pai et al., 2004; Norata et al., 2007; Terra et al., 2011; Aleksandrova
et al., 2012a, 2012b). Surprisingly, the variance of plasma adipokine levels explained by the
body mass index (BMI) or by waist circumference - which are currently used to define obesity
or abdominal obesity, respectively - is relatively modest, around 36% for leptin and only up
to 10% for most of the other adipokines (Pai et al., 2004; Pischon, 2009; Aleksandrova et al.,
2012a). However, BMI and waist circumference are only crude measures of the amount of
subcutaneous and visceral adipose tissue (SAT and VAT), which are the major compartments
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of human adipose tissue (Ibrahim, 2010). Also, the degree of gene expression on the tissue
level has often not been taken into account as further predictor of plasma levels (Fredriksson
et al., 2006; Campbell et al., 2013).
Magnetic resonance imaging (MRI) allows direct quantification of SAT, VAT and TAT
(Ross, 2003; Karlsson et al., 2013; Lee & Kuk, 2013), but there is inconsistent empirical evi-
dence as to what extent imaging-based assessment of VAT, SAT or TAT predicts adipokine
levels (Fox et al., 2007; Maahs et al., 2007; Won et al., 2009; Arnardottir et al., 2013). Fur-
ther, only few studies have reported on the association of imaging-based adipose tissue (AT)
mass with gene expression and circulating plasma or serum concentrations, have investigated
different research questions, and have mostly focused on specific patient groups and on the
analysis of one or two candidate adipokines (Goldstone et al., 2002; Sutinen et al., 2003;
Berndt et al., 2005; Pietila¨inen et al., 2006; Kursawe et al., 2010).
The aim of our study was therefore to examine to which extent circulating plasma
adipokines levels can be predicted the amount of SAT, VAT (assessed by MRI), and by
AT gene expression (measured in SAT). Our hypothesis was that direct quantification of
SAT and VAT as well as AT gene expression explain a substantial amount of the variance in
adipokine levels. As secondary aim, it was investigated which anthropometric measures show
the strongest association with adipokine AT gene expression and plasma levels.
A.4.5.3 Methods and materials
In the analysis, the study sample described in section 5.2.1.1, MRI-based AT measures de-
scribed in section A.4.4.1, gene expression levels in SAT of the candidate adipokines measured
by PCR (see section A.4.4.13) and plasma concentrations of the candidate adipokine mea-
sured by ELISA (see section A.4.4.14) were used. Statistical analyses were performed using R
version 3.3.1. All gene expression, plasma concentration, and MRI-based AT mass measures
were log-transformed to yield normally-distributed measures for the analysis. For descrip-
tive statistics, mean/standard deviation (SD), median/median absolute deviation (MAD), or
frequencies of selected study characteristics are described. Partial Pearson correlation coef-
ficients of the AT measures with gene expression and protein levels, adjusted for sex, age,
physical activity and occupational training were calculated. In sensitivity analyses, we also
calculated Spearman correlation coefficients and found very similar results (data not shown).
Linear regression models were fitted for the primary question how much of the variance of
plasma concentrations can be explained by gene expression, AT mass, SAT gene expression
x SAT mass, and personal/environmental factors, measured by the adjusted R2 accounting
for the number of predictors in the model. Here, the interaction of SAT gene expression
and SAT mass also carries the biological interpretation of the cell-based measure of tran-
scriptomic activity multiplied by the amount of tissue (i.e., number and size of cells). In
each part, a complete-data analysis of the respective maximally available sample size was
performed and missing values were removed. This yielded sample sizes between 200 (e.g., of
descriptive statistics for anthropometric traits and personal characteristics) and 149 (in the
full regression model 14 in Supplementary Table A.39 including all plasma concentrations,
gene expression levels, AT measures, and personal characteristics) in the reported analyses
below.
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A.4.5.4 Results: sample characteristics
Descriptive statistics of the study participants regarding their personal characteristics, disease
prevalence, AT measures, and gene expression and plasma concentration of biomarkers are
shown in Table 5.6 and Supplementary Table A.34. The sample contained slightly more
women than men (57% women, 43% men), with an average age of 65.1years (SD=9.0 years),
a mean BMI of 27.9 (SD=4.2), and a low prevalence of cardiovascular and cardiometabolic
diseases. SAT was on average 20.1kg (SD=5.2kg) for women, and 14.8kg (SD=4.3kg) for
men. Both plasma levels and gene expression showed variation between persons and sexes.
For example, leptin plasma levels were on median 44.6µg/ml (MAD=25.2µg/ml) in women
and 44.6µg/ml (MAD=25.2µg/ml) in men, and the MAD of gene expression was also about
half of its median.
A.4.5.5 Results: Correlation of adipokine concentations with body fat compart-
ments
On the level of plasma concentrations (Supplementary Table A.35), for leptin and FABP4,
the highest correlations (adjusted for sex, age, physical activity, occupational training) were
observed with TAT (r = 0.80, 95%CI = [0.74; 0.85] and r = 0.53, 95%CI = [0.41; 0.63]),
which were of similar size compared to SAT (r = 0.79, 95%CI = [0.72; 0.84] and r = 0.50,
95%CI = [0.37; 0.61]), and larger compared to the correlation with VAT (r = 0.59, 95%CI =
[0.47; 0.68] and r = 0.44, 95%CI = [0.31; 0.56]). For sOB-R, IL6, total, HMW, and LMW
adiponectin, and resistin, the correlation of each adipokine with SAT, VAT, and TAT was of
similar size (around r = −0.40, r = 0.31, r = −0.25, r = −0.25, r = −0.10 and r = 0.05,
respectively). For MMW adiponectin, the correlations with VAT were higher compared to
SAT and TAT (r = −0.32 for VAT versus r = −0.14 for TAT and r = −0.08 for SAT). For
leptin, MMW adiponectin, and FABP4, MRI fat mass measures showed stronger correlations
with plasma levels compared to the traditional measures (BMI, WC, HC, and WHR), whereas
for all remaining adipokines, correlations with MRI measures were in a similar range as their
correlations with traditional measures. The correlations of plasma adipokine levels with
BMI were generally in a similar range as their correlations with WC. CAT showed smaller
or equal correlations compared to VAT, SAT, TAT for all investigated adipokines. Finally,
the correlations of absolute fat measures (SAT, TAT, VAT) were very similar compared to
correlations using relative fat measures (i.e., SATTBV ,
VAT
TBV ,
TAT
TBV) for most biomarkers (data not
shown).
A.4.5.6 Results: Correlation of subcutaneous adipose tissue adipokine expres-
sion with body fat compartments
In general, correlations between adipokine gene expressions and AT measures (Supplementary
Table A.36) were weaker as compared to the correlations between plasma concentrations and
ATmeasures (Supplementary Table A.35). Leptin expression showed the strongest correlation
with SAT (r = 0.37); whereas sOB-R, resistin, FABP4, adiponectin, and IL6 showed similar
associations with SAT, VAT and TAT (r = 0.06 to 0.17, r = 0.15 to 0.20, r = −0.27 to −0.24,
r = −0.30 to −0.25, and r = 0.19 to 0.26, respectively, see Supplementary Table A.36).
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A.4.5.7 Results: Correlation of SAT gene expression with adipokine concentra-
tions
SAT leptin gene expression was moderately correlated with leptin concentrations (r = 0.52,
Supplementary Table A.37). Correlations between SAT gene expression and plasma levels
were modest for total, HMW, and MMW adiponectin (r = 0.22; r = 0.24; and r = 0.22,
respectively), and weak for sOB-R (r = −0.03), FABP4 (r = 0.09), resistin (r = 0.11), LMW
adiponectin (r = 0.06), and IL6 (r = 0.15).
A.4.5.8 Results: Prediction of adipokine plasma concentrations
For the primary aim, we examined how much of the variance in the biomarker plasma con-
centrations can be explained by VAT mass as well as SAT mass, SAT gene expression and
their interaction, in form of the total explained variance (adjusted R2) from linear regression
models (Supplementary Table A.38). The interaction of SAT mass and SAT gene expression
can be interpreted as the relative metabolic activity of SAT projected onto its absolute mass.
Overall, a substantial proportion of the plasma concentration was explained by these predic-
tors for leptin and, albeit to a somewhat smaller extent, for FABP4. In contrast, the variance
explained by these predictors was low for the remaining adipokines. In more detail, SAT
gene expression explained 45%, SAT mass 72%, VAT mass 0%, and gene expression together
with SAT 76% of variance in leptin plasma levels. For FABP4, the explained variance was
1% by gene expression, 31% by SAT, 1% by VAT, and 36% by SAT and gene expression.
For sOB-R, the explained variance was 0% by gene expression, 13% by SAT, and 6% by
VAT. For total, HMW, and MMW adiponectin, SAT mass as single predictor did not explain
any of their variance, but VAT explained about 10-12% and gene expression explained about
6-7%. For IL-6, VAT explained 12%, SAT 1% and gene expression 1%. For resistin and
LMW adiponectin, the variance explained by SAT, VAT, and gene expression was close to
zero. The interaction of SAT gene expression and SAT mass accounted for 31% of leptin,
and about 10% of sOB-R and FABP4 levels, but did not explain any variance on top of the
main effects. When VAT was added to gene expression and SAT, the explained variance
increased by 1% (leptin), 4% (sOB-R), 0% (resistin), 1% (FABP4), 8% (total adiponectin),
9% (HMW adiponectin), 8% (MMW adiponectin), 2% (LMW adiponectin), and 10% (IL6),
see Supplementary Table A.38. It should be noted that without accounting for sex differences
(cf. Supplementary Table A.35), the contribution of SAT and VAT cannot be assessed since
they are sex-dependent, and otherwise they seem to explain 0% variance for some adipokines.
A.4.5.9 Results: Additional predictors of adipokine concentrations
In addition to the primary aim, we also investigated to what extent sex differences may
explain variance in plasma adipokine concentrations (Supplementary Table A.39). While sex
alone explained 28% of variance in leptin levels and 16% of FABP4 levels, it explained little of
the variance in the remaining adipokines. Further, when sex was added to GE, SAT and VAT,
it did not increase the explained variance in leptin levels, suggesting that variance in leptin
differences between sexes were accounted for by differences in SAT mass and gene expression.
Only for FABP4, sex explained additional variance (5%) on top of gene expression and AT
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mass.
We also considered to what extent other factors may increase the explained variance in
adipokine levels, including: 1) age, occupational training, physical activity, 2) all other an-
thropometric measures, 3) gene expression levels of all remaining adipokines, 4) plasma con-
centrations of all remaining adipokines, and 5) employment status, partner status, smoking,
socioeconomic status and diabetes (Supplementary Table A.39). In general, small increases
(at least 5%) in explained variance were only observed for the following adipokines: For sOB-
R, the other anthropometric factors, leptin gene expression and leptin plasma concentration
each explained about 6% additional variance (non-additively); for resistin, age, physical ac-
tivity and FABP4 plasma concentration increased the explained variance from 1% to 14%;
for FABP4, the largest increase was seen when other anthropometric factors (9%) or resistin
plasma levels (6%) were included; for HMW adiponectin, the largest increases were observed
when including further sociocultural factors (from 13% to 20%); for MMW adiponectin, when
including all other gene expressions (from 12% to 25%); and for IL6 when including all other
plasma levels (from 12% to 24%).
A.4.5.10 Additional results
Supplementary Tables A.40-A.43 show correlations (Pearson correlation coefficient r) between
the mRNA expression of the different genes (Supplementary Table A.40), between the concen-
trations of the plasma concentrations (Supplementary Table A.41), between the different MRI
and anthropometric measures (Supplementary Table A.42) and between the gene expression
and plasma levels (Supplementary Table A.43). On the mRNA expression level, the highest
correlations were observed between adiponectin and FABP4 (r = 0.64), adiponectin and lep-
tin (r = 0.37), leptin and IL6 (r = 0.34). On the protein plasma level, the highest correlations
were between leptin and FABP4 (r = 0.53) and leptin and leptin receptor (r = −0.42), beside
the correlation between the different adiponectin molecular fractions. Regarding the obesity
measures, BMI showed a high correlation with overall mass measures (r = 0.85 with TBV,
r = 0.80 with TAT), intermediate correlation with SAT (r = 0.69), and only moderate or
small correlation with VAT and CAT mass (r < 0.5). WC and WHR had higher correlation
with internal AT (r = 0.80/0.76 with VAT, r = 0.74/0.72 with CAT), but very different
correlations with overall mass measures (r = 0.88/0.51 with TBV; r = 0.59/0.05 with TAT;
r = 0.36/− 0.22 with SAT). Regarding the MRI measures, the correlation of TAT was high
with SAT (r = 0.95) but only moderate with TBV (r = 0.68) and even smaller with VAT
(r = 0.42).
A.4.5.11 Discussion
This study investigated to what extent plasma adipokine concentrations can be predicted
based on MRI-derived AT mass of different body compartments, including SAT and VAT,
and by SAT gene expression. Except for leptin and in part FABP4, surprisingly little vari-
ance was explained for the remaining adipokines. For all adipokines, AT mass was the main
contributor to these percentages and played a much larger role compared to SAT gene ex-
pression. These data suggest that factors other than obesity and AT gene expression may be
main determinants of these plasma adipokine concentrations. Further, while these findings
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do not contradict a potential role of these adipokines in disease development, they suggest
that these adipokines are unlikely to account for a large proportion of the association between
adiposity and disease risk observed in epidemiological studies.
Leptin is a 16 kDa protein hormone encoded by the ob gene that is mostly produced
by white adipose tissue (Zhang et al., 1994). It was originally discovered in 1994 as a long-
term regulator of food intake and energy balance acting in the hypothalamus (Zhang et
al., 1994). Today, it is well known that leptin also effects metabolism, energy homeostasis,
neuroendocrine, and immune function (Ibrahim, 2010; Mantzoros et al., 2011; Friedman,
2016). In our analysis, a large proportion of the variance (72%) of circulating leptin levels was
predicted by SAT. While gene expression explained 45% when considered alone, it contributed
only little additional information when added to SAT mass. These data confirm that leptin
is primarily a biomarker for SAT mass. However, SAT mass was also associated with leptin
gene expression, so that the effect of SAT on circulating leptin could also contain part of the
effect of leptin gene expression. The association of VAT mass with leptin levels was much
smaller, but some of the remaining unexplained variance of leptin levels might be explained
by VAT gene expression which was not assessed in this study.
FABP4 acts as a carrier for fatty acids and while it is also expressed in the liver or
placenta, it is primarily expressed in adipocytes and macrophages (Furuhashi & Hotamisligil,
2008). In our study, about one third of the variance of FABP4 was explained, with rather
similar contributions of SAT and VAT (Supplementary Table A.35). Gene expression did not
contribute at all to the explained variance. Thus, somewhat similar as for leptin, these data
suggest that FABP4 is a biomarker for AT mass, although about two thirds of the variance
remain unexplained.
sOB-R is the main leptin-binding protein, and its expression has been reported in mul-
tiple other tissues besides AT, most notably in the hypothalamus (Zhang et al., 1994). The
exact role of sOB-R is not entirely clear. Binding to sOB-R may delay the clearance of lep-
tin from the circulation and thereby prolong bioavailability, but it may also neutralize the
action of leptin and thereby reduce bioavailability (Zastrow et al., 2003; Zhang & Scarpace,
2009). In humans, sOB-R is inversely related to obesity and insulin resistance (Magni et
al., 2005). Interestingly, recent studies found high sOB-R to be associated with lower risk of
type 2 diabetes and colorectal cancer, independent of leptin concentrations (Sun et al., 2009;
Aleksandrova et al., 2012a). In our analysis, the variance in plasma levels explained by SAT,
VAT or gene expression was low (16%). Of these, SAT and VAT were the main contributors
whereas gene expression did not contribute at all.
Adiponectin is involved, among others, in the regulation of insulin sensitivity and en-
ergy homeostasis. It circulates in different molecular fractions and is predominantly synthe-
sized and secreted from adipocytes in VAT and SAT with different findings regarding their
metabolic activity (Fredriksson et al., 2006; Goldstein et al., 2009; Pischon, 2009; Kovacova
et al., 2012; Lihn et al., 2014). In our analysis, VAT explained slightly more to the variance of
total and HMW adiponectin as compared to SAT, and was the main contributor for MMW
adiponectin. However, the total variance explained was very low and only about 10-12%
for total, HMW, and MMW adiponectin, and 2% for LMW adiponectin. This is surpris-
ing, given that adiponectin is often considered as ”the” classical adipokine. There is a vast
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body of literature on the hormonal and metabolic effects of adiponectin, and on the potential
role in disease development (Woodward et al., 2016). In contrast to most other adipokines,
adiponectin is inversely associated with obesity, and it is considered to have beneficial effects:
it increases insulin sensitivity, decreases inflammation, and it is inversely associated with risk
of type 2 diabetes, coronary heart disease, and several types of cancer (Spranger et al., 2003;
Pischon et al., 2004; Aleksandrova et al., 2012b). However, the effects of adiponectin are not
as straightforward as initially considered, since studies have also found high adiponectin levels
to be associated with adverse health outcome in certain populations, particularly in those
with preexisting cardiovascular disease (Wannamethee et al., 2007; Dekker et al., 2008). It is
not clear why the variance in plasma adiponectin levels explained by AT and gene expression
observed in our study was so low. Measurement error appears unlikely since assays we used
to measure adiponectin are well established and have been used in several other studies, the
coefficients of variation were low (11% or less for total adiponectin and the fractions), and
the strength of the correlation between adiponectin and BMI and waist circumference was
similar to what has been reported in other studies (Maahs et al., 2007). These were also
true for all other investigated adipokines, and the substantial correlations of AT measures
with leptin can serve as a positive control. We speculate whether other factors, for example,
post-translational modifications, may account for some of the variance in adiponectin levels.
Resistin is an adipokine that was initially reported to be elevated in obese C57Bl/6J
mice on a high-fat diet and suppressed by treatment with thiazolidinediones (Steppan et al.,
2001). Treatment of wild-type mice with recombinant resistin resulted in insulin resistance,
whereas administration of an antiresistin antibody increased insulin sensitivity in obese and
insulin-resistant animals (Steppan et al., 2001). However, the role of resistin in humans is
less clear. Studies have found high plasma resistin levels to be associated with inflammation
and with higher risk of coronary heart disease and with other inflammatory related diseases
(Pischon et al., 2005; Weikert et al., 2008; Yang et al., 2016; Akram et al., 2017). However, in
contrast to mice, human resistin is expressed at lower levels in adipocytes but at higher levels
in circulating blood monocytes (Savage et al., 2001). This is in line with our observation that
AT and gene expression did not predict circulating resistin levels. Taken together, these data
question whether resistin can truly be considered an adipokine in humans.
Finally, the proinflammatory cytokine IL6 is secreted by multiple cell types including
monocytes, macrophages, and adipocytes (Pischon, 2009). Although it was initially consid-
ered to be primarily an unspecific pro-inflammatory cytokine, studies have shown higher IL-6
levels in obese persons, and IL-6 was also shown to be directly secreted from the adipose
tissue (Kern et al., 2001; Wallenius et al., 2002). This has led to the notion that obesity is
associated with low-grade subclinical inflammation (Xu et al., 2003a). Nevertheless, results
from our study suggest that obesity explains only a small proportion of circulating IL-6 levels
in humans.
Without the assessment of VAT gene expression and secretion rates from SAT and VAT,
parts of the overall molecular picture remain unclear. However, assessing VAT in a population-
based study is rarely possible, and it might be questionable if VAT gene expression measured
after bariatric or other surgeries allows for a valid approximation of the metabolic activity
in healthy participants. Since adipokine secretion as well as their biological function can be
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regulated on the transcriptional or post-transcriptional level, gene expression which might
not be the best proxy for the metabolic activity of AT and might differ from the secretion
rate (Liu & Liu, 2012; Hotamisligil & Bernlohr, 2015). Also, some adipokines are expressed
and secreted into plasma from other tissues (Jamaluddin et al., 2012; Hunter & Jones, 2015).
Furthermore, some factors such as lifestyle factors, clinical parameters and other circulating
proteins which that have been identified in previous studies to affect adipokine serum levels
were not included in the present study (Thomas et al., 2000; Chan et al., 2002; Norata et al.,
2007; Yamagishi et al., 2009; Hong et al., 2015; Ishimura et al., 2013). The additional lifestyle
factors and other predictors investigated in the current study did not explain a substantial
amount of the unexplained variance. Interesting markers for future studies include diet mea-
sures (Campbell et al., 2013) and genetic markers that don’t affect mRNA abundance but
circulating levels through other processes, which could also help to infer more about the causal
mechanisms and molecular processes through mendelian randomization techniques (Smith &
Ebrahim 2003).
In conclusion, our study shows that while for leptin, most of the variance in plasma con-
centrations can be explained by AT mass (particularly SAT mass) and SAT gene expression,
this is less so for FABP4. In contrast, and counterintuitively, most of the variance in the
plasma concentrations of the so-called adipokines sOB-R, resistin, adiponectin, and IL6 can-
not be explained by AT mass or SAT gene expression. These data suggest that other factors
are the main determinants of these plasma concentrations. Further, while these findings do
not contradict a potential role of these adipokines in disease development, they suggest that
these adipokines are unlikely to account for a large proportion of the association between
adiposity and disease risk observed in epidemiological studies.
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A.5.2 Simulation study: single-marker versus multi-marker tests
Error
Distribution
SKAT SKAT-O Burden SMT - BH SMT - Bonferroni
SMT - Bonferroni
MAC>1
SMT - Bonferroni
MAC>2
N(0, 1) 4.94× 10−2 5.22× 10−2 5.01× 10−2 4.39× 10−2 4.93× 10−2 – –
t8 5.17× 10−2 5.39× 10−2 5.00× 10−2 12.68× 10−2 12.01× 10−2 6.53× 10−2 5.09× 10−2
t4 6.13× 10−2 6.09× 10−2 5.00× 10−2 21.30× 10−2 20.61× 10−2 10.64× 10−2 7.57× 10−2
logN(0, 1) 8.84× 10−2 7.95× 10−2 4.96× 10−2 33.63× 10−2 33.05× 10−2 18.88× 10−2 13.47× 10−2
Supplementary Table A.1: Empirical type I error estimates of the SMT and MMTs for the nominal level
α = 0.05 when the distribution of the phenotype is misspecified. Data was generated from the null model
with size n = 1, 000 for m = 10, 000, 000 replicates, with the error distribution of the phenotype given
covariates chosen to be from a standard normal (cf. Table 4.1), t4, t8, or log-standard normal distribution.
Adjustments for multiple testing of all SNVs in a gene with the SMT were done using the BH and Bonferroni
corrections. The type I error estimates are based on analyses using all rare and (non-causal) common SNVs
in a gene, as well as restricting the analysis to SNVs with at least 2 (’MAC>1’) or 3 (’MAC>2’) observed
minor alleles for the SMT. For other nominal levels (e.g., 10−2, 10−3, 10−4, 10−5, 2.5 × 10−6, SKAT,
SKAT-O and the SMT showed similar results and inflated type I errors, with a much higher inflation for
the SMT.
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Scenario
Using all rare and common SNVs Using all rare SNVs
SKAT SKAT-O Burden SMT SKAT SKAT-O Burden SMT
1 0.341 0.337 0.107 0.546 0.358 0.357 0.242 0.563
2 0.199 0.187 0.080 0.192 0.209 0.204 0.140 0.200
3 0.127 0.124 0.062 0.100 0.130 0.130 0.099 0.106
4 0.532 0.534 0.170 0.736 0.553 0.559 0.414 0.752
5 0.299 0.293 0.102 0.282 0.316 0.317 0.230 0.297
6 0.168 0.170 0.076 0.130 0.182 0.185 0.148 0.137
7 0.764 0.783 0.290 0.907 0.792 0.815 0.698 0.917
8 0.477 0.492 0.159 0.440 0.507 0.532 0.440 0.458
9 0.289 0.311 0.115 0.209 0.308 0.337 0.284 0.220
10 0.986 0.996 0.583 0.997 0.993 0.999 0.992 0.998
11 0.825 0.895 0.352 0.730 0.861 0.928 0.896 0.755
12 0.580 0.695 0.242 0.407 0.619 0.752 0.721 0.433
13 0.352 0.346 0.113 0.554 0.368 0.361 0.245 0.570
14 0.188 0.180 0.075 0.187 0.197 0.193 0.133 0.196
15 0.113 0.108 0.060 0.094 0.119 0.113 0.089 0.099
16 0.516 0.497 0.136 0.727 0.540 0.522 0.310 0.744
17 0.300 0.277 0.086 0.280 0.318 0.296 0.170 0.293
18 0.165 0.151 0.070 0.132 0.177 0.163 0.107 0.139
19 0.761 0.747 0.227 0.903 0.785 0.777 0.523 0.913
20 0.473 0.454 0.131 0.432 0.503 0.489 0.310 0.456
21 0.282 0.269 0.093 0.198 0.297 0.290 0.196 0.211
22 0.981 0.981 0.410 0.996 0.988 0.989 0.837 0.997
23 0.806 0.811 0.229 0.713 0.842 0.849 0.625 0.737
24 0.541 0.549 0.163 0.374 0.583 0.602 0.445 0.399
25 0.352 0.335 0.098 0.543 0.367 0.351 0.200 0.561
26 0.195 0.179 0.075 0.188 0.206 0.188 0.117 0.199
27 0.125 0.114 0.058 0.093 0.128 0.117 0.078 0.098
28 0.528 0.499 0.132 0.732 0.548 0.519 0.274 0.749
29 0.295 0.270 0.084 0.286 0.314 0.292 0.159 0.303
30 0.163 0.148 0.063 0.125 0.172 0.158 0.105 0.134
31 0.755 0.727 0.187 0.903 0.782 0.752 0.390 0.914
32 0.460 0.422 0.103 0.416 0.488 0.452 0.224 0.438
33 0.270 0.235 0.076 0.184 0.289 0.255 0.136 0.200
34 0.981 0.973 0.280 0.995 0.986 0.981 0.577 0.997
35 0.801 0.763 0.156 0.692 0.838 0.802 0.346 0.718
36 0.526 0.472 0.111 0.352 0.566 0.514 0.233 0.376
Supplementary Table A.2: Power estimates of the SMT and MMTs under the nominal α level of 0.05.
Data was generated under the alternative-hypothesis model described in scenarios 1-36 in Table 4.1 with
size n = 1, 000 for m = 10, 000 replicates. Adjustments for multiple testing of all SNVs in a gene with
the SMT were done using the BH correction. The power results are provided for analyses using all rare
and (non-causal) common SNVs in a gene, and for using all rare SNVs in a gene by excluding the common
SNVs from the analysis.
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Scenario
Using all rare and common SNVs Using all rare SNVs
SKAT SKAT-O Burden SMT SKAT SKAT-O Burden SMT
1 0.118 0.111 0.012 0.156 0.129 0.122 0.050 0.159
2 0.007 0.008 0.002 0.005 0.008 0.009 0.004 0.005
3 0.001 0.001 <0.001 0.001 0.001 0.001 0.001 0.001
4 0.223 0.215 0.024 0.263 0.243 0.235 0.121 0.268
5 0.021 0.021 0.004 0.014 0.022 0.022 0.015 0.014
6 0.004 0.004 <0.001 0.002 0.003 0.004 0.002 0.002
7 0.410 0.414 0.065 0.422 0.443 0.451 0.306 0.428
8 0.063 0.071 0.012 0.043 0.067 0.077 0.056 0.045
9 0.014 0.016 0.003 0.009 0.015 0.018 0.014 0.009
10 0.797 0.867 0.207 0.698 0.849 0.927 0.874 0.707
11 0.248 0.350 0.070 0.155 0.273 0.421 0.388 0.156
12 0.093 0.128 0.036 0.059 0.095 0.147 0.139 0.060
13 0.124 0.117 0.013 0.158 0.134 0.128 0.053 0.162
14 0.007 0.006 0.001 0.005 0.007 0.007 0.003 0.005
15 0.001 0.001 0 0.001 0.001 0.001 <0.001 0.001
16 0.210 0.200 0.016 0.250 0.227 0.216 0.068 0.256
17 0.015 0.014 0.001 0.008 0.016 0.015 0.006 0.008
18 0.002 0.002 <0.001 0.001 0.002 0.002 0.001 0.001
19 0.393 0.380 0.038 0.406 0.425 0.415 0.178 0.414
20 0.050 0.048 0.007 0.029 0.055 0.054 0.028 0.031
21 0.011 0.015 0.001 0.006 0.011 0.012 0.007 0.006
22 0.764 0.771 0.108 0.667 0.815 0.828 0.522 0.678
23 0.203 0.212 0.038 0.110 0.228 0.246 0.159 0.111
24 0.057 0.063 0.015 0.035 0.060 0.067 0.053 0.035
25 0.123 0.114 0.009 0.161 0.137 0.128 0.035 0.164
26 0.007 0.006 <0.001 0.004 0.008 0.007 0.002 0.005
27 <0.001 <0.001 0 <0.001 0.001 <0.001 <0.001 <0.001
28 0.212 0.199 0.015 0.252 0.231 0.217 0.060 0.257
29 0.016 0.014 0.001 0.009 0.018 0.015 0.005 0.009
30 0.002 0.001 <0.001 0.001 0.001 0.001 0.001 0.001
31 0.393 0.375 0.025 0.403 0.424 0.405 0.105 0.411
32 0.039 0.034 0.004 0.020 0.045 0.038 0.013 0.021
33 0.006 0.006 0 0.003 0.006 0.006 0.003 0.003
34 0.746 0.732 0.047 0.661 0.792 0.782 0.207 0.671
35 0.166 0.147 0.009 0.068 0.187 0.165 0.042 0.070
36 0.035 0.031 0.004 0.016 0.038 0.033 0.012 0.017
Supplementary Table A.3: Power estimates of the SMT and MMTs under the nominal α level of
2.5 × 10−6. Data was generated under the alternative-hypothesis model described in scenarios 1-36 in
Table 4.1 with size n = 1, 000 for m = 10, 000 replicates. Adjustments for multiple testing of all SNVs in
a gene with the SMT were done using the BH correction. Power results are provided for analyses using
all rare and (non-causal) common SNVs in a gene, and for using all rare SNVs in a gene by excluding the
common SNVs from the analysis.
136 APPENDIX
Scenario
Using all rare and common SNVs Using all rare SNVs
SKAT SKAT-O Burden SMT SKAT SKAT-O Burden SMT
1 0.276 0.271 0.063 0.558 0.282 0.280 0.173 0.561
2 0.153 0.148 0.027 0.195 0.160 0.155 0.077 0.196
3 0.060 0.058 0.011 0.047 0.062 0.061 0.029 0.048
4 0.462 0.463 0.117 0.774 0.473 0.480 0.341 0.777
5 0.269 0.265 0.053 0.315 0.279 0.276 0.162 0.318
6 0.117 0.116 0.024 0.088 0.124 0.123 0.075 0.090
7 0.722 0.764 0.243 0.934 0.737 0.792 0.677 0.936
8 0.484 0.497 0.109 0.517 0.505 0.524 0.387 0.521
9 0.252 0.266 0.063 0.167 0.269 0.290 0.208 0.170
10 0.984 0.999 0.583 0.999 0.990 1 0.997 1
11 0.862 0.938 0.309 0.813 0.883 0.965 0.931 0.816
12 0.632 0.765 0.178 0.374 0.664 0.827 0.771 0.379
Supplementary Table A.4: Power estimates of the SMT and MMTs under the nominal α level of
2.5 × 10−6, for a sample size of 5,000 and genes including 58 SNVs on average. Data was generated
under the alternative-hypothesis model described in scenarios 1-12 in Table 4.1 with size n = 5, 000 for
m = 10, 000 replicates. Adjustments for multiple testing of all SNVs in a gene with the SMT were done
using the BH correction. Power results are provided for analyses using all rare and (non-causal) common
SNVs in a gene, and for using all rare SNVs in a gene by excluding the common SNVs from the analysis.
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Scenario
Using all rare and common SNVs Using all rare SNVs
SKAT SKAT-O Burden SMT SKAT SKAT-O Burden SMT
1 0.861 0.865 0.304 0.998 0.872 0.876 0.724 0.998
2 0.622 0.615 0.191 0.782 0.664 0.660 0.500 0.784
3 0.387 0.391 0.133 0.335 0.414 0.425 0.329 0.339
4 0.989 0.992 0.468 1 0.992 0.995 0.963 1
5 0.887 0.895 0.304 0.936 0.915 0.930 0.854 0.937
6 0.694 0.717 0.241 0.605 0.737 0.775 0.692 0.608
7 1 1 0.681 1 1 1 1 1
8 0.994 0.998 0.480 0.994 0.997 1 0.997 0.994
9 0.944 0.971 0.364 0.874 0.971 0.991 0.982 0.874
10 1 1 0.877 1 1 1 1 1
11 1 1 0.788 1 1 1 1 1
12 1 1 0.679 0.998 1 1 1 0.998
Supplementary Table A.5: Power estimates of the SMT and MMTs under the nominal α level of
2.5 × 10−6, for a sample size of 5,000 and genes including 572 SNVs on average. Data was generated
under the alternative-hypothesis model described in scenarios 1-12 in Table 4.1 with size n = 5, 000 for
m = 10, 000 replicates. Adjustments for multiple testing of all SNVs in a gene with the SMT were done
using the BH correction. Power results are provided for analyses using all rare and (non-causal) common
SNVs in a gene, and for using all rare SNVs in a gene by excluding the common SNVs from the analysis.
Scenario SKAT SKAT-O Burden SMT
1 0.363 0.350 0.002 0.515
4 0.565 0.554 0.006 0.715
7 0.860 0.864 0.041 0.928
8 0.388 0.406 0.002 0.190
12 0.531 0.733 0.002 0.231
Supplementary Table A.6: Power estimates of the SMT and MMTs under the nominal α level of
2.5 × 10−6, for a sample size of 2,000 and genes including 67 SNVs. As genetic data, the available
genotypes of the 67 SNVs of n = 2, 000 individuals in the ’SKAT.example’ data in the SKAT R package
were used in each replicate. Data was generated under the alternative-hypothesis model described in
scenarios 1, 4, 7, 8, 12 in Table 4.1 with size n = 2, 000 for m = 10, 000 replicates. Adjustments for
multiple testing of all SNVs in a gene with the SMT were done using the BH correction. Power results are
provided for analyses using all rare and (non-causal) common SNVs in a gene.
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Scenario SKAT SKAT-O Burden SMT - BH SMT - Bonferroni
1 0.118 0.111 0.012 0.156 0.153
2 0.007 0.008 0.002 0.005 0.004
3 0.001 0.001 <0.001 0.001 <0.001
4 0.223 0.215 0.024 0.263 0.259
5 0.021 0.021 0.004 0.014 0.011
6 0.004 0.004 <0.001 0.002 0.002
7 0.410 0.414 0.065 0.422 0.415
8 0.063 0.071 0.012 0.043 0.040
9 0.014 0.016 0.003 0.009 0.007
10 0.797 0.867 0.207 0.698 0.692
11 0.248 0.350 0.070 0.155 0.147
12 0.093 0.128 0.036 0.059 0.053
Supplementary Table A.7: Power estimates of the SMT and MMTs under the nominal α level of
2.5 × 10−6 to compare the BH and Bonferroni correction for SMTs. Data was generated under the
alternative-hypothesis model described in scenarios 1-12 in Table 4.1 with size n = 1, 000 for m = 10, 000
replicates. Adjustments for multiple testing of all SNVs in a gene with the SMT were done using the BH or
the Bonferroni correction. Power results are provided for analyses using all rare and (non-causal) common
SNVs in a gene.
α Scenario SKAT SKAT-O Burden SMT
0.05
1 0.166 0.157 0.070 0.062
4 0.247 0.238 0.086 0.097
7 0.397 0.408 0.139 0.162
8 0.164 0.178 0.083 0.043
12 0.200 0.270 0.112 0.051
2.5× 10−6
1 0.003 0.003 <0.001 0
4 0.009 0.009 0.001 0
7 0.029 0.032 0.005 <0.001
8 0.002 0.002 <0.001 0
12 0.003 0.005 <0.001 0
Supplementary Table A.8: Power estimates of the SMT and MMTs for analyzing a binary trait under the
nominal α levels of 0.05 and 2.5×10−6. Case-control data was generated under the alternative-hypothesis
model described in scenarios 1, 4, 7, 8, 12 in Table 4.1 with size n = 1, 000 for m = 10, 000 replicates for
a binary trait. Adjustments for multiple testing of all SNVs in a gene with the SMT were done using the
BH correction. All rare and (non-causal) common SNVs were incorporated in the analysis.
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Scenario
Gene-level SNV-level
SKAT-O SMT
SMT for SNVs
with MAF = 0.002
SMT for SNVs
with MAF = 0.005
13 0.117 0.158 0.022 0.188
14 0.006 0.005 0 0
15 0.001 0.001 0 0.010
16 0.200 0.250 0.016 0.220
17 0.014 0.008 0 0.006
18 0.002 0.001 0 0
19 0.380 0.406 0.022 0.203
20 0.048 0.029 0 0.034
21 0.015 0.006 0 0.005
22 0.771 0.667 0.023 0.225
23 0.212 0.110 <0.001 0.055
24 0.063 0.035 0 0.010
Supplementary Table A.9: Comparison of power estimates for identifying a causal gene and a causal
SNV with a given MAF. Data was generated under the alternative-hypothesis model described in scenarios
13-24 in Table 4.1 with size n = 1, 000 for m = 10, 000 replicates. The nominal α was set to 2.5×10−6 for
the gene-level evaluation of SMT and SKAT-O (representing the Bonferroni-correction for testing 20,000
genes), and to 10−7 for the SNV-level evaluation of SMT (representing the Bonferroni-correction for testing
500,000 SNVs). Adjustments for multiple testing of all SNVs in a gene were done using the BH-correction.
The power of the SMT for identifying a causal SNV with a given MAF is based on all causal SNVs in
the m = 10, 000 replicates with the specified MAF. It is estimated by the number of significant causal
SNVs (with p-values smaller than 10−7 divided by the total number of causal SNVs with the specified
MAF. The power for testing singletons and doubletons is even smaller than the power of testing SNVs with
MAF=0.002.
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Scenario
SNV with
MAF = 0.0005
SNV with
MAF = 0.001
SNV with
MAF = 0.002
SNV with
MAF = 0.005
13 0.133 0.280 0.555 0.875
14 0.020 0.033 0.055 0.200
15 0.008 0.011 0.022 0.039
16 0.131 0.283 0.542 0.873
17 0.015 0.032 0.072 0.179
18 0.009 0.008 0.022 0.052
19 0.127 0.268 0.506 0.859
20 0.018 0.033 0.069 0.290
21 0.008 0.010 0.021 0.082
22 0.114 0.237 0.461 0.801
23 0.021 0.037 0.072 0.267
24 0.009 0.014 0.025 0.158
Supplementary Table A.10: Conditional power estimates of the SMT for identifying a causal SNV, given
that the gene contains a causal SNV. Data was generated under an alternative-hypothesis model described
in scenarios 13-24 in Table 4.1 with size n = 1, 000 for m = 10, 000 replicates. The nominal α level was set
to 0.002, representing the Bonferroni-correction for testing 25 SNVs in a gene (assuming 500,000 SNVs in
total within 20,000 genes). The power of the SMT for identifying a causal SNV with a given MAF is based
on all causal SNVs in the m = 10, 000 replicates with the specified MAF. It is estimated by the number
of significant causal SNVs (with p-values smaller than 0.002) divided by the total number of causal SNVs
with the specified MAF.
Gene
SKAT SKAT-O Burden SMT
All SNVs Rare SNVs All SNVs Rare SNVs All SNVs Rare SNVs All SNVs Rare SNVs
INSR 0.51 0.73 0.72 0.76 0.27 0.70 0.14 0.07
RRAS 0.33 0.32 0.49 0.46 0.59 0.34 0.26 0.18
ZNF101 0.94 0.93 0.91 0.87 0.97 0.72 0.98 0.97
ELAVL3 0.46 0.44 0.29 0.42 0.12 0.27 0.76 0.74
RGL3 0.21 0.13 0.32 0.22 0.46 0.22 0.03 0.02
AMH 0.30 0.24 0.46 0.38 0.65 0.73 0.18 0.12
DOT1L 0.59 0.60 0.78 0.79 0.43 0.73 0.70 0.51
PLEKHJ1 0.59 0.50 0.79 0.72 0.33 0.67 0.18 0.13
SF3A2 0.50 0.36 0.70 0.54 0.41 0.97 0.23 0.15
Supplementary Table A.11: Gene-level p-values for the association tests of candidate genes with SBP
in the Genetic Analysis 19 data analysis: Unadjusted p-values from gene-level genetic association analysis
with SBP, of all common and rare SNVs (’all SNVs’), and only rare SNVs (’rare SNVs’) in 9 candidate
genes. Adjustments for multiple testing of all SNVs in SMTs in a gene were done using the BH-correction.
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A.5.3 Simulation study: C-JAMP
Dependence MAC βˆXY SD(βˆXY ) SˆE(βˆXY )
τ = 0.2
1 -0.048 1.00 0.99
2 -0.012 0.70 0.69
4 -0.002 0.49 0.49
10 0.002 0.31 0.31
τ = 0.5
1 0.308 1.00 1.20
2 0.112 0.67 0.69
4 0.046 0.46 0.46
10 0.017 0.28 0.28
τ = 0.8
1 0.610 1.00 0.90
2 0.213 0.62 0.57
4 0.079 0.41 0.39
10 0.027 0.25 0.24
Supplementary Table A.12: Bias of the point estimates and standard error estimates of C-JAMP Wald
test statistics. Data was generated from the null model described in scenario 0 in Table 4.4 for n = 1, 000
individuals with m = 100, 000 replicates, and under different dependencies between the two traits Y1, Y2
(Kendall’s τ = 0.2, 0.5, 0.8). Shown are the mean of the coefficient estimates, standard deviation of the
coefficient estimates, and mean standard error estimates of the genetic effect based on all SNVs with the
given MAC in all replicates.
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Nominal α Dependence C-JAMP Nominal α Dependence C-JAMP
5× 10−2
τ = 0.1 0.051
10−4
τ = 0.1 1.5× 10−4
τ = 0.2 0.050 τ = 0.2 1.8× 10−4
τ = 0.3 0.044 τ = 0.3 1.0× 10−4
τ = 0.4 0.033 τ = 0.4 6.0× 10−5
τ = 0.5 0.031 τ = 0.5 1.3× 10−4
τ = 0.6 0.068 τ = 0.6 3.1× 10−4
τ = 0.7 0.161 τ = 0.7 1.6× 10−3
τ = 0.8 0.206 τ = 0.8 3.1× 10−3
τ = 0.9 0.234 τ = 0.9 1.9× 10−2
10−2
τ = 0.1 0.011
10−5
τ = 0.1 2.0× 10−5
τ = 0.2 0.011 τ = 0.2 3.1× 10−5
τ = 0.3 0.010 τ = 0.3 2.0× 10−5
τ = 0.4 0.007 τ = 0.4 1.0× 10−5
τ = 0.5 0.007 τ = 0.5 0× 10−5
τ = 0.6 0.016 τ = 0.6 6.0× 10−5
τ = 0.7 0.051 τ = 0.7 3.1× 10−4
τ = 0.8 0.072 τ = 0.8 6.8× 10−4
τ = 0.9 0.103 τ = 0.9 1.1× 10−2
10−3
τ = 0.1 1.3× 10−3
τ = 0.2 1.2× 10−3
τ = 0.3 1.1× 10−3
τ = 0.4 8.5× 10−4
τ = 0.5 9.5× 10−4
τ = 0.6 2.1× 10−3
τ = 0.7 9.6× 10−3
τ = 0.8 1.5× 10−2
τ = 0.9 3.9× 10−2
Supplementary Table A.13: Gene-level type I error estimates using unadjusted C-JAMP Wald test
statistics. Data was generated from the null model described in scenario 0 in Table 4.4 for n = 1, 000
individuals with m = 100, 000 replicates, and under different dependencies between the two traits Y1, Y2
(Kendall’s τ = 0.2, 0.5, 0.8). Adjustments for multiple testing of all SNVs in a gene were done using the
Bonferroni correction. Type I error estimates are for testing the association with the first trait, Y1.
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Dependence all variants MAF=0.0005 MAF=0.001 MAF=0.002 MAF=0.005
τ = 0.1 0.053 0.055 0.052 0.052 0.052
τ = 0.2 0.052 0.054 0.053 0.051 0.051
τ = 0.3 0.049 0.046 0.051 0.052 0.053
τ = 0.4 0.042 0.030 0.048 0.051 0.055
τ = 0.5 0.040 0.025 0.046 0.051 0.054
τ = 0.6 0.060 0.069 0.059 0.054 0.050
τ = 0.7 0.084 0.120 0.075 0.059 0.053
τ = 0.8 0.092 0.134 0.086 0.063 0.056
τ = 0.9 0.094 0.138 0.089 0.065 0.055
Supplementary Table A.14: SNV-level type I error estimates using unadjusted C-JAMP Wald test
statistics under different dependencies between the traits. SNV-level type I errors are estimated by the
number of significant SNVs (with p-values smaller than 0.05) divided by the total number of tested SNVs.
Data was generated from the null model described in scenario 0 in Table 4.4 for n = 1, 000 individuals
with m = 100, 000 replicates. The nominal α level was set to 0.05. Type I error estimates are for testing
the association with the first trait, Y1. MAFs of 0.0005, 0.001, 0.002, 0.005 equal 1, 2, 4, and 10 copies
of the minor allele, respectively.
Dependence Estimate Parameters Values of Parameters
τ = 0.5
Intercept
A -2.25244
B 11.04387
C 0.62228
Slope
A -0.67510
B 2.15985
C 4.22380
τ = 0.8
Intercept
A -2.91350
B 5.40099
C 0.54384
Slope
A 23.36902
B 38.66929
C 0.58071
Supplementary Table A.15: Parameter estimates for the functional form of the relationship between
MAC and intercept/slope estimates for the C-JAMP Wald test statistic adjustment in equation (A.4.2),
for different Kendall’s τ .
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Dependence all variants MAF=0.0005 MAF=0.001 MAF=0.002 MAF=0.005
τ = 0.2 0.052 0.054 0.053 0.051 0.051
τ = 0.5 0.049 0.049 0.044 0.053 0.053
τ = 0.8 0.050 0.050 0.045 0.067 0.040
Supplementary Table A.16: SNV-based type I error estimates of C-JAMP using adjusted Wald test
statistics for testing the association with SNVs of a specific MAF. SNV-level type I errors are estimated
by the number of significant SNVs (with p-values smaller than 0.05) divided by the total number of tested
SNVs with the specified MAF. Data was generated from the null model described in scenario 0 in Table
4.4 for n = 1, 000 individuals with m = 100, 000 replicates. The nominal α level was set to 0.05. Type I
error estimates are for testing the association with the first trait, Y1. MAFs of 0.0005, 0.001, 0.002, 0.005
equal 1, 2, 4, and 10 copies of the minor allele.
Dependence Bonferroni correction BH correction
τ = 0.2 0.054 0.056
τ = 0.5 0.053 0.064
τ = 0.8 0.029 0.037
Supplementary Table A.17: Type I error estimates of C-JAMP using adjusted Wald test statistics under a
misspecified joint model. Data was generated from a bivariate normal model under the null model described
in scenario 0 in Table 4.4 for n = 1, 000 individuals with m = 1, 000 replicates, as described in section
A.4.2.2. The nominal α level was set to 0.05. Adjustments for multiple testing of all SNVs in a gene were
done using the Bonferroni or the BH correction. Type I error estimates are for testing the association with
the first trait, Y1.
Scenario Dependence Bonferroni correction BH correction
13
τ = 0.2 0.036 0.042
τ = 0.5 0.042 0.047
τ = 0.8 0.128 0.139
14
τ = 0.2 0.056 0.063
τ = 0.5 0.039 0.041
τ = 0.8 0.078 0.092
15
τ = 0.2 0.038 0.045
τ = 0.5 0.046 0.050
τ = 0.8 0.070 0.079
Supplementary Table A.18: Type I error estimates of C-JAMP for testing the association of SNVs with
the second, not-associated trait in scenarios 13-15. Data was generated under the null model for the
second trait Y2 and under the alternative-hypothesis model for the first trait Y1 as described in scenarios
13-15 in Table 4.4 for n = 1, 000 individuals with m = 1, 000 replicates. The nominal α level was set to
0.05. Adjustments for multiple testing of all SNVs in a gene were done using the Bonferroni or the BH
correction. Type I error estimates are for testing the association with the second trait, Y2.
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α Scenario SKAT SKAT-O Burden SMT
C-JAMP
τ = 0.2
C-JAMP
τ = 0.5
C-JAMP
τ = 0.8
0.05
1 0.341 0.337 0.107 0.546 0.560 0.582 0.627
2 0.199 0.187 0.080 0.192 0.193 0.227 0.276
3 0.127 0.124 0.062 0.100 0.098 0.106 0.134
4 0.532 0.534 0.170 0.736 0.736 0.756 0.799
5 0.299 0.293 0.102 0.282 0.285 0.342 0.404
6 0.168 0.170 0.076 0.130 0.132 0.145 0.205
7 0.764 0.783 0.290 0.907 0.904 0.923 0.942
8 0.477 0.492 0.159 0.440 0.440 0.507 0.605
9 0.289 0.311 0.115 0.209 0.203 0.242 0.303
10 0.986 0.996 0.583 0.997 0.994 0.997 0.999
11 0.825 0.895 0.352 0.730 0.724 0.798 0.865
12 0.580 0.695 0.242 0.407 0.409 0.463 0.569
2.5× 10−6
1 0.118 0.111 0.012 0.156 0.175 0.220 0.284
2 0.007 0.008 0.002 0.005 0.004 0.012 0.022
3 0.001 0.001 <0.001 0.001 0.001 0.001 0.002
4 0.223 0.215 0.024 0.263 0.285 0.348 0.418
5 0.021 0.021 0.004 0.014 0.016 0.023 0.045
6 0.004 0.004 <0.001 0.002 0.002 0.004 0.009
7 0.410 0.414 0.065 0.422 0.453 0.540 0.630
8 0.063 0.071 0.012 0.043 0.042 0.059 0.091
9 0.014 0.016 0.003 0.009 0.009 0.013 0.024
10 0.797 0.867 0.207 0.698 0.723 0.820 0.888
11 0.248 0.350 0.070 0.155 0.160 0.192 0.257
12 0.093 0.128 0.036 0.059 0.056 0.077 0.110
Supplementary Table A.19: Power estimates of C-JAMP in comparison to the univariate SMT and MMTs
under the nominal α levels of 0.05 and 2.5 × 10−6. Data was generated under an alternative-hypothesis
model described in scenarios 1-12 in Table 4.4 for n = 1, 000 individuals with m = 10, 000 replicates.
Adjustments for multiple testing of all SNVs in a gene were done using the Bonferroni correction for C-
JAMP and the BH-correction for the SMT. Results of C-JAMP are based on adjusted Wald test statistics.
Power estimates are for testing the association with the first trait, Y1. These results are also shown in
Figure 4.3.
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τ Scenario C-JAMP aSPUset aSPUset-Score
0.2
1 0.560 0.127 0.375
2 0.193 0.080 0.115
3 0.098 0.060 0.077
4 0.736 0.191 0.612
5 0.285 0.111 0.182
6 0.132 0.077 0.098
7 0.904 0.307 0.894
8 0.440 0.155 0.351
9 0.203 0.110 0.160
10 0.994 0.600 1
11 0.724 0.348 0.801
12 0.409 0.229 0.424
0.5
1 0.582 0.110 0.284
2 0.227 0.071 0.089
3 0.106 0.065 0.068
4 0.756 0.154 0.485
5 0.342 0.096 0.131
6 0.145 0.069 0.077
7 0.923 0.258 0.799
8 0.507 0.136 0.247
9 0.242 0.100 0.120
10 0.997 0.534 1
11 0.798 0.297 0.641
12 0.463 0.198 0.310
0.8
1 0.627 0.096 0.172
2 0.276 0.065 0.076
3 0.134 0.057 0.062
4 0.799 0.150 0.303
5 0.404 0.085 0.098
6 0.205 0.068 0.072
7 0.942 0.233 0.576
8 0.605 0.127 0.167
9 0.303 0.095 0.101
10 0.999 0.502 0.963
11 0.865 0.279 0.422
12 0.569 0.180 0.220
Supplementary Table A.20: Power estimates of C-JAMP in comparison to the multivariate tests under
the nominal α level of 0.05, for different dependences τ between Y1 and Y2. Data was generated under
an alternative-hypothesis model described in scenarios 1-12 in Table 4.4 for n = 1, 000 individuals with
m = 10, 000 replicates. Adjustments for multiple testing of all SNVs in a gene were done using the
Bonferroni correction for C-JAMP. Results of C-JAMP are based on adjusted Wald test statistics. Power
estimates are for testing the association with the first trait, Y1 for C-JAMP, and with respect to both traits
for aSPUset and aSPUset-Score.
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τ α Scenario % causal variants cY1 cY2 C-JAMP aSPUset aSPUset-Score
0.2
0.05
13 10% 0.6 0 0.763 0.183 0.495
16 10% 0.6 0.1 0.738 0.171 0.473
17 10% 0.6 0.2 0.740 0.170 0.456
4 10% 0.6 0.6 0.736 0.191 0.612
14 20% 0.3 0 0.450 0.149 0.265
8 20% 0.3 0.3 0.440 0.155 0.351
15 50% 0.2 0 0.430 0.212 0.324
12 50% 0.2 0.2 0.409 0.229 0.424
2.5× 10−6
13 10% 0.6 0 0.290 - -
16 10% 0.6 0.1 0.273 - -
17 10% 0.6 0.2 0.294 - -
4 10% 0.6 0.6 0.285 - -
14 20% 0.3 0 0.039 - -
8 20% 0.3 0.3 0.042 - -
15 50% 0.2 0 0.060 - -
12 50% 0.2 0.2 0.056 - -
Supplementary Table A.21: Power estimates of C-JAMP and the multivariate tests for nominal α
levels of 0.05 and 2.5 × 10−6. Data was generated under scenarios 13-17 in Table 4.4 for n = 1, 000
individuals with m = 1, 000 replicates, and scenarios 4, 8, 12 from Supplementary Tables A.20 are shown
for comparison. Adjustments for multiple testing of all SNVs in a gene with C-JAMP were done using the
Bonferroni correction. Results of C-JAMP are based on adjusted Wald test statistics. Power estimates are
for testing the association with the first trait, Y1 for C-JAMP, and with respect to both traits for aSPUset
and aSPUset-Score.
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A.5.4 Simulation study: CIEE
Scenario MAF
CIEE BS MR RR SEM
αˆXY SˆE(αˆXY ) SˆE(αˆXY ) αˆXY SˆE(αˆXY ) αˆXY SˆE(αˆXY ) αˆXY SˆE(αˆXY )
1
0.05 5× 10−4 (0.10) (0.10) −1× 10−3 (0.10) −1× 10−3 (0.10) 3× 10−4 (0.10)
0.1 7× 10−4 (0.07) (0.07) −6× 10−4 (0.08) −6× 10−4 (0.07) −2× 10−4 (0.07)
0.2 1× 10−4 (0.06) (0.06) −6× 10−5 (0.06) −6× 10−5 (0.06) −6× 10−4 (0.06)
0.4 3× 10−4 (0.05) (0.05) −3× 10−4 (0.05) −3× 10−4 (0.05) −4× 10−5 (0.05)
2
0.05 −1× 10−3 (0.10) (0.10) −2× 10−3 (0.10) −2× 10−3 (0.10) −3× 10−4 (0.10)
0.1 1× 10−3 (0.07) (0.08) −1× 10−4 (0.08) −1× 10−4 (0.07) 8× 10−4 (0.08)
0.2 −3× 10−4 (0.06) (0.06) −2× 10−4 (0.06) −2× 10−4 (0.06) 1× 10−4 (0.06)
0.4 3× 10−4 (0.05) (0.05) −2× 10−4 (0.05) −2× 10−4 (0.05) 8× 10−4 (0.05)
3
0.05 1× 10−3 (0.10) (0.10) −1× 10−3 (0.10) −1× 10−3 (0.10) 1× 10−3 (0.10)
0.1 1× 10−3 (0.07) (0.07) −7× 10−4 (0.08) −7× 10−4 (0.07) 2× 10−3 (0.08)
0.2 −1× 10−4 (0.06) (0.06) −7× 10−5 (0.06) −6× 10−5 (0.06) 4× 10−4 (0.06)
0.4 −1× 10−4 (0.05) (0.05) −4× 10−4 (0.05) −3× 10−4 (0.05) 1× 10−4 (0.05)
4
0.05 −1× 10−3 (0.11) (0.11) −2× 10−2 (0.11) −2× 10−2 (0.11) −7× 10−3 (0.11)
0.1 −1× 10−4 (0.08) (0.08) −2× 10−2 (0.08) −1× 10−2 (0.07) −6× 10−3 (0.08)
0.2 −2× 10−3 (0.06) (0.06) −2× 10−2 (0.06) −2× 10−2 (0.06) −6× 10−3 (0.06)
0.4 −4× 10−5 (0.05) (0.05) −2× 10−2 (0.05) −2× 10−2 (0.05) −6× 10−3 (0.05)
5
0.05 −2× 10−3 (0.11) (0.11) −2× 10−2 (0.11) −2× 10−2 (0.11) −6× 10−3 (0.11)
0.1 −5× 10−4 (0.08) (0.08) −2× 10−2 (0.08) −2× 10−2 (0.07) −6× 10−3 (0.08)
0.2 −5× 10−4 (0.06) (0.06) −2× 10−2 (0.06) −2× 10−2 (0.06) −6× 10−3 (0.06)
0.4 2× 10−5 (0.05) (0.05) −2× 10−2 (0.05) −2× 10−2 (0.05) −7× 10−3 (0.05)
6
0.05 1× 10−3 (0.11) (0.11) −1× 10−3 (0.10) −1× 10−3 (0.10) −2× 10−2 (0.11)
0.1 7× 10−4 (0.08) (0.08) −4× 10−4 (0.08) −4× 10−4 (0.07) −2× 10−2 (0.08)
0.2 −6× 10−4 (0.06) (0.06) −1× 10−4 (0.06) −1× 10−4 (0.06) −2× 10−2 (0.06)
0.4 −5× 10−4 (0.05) (0.05) −6× 10−4 (0.05) −6× 10−4 (0.05) −2× 10−2 (0.05)
7
0.05 4× 10−4 (0.13) (0.13) −2× 10−1 (0.12) −2× 10−1 (0.11) −1× 10−1 (0.12)
0.1 −4× 10−4 (0.10) (0.10) −2× 10−1 (0.09) −2× 10−1 (0.08) −1× 10−1 (0.09)
0.2 1× 10−3 (0.08) (0.08) −2× 10−1 (0.08) −1× 10−1 (0.06) −1× 10−1 (0.08)
0.4 3× 10−4 (0.07) (0.07) −2× 10−1 (0.07) −1× 10−1 (0.05) −1× 10−1 (0.07)
Supplementary Table A.22: Empirical mean of the direct effect estimates αˆXY and their standard
error estimates obtained through different methods under the null hypothesis in the LM setting, over the
m = 10, 000 replicates. CIEE is the proposed method using estimating equations; BS is CIEE using
nonparametric bootstrap standard errors; MR is multiple regression; RR is residual regression; SEM is
structural equation modeling. Coefficient estimates obtained from BS are identical to those of CIEE and
not shown. Data was generated for n = 1, 000 individuals. The scenarios when the amount of bias of αˆXY
was larger than 0.01 are highlighted in red.
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Scenario αXY
CIEE BS MR RR SEM
αˆXY SˆE(αˆXY ) SˆE(αˆXY ) αˆXY SˆE(αˆXY ) αˆXY SˆE(αˆXY ) αˆXY SˆE(αˆXY )
1
0.1 0.10 (0.06) (0.06) 0.10 (0.06) 0.10 (0.06) 0.10 (0.06)
0.2 0.20 (0.06) (0.06) 0.20 (0.06) 0.20 (0.06) 0.20 (0.06)
2
0.1 0.10 (0.06) (0.06) 0.10 (0.06) 0.10 (0.06) 0.10 (0.06)
0.2 0.20 (0.06) (0.06) 0.20 (0.06) 0.20 (0.06) 0.20 (0.06)
3
0.1 0.10 (0.06) (0.06) 0.10 (0.06) 0.10 (0.06) 0.10 (0.06)
0.2 0.20 (0.06) (0.06) 0.20 (0.06) 0.19 (0.06) 0.20 (0.06)
4
0.1 0.10 (0.06) (0.06) 0.08 (0.06) 0.08 (0.06) 0.09 (0.06)
0.2 0.20 (0.06) (0.06) 0.18 (0.06) 0.18 (0.06) 0.19 (0.06)
5
0.1 0.10 (0.06) (0.06) 0.08 (0.06) 0.08 (0.06) 0.09 (0.06)
0.2 0.20 (0.06) (0.06) 0.18 (0.06) 0.18 (0.06) 0.19 (0.06)
Supplementary Table A.23: Empirical mean of the direct effect estimates αˆXY and their standard error
estimates obtained through different methods under the alternative hypotheses in the LM setting, over
the m = 10, 000 replicates. CIEE is the proposed method using estimating equations; BS is CIEE using
nonparametric bootstrap standard errors; MR is multiple regression; RR is residual regression. Coefficient
estimates from BS are identical to those of CIEE and not shown. Data was generated for n = 1, 000
individuals for a genetic marker with MAFX = 0.2. The scenarios where the amount of bias of αˆXY was
larger than or equal to 0.01 are highlighted in red.
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Scenario Censoring
CIEE BS G-Estimation MR
αˆXY SˆE(αˆXY ) SˆE(αˆXY ) αˆXY αˆXY SˆE(αˆXY )
1
10% 3× 10−4 (0.06) (0.06) 0.20 4× 10−4 (0.06)
30% −1× 10−4 (0.06) (0.06) 0.15 −4× 10−4 (0.06)
50% −3× 10−5 (0.07) (0.07) 0.11 8× 10−4 (0.07)
2
10% −5× 10−4 (0.06) (0.06) 0.25 1× 10−4 (0.06)
30% −1× 10−4 (0.06) (0.06) 0.20 −5× 10−4 (0.06)
50% −2× 10−4 (0.07) (0.07) 0.15 −2× 10−5 (0.07)
3
10% −1× 10−3 (0.06) (0.06) 0.25 −2× 10−4 (0.06)
30% −7× 10−4 (0.06) (0.06) 0.19 1× 10−3 (0.06)
50% −2× 10−4 (0.07) (0.07) 0.15 1× 10−3 (0.07)
4
10% −3× 10−4 (0.06) (0.06) 0.25 −2× 10−2 (0.06)
30% 3× 10−4 (0.06) (0.06) 0.19 −2× 10−2 (0.06)
50% −7× 10−4 (0.07) (0.07) 0.14 −2× 10−2 (0.07)
5
10% 1× 10−3 (0.06) (0.06) 1× 10−3 −2× 10−2 (0.06)
30% −1× 10−3 (0.06) (0.06) −2× 10−3 −2× 10−2 (0.06)
50% 1× 10−3 (0.07) (0.07) 8× 10−4 −2× 10−2 (0.07)
Supplementary Table A.24: Empirical mean of the direct effect estimates αˆXY and their standard
error estimates obtained through different methods under the null hypothesis in the AFT setting, over
the m = 10, 000 replicates. CIEE is the proposed method using estimating equations; BS is CIEE using
nonparametric bootstrap standard errors; G-Estimation is the sequential G-estimation approach (Lipman et
al., 2011); MR is multiple regression. Coefficient estimates from BS are identical to those of CIEE and not
shown. Data was generated for n = 1, 000 individuals for a genetic marker with MAFX = 0.2 and different
censoring rates. The scenarios where the amount of bias of αˆXY was larger than 0.01 are highlighted in
red.
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Scenario αXY
CIEE BS MR
αˆXY SˆE(αˆXY ) SˆE(αˆXY ) αˆXY SˆE(αˆXY )
1
0.1 0.10 (0.06) (0.06) 0.10 (0.06)
0.2 0.20 (0.06) (0.06) 0.20 (0.06)
2
0.1 0.10 (0.06) (0.06) 0.10 (0.06)
0.2 0.20 (0.06) (0.06) 0.20 (0.06)
3
0.1 0.10 (0.06) (0.06) 0.10 (0.06)
0.2 0.20 (0.06) (0.06) 0.20 (0.06)
4
0.1 0.10 (0.06) (0.06) 0.08 (0.06)
0.2 0.20 (0.06) (0.06) 0.18 (0.06)
5
0.1 0.10 (0.06) (0.06) 0.08 (0.06)
0.2 0.20 (0.06) (0.06) 0.18 (0.06)
Supplementary Table A.25: Empirical mean of the direct effect estimates αˆXY and their standard error
estimates obtained through different methods under the alternative hypotheses in the AFT setting, over
the m = 10, 000 replicates. CIEE is the proposed method using estimating equations; BS is CIEE using
nonparametric bootstrap standard errors; MR is multiple regression. Coefficient estimates obtained through
BS are identical to those of CIEE and not shown. Data was generated for n = 1, 000 individuals for a
genetic marker with MAFX = 0.2, with 30% censoring. The scenarios where the amount of bias of αˆXY
was larger than 0.01 are highlighted in red.
Distribution of Y |X,K,L,U αˆXY SˆE(αˆXY ) Type I error
N(0, 1) 1× 10−3 0.08 4.97%
t8 −3× 10−4 0.09 5.17%
t4 9× 10−4 0.11 4.92%
logN(0, 1) 6× 10−4 0.16 4.87%
Supplementary Table A.26: Results of CIEE under the null hypothesis when the distribution of the
primary phenotype is misspecified. Shown are mean estimates of the direct genetic effect, αˆXY , mean
standard error estimates of the estimated direct genetic effect, SˆE(αˆXY ), standard deviation of the direct
genetic effect estimates, SD(αˆXY ), and empirical type I error estimates obtained through CIEE under
the null hypothesis in the LM setting. Data was generated for n = 1, 000 individuals and m = 10, 000
replicates for a genetic marker with MAFX = 0.2, from scenario 7 under the null hypothesis in the LM
setting. The distribution of the primary phenotype given covariates in the data generation was chosen
to be from a standard normal (cf. Supplementary Table A.22, Table 4.9), t4, t8, or log-standard normal
distribution.
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λ β1 β2 βˆ2 SD(βˆ2)
Proportion of p-values<0.05
X=0 X=1
1.0
0.2 0.2 -0.169 0.034 0.553 0.134
1.0 0.2 -0.150 0.032 0.515 0.088
0.2 1.0 -0.822 0.121 1 0.755
1.0 1.0 -0.789 0.125 1 0.444
1.5
0.2 0.2 -0.108 0.024 0.387 0.119
1.0 0.2 -0.097 0.023 0.362 0.086
0.2 1.0 -0.465 0.042 1 0.852
1.0 1.0 -0.439 0.043 1 0.634
Supplementary Table A.27: Bias of parameter estimates and inflated type I errors of the G-estimation
approach under the AFT setting. Shown are the empirical mean and empirical standard deviation (SD)
of the G-estimation parameter estimates βˆ2 under the model T˜ = β0 + β1x + β2k + ε with E(ε) = 0
and
√
V ar(ε) > 0 in section A.4.3. In addition, the proportion of rejected null hypothesis that there is
no association between the intermediate phenotype and the adjusted target time-to-event phenotype (i.e.,
β2 = 0) is reported, for each stratum of X (i.e., for X = 0 and X = 1).
A.5.5 Transcriptomic effects on obesity
GO ID Term Annot Signif Expect Fisher Classic KS Elim KS
1 0046903 secretion 1421 64 33.6 3.1× 10−7 5.5× 10−12 7.1× 10−2
2 0045055 regulated exocytosis 714 40 16.88 3.6× 10−7 3.4× 10−12 2.1× 10−1
3 0006887 exocytosis 823 43 19.46 8.4× 10−7 1.1× 10−12 1.1× 10−1
4 0016192 vesicle-mediated transport 1758 73 41.56 9.1× 10−7 1.1× 10−23 1.6× 10−3
5 0002275 myeloid cell activation in immune response 525 32 12.4 9.6× 10−7 2.3× 10−12 5.7× 10−2
6 0008283 cell proliferation 1799 74 42.53 1.1× 10−6 3.9× 10−9 1.8× 10−2
7 1902578 single-organism localization 2956 107 69.89 1.3× 10−6 6.2× 10−12 3.2× 10−1
8 0042127 regulation of cell proliferation 1421 62 33.6 1.5× 10−6 2.7× 10−8 5.4× 10−2
9 0032940 secretion by cell 1308 58 30.92 2.0× 10−6 1.4× 10−12 1.2× 10−2
10 0044699 single-organism process 11716 310 277 3.5× 10−6 1.2× 10−14 1.3× 10−1
11 0002252 immune effector process 1033 48 24.4 5.1× 10−6 3.3× 10−24 1.9× 10−2
12 0009605 response to external stimulus 1842 73 43.6 5.1× 10−6 1.1× 10−9 1.1× 10−2
13 0002274 myeloid leukocyte activation 600 33 14.2 6.0× 10−6 7.7× 10−14 8.9× 10−3
14 0043299 leukocyte degranulation 519 30 12.27 6.2× 10−6 3.9× 10−12 1.2× 10−2
15 0002376 immune system process 2489 91 58.9 7.5× 10−6 < 1.0× 10−30 3.1× 10−2
16 0044765 single-organism transport 2819 100 66.65 8.3× 10−6 3.3× 10−11 5.9× 10−1
17 0002283 neutrophil activation in immune response 476 28 11.25 9.2× 10−6 7.8× 10−12 1
18 0043312 neutrophil degranulation 476 28 11.25 9.2× 10−6 7.8× 10−12 7.8× 10−12
19 0002444 myeloid leukocyte mediated immunity 530 30 12.53 9.3× 10−6 6.7× 10−12 1.3× 10−2
20 0002366 leukocyte activation in immune response 645 34 15.25 1.1× 10−5 5.1× 10−17 1.0× 10−2
Supplementary Table A.28: Results of the GO term enrichment analysis of the 441 genes associated
with SAT, top 20 GO terms with smallest p-values based on classic Fisher’s test. Shown are the GO term
ID and name, the number of annotated genes (’Annot’), number of significant genes (’Signif’), expected
number of significant genes (’Expect’), and unadjusted p-values based on the Fisher’s exact test as well as
classic and elim KS test.
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GO ID Term Annot Signif Expect Fisher Classic KS Elim KS
1 0002376 immune system process 2489 91 58.85 7.5× 10−6 < 1× 10−30 3.1× 10−1
2 0006955 immune response 1716 66 40.57 4.1× 10−5 < 1× 10−30 5.9× 10−4
3 0002682 regulation of immune system process 1250 41 29.6 2.1× 10−2 3.2× 10−29 3.8× 10−1
4 0001775 cell activation 1247 51 29.48 7.9× 10−5 1.1× 10−28 4.1× 10−1
5 0045321 leukocyte activation 1104 46 26.1 1.2× 10−4 1.7× 10−28 1.7× 10−1
6 0002252 immune effector process 1033 48 24.4 5.1× 10−6 3.3× 10−24 1.9× 10−1
7 0002684 positive regulation of immune system process 872 29 20.62 4.0× 10−2 8.5× 10−24 2.4× 10−1
8 0016192 vesicle-mediated transport 1758 73 41.56 9.1× 10−7 1.1× 10−23 1.6× 10−3
9 0050776 regulation of immune response 821 30 19.4 1.2× 10−2 2.7× 10−23 1.5× 10−4
10 0051234 establishment of localization 4717 142 112 3.3× 10−4 2.0× 10−20 5.2× 10−1
11 0046649 lymphocyte activation 584 14 13.81 5.2× 10−1 8.9× 10−20 1.4× 10−1
12 0051179 localization 5684 167 134.38 2.2× 10−4 9.5× 10−19 2.7× 10−1
13 0050778 positive regulation of immune response 618 22 14.61 3.7× 10−2 1.3× 10−18 5.0× 10−3
14 0006810 transport 4595 135 108.64 1.5× 10−3 2.9× 10−18 8.2× 10−3
15 0002263 cell activation involved in immune response 647 34 15.3 1.1× 10−5 2.6× 10−17 5.8× 10−3
16 0042110 T cell activation 419 11 9.91 4.0× 10−1 3.6× 10−17 1.4× 10−3
17 0002366 leukocyte activation involved in immune response 645 34 15.25 1.1× 10−5 5.1× 10−17 1.0× 10−2
18 0019882 antigen processing and presentation 222 11 5.25 1.7× 10−2 8.9× 10−17 7.8× 10−3
19 0048002 antigen processing & presentation of peptide antigen 177 6 4.18 2.4× 10−1 3.2× 10−16 2.8× 10−2
20 0050896 response to stimulus 7354 205 173.87 4.8× 10−4 5.5× 10−16 3.4× 10−1
Supplementary Table A.29: Results of the GO term enrichment analysis of the 441 genes associated
with SAT, top 20 GO terms with smallest p-values based on classic KS test. Shown are the GO term
ID and name, the number of annotated genes (’Annot’), number of significant genes (’Signif’), expected
number of significant genes (’Expect’), and unadjusted p-values based on the Fisher’s exact test as well as
classic and elim KS test.
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GO ID Term Annot Signif Expect Fisher Classic KS Elim KS
1 0043312 neutrophil degranulation 476 28 11.25 9.2× 10−6 7.8× 10−12 7.8× 10−12
2 0038095 Fc-epsilon receptor signaling pathway 125 2 2.96 8.0× 10−1 1.0× 10−10 1.0× 10−10
3 0031145
anaphase-promoting complex-dependent
catabolic process
81 1 1.92 8.6× 10−1 1.4× 10−9 1.4× 10−9
4 0002479
antigen processing & presentation of
exogenous peptide antigen via MHC class I
75 0 1.77 1 4.0× 10−9 4.0× 10−9
5 0050852 T cell receptor signaling pathway 168 1 3.97 9.8× 10−1 9.4× 10−9 1.1× 10−8
6 0051436
negative regulation of ubiquitin-protein
ligase activity in mitotic cell cycle
72 1 1.7 8.2× 10−1 4.0× 10−8 4.0× 10−8
7 0038061 NIK/NF-kappaB signaling 120 5 2.84 1.6× 10−1 1.2× 10−9 4.2× 10−8
8 0019886
antigen processing & presentation of exogenous
peptide antigen via MHC class II
88 5 2.08 5.7× 10−2 9.1× 10−8 9.1× 10−8
9 0032729 positive regulation of interferon-gamma production 59 4 1.39 5.1× 10−2 1.0× 10−7 1.0× 10−7
10 0033209 tumor necrosis factor-mediated signaling pathway 163 8 3.85 4.0× 10−2 1.1× 10−7 1.1× 10−7
11 0002223 stimulatory C-type lectin receptor signaling pathway 114 1 2.7 9.4× 10−1 1.6× 10−7 1.6× 10−7
12 0030574 collagen catabolic process 63 5 1.49 1.6× 10−2 2.1× 10−7 2.1× 10−7
13 0006521 regulation of cellular amino acid metabolic process 58 1 1.37 7.5× 10−1 3.3× 10−7 3.3× 10−7
14 0051437
positive regulation of ubiquitin-protein ligase
activity in regulation of mitotic cell cycle transition
77 1 1.82 8.4× 10−1 8.7× 10−7 8.7× 10−7
15 0031295 T cell costimulation 73 3 1.73 2.5× 10−1 9.6× 10−7 9.6× 10−7
16 0060071 Wnt signaling pathway, planar cell polarity pathway 110 5 2.6 1.2× 10−1 1.3× 10−6 1.3× 10−6
17 0002250 adaptive immune response 316 14 7.47 1.8× 10−2 2.9× 10−11 1.8× 10−6
18 0051301 cell division 546 16 12.91 2.2× 10−1 3.3× 10−8 1.9× 10−6
19 0050690 regulation of defense response to virus by virus 28 3 0.66 2.8× 10−2 3.0× 10−6 3.0× 10−6
20 0031146
SCF-dependent proteasomal ubiquitin-dependent
protein catabolic process
72 0 1.7 1 3.3× 10−6 3.3× 10−6
Supplementary Table A.30: Results of the GO term enrichment analysis of the 441 genes associated
with SAT, top 20 GO terms with smallest p-values based on elim KS test. Shown are the GO term ID and
name, the number of annotated genes (’Annot’), number of significant genes (’Signif’), expected number
of significant genes (’Expect’), and unadjusted p-values based on the Fisher’s exact test as well as classic
and elim KS test.
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GO ID Term Annot Signif Expect Fisher Classic KS Elim KS
1 0016054 organic acid catabolic process 223 22 2.8 6.9× 10−14 5.50× 10−14 7.0× 10−2
2 0046395 carboxylic acid catabolic process 223 22 2.8 6.9× 10−14 5.50× 10−14 7.0× 10−2
3 0043436 oxoacid metabolic process 997 44 12.52 1.2× 10−13 1.00× 10−17 4.4× 10−1
4 0006082 organic acid metabolic process 1013 44 12.72 2.0× 10−13 7.00× 10−18 2.8× 10−1
5 0055114 oxidation-reduction process 946 42 11.88 3.9× 10−13 9.10× 10−19 1.2× 10−6
6 0019752 carboxylic acid metabolic process 890 40 11.17 1.1× 10−12 9.90× 10−15 6.3× 10−1
7 0044281 small molecule metabolic process 1925 61 24.17 2.0× 10−12 3.70× 10−28 3.7× 10−3
8 0044282 small molecule catabolic process 329 23 4.13 2.5× 10−11 2.10× 10−12 6.6× 10−1
9 0044710 single-organism metabolic process 3990 89 50.1 8.1× 10−10 3.10× 10−28 7.2× 10−3
10 0009063 cellular amino acid catabolic process 109 13 1.37 1.0× 10−9 8.20× 10−9 5.0× 10−2
11 0032787 monocarboxylic acid metabolic process 512 26 6.43 1.3× 10−9 3.70× 10−15 1.8× 10−2
12 0072329 monocarboxylic acid catabolic process 111 13 1.39 1.3× 10−9 5.50× 10−9 7.6× 10−3
13 0044712 single-organism catabolic process 890 35 11.17 1.3× 10−9 1.60× 10−13 2.0× 10−1
14 0044283 small molecule biosynthetic process 489 25 6.14 2.4× 10−9 4.10× 10−7 5.5× 10−4
15 1901606 alpha-amino acid catabolic process 94 11 1.18 2.5× 10−8 2.50× 10−7 1.9× 10−5
16 0006631 fatty acid metabolic process 318 18 3.99 1.1× 10−7 5.00× 10−10 1.5× 10−1
17 0009083 branched-chain amino acid catabolic process 20 6 0.25 1.2× 10−7 3.00× 10−8 3.0× 10−8
18 0009062 fatty acid catabolic process 91 10 1.14 2.0× 10−7 7.50× 10−9 3.3× 10−2
19 0006635 fatty acid beta-oxidation 70 9 0.88 2.2× 10−7 6.70× 10−9 1.7× 10−5
20 0009081 branched-chain amino acid metabolic process 23 6 0.29 3.1× 10−7 3.60× 10−8 3.7× 10−2
Supplementary Table A.31: Results of the GO term enrichment analysis of the 225 genes associated
with SATTAT , top 20 GO terms with smallest p-values based on classic Fisher’s test. Shown are the GO term
ID and name, the number of annotated genes (’Annot’), number of significant genes (’Signif’), expected
number of significant genes (’Expect’), and unadjusted p-values based on the Fisher’s exact test as well as
classic and elim KS test.
GO ID Term Annot Signif Expect Fisher Classic KS Elim KS
1 0044710 single-organism metabolic process 3990 89 50.1 8.1× 10−10 3.1× 10−28 7.2× 10−3
2 0044281 small molecule metabolic process 1925 61 24.17 2.0× 10−12 3.7× 10−28 3.7× 10−3
3 0044699 single-organism process 11716 168 147.11 4.9× 10−5 2.9× 10−24 8.3× 10−3
4 0044763 single-organism cellular process 9699 148 121.78 2.1× 10−5 1.2× 10−23 7.6× 10−3
5 0002376 immune system process 2489 35 31.25 2.6× 10−1 2.8× 10−23 1.4× 10−1
6 0001775 cell activation 1247 13 15.66 7.9× 10−1 1.6× 10−22 2.0× 10−1
7 0006955 immune response 1716 24 21.55 3.2× 10−1 7.9× 10−22 4.3× 10−4
8 0045321 leukocyte activation 1104 10 13.86 8.9× 10−1 2.6× 10−21 1.2× 10−1
9 0055114 oxidation-reduction process 946 42 11.88 3.9× 10−13 9.1× 10−19 1.2× 10−6
10 0006082 organic acid metabolic process 1013 44 12.72 2.0× 10−13 7.0× 10−18 2.8× 10−1
11 0002684 positive regulation of immune system process 872 17 10.95 4.8× 10−2 9.8× 10−18 5.4× 10−2
12 0043436 oxoacid metabolic process 997 44 12.52 1.2× 10−13 1.0× 10−17 4.4× 10−1
13 0002682 regulation of immune system process 1252 17 15.72 4.0× 10−1 7.0× 10−16 3.4× 10−1
14 0032787 monocarboxylic acid metabolic process 512 26 6.43 1.3× 10−9 3.7× 10−15 1.8× 10−2
15 1902578 single-organism localization 2956 48 37.12 3.0× 10−2 5.2× 10−15 3.9× 10−1
16 0006954 inflammatory response 605 20 7.6 7.6× 10−5 5.8× 10−15 5.4× 10−13
17 0019752 carboxylic acid metabolic process 890 40 11.17 1.1× 10−12 9.9× 10−15 6.3× 10−1
18 0044765 single-organism transport 2819 47 35.4 2.1× 10−2 1.2× 10−14 7.2× 10−1
19 0006091 generation of precursor metabolites and energy 343 16 4.31 6.9× 10−6 1.8× 10−14 2.5× 10−2
20 0006629 lipid metabolic process 1252 31 15.72 1.9× 10−4 2.5× 10−14 2.4× 10−2
Supplementary Table A.32: Results of the GO term enrichment analysis of the 225 genes associated
with SATTAT , top 20 GO terms with smallest p-values based on classic KS test. Shown are the GO term ID and
name, the number of annotated genes (’Annot’), number of significant genes (’Signif’), expected number
of significant genes (’Expect’), and unadjusted p-values based on the Fisher’s exact test as well as classic
and elim KS test.
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GO ID Term Annot Signif Expect Fisher Classic KS Elim KS
1 0006954 inflammatory response 605 20 7.6 7.6× 10−5 5.8× 10−15 5.4× 10−13
2 0043312 neutrophil degranulation 476 5 5.98 7.2× 10−1 1.1× 10−8 1.1× 10−8
3 0006099 tricarboxylic acid cycle 30 1 0.38 3.2× 10−1 1.5× 10−8 1.5× 10−8
4 0032981
mitochondrial respiratory chain
complex I assembly
57 1 0.72 5.1× 10−1 2.4× 10−8 2.4× 10−8
5 0009083 branched-chain amino acid catabolic process 20 6 0.25 1.2× 10−7 3.0× 10−8 3.0× 10−8
6 0002576 platelet degranulation 122 6 1.53 4.4× 10−3 8.0× 10−8 8.0× 10−8
7 0006120 mitochondrial electron transport 46 2 0.58 1.1× 10−1 1.2× 10−7 1.2× 10−7
8 0046321 positive regulation of fatty acid oxidation 14 2 0.18 1.3× 10−2 5.3× 10−7 5.3× 10−7
9 0046487 glyoxylate metabolic process 26 1 0.33 2.8× 10−1 9.7× 10−7 9.7× 10−7
10 0055114 oxidation-reduction process 946 42 11.88 3.9× 10−13 9.1× 10−19 1.2× 10−6
11 0050853 B cell receptor signaling pathway 43 0 0.54 1 3.1× 10−7 7.7× 10−6
12 0019432 triglyceride biosynthetic process 41 1 0.51 4.0× 10−1 8.5× 10−6 8.5× 10−6
13 0006635 fatty acid beta-oxidation 70 9 0.88 2.2× 10−7 6.7× 10−9 1.7× 10−5
14 1901606 alpha-amino acid catabolic process 94 11 1.18 2.5× 10−8 2.5× 10−7 1.9× 10−5
15 1901136 carbohydrate derivative catabolic process 168 2 2.11 6.3× 10−1 7.3× 10−5 2.5× 10−5
16 0038096
Fc-gamma receptor signaling pathway
involved in phagocytosis
72 1 0.9 6.0× 10−1 2.8× 10−5 2.8× 10−5
17 0002690 positive regulation of leukocyte chemotaxis 84 4 1.05 2.1× 10−2 3.1× 10−8 3.2× 10−5
18 0071222 cellular response to lipopolysaccharide 147 4 1.85 1.1× 10−1 3.8× 10−5 3.8× 10−5
19 0042493 response to drug 381 6 4.78 3.4× 10−1 3.9× 10−5 3.9× 10−5
20 0050900 leukocyte migration 380 17 4.77 6.2× 10−6 2.8× 10−11 6.1× 10−5
Supplementary Table A.33: Results of the GO term enrichment analysis of the 225 genes associated
with SATTAT , top 20 GO terms with smallest p-values based on elim KS test. Shown are the GO term ID and
name, the number of annotated genes (’Annot’), number of significant genes (’Signif’), expected number
of significant genes (’Expect’), and unadjusted p-values based on the Fisher’s exact test as well as classic
and elim KS test.
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A.5.6 Study to predict adipokine plasma levels
Measures Women Men
Plasma concentration
Leptin, ng/mL 44.6 (25.2) 18.0 (13.4)
sOB-R, ng/mL 20.0 (8.5) 22.8 (7.1)
Resistin, ng/mL 3.9 (1.1) 4.2 (1.3)
FABP4, ng/mL 32.5 (11.8) 21.3 (7.7)
IL6, pg/mL 1.7 (0.8) 1.9 (0.8)
Total adiponectin, µg/mL 8.5 (3.9) 5.7 (2.0)
HMW adiponectin, µg/mL 4.9 (2.5) 2.8 (1.5)
MMW adiponectin, µg/mL 1.5 (0.9) 1.2 (0.5)
LMW adiponectin, µg/mL 2.0 (1.1) 1.6 (0.5)
SAT gene expression
Leptin 1× 10−3 (4× 10−4) 7× 10−4 (3× 10−4)
sOB-R 3× 10−5 (1× 10−5) 4× 10−5 (1× 10−5)
Resistin 2× 10−7 (2× 10−7) 7× 10−8 (7× 10−8)
FABP4 3× 10−2 (6× 10−3) 3× 10−2 (6× 10−3)
IL6 5× 10−6 (3× 10−6) 4× 10−6 (2× 10−6)
Adiponectin 3× 10−3 (1× 10−3) 2× 10−3 (7× 10−4)
Supplementary Table A.34: Gender-stratified characteristics of the study population. Values are median
and median absolute deviation. Gene expression is shown relative to the housekeeping gene expression in
the unit 2−∆Ct, with higher values representing higher expression levels.
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Leptin sOB-R Resistin FABP4
Total
Adiponectin
HMW
Adiponectin
MMW
Adiponectin
LMW
Adiponectin
IL6
Weight 0.59 -0.33 -0.05 0.32 -0.31 -0.20 -0.16 -0.11 0.23
BMI 0.62 -0.38 -0.04 0.42 -0.33 -0.24 -0.12 -0.14 0.26
WC 0.62 -0.39 0.00 0.40 -0.28 -0.22 -0.18 -0.16 0.26
HC 0.59 -0.36 0.00 0.35 -0.23 -0.16 -0.09 -0.14 0.23
WHR 0.33 -0.24 0.01 0.25 -0.20 -0.17 -0.20 -0.11 0.17
VAT 0.59 -0.40 -0.06 0.44 -0.28 -0.28 -0.32 -0.10 0.31
CAT 0.51 -0.30 -0.01 0.43 -0.20 -0.28 -0.24 -0.06 0.33
SAT 0.79 -0.37 -0.04 0.50 -0.23 -0.22 -0.08 -0.10 0.27
TAT 0.80 -0.40 -0.05 0.53 -0.25 -0.25 -0.14 -0.12 0.31
Supplementary Table A.35: Partial Pearson correlation coefficients (adjusted for gender, age, physical
activity, occupational training) between anthropometric measures and plasma adipokine concentrations.
Plasma adipokine concentrations, VAT, CAT, SAT and TAT were log-transformed for the analysis. Cor-
relations of adipokines with the traditional anthropometric measures with r>|0.14| and correlations of
adipokines with the MRI-based measures with r > |0.16| correspond to p-values<0.05. Correlations of
r > |0.25| and r > |0.27|, respectively, correspond to Bonferroni-adjusted p-values<0.05 adjusted for
90 comparisons. HMW, high molecular weight; MMW, medium molecular weight; LMW, low molecular
weight.
Leptin sOB-R Resistin FABP4 Adiponectin IL6
Weight 0.20 0.13 0.13 -0.21 -0.21 0.20
BMI 0.26 0.11 0.13 -0.19 -0.21 0.22
WC 0.24 0.11 0.13 -0.22 -0.22 0.20
HC 0.28 0.08 0.08 -0.21 -0.19 0.17
WHR 0.08 0.09 0.11 -0.14 -0.14 0.13
VAT 0.25 0.17 0.20 -0.27 -0.30 0.26
CAT 0.22 0.12 0.10 -0.16 -0.21 0.18
SAT 0.37 0.06 0.15 -0.24 -0.25 0.19
TAT 0.35 0.09 0.17 -0.26 -0.28 0.21
Supplementary Table A.36: Partial Pearson correlation coefficients (adjusted for gender, age, physical
activity, occupational training) between anthropometric measures and SAT adipokine gene expressions.
Gene expression, VAT, CAT, SAT and TAT were log-transformed for the analysis. Correlations of gene
expression with the traditional anthropometric measures with r>|0.13| and correlations of gene expression
with the MRI-based measures with r > |0.15| correspond to p-values<0.05. Correlations of r > |0.23| and
r > |0.26|, respectively, correspond to Bonferroni-adjusted p-values<0.05 adjusted for 60 comparisons.
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Biomarker Leptin sOB-R Resistin FABP4
Total
Adiponectin
HMW
Adiponectin
MMW
Adiponectin
LMW
Adiponectin
IL6
r 0.52 -0.03 0.11 0.09 0.22 0.24 0.22 0.06 0.15
Supplementary Table A.37: Partial Pearson correlation coefficients r (adjusted for gender) between
adipokine plasma concentrations and SAT adipokine gene expressions. Plasma concentrations and SAT
gene expressions were log-transformed for the analysis. Correlations r > |0.15| correspond to p-values<0.05,
and correlations r > |0.19| correspond to Bonferroni-adjusted p-values<0.05 adjusted for the 9 comparisons.
HMW, high molecular weight; MMW, medium molecular weight; LMW, low molecular.
Model Variables Leptin sOB-R Resistin FABP4
Total
Adiponectin
HMW
Adiponectin
MMW
Adiponectin
LMW
Adiponectin
IL6
1 GE 0.45 0 0 0.01 0.07 0.06 0.07 0.01 0.01
2 SAT 0.72 0.13 0.01 0.31 0 0 0 0 0.01
3 VAT 0 0.06 0 0.01 0.11 0.12 0.11 0.02 0.12
4 GE×SAT 0.31 0.10 0.02 0.13 0.01 0 0 0 0
5 GE, SAT 0.76 0.12 0.01 0.36 0.02 0.02 0.04 0 0.02
6 GE, SAT, GE×SAT 0.76 0.12 0.01 0.37 0.02 0.01 0.06 0 0.04
7 GE, SAT, VAT 0.77 0.16 0.01 0.37 0.10 0.11 0.12 0.02 0.12
Supplementary Table A.38: Explained variance (adjusted R2) of the log-plasma levels (PL) by the pre-
dictors SAT, VAT and gene expression. Plasma adipokine concentrations, SAT adipokine gene expression,
VAT, SAT, and all other other MRI-based measures were log-transformed for the analysis. GE, gene ex-
pression; PL, plasma levels; HMW, high molecular weight; MMW, medium molecular weight; LMW, low
molecular weight.
Model Variables Leptin sOB-R Resistin FABP4
Total
Adiponectin
HMW
Adiponectin
MMW
Adiponectin
LMW
Adiponectin
IL6
7 GE, SAT, VAT 0.77 0.16 0.01 0.37 0.10 0.11 0.12 0.02 0.12
8 Sex 0.28 0.01 0.01 0.16 0.08 0.11 0.06 0.04 0.02
9 Sex, GE, SAT, VAT 0.77 0.16 0.01 0.42 0.11 0.13 0.12 0.02 0.12
10 9 + personal 0.77 0.16 0.06 0.42 0.09 0.14 0.17 0.02 0.20
11 10 + other anthr. 0.81 0.22 0.10 0.51 0.09 0.12 0.12 0 0.22
12 10 + other GE 0.79 0.21 0.06 0.48 0.12 0.17 0.25 0.02 0.21
13 10 + other PL 0.77 0.20 0.14 0.47 0.10 0.18 0.19 0.04 0.24
14 10 + other socio 0.78 0.15 0.03 0.43 0.09 0.20 0.13 0 0.19
Supplementary Table A.39: Explained variance (adjusted R2) of the log-plasma levels (PL) in regression
models with additional variables in the left column as predictors, on top of model 7 in Supplementary Table
A.38. Plasma adipokine concentrations, SAT adipokine gene expression, VAT, SAT, and all other other
MRI-based measures were log-transformed for the analysis. Model 10 includes the variables from model 9
as well as the personal variables age, occupational training, and physical activity. Models 11-14 include the
predictors of model 10 in addition to all other MRI-based body compartment measures, all other GE, all
other PL, and further personal variables employment status, partner status, smoking status, socioeconomic
status and diabetes status. GE, gene expression; PL, plasma levels; HMW, high molecular weight; MMW,
medium molecular weight; LMW, low molecular weight.
160 APPENDIX
Leptin sOB-R Resistin FABP4 Adiponectin IL6
Leptin 1
sOB-R 0.24 1
Resistin 0.02 0.14 1
FABP4 0.16 0.30 0.05 1
Adiponectin 0.37 0.22 -0.20 0.64 1
IL6 0.34 0.30 0.32 0.09 0.06 1
Supplementary Table A.40: Pearson correlation coefficients between the different gene expressions.
Gene expressions are shown relative to the housekeeping gene expression in the unit 2−∆Ct and were
log-transformed for the analysis.
Leptin sOB-R Resistin FABP4 IL6
Total
Adiponectin
HMW
Adiponectin
MMW
Adiponectin
LMW
Adiponectin
Leptin 1
sOB-R -0.42 1
Resistin -0.04 -0.08 1
FABP4 0.53 -0.18 0.11 1
IL6 0.02 -0.01 0.18 0.20 1
Total Adiponectin -0.02 0.22 -0.11 -0.06 -0.15 1
HMW Adiponectin 0.01 0.23 -0.15 -0.06 -0.17 0.13 1
MMW Adiponectin 0.04 0.24 -0.08 0.15 -0.14 0.57 0.59 1
LMW Adiponectin -0.04 0.06 -0.02 -0.05 0.01 0.50 0.32 0.00 1
Supplementary Table A.41: Pearson correlation coefficients between the different plasma adipokine
concentrations. Plasma concentrations were log-transformed for the analysis. HMW, high molecular weight;
MMW, medium molecular weight; LMW, low molecular weight.
BMI WC WHR TBV VAT CAT SAT TAT
BMI 1
WC 0.81 1
WHR 0.31 0.74 1
TBV 0.85 0.88 0.51 1
VAT 0.53 0.80 0.76 0.69 1
CAT 0.49 0.74 0.72 0.63 0.83 1
SAT 0.69 0.36 -0.22 0.50 0.11 0.10 1
TAT 0.80 0.59 0.05 0.68 0.42 0.36 0.95 1
Supplementary Table A.42: Pearson correlation coefficients between the different anthropometric and
MRI measures. TBV, VAT, CAT, SAT and TAT were log-transformed for the analysis. TBV, total body
volume.
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Biomarker Leptin sOB-R Resistin FABP4 Adiponectin IL6
Leptin 0.52 0.11 0.21 -0.23 -0.24 0.29
sOB-R -0.31 -0.03 -0.10 0.21 0.18 -0.21
Resistin 0.08 0.01 0.11 0.01 0.05 0.05
FABP4 0.11 0.14 0.26 0.09 -0.17 0.18
Total Adiponectin -0.17 -0.13 -0.07 0.19 0.22 -0.07
HMW Adiponectin -0.17 -0.15 -0.13 0.13 0.20 -0.14
MMW Adiponectin -0.20 -0.07 -0.03 0.19 0.22 0.03
LMW Adiponectin -0.11 -0.14 -0.09 0.07 0.06 -0.17
IL6 0.05 0 0.16 0 -0.10 0.15
Supplementary Table A.43: Partial Pearson correlation coefficients (adjusted for gender) between plasma
adipokine concentrations and SAT adipokine gene expressions. Plasma concentrations and gene expressions
were log-transformed for the analysis. HMW, high molecular weight; MMW, medium molecular weight;
LMW, low molecular weight.
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A.6.2 Simulation study: single-marker versus multi-marker tests
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Supplementary Figure A.1: Illustration of the Beta(1, 25) distribution, which is used for the computation
of weights wj of SNVs xj with a given minor allele frequency in SKAT, SKAT-O, and MURAT.
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Supplementary Figure A.2: Histogram of the SMT t-test statistic values for singletons, doubletons,
and for all SNVs. Datasets were generated from the null model described in scenario 0 in Table 4.1
with size n = 1, 000 for m = 10, 000, 000 replicates. The histograms and provided descriptive statistics
(mean, standard deviation) are based on the 132,797,000 t-test statistics of all singletons in all replicates
(left panel), on the 41,341,000 t-test statistics of all doubletons in all replicates (middle panel), and on
the 325,393,000 t-test statistics of all SNVs in all replicates (right panel). Overlaid in a blue line is the
empirical estimate of the density function. The theoretical mean and standard deviation (SD) of the t1000−4
distribution are 0 and 996/994 = 1.001.
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A.6.3 Simulation study: C-JAMP
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Supplementary Figure A.3: Histograms and density curves of unadjusted C-JAMP Wald test statistics.
Data was generated from the null model described in scenario 0 in Table 4.4 for n = 1, 000 individuals
with m = 100, 000 replicates, and under different dependencies between the two traits Y1, Y2 (Kendall’s
τ = 0.2, 0.5, 0.8). Shown are histograms and density curves of the unadjusted Wald test statistics based
on all SNVs with the given MAC in all replicates.
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Supplementary Figure A.4: Scatterplots of the intercept/slope parameter estimates to obtain adjusted
C-JAMP Wald test statistics by MAC obtained from fitting equation (A.4.2).
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Supplementary Figure A.5: Histograms and density curves of adjusted C-JAMP Wald test statistics.
Data was generated from the null model described in scenario 0 in Table 4.4 for n = 1, 000 individuals
with m = 100, 000 replicates, and under different dependencies between the two traits Y1, Y2 (Kendall’s
τ = 0.5, 0.8). Shown are histograms and density curves of the adjusted Wald test statistics based on all
SNVs with the given MAC in all replicates.
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Supplementary Figure A.6: Plot of the functional form of the relationship between MAC and intercep-
t/slope estimates in equation (A.4.2), for different Kendall’s τ .
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Supplementary Figure A.7: Histograms and density curves of adjusted C-JAMP Wald test statistics
using the functional approach through equations (A.4.4)-(A.4.6). Data was generated from the null model
described in scenario 0 in Table 4.4 for n = 1, 000 individuals with m = 100, 000 replicates, and under
different dependencies between the two traits Y1, Y2 (Kendall’s τ = 0.5, 0.8). Shown are histograms and
density curves of the adjusted Wald test statistics based on all SNVs with the given MAC in all replicates.
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A.6.4 Simulation study: CIEE
X T
K
Supplementary Figure A.8: DAG considered in the evaluation of the G-estimation approach described
in section A.4.3.
A.6.5 Application: Obesity study
A.6.5.1 Distribution of fat mass and fat distribution measures
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Supplementary Figure A.9: Histograms of log(SAT) and SATTAT .
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Supplementary Figure A.10: Histograms of SATTAT , stratified by gender.
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A.6.5.2 Quality control of raw sequencing reads
Supplementary Figure A.11: Barplot of the number of raw sequencing reads.
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Supplementary Figure A.12: Histogram of the samples’ percentage of bases with high quality.
Supplementary Figure A.13: Histogram of the mean base quality score of the reads.
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Supplementary Figure A.14: Quality scores across base pairs of all reads, from one exemplary probe.
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Supplementary Figure A.15: Distribution of quality scores across all reads, from one exemplary probe.
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Supplementary Figure A.16: GC distribution across all reads, from one exemplary probe.
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Supplementary Figure A.17: Sequence content across all bases, from one exemplary probe.
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Supplementary Figure A.18: Adapter percentage across all bases, from one exemplary probe.
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Supplementary Figure A.19: Percentage of duplicated sequences, from one exemplary probe.
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A.6.5.3 Quality control of aligned sequencing reads
Supplementary Figure A.20: Barplot of the number of mapped reads.
Supplementary Figure A.21: Histogram of the percentage of mapped reads.
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Supplementary Figure A.22: Barplot of the number of mapped pairs.
Supplementary Figure A.23: Histogram of the percentage of mapped pairs.
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Supplementary Figure A.24: Barplot of the number of mapped reads with high-quality mapping.
Supplementary Figure A.25: Histogram of the percentage of high-quality mapped reads.
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A.6.5.4 Descriptive statistics and quality control of raw and normalized read
counts
Supplementary Figure A.26: Barplot of the number of mapped and counted reads.
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Supplementary Figure A.27: Histogram of the percentage of the number of mapped and counted reads.
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Supplementary Figure A.28: Histograms of the number of genes with at least 1, 5, 10, 50 counts per
sample.
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Supplementary Figure A.29: Histogram of the average read counts per gene. The maximum average
count of a gene is 457,066 using 6 samples per lane, 992,782 using 3 samples per lane, and 2,995,596 using
1 sample per lane.
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Supplementary Figure A.30: Biodetection plot contrasting the detected features (with at least 1 count)
in one deeply sequenced probe (”Probe B”) with 1 sample per lane, and one probe (”Probe A”) sequenced
with 6 probes per lane, generated with the R package NOISeq.
Supplementary Figure A.31: Biodetection plot contrasting the detected features (with at least 1 count)
of the two deeply sequenced probe with 1 sample per lane, generated with the R package NOISeq.
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Supplementary Figure A.32: Scatterplots of the mean gene expression (over all samples) of a gene versus
its GC content, for all genes (upper panel) and zoomed in to the genes with lower expression (lower panel).
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Supplementary Figure A.33: Histograms of the TMM-normalized TPM counts for the 6 candidate genes
investigated in the study described in section A.4.5.
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Supplementary Figure A.34: Scatterplots of the TPM counts for the 6 candidate genes investigated in
the study described in section A.4.5, with and without TMM-normalization, with the diagonal for reference.
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Supplementary Figure A.35: Density estimates of the distribution of the TPM counts for the 6 candidate
genes investigated in the study described in section A.4.5, with and without TMM-normalization.
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Supplementary Figure A.36: Scatterplots between the gene expression measures from RNA-seq and
qPCR for the 6 candidate genes investigated in the study described in section A.4.5, with the diagonal for
reference.
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A.6.5.5 Distribution and transformations of normalized read counts
Supplementary Figure A.37: Histogram of the skewness index in all 48,019 expressed genes with non-zero
counts for at least 1 sequenced probe.
Supplementary Figure A.38: Histogram of the skewness index in the 30,917 genes with non-zero counts
for at least 25% percent of all probes.
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Supplementary Figure A.39: Histogram of the skewness index in the 30,917 genes with non-zero counts
for at least 25% percent of all probes, after those genes with skewness greater than 1 were log-transformed
(after adding the constant 0.000001).
Supplementary Figure A.40: Histogram of the skewness index in the 30,917 genes with non-zero counts
for at least 25% percent of all probes, after those genes with skewness greater than 1 were transformed
using the Yeo-Johnson transformation in the car R package.
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Supplementary Figure A.41: Histograms of the first 25 of the 30,917 genes with non-zero counts for at
least 25% percent of all probes, after those genes with skewness greater than 1 were transformed using the
Yeo-Johnson transformation in the car R package
A.5 SUPPLEMENTARY FIGURES 197
Supplementary Figure A.42: Histograms of genes 26-50 of the 30,917 genes with non-zero counts for
at least 25% percent of all probes, after those genes with skewness greater than 1 were transformed using
the Yeo-Johnson transformation in the car R package.
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A.6.5.6 Descriptive statistics of the called SNVs
Supplementary Figure A.43: Histogram of the MAF of the quality-controlled 509,009 SNVs that were
analyzed in the main analysis of the obesity study.
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A.7 R code
In the following, the R functions of the CJAMP and CIEE packages are illustrated in their use
to generate sample data, fit a copula model, and show the formatted output.
A.7.1 C-JAMP
# Load C-JAMP package
library(CJAMP)
library(ggplot2)
# Generate genetic data:
genodata <- generate_genodata(n_SNV = 20, n_ind = 1000)
compute_MAF(genodata)
## SNV1 SNV2 SNV3 SNV4 SNV5 SNV6 SNV7 SNV8 SNV9 SNV10 SNV11
## 0.357 0.287 0.060 0.456 0.253 0.227 0.476 0.060 0.325 0.116 0.003
## SNV12 SNV13 SNV14 SNV15 SNV16 SNV17 SNV18 SNV19 SNV20
## 0.298 0.150 0.022 0.272 0.180 0.229 0.477 0.155 0.177
# Generate phenotype data from the Clayton copula:
dat1a <- generate_clayton_copula(n = 1000, phi = 0.5)
head(dat1a)
## Y1 Y2
## 1 -0.4330635 0.69184891
## 2 -0.8775747 0.09145315
## 3 -0.6970692 0.68681678
## 4 0.6685981 -0.27464723
## 5 0.1135054 0.92042670
## 6 0.5343440 0.27794493
dat1b <- generate_clayton_copula(n = 1000, phi = 2)
dat1c <- generate_clayton_copula(n = 1000, phi = 8)
# Generate phenotypes from bivariate normal distribution
# given covariates:
phenodata_bvn <- generate_phenodata_2_bvn(genodata = genodata,
tau = 0.5, b1 = 1, b2 = 2)
ggplot(phenodata_bvn, aes(x=Y1, y=Y2)) + geom_point() +
labs(title="Scatterplot of bivariate normal Y1, Y2 with tau=0.5")
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Scatterplot of bivariate normal Y1, Y2 with tau=0.5
# Generate phenotype data from the Clayton copula given covariates:
phenodata <- generate_phenodata_2_copula(genodata = genodata$SNV1,
MAF_cutoff = 1,
prop_causal = 1, tau = 0.5,
b1 = 0.3, b2 = 0.3)
ggplot(phenodata, aes(x=Y1, y=Y2)) + geom_point() +
labs(title="Scatterplot of Y1, Y2 from Clayton copula with tau=0.5")
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Scatterplot of Y1, Y2 from Clayton copula with tau=0.5
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# Check how much of the phenotypic variance (of Y1) is explained
# by the genetic markers:
compute_expl_var(genodata = genodata, phenodata = phenodata$Y1,
type = c("Rsquared_unadj", "Rsquared_adj",
"MAF_based", "MAF_based_Y_adjusted"),
causal_idx = rep(TRUE,20), effect_causal =
c(0.3 * abs(log10(compute_MAF(genodata$SNV1))),
rep(0,19)))
## $Rsquared_unadj
## [1] 0.02028775
##
## $Rsquared_adj
## [1] 0.0002731993
##
## $MAF_based
## [1] 0.008268204
##
## $MAF_based_Y_adjusted
## [1] 0.006200331
# Compute naive estimates of all parameters in the model
predictors <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2,
SNV = genodata$SNV1)
get_estimates_naive(Y1 = phenodata$Y1, Y2 = phenodata$Y2,
predictors_Y1 = predictors,
predictors_Y2 = predictors,
copula_param = "both")
## log_phi log_theta_minus1 Y1_log_sigma Y2_log_sigma
## 0.872799990 0.179652810 0.029125972 0.032939381
## Y1_(Intercept) Y1_X1 Y1_X2 Y1_SNV
## 0.007367563 0.459359315 0.530724415 0.079456860
## Y2_(Intercept) Y2_X1 Y2_X2 Y2_SNV
## 0.030867828 0.423911195 0.531748193 0.069895600
# Compute the minus log-likelihood of the copula model
predictors <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2,
genodata[, 1:5])
estimates <- get_estimates_naive(Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors_Y1 = predictors,
predictors_Y2 = predictors,
copula_param = "both")
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minusloglik(Y1 = phenodata$Y1, Y2 = phenodata$Y2,
predictors_Y1 = predictors, predictors_Y2 = predictors,
parameters = estimates, copula = "2param")
## [1] 3245.192
# Perform LRT to test whether 2-parameter copula model has a better
# model fit compared to Clayton copula (no).
predictors <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2,
SNV = genodata$SNV1)
estimates_c <- get_estimates_naive(Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors_Y1 = predictors,
predictors_Y2 = predictors,
copula_param = "phi")
minusloglik_Clayton <- minusloglik(Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors_Y1 = predictors,
predictors_Y2 = predictors,
parameters = estimates_c,
copula = "Clayton")
estimates_2p <- get_estimates_naive(Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors_Y1 = predictors,
predictors_Y2 = predictors,
copula_param = "both")
minusloglik_2param <- minusloglik(Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors_Y1 = predictors,
predictors_Y2 = predictors,
parameters = estimates_2p,
copula = "2param")
lrt_copula(minusloglik_Clayton, minusloglik_2param)
## $chisq
## [1] -1552.009
##
## $pval
## [1] 0.5
# Perform LRT to test the marginal parameters
# (alternative model has better fit).
predictors_1 <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2)
estimates_1 <- get_estimates_naive(Y1 = phenodata$Y1,
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Y2 = phenodata$Y2,
predictors_Y1 = predictors_1,
predictors_Y2 = predictors_1,
copula = "phi")
minusloglik_1 <- minusloglik(Y1 = phenodata$Y1, Y2 = phenodata$Y2,
predictors_Y1 = predictors_1,
predictors_Y2 = predictors_1,
parameters = estimates_1,
copula = "Clayton")
predictors_2 <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2,
SNV = genodata$SNV1)
estimates_2 <- get_estimates_naive(Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors_Y1 = predictors_2,
predictors_Y2 = predictors_2,
copula = "phi")
minusloglik_2 <- minusloglik(Y1 = phenodata$Y1, Y2 = phenodata$Y2,
predictors_Y1 = predictors_2,
predictors_Y2 = predictors_2,
parameters = estimates_2,
copula = "Clayton")
lrt_param(minusloglik_1, minusloglik_2, df=2)
## $chisq
## [1] 6.53667
##
## $pval
## [1] 0.03806977
# Main function of the package: Compute C-JAMP and show results
predictors <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2,
genodata[, 1:3])
cjamp_res <- cjamp(copula = "2param", Y1 = phenodata$Y1,
Y2 = phenodata$Y2, predictors_Y1 = predictors,
predictors_Y2 = predictors, scale_var = FALSE,
optim_method = "BFGS", trace = 0,
kkt2tol = 1E-16, SE_est = TRUE, pval_est = TRUE,
n_iter_max = 10)
cjamp_res
## $`Parameter point estimates`
## Y1_sigma Y2_sigma Y1_(Intercept) Y1_X1
## 1.018039e+00 1.024030e+00 -3.263697e-03 4.577113e-01
## Y1_X2 Y1_SNV1 Y1_SNV2 Y1_SNV3
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## 4.778287e-01 1.111108e-01 -7.478800e-03 1.524211e-01
## Y2_(Intercept) Y2_X1 Y2_X2 Y2_SNV1
## 3.225616e-03 4.562371e-01 5.021090e-01 1.072456e-01
## Y2_SNV2 Y2_SNV3 phi theta
## -3.026763e-03 1.119920e-01 2.029883e+00 1.000002e+00
## tau lambda_l lambda_u
## 5.037089e-01 7.107243e-01 3.417528e-06
##
## $`Parameter standard error estimates`
## Y1_sigma Y2_sigma Y1_(Intercept) Y1_X1
## 0.0207191670 0.0208030635 0.0595696133 0.0274704660
## Y1_X2 Y1_SNV1 Y1_SNV2 Y1_SNV3
## 0.0560816396 0.0412244792 0.0434147479 0.0814883054
## Y2_(Intercept) Y2_X1 Y2_X2 Y2_SNV1
## 0.0602285864 0.0278789350 0.0562067891 0.0418147801
## Y2_SNV2 Y2_SNV3 phi theta
## 0.0435238260 0.0829850914 0.1179059134 0.0004222667
## tau lambda_l lambda_u
## 0.0145197170 0.0140960373 0.0005853820
##
## $`Parameter p-values`
## Y1_(Intercept) Y1_X1 Y1_X2 Y1_SNV1
## 9.563074e-01 2.478419e-62 1.592311e-17 7.033319e-03
## Y1_SNV2 Y1_SNV3 Y2_(Intercept) Y2_X1
## 8.632300e-01 6.141915e-02 9.572887e-01 3.403589e-60
## Y2_X2 Y2_SNV1 Y2_SNV2 Y2_SNV3
## 4.136946e-19 1.032421e-02 9.445577e-01 1.771624e-01
##
## $`Convergence code of optimx function`
## convcode
## 0
##
## $`Karush-Kuhn-Tucker conditions 1 and 2`
## KKT1 KKT2
## TRUE TRUE
##
## $`Maximum log-likelihood`
## maxloglik
## 2443.347
##
## attr(,"class")
## [1] "cjamp"
# Wrapper of cjamp function to analyze multiple SNVs sequentially
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covariates <- data.frame(X1 = phenodata$X1, X2 = phenodata$X2)
predictors <- genodata
cjamp_loop_res <- cjamp_loop(copula = "Clayton", Y1 = phenodata$Y1,
Y2 = phenodata$Y2,
predictors = predictors,
covariates_Y1 = covariates,
covariates_Y2 = covariates,
scale_var = FALSE,
optim_method = "BFGS",
trace = 0, kkt2tol = 1E-16,
SE_est = TRUE, pval_est = TRUE,
n_iter_max = 10)
cjamp_loop_res
## $`Parameter point estimates for effects of predictors on Y1`
## SNV1 SNV2 SNV3 SNV4 SNV5
## 0.106697023 -0.006888141 0.140730286 0.043119631 -0.056822154
## SNV6 SNV7 SNV8 SNV9 SNV10
## 0.061547846 0.042328067 -0.028755051 0.012920556 -0.029087665
## SNV11 SNV12 SNV13 SNV14 SNV15
## 0.399968842 0.008051045 0.053995839 0.054145340 0.038479840
## SNV16 SNV17 SNV18 SNV19 SNV20
## -0.038479431 0.029074078 -0.028184904 -0.023865019 0.003464513
##
## $`Parameter point estimates for effects of predictors on Y2`
## SNV1 SNV2 SNV3 SNV4 SNV5
## 0.104571428 -0.002372445 0.102154014 0.003258226 -0.055813884
## SNV6 SNV7 SNV8 SNV9 SNV10
## 0.055261870 0.033801549 0.007901566 0.030418373 0.093229315
## SNV11 SNV12 SNV13 SNV14 SNV15
## 0.031250816 0.010929721 0.099484751 0.088670269 0.029236045
## SNV16 SNV17 SNV18 SNV19 SNV20
## -0.005803029 0.053461354 -0.041143949 -0.035529587 0.041571513
##
## $`Parameter standard error estimates for effects on Y1`
## SNV1 SNV2 SNV3 SNV4 SNV5 SNV6
## 0.04114480 0.04360486 0.08148113 0.03909485 0.04596326 0.04707007
## SNV7 SNV8 SNV9 SNV10 SNV11 SNV12
## 0.03940785 0.08367532 0.04212457 0.06268610 0.37252599 0.04304969
## SNV13 SNV14 SNV15 SNV16 SNV17 SNV18
## 0.05582313 0.14138213 0.04399573 0.05163744 0.04726034 0.03981132
## SNV19 SNV20
## 0.05493949 0.05122328
##
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## $`Parameter standard error estimates for effects on Y2`
## SNV1 SNV2 SNV3 SNV4 SNV5 SNV6
## 0.04180830 0.04373260 0.08309615 0.03978259 0.04602636 0.04735030
## SNV7 SNV8 SNV9 SNV10 SNV11 SNV12
## 0.04000655 0.08412875 0.04174953 0.06280148 0.38128497 0.04401251
## SNV13 SNV14 SNV15 SNV16 SNV17 SNV18
## 0.05628767 0.14468444 0.04405795 0.05181463 0.04736861 0.03963240
## SNV19 SNV20
## 0.05466032 0.05170494
##
## $`Parameter p-values for effects of predictors on Y1`
## SNV1 SNV2 SNV3 SNV4 SNV5
## 0.009508533 0.874482590 0.084140406 0.270049290 0.216365020
## SNV6 SNV7 SNV8 SNV9 SNV10
## 0.191016022 0.282776731 0.731109263 0.759054548 0.642632736
## SNV11 SNV12 SNV13 SNV14 SNV15
## 0.282971981 0.851646923 0.333410825 0.701740823 0.381777009
## SNV16 SNV17 SNV18 SNV19 SNV20
## 0.456160068 0.538429355 0.478968782 0.664007179 0.946075777
##
## $`Parameter p-values for effects of predictors on Y2`
## SNV1 SNV2 SNV3 SNV4 SNV5 SNV6
## 0.01237691 0.95673686 0.21894168 0.93472560 0.22526351 0.24317562
## SNV7 SNV8 SNV9 SNV10 SNV11 SNV12
## 0.39816642 0.92517087 0.46625126 0.13767413 0.93467706 0.80387743
## SNV13 SNV14 SNV15 SNV16 SNV17 SNV18
## 0.07715553 0.53997365 0.50695814 0.91082662 0.25905640 0.29920523
## SNV19 SNV20
## 0.51568773 0.42138871
##
## $`Convergence code of optimx function`
## [1] 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
##
## $`Karush-Kuhn-Tucker conditions 1 and 2`
## [1] TRUE TRUE TRUE TRUE TRUE TRUE TRUE TRUE TRUE TRUE TRUE TRUE
## [12] TRUE TRUE TRUE TRUE TRUE TRUE TRUE TRUE
##
## $`Maximum log-likelihood`
## [1] 2445.109 2448.779 2447.307 2447.575 2447.934 2447.893 2448.249
## [8] 2448.587 2448.464 2444.984 2447.911 2448.766 2447.075 2448.593
## [15] 2448.414 2448.286 2448.095 2448.245 2448.581 2448.143
##
## attr(,"class")
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## [1] "cjamp"
# Summary of regular cjamp function output
summary(cjamp_res)
## [1] "C-JAMP estimates of marginal parameters."
## point_estimates SE_estimates pvalues
## Y1_(Intercept) -0.003263697 0.05956961 9.563074e-01
## Y1_X1 0.457711329 0.02747047 2.478419e-62
## Y1_X2 0.477828702 0.05608164 1.592311e-17
## Y1_SNV1 0.111110794 0.04122448 7.033319e-03
## Y1_SNV2 -0.007478800 0.04341475 8.632300e-01
## Y1_SNV3 0.152421095 0.08148831 6.141915e-02
## Y2_(Intercept) 0.003225616 0.06022859 9.572887e-01
## Y2_X1 0.456237118 0.02787893 3.403589e-60
## Y2_X2 0.502108981 0.05620679 4.136946e-19
## Y2_SNV1 0.107245591 0.04181478 1.032421e-02
## Y2_SNV2 -0.003026763 0.04352383 9.445577e-01
## Y2_SNV3 0.111992006 0.08298509 1.771624e-01
# Summary of looped cjamp function output
summary(cjamp_loop_res)
## [1] "C-JAMP estimates of marginal parameters on Y1."
## point_estimates SE_estimates pvalues
## Y1_SNV1 0.106697023 0.04114480 0.009508533
## Y1_SNV2 -0.006888141 0.04360486 0.874482590
## Y1_SNV3 0.140730286 0.08148113 0.084140406
## Y1_SNV4 0.043119631 0.03909485 0.270049290
## Y1_SNV5 -0.056822154 0.04596326 0.216365020
## Y1_SNV6 0.061547846 0.04707007 0.191016022
## Y1_SNV7 0.042328067 0.03940785 0.282776731
## Y1_SNV8 -0.028755051 0.08367532 0.731109263
## Y1_SNV9 0.012920556 0.04212457 0.759054548
## Y1_SNV10 -0.029087665 0.06268610 0.642632736
## Y1_SNV11 0.399968842 0.37252599 0.282971981
## Y1_SNV12 0.008051045 0.04304969 0.851646923
## Y1_SNV13 0.053995839 0.05582313 0.333410825
## Y1_SNV14 0.054145340 0.14138213 0.701740823
## Y1_SNV15 0.038479840 0.04399573 0.381777009
## Y1_SNV16 -0.038479431 0.05163744 0.456160068
## Y1_SNV17 0.029074078 0.04726034 0.538429355
## Y1_SNV18 -0.028184904 0.03981132 0.478968782
## Y1_SNV19 -0.023865019 0.05493949 0.664007179
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## Y1_SNV20 0.003464513 0.05122328 0.946075777
## [1] "C-JAMP estimates of marginal parameters on Y2."
## point_estimates SE_estimates pvalues
## Y2_SNV1 0.104571428 0.04180830 0.01237691
## Y2_SNV2 -0.002372445 0.04373260 0.95673686
## Y2_SNV3 0.102154014 0.08309615 0.21894168
## Y2_SNV4 0.003258226 0.03978259 0.93472560
## Y2_SNV5 -0.055813884 0.04602636 0.22526351
## Y2_SNV6 0.055261870 0.04735030 0.24317562
## Y2_SNV7 0.033801549 0.04000655 0.39816642
## Y2_SNV8 0.007901566 0.08412875 0.92517087
## Y2_SNV9 0.030418373 0.04174953 0.46625126
## Y2_SNV10 0.093229315 0.06280148 0.13767413
## Y2_SNV11 0.031250816 0.38128497 0.93467706
## Y2_SNV12 0.010929721 0.04401251 0.80387743
## Y2_SNV13 0.099484751 0.05628767 0.07715553
## Y2_SNV14 0.088670269 0.14468444 0.53997365
## Y2_SNV15 0.029236045 0.04405795 0.50695814
## Y2_SNV16 -0.005803029 0.05181463 0.91082662
## Y2_SNV17 0.053461354 0.04736861 0.25905640
## Y2_SNV18 -0.041143949 0.03963240 0.29920523
## Y2_SNV19 -0.035529587 0.05466032 0.51568773
## Y2_SNV20 0.041571513 0.05170494 0.42138871
A.7.2 CIEE
# Load CIEE package
library(CIEE)
# Generate sample data with a quantitative primary trait Y
dat <- generate_data(setting="GLM", n = 1000, maf = 0.2,
cens = 0.3,a = NULL, b = NULL, aUL = 0,
aXL = 0, aXK = 0.2, aLK = 0, aUY = 0,
aKY = 0.3, aXY = 0.1, aLY = 0, mu_U = 0,
sd_U = 1, X_orth_U = TRUE, mu_X = NULL,
sd_X = NULL, mu_L = 0, sd_L = 1, mu_K = 0,
sd_K = 1, mu_Y = 0, sd_Y = 1)
head(dat)
## Y K X L U
## 1 2.4983614 -0.35718347 1 1.298456 0.58709350
## 2 -0.3869956 -0.64368400 1 1.348275 0.03172375
## 3 -2.8471634 -0.61360554 0 -2.221457 -1.39594743
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## 4 -0.3011392 -0.05166774 0 -2.476211 0.26689396
## 5 1.5321377 -0.23907867 0 -1.521010 -0.14122163
## 6 -0.5806856 0.18039008 0 1.133556 0.18819211
# Obtain estimates and perform hypothesis tests under the
# traditional regression approaches
mult_reg(setting = "GLM", Y = dat$Y, X = dat$X, K = dat$K,
L = dat$L)
## $point_estimates
## alpha_0 alpha_1 alpha_XY alpha_2
## -0.01822490 0.27671667 0.13346492 -0.01232202
##
## $SE_estimates
## alpha_0 alpha_1 alpha_XY alpha_2
## 0.03687934 0.02978589 0.05247700 0.02960048
##
## $pvalues
## alpha_0 alpha_1 alpha_XY alpha_2
## 6.212906e-01 9.406853e-20 1.113124e-02 6.772964e-01
res_reg(Y = dat$Y, X = dat$X, K = dat$K, L = dat$L)
## $point_estimates
## alpha_0 alpha_1 alpha_2 alpha_3 alpha_XY
## 0.03444987 0.28261304 -0.01268054 -0.05279386 0.13264790
##
## $SE_estimates
## alpha_0 alpha_1 alpha_2 alpha_3 alpha_XY
## 0.03059805 0.02977685 0.02968121 0.03680861 0.05226472
##
## $pvalues
## alpha_0 alpha_1 alpha_2 alpha_3 alpha_XY
## 2.604853e-01 1.628744e-20 6.693082e-01 1.518056e-01 1.129989e-02
# Obtain estimates and perform hypothesis tests under the SEM
sem_appl(Y = dat$Y, X = dat$X, K = dat$K, L = dat$L)
## $point_estimates
## alpha_1 alpha_3 alpha_4 alpha_6 alpha_XY
## -0.01411334 0.13713065 -0.04066894 0.27722407 0.13356893
##
## $SE_estimates
## alpha_1 alpha_3 alpha_4 alpha_6 alpha_XY
## 0.05593721 0.05554422 0.03139961 0.02970394 0.05237590
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##
## $pvalues
## alpha_1 alpha_3 alpha_4 alpha_6 alpha_XY
## 8.008039e-01 1.355460e-02 1.952495e-01 1.030064e-20 1.076616e-02
# For CIEE:
# Compute expressions of the functions in equations 3.2.5, 3.2.6
estfunct_GLM <- est_funct_expr(setting="GLM")
estfunct_AFT <- est_funct_expr(setting = "AFT")
estfunct_GLM
## $logL1
## expression(log((1/sqrt(sigma1sq)) * dnorm((y_i - alpha0 - alpha1 *
## k_i - alpha2 * x_i - alpha3 * l_i)/sqrt(sigma1sq), mean = 0,
## sd = 1)))
##
## $logL2
## expression(log((1/sqrt(sigma2sq)) * dnorm((y_i - y_bar - alpha1 *
## (k_i - k_bar) - alpha4 - alphaXY * x_i)/sqrt(sigma2sq), mean = 0,
## sd = 1)))
estfunct_AFT
## $logL1
## expression(-c_i * log(sigma1) + c_i * log(dnorm((y_i - alpha0 -
## alpha1 * k_i - alpha2 * x_i - alpha3 * l_i)/sigma1, mean = 0,
## sd = 1)) + (1 - c_i) * log(1 - pnorm((y_i - alpha0 - alpha1 *
## k_i - alpha2 * x_i - alpha3 * l_i)/sigma1, mean = 0, sd = 1)))
##
## $logL2
## expression(log((1/sqrt(sigma2sq)) * dnorm(((c_i * y_i + (1 -
## c_i) * ((alpha0 + alpha1 * k_i + alpha2 * x_i + alpha3 *
## l_i) + (sigma1 * dnorm((y_i - alpha0 - alpha1 * k_i - alpha2 *
## x_i - alpha3 * l_i)/sigma1, mean = 0, sd = 1)/(1 - pnorm((y_i -
## alpha0 - alpha1 * k_i - alpha2 * x_i - alpha3 * l_i)/sigma1,
## mean = 0, sd = 1))))) - y_adj_bar - alpha1 * (k_i - k_bar) -
## alpha4 - alphaXY * x_i)/sqrt(sigma2sq), mean = 0, sd = 1)))
# Obtain parameter estimates
estimates <- get_estimates(setting = "GLM", Y = dat$Y, X = dat$X,
K = dat$K, L = dat$L)
# Compute the score and hessian matrix
derivobj <- deriv_obj(setting = "GLM", logL1 = estfunct_GLM$logL1,
logL2 = estfunct_GLM$logL2, Y = dat$Y, X = dat$X,
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K = dat$K, L = dat$L, estimates = estimates)
score_matrix <- scores(derivobj)
hessian_matrix <- hessian(derivobj)
# Compute sandwich standard errors
sandwich_se(scores = score_matrix, hessian = hessian_matrix)
## alpha_0 alpha_1 alpha_2 alpha_3 sigma_1_sq alpha_4
## 0.03751627 0.03147702 0.05078096 0.02879671 0.04157306 0.03745880
## alpha_XY sigma_2_sq
## 0.05076842 0.04155998
# Compute bootstrap standard errors
bootstrap_se(setting = "GLM", BS_rep = 1000, Y = dat$Y, X = dat$X,
K = dat$K, L = dat$L)
## alpha_0 alpha_1 alpha_2 alpha_3 sigma_1_sq alpha_4
## 0.03684819 0.03183278 0.05086000 0.02954175 0.04266883 0.02020396
## alpha_XY sigma_2_sq
## 0.05076752 0.04264079
# Compute naive standard errors
naive_se(setting = "GLM", Y = dat$Y, X = dat$X, K = dat$K,
L = dat$L)
## alpha_0 alpha_1 alpha_2 alpha_3 sigma_1_sq alpha_4
## 0.03687934 0.02978589 0.05247700 0.02960048 NA 0.03681109
## alpha_XY sigma_2_sq
## 0.05226824 NA
# Main function to compute CIEE based on all above functions
# Estimates and hypothesis tests under the alternative methods
# can also be performed
results_ciee <- ciee(setting = "GLM", Y = dat$Y, X = dat$X,
K = dat$K, L = dat$L, estimates = c("ee",
"mult_reg", "res_reg", "sem"), ee_se = "sandwich")
results_ciee
## $results_ee
## $results_ee$point_estimates
## alpha_0 alpha_1 alpha_2 alpha_3 sigma_1_sq
## -0.01822490 0.27671667 0.13346492 -0.01232202 0.92029662
## alpha_4 alpha_XY sigma_2_sq
## -0.05318825 0.13363882 0.92045700
##
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## $results_ee$SE_estimates
## alpha_0 alpha_1 alpha_2 alpha_3 sigma_1_sq alpha_4
## 0.03751627 0.03147702 0.05078096 0.02879671 0.04157306 0.03745880
## alpha_XY sigma_2_sq
## 0.05076842 0.04155998
##
## $results_ee$wald_test_stat
## alpha_0 alpha_1 alpha_2 alpha_3 sigma_1_sq alpha_4
## -0.4857865 8.7910704 2.6282473 -0.4278968 22.1368523 -1.4199133
## alpha_XY sigma_2_sq
## 2.6323219 22.1476747
##
## $results_ee$pvalues
## alpha_0 alpha_1 alpha_2 alpha_3
## 6.271186e-01 1.481417e-18 8.582611e-03 6.687262e-01
## sigma_1_sq alpha_4 alpha_XY sigma_2_sq
## 1.396557e-108 1.556329e-01 8.480347e-03 1.098440e-108
##
##
## $results_mult_reg
## $results_mult_reg$point_estimates
## alpha_0 alpha_1 alpha_XY alpha_2
## -0.01822490 0.27671667 0.13346492 -0.01232202
##
## $results_mult_reg$SE_estimates
## alpha_0 alpha_1 alpha_XY alpha_2
## 0.03687934 0.02978589 0.05247700 0.02960048
##
## $results_mult_reg$pvalues
## alpha_0 alpha_1 alpha_XY alpha_2
## 6.212906e-01 9.406853e-20 1.113124e-02 6.772964e-01
##
##
## $results_res_reg
## $results_res_reg$point_estimates
## alpha_0 alpha_1 alpha_2 alpha_3 alpha_XY
## 0.03444987 0.28261304 -0.01268054 -0.05279386 0.13264790
##
## $results_res_reg$SE_estimates
## alpha_0 alpha_1 alpha_2 alpha_3 alpha_XY
## 0.03059805 0.02977685 0.02968121 0.03680861 0.05226472
##
## $results_res_reg$pvalues
A.6 R CODE 213
## alpha_0 alpha_1 alpha_2 alpha_3 alpha_XY
## 2.604853e-01 1.628744e-20 6.693082e-01 1.518056e-01 1.129989e-02
##
##
## $results_sem
## $results_sem$point_estimates
## alpha_1 alpha_3 alpha_4 alpha_6 alpha_XY
## -0.01411334 0.13713065 -0.04066894 0.27722407 0.13356893
##
## $results_sem$SE_estimates
## alpha_1 alpha_3 alpha_4 alpha_6 alpha_XY
## 0.05593721 0.05554422 0.03139961 0.02970394 0.05237590
##
## $results_sem$pvalues
## alpha_1 alpha_3 alpha_4 alpha_6 alpha_XY
## 8.008039e-01 1.355460e-02 1.952495e-01 1.030064e-20 1.076616e-02
##
##
## attr(,"class")
## [1] "ciee"
# Wrapper of ciee function to analyze multiple SNVs sequentially
maf <- 0.2
n <- 1000
dat <- generate_data(n = n, maf = maf)
datX <- data.frame(X = dat$X)
names(datX)[1] <- "X1"
for(i in 2:10){
X <- rbinom(n, size = 2, prob = maf)
datX$X <- X
names(datX)[i] <- paste("X", i, sep="")
}
results_ciee_loop <- ciee_loop(setting = "GLM", Y = dat$Y, X = datX,
K = dat$K, L = dat$L)
results_ciee_loop
## $results_ee
## $results_ee$point_estimates
## X1 X2 X3 X4 X5
## 0.001294153 0.006898206 -0.021326542 0.007787436 0.002209479
## X6 X7 X8 X9 X10
## 0.019024904 0.024567674 0.090631472 -0.069561087 0.016969094
##
## $results_ee$SE_estimates
214 APPENDIX
## X1 X2 X3 X4 X5 X6
## 0.05284822 0.05249032 0.05825832 0.05431078 0.05422003 0.05004800
## X7 X8 X9 X10
## 0.05248844 0.05156188 0.05333335 0.05667113
##
## $results_ee$wald_test_stat
## X1 X2 X3 X4 X5
## 0.02448810 0.13141862 -0.36606860 0.14338657 0.04075024
## X6 X7 X8 X9 X10
## 0.38013314 0.46805881 1.75772234 -1.30427003 0.29943103
##
## $results_ee$pvalues
## X1 X2 X3 X4 X5 X6
## 0.98046327 0.89544416 0.71431389 0.88598489 0.96749501 0.70384659
## X7 X8 X9 X10
## 0.63974254 0.07879476 0.19214153 0.76461119
##
##
## $results_mult_reg
## $results_mult_reg$point_estimates
## X1 X2 X3 X4 X5
## 0.001288740 0.006962460 -0.021669079 0.007790108 0.002254990
## X6 X7 X8 X9 X10
## 0.018939691 0.024558364 0.090638752 -0.070201044 0.017164744
##
## $results_mult_reg$SE_estimates
## X1 X2 X3 X4 X5 X6
## 0.05209189 0.05347009 0.05475888 0.05307842 0.05304104 0.05215047
## X7 X8 X9 X10
## 0.05442412 0.05464559 0.05475659 0.05763805
##
## $results_mult_reg$pvalues
## X1 X2 X3 X4 X5 X6
## 0.98026751 0.89642480 0.69239776 0.88334641 0.96609743 0.71655204
## X7 X8 X9 X10
## 0.65191450 0.09749807 0.20012111 0.76591616
##
##
## $results_res_reg
## $results_res_reg$point_estimates
## X1 X2 X3 X4 X5
## 0.001270285 0.006951005 -0.021511171 0.007777435 0.002252196
## X6 X7 X8 X9 X10
A.6 R CODE 215
## 0.018865254 0.024532738 0.090519496 -0.069738927 0.017128832
##
## $results_res_reg$SE_estimates
## X1 X2 X3 X4 X5 X6
## 0.05166572 0.05337253 0.05450433 0.05298206 0.05295503 0.05199572
## X7 X8 X9 X10
## 0.05434119 0.05455498 0.05452165 0.05752001
##
## $results_res_reg$pvalues
## X1 X2 X3 X4 X5 X6
## 0.98038961 0.89640624 0.69317148 0.88332447 0.96608443 0.71681381
## X7 X8 X9 X10
## 0.65175794 0.09738278 0.20115730 0.76592610
##
##
## $results_sem
## $results_sem$point_estimates
## X1 X2 X3 X4 X5
## 0.001280605 0.006893870 -0.021317838 0.007792080 0.002205729
## X6 X7 X8 X9 X10
## 0.019020168 0.024571386 0.090635872 -0.069570486 0.016969045
##
## $results_sem$SE_estimates
## X1 X2 X3 X4 X5 X6
## 0.05198753 0.05335219 0.05450744 0.05297224 0.05292888 0.05202060
## X7 X8 X9 X10
## 0.05431481 0.05453628 0.05449757 0.05746261
##
## $results_sem$pvalues
## X1 X2 X3 X4 X5 X6
## 0.98034776 0.89718802 0.69572361 0.88305513 0.96675902 0.71464299
## X7 X8 X9 X10
## 0.65098926 0.09652534 0.20175073 0.76776026
##
##
## attr(,"class")
## [1] "ciee"
# Summary functions of the CIEE output
summary(results_ciee)
## [1] "Results based on estimating equations."
## point_estimates SE_estimates wald_test_stat pvalues
## CIEE_alpha_0 -0.01822490 0.03751627 -0.4857865 6.271e-01
216 APPENDIX
## CIEE_alpha_1 0.27671667 0.03147702 8.7910704 1.481e-18
## CIEE_alpha_2 0.13346492 0.05078096 2.6282473 8.583e-03
## CIEE_alpha_3 -0.01232202 0.02879671 -0.4278968 6.687e-01
## CIEE_sigma_1_sq 0.92029662 0.04157306 22.1368523 1.40e-108
## CIEE_alpha_4 -0.05318825 0.03745880 -1.4199133 1.556e-01
## CIEE_alpha_XY 0.13363882 0.05076842 2.6323219 8.480e-03
## CIEE_sigma_2_sq 0.92045700 0.04155998 22.1476747 1.10e-108
## [1] "Results based on traditional multiple regression."
## point_estimates SE_estimates pvalues
## MR_alpha_0 -0.01822490 0.03687934 6.212906e-01
## MR_alpha_1 0.27671667 0.02978589 9.406853e-20
## MR_alpha_XY 0.13346492 0.05247700 1.113124e-02
## MR_alpha_2 -0.01232202 0.02960048 6.772964e-01
## [1] "Results based on traditional regression of residuals."
## point_estimates SE_estimates pvalues
## RR_alpha_0 0.03444987 0.03059805 2.604853e-01
## RR_alpha_1 0.28261304 0.02977685 1.628744e-20
## RR_alpha_2 -0.01268054 0.02968121 6.693082e-01
## RR_alpha_3 -0.05279386 0.03680861 1.518056e-01
## RR_alpha_XY 0.13264790 0.05226472 1.129989e-02
## [1] "Results based on structural equation modeling."
## point_estimates SE_estimates pvalues
## SEM_alpha_1 -0.01411334 0.05593721 8.008039e-01
## SEM_alpha_3 0.13713065 0.05554422 1.355460e-02
## SEM_alpha_4 -0.04066894 0.03139961 1.952495e-01
## SEM_alpha_6 0.27722407 0.02970394 1.030064e-20
## SEM_alpha_XY 0.13356893 0.05237590 1.076616e-02
summary(results_ciee_loop)
## [1] "Results based on estimating equations."
## point_estimates SE_estimates wald_test_stat pvalues
## CIEE_X1 0.001294153 0.05284822 0.02448810 0.98046327
## CIEE_X2 0.006898206 0.05249032 0.13141862 0.89544416
## CIEE_X3 -0.021326542 0.05825832 -0.36606860 0.71431389
## CIEE_X4 0.007787436 0.05431078 0.14338657 0.88598489
## CIEE_X5 0.002209479 0.05422003 0.04075024 0.96749501
## CIEE_X6 0.019024904 0.05004800 0.38013314 0.70384659
## CIEE_X7 0.024567674 0.05248844 0.46805881 0.63974254
## CIEE_X8 0.090631472 0.05156188 1.75772234 0.07879476
## CIEE_X9 -0.069561087 0.05333335 -1.30427003 0.19214153
## CIEE_X10 0.016969094 0.05667113 0.29943103 0.76461119
## [1] "Results based on traditional multiple regression."
## point_estimates SE_estimates pvalues
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## MR_X1 0.001288740 0.05209189 0.98026751
## MR_X2 0.006962460 0.05347009 0.89642480
## MR_X3 -0.021669079 0.05475888 0.69239776
## MR_X4 0.007790108 0.05307842 0.88334641
## MR_X5 0.002254990 0.05304104 0.96609743
## MR_X6 0.018939691 0.05215047 0.71655204
## MR_X7 0.024558364 0.05442412 0.65191450
## MR_X8 0.090638752 0.05464559 0.09749807
## MR_X9 -0.070201044 0.05475659 0.20012111
## MR_X10 0.017164744 0.05763805 0.76591616
## [1] "Results based on traditional regression of residuals."
## point_estimates SE_estimates pvalues
## RR_X1 0.001270285 0.05166572 0.98038961
## RR_X2 0.006951005 0.05337253 0.89640624
## RR_X3 -0.021511171 0.05450433 0.69317148
## RR_X4 0.007777435 0.05298206 0.88332447
## RR_X5 0.002252196 0.05295503 0.96608443
## RR_X6 0.018865254 0.05199572 0.71681381
## RR_X7 0.024532738 0.05434119 0.65175794
## RR_X8 0.090519496 0.05455498 0.09738278
## RR_X9 -0.069738927 0.05452165 0.20115730
## RR_X10 0.017128832 0.05752001 0.76592610
## [1] "Results based on structural equation modeling."
## point_estimates SE_estimates pvalues
## SEM_X1 0.001280605 0.05198753 0.98034776
## SEM_X2 0.006893870 0.05335219 0.89718802
## SEM_X3 -0.021317838 0.05450744 0.69572361
## SEM_X4 0.007792080 0.05297224 0.88305513
## SEM_X5 0.002205729 0.05292888 0.96675902
## SEM_X6 0.019020168 0.05202060 0.71464299
## SEM_X7 0.024571386 0.05431481 0.65098926
## SEM_X8 0.090635872 0.05453628 0.09652534
## SEM_X9 -0.069570486 0.05449757 0.20175073
## SEM_X10 0.016969045 0.05746261 0.76776026
